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Abstract 
 
Disruption of spinal pathways following traumatic spinal cord injury (SCI) results in 
significant functional impairments.  This is partly due to cellular and molecular ‘secondary injury’ 
immune responses that compromise the integrity of intact but vulnerable neural tissue surrounding 
the primary site of damage. The innate immune complement system is a critical modulator of this 
response. However, the functions of two potent complement anaphylatoxins, C3a and C5a, have 
remained largely unknown in the context of SCI. The main aim of this PhD thesis was therefore to 
comprehensively investigate the role of these peptides in SCI, and examine whether their receptors, 
C3aR and C5aR, can be targeted therapeutically to improve SCI outcomes. The central working 
hypothesis at the outset was that both receptors would have a pro-inflammatory, detrimental role in 
secondary injury. A series of behavioural and molecular experiments in wild-type and C3ar
-/-
 mice 
revealed that C3aR is in fact a key facilitator of neurological recovery by negatively regulating the 
mobilisation of peripheral granulocytes from their reservoirs in response to SCI; recruitment of 
mobilised granulocytes to the lesion site exacerbated tissue damage whereas their depletion 
alleviated the C3ar
-/-
 phenotype. Activation of C3aR in the acute phase of SCI may thus be a novel 
therapeutic strategy to improve recovery. In contrast, both genetic ablation and pharmacological 
antagonism of C5aR significantly improved injury outcomes in the (sub-) acute stage of injury. 
However, C5aR appeared to serve a reparative role in the chronic phase, as absence of C5aR 
signalling ultimately impaired long-term recovery. Regulation of astrocyte proliferation and glial 
scar development, which normally protects spared tissue, was identified as a novel mechanism for 
this chronic phenotype. Translation of putative SCI therapies, including those targeting complement 
proteins like C3aR and C5aR, would be greatly facilitated by the development of non-invasive, 
quantitative techniques that can stratify subjects based on injury severity, provide a functional 
prognosis in association, and visualise therapeutic efficacy. It was determined that diffusion tensor 
imaging (DTI) can reliably monitor the progression of secondary injury in ventrolateral white 
matter following a dorsally inflicted contusive SCI, revealing a therapeutic window here for at least 
three days post-SCI. Post-mortem histological analysis showed that SCI-induced spatial changes in 
select DTI indices were reflective of demyelination, axonal loss, Wallerian degeneration and 
gliosis, respectively. Preliminary studies further showed that DTI is also sensitive enough to detect 
beneficial changes in SCI outcomes following therapeutic intervention. Collectively, the insights 
gained with regards to involvement of complement peptides in neuroinflammatory responses to 
SCI, along with characterising advanced and transferable imaging techniques, may facilitate the 
development and implementation of novel therapeutic approaches for acute SCI into the clinic.   
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1.1 Introduction to the spinal cord 
 
1.1.1 General anatomy and physiology of the spinal cord  
The adult mammalian spinal cord is part of the central nervous system (CNS) located within 
and protected by the vertebral column. At the rostral end, the spinal cord is continuous with the 
medulla oblongata of the brainstem. The spinal cord ends caudally at the cone-shaped conus 
medullaris, which is anchored to the dural sac via the filum terminale. In addition to the dura mater, 
two other meningeal layers cover the spinal cord. Closest to the spinal cord is the pia mater, which 
also extends into the ventral surface along the length of the spinal cord as part of the anterior 
median fissure, which is deepest at cervical (C) level 5 in the human (Fountas et al., 1998). Dorsally 
the pia mater extends inward, almost to the commissural grey matter, forming the posterior median 
sulcus. Situated between the pial tissue and the dura mater is the arachnoid mater. Pairs of 
denticulate ligaments extend from the pia mater on the spinal surface, serving as anchor points to 
the outer meninges. In contrast to the cranium, the dura mater of the spinal cord is not adhesive to 
the bony tissue of the vertebral column. Instead, there is an epidural space between the dura and the 
periosteum of the vertebral column that is filled with fat and lymphatic tissue, small arteries and a 
venous plexus, derived from a ventral spinal artery and two dorsal spinal arteries, which supply the 
spinal cord.  
Running longitudinally through the centre of cord is the central canal, which is continuous 
with the fourth ventricle of the brainstem rostrally and ends as the terminal ventricle in the conus 
medullaris caudally. In the rodent, this space is mostly filled with cerebrospinal fluid (CSF), a clear 
liquid that is mainly produced by the choroid plexus (Weed, 1914). About 0.3 ml/min of CSF is 
produced in humans (Rubin et al., 1966; Cutler et al., 1968; Watters et al., 1969) and 0.4 µl/min in 
mice (Oshio et al., 2005). In humans, the central canal appears to mostly contain Reissner’s fibre, a 
filamentous protein that is secreted into the CSF by the subcommissural organ (Reissner, 1860). In 
all mammalian species, CSF also fills the subarachnoid space around the spinal cord, functioning to 
maintain buoyancy, shock absorption, and chemical homeostasis, as well as being involved in 
development and repair (Redzic et al., 2005). 
In the human, 31 pairs of spinal nerves demarcate cervical (C1-C8), thoracic (T1-T12), 
lumbar (L1-L5), sacral (S1-S5), and coccygeal (Co1) segments. The rodent spinal cord is similar in 
gross anatomy compared to the primate spinal cord, though it is obviously smaller in size, and is 
divided into 34 segments rather than 31 (8 cervical, 13 thoracic, 6 lumbar, 4 sacral and 3 
coccygeal). In all mammals, the vertebral column develops faster than the spinal cord and extends 
past it (Sakla, 1969). Thus, only the cervical spinal segments are approximately aligned with their 
corresponding vertebral level (Ranson and Clark, 1953). In the lumbar region, the spinal cord 
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commonly ends at the level of the 2
nd
 lumbar (L2) vertebra, with the spinal nerves extending 
beyond the conus medullaris to form the cauda equina (horse’s tail) (Watson et al., 2009).  
Each projecting spinal nerve originates from branches of anterior and posterior rootlets that 
extend from the spinal cord and amalgamate into a motor root ventrally and a sensory root dorsally 
(Magendie, 1822) (Fig. 1.1). The dorsal spinal roots contain a dorsal root ganglion, which houses 
cell bodies of primary sensory neurons that convey information from the skin, viscera, 
subcutaneous, and deep tissues. The motor and sensory roots converge into a spinal nerve, which 
exits the vertebral canal through the intervertebral foramen. The tributaries and networks of the 
spinal nerves comprise the peripheral nervous system (PNS).  
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Figure 1.1: Diagram of the gross anatomy of the mammalian spinal cord, showing the major 
anatomical landmarks at the cervical level. A: Rostrocaudal view. The spinal cord is protected by 
the vertebral column and enveloped by three meninges: the pia, arachnoid, and dura mater. B: 
Dorsoventral view. The pia mater follows the anterior median fissure and the posterior median 
sulcus, extending towards the grey commissure.  Emerging dorsal and ventral nerve rootlets give 
rise to a dorsal and ventral nerve root, which converge into a spinal nerve containing sensory and 
motor neurons. The central, butterfly-shaped grey matter is divided into three horns (dorsal, lateral, 
and ventral). The dorsal columns, lateral funiculi and ventral funiculi surround the grey matter, and 
accommodate millions of myelinated, longitudinally projecting axons (Figure adapted from Marieb 
and Hoehn, 2007). 
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The widest segments of the spinal cord are the cervical (C5-T1) and lumbar (L2-S2) 
enlargements, from which the brachial and lumbosacral plexes arise (Barson and Sands, 1977). 
These enlargements contain many somatic efferent motor fibres that arise from prominent motor 
neuron pools in the ventral horn and terminate in skeletal muscles of the upper and lower limb 
extremities; they do not contain autonomic neurons. While voluntary control of limb movements is 
ultimately orchestrated by descending motor pathways from the brain, intrinsic spinal circuits 
capable of producing coordinated activity of flexor and extensor motor neurons are thought to exist 
in all vertebrates. These spinal networks, commonly referred to as central pattern generators 
(CPGs), are thus engaged by descending motor command to initiate voluntary movement. However, 
with the right stimulation, such as spinal cord trauma, CPGs can also evoke stepping patterns in the 
absence of cortical control (Brown, 1911; Grillner et al., 1981; Barbeau and Rossignol, 1987; 
Edgerton et al., 1992; Dimitrijevic et al., 1998; Fedirchuk et al., 1998; Kiehn and Butt, 2003; 
Whelan, 2003). There is at least one CPG for each hindlimb (Forssberg et al., 1980). Sophisticated 
movements, such as rhythmic locomotion, result from interplay between tonic excitation of 
excitatory interneurons and the reciprocal antagonism between them (Jankowska et al., 1967; Rybak 
et al., 2006). Somatic afferent fibres are the processes of dorsal root ganglia neurons, and comprise 
more than 90% of the afferent fibres in the dorsal roots because of their role in relaying sensory 
information from the skin, subcutaneous tissue, skeletal muscles, tendons and joints (Watson et al., 
2009).  
The thoracic and sacral segments have a smaller cross-sectional area than cervical and 
lumbar segments, as they do not contain large motor neuron pools and interneuron networks 
associated with the upper and lower limbs. They do, however, contain efferent visceral fibres of the 
sympathetic nervous system (T1-L2 in mouse and T1-L3 in human) and parasympathetic pathways 
(L6-S1 in mouse and S2-S4 in human), providing autonomic motor control to endocrine and 
exocrine glands, smooth and cardiac muscles, fat, and lymphoid organs. Each spinal nerve thus also 
contains visceral afferent fibres that convey sensory information from visceral tissues. Other 
prominent features of the spinal cord include the phrenic nucleus in the medial portions of the 
ventral horn at C3-C5, which gives to the phrenic nerves that control the diaphragm muscle. For this 
reason, this segment of the spinal cord is critically involved in the regulation of breathing (Keswani 
and Hollinshead, 1955). In the lower thoracic and upper lumbar cord, the Clarke’s nucleus can be 
found, from which ascending fibres of the spinocerebellar tracts arise (see Section 1.1.2).  
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1.1.2 Spinal cord histology 
In cross section, intraspinal neurons can be observed within a butterfly-shaped core of grey 
matter. These neuronal cell bodies are arranged in successive layers (Rexed laminae) that integrate 
incoming information from converging neural circuits (Rexed, 1952). The dorsal wings of the grey 
matter, the dorsal horns, extend to the spinal cord perimeter, up to the point of the dorsolateral 
sulcus where the dorsal nerve rootlets enter the spinal cord. The dorsal horns contain central 
branches of dorsal root ganglion sensory cells, particularly those that facilitate intraspinal reflexes 
or are part of the anterolateral system, which relays protective sensations such as pain, temperature, 
and itch to higher brain centres. The bilateral ventral extensions of grey matter, which contain the 
large cell bodies of motor neurons, are called the ventral horns. Lateral horns in the thoracic and 
upper lumbar segments contain autonomic cell bodies of the sympathetic motor system. The 
intermediate grey matter contains interneurons important for response modulation and relay (see 
Section 1.1.3 below for a more detailed discussion on the various cell types of the spinal cord). 
Millions of myelinated ascending and descending axon fibres are contained within the white 
matter surrounding the grey matter, except at the region of the dorsolateral sulcus where dorsal root 
fibres enter the spinal cord. Anatomically, the white matter can be divided into three main areas or 
funiculi: ventral (anterior), lateral, and dorsal (posterior), with the dorsal funiculi being formed by 
longitudinal columns either side of the dorsal median sulcus. The funiculi can be further divided 
into smaller regions, or fasiculi. Fasiculi contain groups of fibres, also known as spinal tracts, which 
have the same origin, course and function. In primates, sensory axons of the ascending anterolateral 
system, spinocerebellar and spinotectal tracts are located in the lateral and ventral funiculi. The 
dorsal funiculus contains the cuneate and gracile fasiculi, which are essential pathways for 
conveying finer aspects of skin sensation (discriminative touch) and position sense (proprioception) 
from the limbs and trunk to the brain.  
Some ascending fibres between T1-L3 project to the neurons of the dorsal nucleus (column 
of Clarke), which is situated within the medial gray matter of lamina 5. These neurons project 
ipsilaterally to the inferior cerebellar peduncle via the dorsal spinocerebellar tract, and convey 
information about limb and joint position to the cerebellum (unconscious proprioception) (Rivero-
Melian and Grant, 1990). As indicated above, the dorsal column pathway for conscious perception 
includes the gracile fasiculus, containing afferents from the trunk and extremities below T6, and the 
cuneate fasiculus from C1-T6, which contains afferents from the upper trunk and extremities. These 
axons terminate at the medullary dorsal column nuclei. Projections of second order neurons cross 
the midline here and go on to form the medial leminiscus. This pathway terminates in the thalamus, 
and from here information is relayed the somatosensory cortex for conscious perception. Through 
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this route, the dorsal column-medial lemniscus pathway transmits information on discriminatory 
touch, deep pressure, proprioception, joint position and vibration sense.  
Like the various ascending pathways, key descending motor pathways, such as the 
corticospinal, rubrospinal, vestibulospinal, tectospinal and reticulospinal tracts, are also contained 
within the ventrolateral white matter, as are descending autonomic projections from the 
hypothalamus. Of note, and unlike in humans, the corticospinal tract (CST), which facilitates 
voluntary and skilled limb movements, is not located in the lateral funiculi in rodents and many 
other non-primate mammals. Rather, the CST in these animals is contained within the most ventral 
part of the dorsal columns in a region that is distinct from the ascending cuneate and gracile fasiculi 
(Fig. 1.2).  
 In addition to these long ascending and descending tracts that ultimately connect the brain 
with the body, a sheath of shorter propriospinal fibres can be found close to the grey matter. These 
fibres connect different spinal segments and/or regions, thus facilitating integration and coordinated 
output. The longest propriospinal pathways connect the cervical and lumbar enlargements to 
coordinate limb movements. In this manner, the structure of the spinal cord enables efficient relay 
of voluntary motor commands from the brain to the muscles, viscera and blood vessels of the limbs 
and trunk. Sensory feedback from these regions contributes to reflexive maintenance of muscle 
tone, balance and posture. This information is also interpreted by the brain to ensure that 
descending motor commands were executed as planned, and to correct or adjust ongoing 
movements as necessary. 
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Figure 1.2: Diagram showing the location of the major spinal cord tracts in the mouse. For 
clarity, the main eight ascending (sensory) tracts are shown in blue, and the main six descending 
(motor) tracts are shown in green. Representative sections at each vertebral level, specifically C8, 
T7, L3 and S2 are shown. cc: central canal; crts: caudal reticulospinal tract; cu: cuneate fasiculus; 
dcs: dorsal corticospinal tract; dsc: dorsal spinocerebellar tract; dl: dorsolateral fasiculus; dlst: 
dorsolateral spinothalamic tract; gr: gracile fasiculus; IML: intermediolateral column; lf: lateral 
funiculi; lst: lateral spinothalamic tract; LSp, lateral spinal nucleus; lvs: lateral vestibulospinal tract; 
mvs: medial vestibulospinal tract; psdc: postsynaptic dorsal column pathway; rrts: rostral 
reticulospinal tract; rs: rubrospinal tract; SPSy: sacral parasympathetic nucleus; vf: ventral funiculus 
vsc: ventral spinocerebellar tract; vst: ventral spinothalamic tract (Figure adapted from Watson and 
Harrison, 2012). 
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1.1.3 Cells of the spinal cord 
Although neurons are the principal cells that ultimately drive cognitive processes and 
behaviour, they are fundamentally supported by a heterogeneous population of support cells known 
as neuroglia. These cells outnumber neurons by a ratio of 1.13:1 in mouse (Bjugn, 1993) and 1.6:1 
in rat (Bjugn and Gundersen, 1993). The term ‘glia’ is derived from the Latin word meaning ‘glue’, 
as they were initially thought to simply hold the CNS tissue together (Virchow, 1846). Although the 
name has been retained, the original view of neuroglia has dramatically changed.  
Astrocytes, identified as the principal non-neuronal population by Ramón y Cajal (1913), 
are marked by expression of glial fibrillary acidic protein (GFAP) and S100β (Eddleston and 
Mucke, 1993; Goncalves et al., 2008). They provide structural, trophic and metabolic support for 
neurons, particularly in regard to maintaining neurotransmitter and ionic homeostasis critical for 
neuronal excitability and synaptic transmission (Markiewicz and Lukomska, 2006). Astrocyte end 
processes also maintain the blood-brain barrier (BBB) / blood-spinal cord barrier (BSB), which is 
key for maintenance of cerebrovascular homeostasis (Allen and Barres, 2009; Sofroniew and 
Vinters, 2010). CNS capillaries are also surrounded by tiny supporting cells, initially described as 
contractile elements over 140 years ago (Rouget, 1873). These pericytes regulate multiple 
microvascular processes, including: contractility and tone, permeability, and endothelial cell 
division and differentiation. In response to disease, pericytes may also modulate morphological 
changes of microvessel structure (Bergers and Song, 2005; Greif and Eichmann, 2014). 
After the discovery of astrocytes, two other glial cell types were described, namely 
oligodendrocytes (del Río-Hortega, 1928), and microglia (del Río-Hortega, 1919). 
Oligodendrocytes extend processes that tightly envelope stretches of axons and form the myelin 
sheath that is essential for efficient action potential propagation and provision of trophic support to 
the ensheathed axon (Nave and Trapp, 2008).  Mature oligodendrocytes can be identified by 
positive immunoreactivity for myelin markers, such as myelin basic protein (MBP) (Sternberger et 
al., 1978), myelin oligodendrocyte glycoprotein (MOG) (Birling et al., 1993), and phospholipid 
protein (PLP) (Sobel et al., 1994). Their cell bodies can also be labelled with the monoclonal 
antibody CC1 (Smith et al., 1993; Bhat et al., 1996). Oligodendrocytes arise from oligodendrocyte 
precursor cells (OPCs) during development, and these stem cells remain a major progenitor cell 
population throughout the adult CNS (Crawford et al., 2014), constituting 5-8% of the total glial 
cell population (Levine et al., 2001). In response to demyelination or increased OPC demand as a 
result of injury (Blight, 1983; Totoiu and Keirstead, 2005), OPCs have the capacity to differentiate 
into functional oligodendrocytes via a process known as remyelination (Levine et al., 2001; 
Franklin and Ffrench-Constant, 2008) which is associated with neuroprotection (Bruce et al., 2010). 
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The microglial population are thus named due to their smaller size in comparison to other 
glia. Microglia originate from myeloid lineage precursors that express macrophage colony-
stimulating factor receptor (CSF-1R/CD115) in the mesodermal yolk sac prior to closure of the 
BBB and restriction of cell migration into the CNS (Alliot et al., 1999; Ginhoux et al., 2010; 
Kierdorf et al., 2013). Resting microglia display a ramified morphology characterised by processes 
that interact with neighbouring blood vessels, neurons and astrocytes. These interactions are 
important for CNS maintenance and neuronal plasticity (Wake et al., 2009; Paolicelli et al., 2011; 
Rigato et al., 2011; Schafer et al., 2012; Parkhurst et al., 2013), including neurogenesis in the adult 
brain (Vukovic et al., 2012). Microglia also act as sentinels of the CNS, using their fine processes to 
constantly scan for dysfunctional synapses, which they can eliminate by phagocytosis (Wake et al., 
2009; Tremblay et al., 2010). The microglial cell surface is equipped with numerous transporters, 
channels and receptors for neurotransmitters, neurohormones, cytokines and chemokines, as well as 
pattern recognition receptors (PRRs), which detect damage or infection (Lee et al., 2002; Olson and 
Miller, 2004; Biber et al., 2008). Once an immune challenge is detected, microglia undergo a 
complex conversion process in which they adopt an amoeboid morphology, proliferate, migrate 
along chemotactic gradients, and contribute to phagocytosis of abnormal material and/or cellular 
debris (Kettenmann et al., 2011; Saijo and Glass, 2011). For this reason, microglia are classically 
considered the resident immune cells of the CNS.  
A fourth and highly specialised type of neuroglia are ependymocytes, ciliated epithelial-like 
cells that are involved in CSF circulation.  
 
1.2 The injured spinal cord  
 
1.2.1 Epidemiology of traumatic spinal cord injury 
As the spinal cord is responsible for successful transmission of electrical/neurochemical 
information from the brain to the periphery and vice versa, a traumatic spinal cord injury (SCI) 
destroying the precise spinal circuitry and cytological architecture is a devastating and costly event 
in both human and social terms. The magnitude and permanency of physical debilitation depends on 
the spinal level, severity, and nature of the SCI (Lubieniecka et al., 2011). However, acute or 
chronic complications of the nervous, musculoskeletal, respiratory, gastrointestinal, urinary and 
integumentary systems as a result of SCI are virtually inevitable. Globally, almost 180 000 new SCI 
cases are reported annually (Lee et al., 2014) (Fig. 1.3).  In Australia, there are over 10 000 cases of 
SCI, with an additional 300 sustained every year (Norton, 2010). The leading causes of SCI 
globally are transport-related accidents, falls, violent acts and recreational sports activities (Sekhon 
and Fehlings, 2001). In developed countries, SCI typically occurs in young males and produces 
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extremely high morbidity but relatively low mortality (4%  at 1 year and 14% at 10 years) 
(O'Connor, 2005). As a result, SCI is one of the most expensive chronic medical conditions. The 
lifetime cost per incidence is approximately $5 million for paraplegia and $9.5 million for 
quadriplegia (Access Economics, 2009). The socioeconomic burden of SCI over the lifetime of 
affected individuals, based on annual incidence rates, is $2 billion in Australia and $10 billion 
annually in the USA (Berkowitz et al., 1998; Access Economics, 2009). 
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Figure 1.3: The incidence of traumatic SCI by country between 1959 and 2011. In Australia, 15 people per million are affected by traumatic SCI, 
with an equal distribution between paraplegia and quadriplegia. The dominant cause of SCI in this country is motor vehicle accidents, with 
approximately 14% of cases result in mortality within the first 10 years after the injury (Figure adapted from Lee et al., 2014). 
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1.2.2 Pathology of spinal cord injury: primary injury 
The immediate mechanical insult to the spinal cord, be it contusion, compression, shearing, 
laceration, hyperflexion, hyperextension, distraction, or a combination of these aetiologies, is 
termed the primary injury (Barnes, 1948; Taylor, 1951; Rowland et al., 2008). This type of injury 
has been recognised for millennia as a catastrophic event, with the first known record of spinal cord 
injury dating back to 1700 B.C. (Fig. 1.4). The most common mechanisms of human SCI, contusion 
and compression, are evident in burst fractures with retropulsed bone fragments compressing the 
cord, fracture-dislocations, and acute disc ruptures. This initial impact elicits haemorrhaging, 
electrolyte shifts, and disrupts the BSB, cell membranes, myelin sheaths, and axonal tracts (Blight, 
1988; Tator, 1995). The predominant region of damage in this phase appears to be the grey matter, 
with relative sparing of white matter (WM) peripheral to the zone of injury. The increased 
compliance of the grey matter to mechanical damage is thought to be a result of its higher 
vascularisation (Martirosyan et al., 2011), and predominance of cell bodies that are more sensitive 
to destruction from mechanical forces (Mautes et al., 2000). Damage caused by the primary injury 
is currently considered irreversible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Plate from the oldest known document on spinal injuries, the hieratic Edwin 
Smith surgical papyrus.  Over 3000 years old and originating from Thebes, Egypt, the script 
accounts the signs and symptoms of six cases of injuries to the spinal column. Here, plate X and XI 
detail five of the cervical SCI cases, including two with dislocation and burst fracture. The ancient 
physician concludes “This is a medical condition that cannot be healed.” (Figure adapted from van 
Middendorp et al., 2010). 
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1.2.3 Pathology of spinal cord injury: secondary injury 
Although the spinal level, severity and nature of the primary SCI are key determinants of a 
patient’s neurological grade at clinical presentation, the final functional prognosis cannot be 
predicted based on this information alone (Dumont et al., 2001). This is due to spinal shock, in 
which numerous neural functions are temporarily depressed, as well as ongoing secondary injury 
processes that progressively destroy tissue neighbouring the primary lesion that would have 
otherwise survived (Blight, 1991a; Tator, 1995; Dumont et al., 2001; Sekhon and Fehlings, 2001; 
Oyinbo, 2011). Secondary injury greatly impedes restorative processes and ultimately predicts long-
term morbidity (Dumont et al., 2001). The scope of cellular and molecular events contributing to 
secondary injury has become more clearly defined as a result of intensive research efforts in this 
area. 
Known drivers of secondary pathology are: ischaemia-reperfusion injury (Senter and Venes, 
1978), oedema, excess Ca
2+
 and excitotoxicity (Faden and Simon, 1988; Park et al., 2004; Baptiste 
and Fehlings, 2006), fluid-electrolyte disturbances (Tator, 1995), apoptosis (Crowe et al., 1997), 
demyelination (Totoiu et al., 2005) and Wallerian degeneration (Zhang et al., 2012a), mitochondrial 
dysfunction and oxidative stress (Azbill et al., 1997), increased endothelial cell permeability and 
vascular dysfunction (Blight, 1991b; Martirosyan et al., 2011), and non-resolving immunological 
and inflammatory injury (see Section 1.3.4) (Donnelly and Popovich, 2008; Popovich and 
McTigue, 2009; Blomster et al., 2013b) (Fig. 1.5). Unlike the primary injury, secondary injury is a 
gradual and biologically driven process, and is therefore amenable to intervention strategies. Studies 
in animal models of SCI have demonstrated that residual survival of only 5-10% of axons following 
either contusion (Blight, 1983; Blight and Decrescito, 1986) or compression injury (Fehlings and 
Tator, 1995) can sustain recovery of some neurological function. Thus, there is a growing field of 
research aiming to limit secondary injury following SCI and, in doing so, improve functional 
outcomes.  
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Figure 1.5: Schematic diagram overviewing the primary and secondary stages of spinal cord 
injury. The initial trauma results in axon disruption (1) and cell death (2). Over time, the injury 
spreads into neighbouring parenchyma that was originally spared, exacerbating cell death and tissue 
pathology. The progressive secondary injury events include: formation of a central lesion 
characterised by ischaemia, excitotoxicity, oxidative stress, and inflammation (3), demyelination 
(4), expression of growth inhibitory molecules in and around the lesion (5), apoptosis (6), Wallerian 
degeneration and vascular dysfunction (7) and, macroscopically, cord atrophy (8) (Figure adapted 
from Ronsyn et al., 2008). 
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1.3. Inflammation in the periphery and CNS 
 
One hallmark of secondary injury that has received increasing attention as a potential 
therapeutic target for SCI is the inflammatory response. In peripheral and regenerating tissues, 
inflammation is a host-protective mechanism that functions to eliminate, neutralise or wall off 
noxious agents and damaged tissue to restore homeostasis (Bethea and Dietrich, 2002). The 
inflammatory response is broadly divided into two arms: innate immunity, which provides rapid 
response to broad classes of stimuli; and adaptive immunity, which is a delayed response mediated 
by clonal selection of antigen-specific cells, and is hallmarked by the development of 
immunological memory (Murphy et al., 2008). However, in the context of the injured CNS, 
inflammation has deleterious components as well beneficial components due to the complexity of 
neuroimmune interactions which inevitably follow BSB breakdown. Before discussing these 
complexities and models for their study in greater detail, the immune system and stages of 
inflammation in the periphery will first be overviewed. 
 
1.3.1 Non-cellular mediators of innate immunity 
In response to injurious or infectious challenge, acute inflammation is initiated by non-
cellular innate immune components, including: eicosanoids, cytokines and the complement system. 
Eicosanoids are cyclooxygenase products such as prostaglandins, which produce fever and 
vasodilation, and leukotrienes, which recruit immune cells (Kalish et al., 2013; Nicolaou, 2013). 
The major cytokines in the immediate innate inflammatory response are the interleukins (IL), 
chemokines, interferons, and colony-stimulating factors (Table 1.1). Finally, the complement 
system has multiple arms which cooperatively mediate direct cell lysis, opsonisation of abnormal 
host cells and foreign material for phagocytosis, and immune cell chemotaxis (see Chapter 2). 
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Table 1.1. Function of major cytokines in the inflammatory response 
Name Producer cells Immune function References 
IL-1 
Monocytes, 
macrophages, 
DCs, 
neutrophils, T 
cells, B cells, 
endothelia, 
epithelia, dying 
cells 
Macrophages, monocytes: cytokine 
production, adhesion, chemotaxis, 
phagocytosis 
DCs: cytokine production, ↑ major 
histocompatibility complex II 
(MHCII) and costimulatory 
molecules 
Neutrophils: survival, adhesion, 
chemotaxis, oxidative burst, protease 
release 
T cells: ↑ TH2 activation, ↑ IL-2 
B cells: proliferation, antibody 
production 
Endothelia: activation, coagulation 
Hypothalamus: fever 
Gillis and Mizel 
(1981); Netea et al. 
(2000); Dinarello 
(2009); Sims and 
Smith (2010); 
Garlanda et al. (2013) 
IL-6 
Macrophages, T 
cells, B cells, 
endothelia 
Monocytes: chemotaxis and 
differentiation into alternatively 
activated macrophages 
Neutrophils: chemotaxis 
T cells: differentiation into TC cells 
B cells: differentiation into plasma 
cells, antibody production 
Hypothalamus: fever 
Kishimoto and Hirano 
(1988); Clark (1989); 
Keller et al. (1996); 
Netea et al. (2000); 
(2011); Fernando et al. 
(2014); Rose-John 
(2014)  
IL-8 
Monocytes, 
macrophages, 
neutrophils, T 
cells, endothelia, 
epithelia, 
fibroblasts 
Neutrophils: adhesion, chemotaxis, 
degranulation and respiratory burst 
Other immune cells: chemotaxis 
Microvessels: angiogenesis 
Baggiolini and Clark-
Lewis (1992); Koch et 
al. (1992); Harada et 
al. (1994); Taub et al. 
(1996). 
IL-10 
Monocytes, 
macrophages, 
DCs, T cells, B 
cells, mast cells 
Macrophages: inhibition of TH1 
cytokine production (↓ IL-2, TNF 
and IFNγ), reduced expression of 
MHCII and costimulators 
B cells: survival, proliferation, 
antibody production 
Bogdan et al. (1991); 
Ho and Moore (1994); 
Itoh and Hirohata 
(1995); Mocellin et al. 
(2005) 
IL-12 
Monocytes, 
macrophages, 
DCs, B cells 
NK cells: growth, cytolytic activity, 
↑ IFNγ, ↑ TNFα 
T cells: ↑ IFNγ, ↑ TNFα, growth, 
differentiation into TC and TH1 cells  
Wolf et al. (1994); 
Trinchieri (1995); 
Hamza et al. (2010). 
IL-15 
Monocytes, 
macrophages, 
DCs, virally-
infected cells 
Macrophages: ↑ IFNα/β, 
NK cells and T cells: proliferation, 
survival, costimulation by APCs 
T cells: survival 
Grabstein et al. (1994); 
Ma et al. (2000); 
Fehniger and Caligiuri 
(2001); Mortier et al. 
(2009) 
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IL-18 
Monocytes, 
macrophages, 
DCs, 
neutrophils, 
endothelia 
Macrophages and DCs: ↑ IFN-γ, ↑ 
IL-6, ↑ TNFα 
Neutrophils: activation, respiratory 
burst, degranulation, ↑ TNFα, ↑ IL-
1α, ↑ IL-6 
NK cells and T  cells: activation, ↑ 
IFN-γ, ↑ TH1 cytokines (with IL-12), 
↑ TH2 cytokines (with IL-4) 
 
Okamura et al. (1995); 
Gardella et al. (1999); 
Leung et al. (2001); 
Nakanishi et al. 
(2001); Gracie et al. 
(2003) 
TNFα 
Monocytes, 
macrophages, T 
cells, NK cells, 
mast cells, 
endothelia, 
fibroblasts 
Macrophages: phagocytosis, ↑ IL-1, 
polarisation toward a classical 
phenotype 
Neutrophils and eosinophils: 
activation, chemotaxis 
Hypothalamus: fever 
Walsh et al. (1991); 
Lukacs et al. (1995); 
Bischoff et al. (1999); 
Netea et al. (2000); 
Parameswaran and 
Patial (2010) 
TGF-β 
Monocytes, 
DCs,  T cells, 
NK cells, 
platelets 
Macrophages: chemotaxis, adhesion, 
↑ IL-1, ↑ IL-6 
Neutrophils: chemotaxis,  
TH cells: differentiation into TReg 
cells and TH17 cells 
B cells: differentiation and survival 
Assoian et al. (1983); 
Sporn et al. (1986); Li 
et al. (2006); Kehrl et 
al. (2014) 
Type-1 IFNs 
IFNα: 
Macrophages, 
DCs 
IFNβ: DCs, 
fibroblasts 
NK cells: activation, viral immunity, 
↑ MHCI 
Hypothalamus: fever 
Netea et al. (2000); 
Perry et al. (2005); 
Trinchieri (2010) 
IFNγ 
Macrophages, 
DCs, T cells, 
NK cells 
Macrophages: activation, 
polarisation toward a classical 
phenotype 
T cells: stimulation of antibody 
responses, TH1 differentiation 
Young and Hardy 
(1995); Frucht et al. 
(2001); Schroder et al. 
(2004) 
MIP-1  
Monocytes, 
macrophages, 
DCs, 
granulocytes, T 
cells, NK cells, 
platelets 
Monocytes, eosinophils: chemotaxis 
Macrophages: proliferation, 
chemotaxis 
T cells: TH1 cell differentiation 
Hypothalamus: fever 
Minano et al. (1990); 
Fahey et al. (1992); 
Rot et al. (1992); Koch 
et al. (1994) 
MCP-1 
(CCL2)  
Monocytes, 
macrophages, 
DCs endothelia, 
epithelia, 
fibroblasts 
Monocytes, macrophages: 
chemotaxis 
Deshmane et al. 
(2009); Conductier et 
al. (2010) 
Chemokines 
Macrophages, T 
cells, endothelia, 
epithelia, 
fibroblasts, 
platelets 
 
Leukocytes: migration and activation 
Lira and Furtado 
(2012); Cardona et al. 
(2013) 
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G-CSF 
Monocytes, 
endothelia, 
fibroblasts, BM 
haematopoietic 
stem/progenitor 
cells 
Stem/progenitor cells: development 
and differentiation into granulocytes, 
Granulocytes: mobilisation 
Metcalf (1985); 
Nagata et al. (1986) 
M-CSF 
Macrophages, 
BM stromal 
cells, 
osteoblasts, 
fibroblasts 
Stem/progenitor cells: development, 
proliferation, differentiation into 
monocytes and macrophages 
Sherr et al. (1988); 
Metcalf (1989) 
GM-CSF 
Macrophages, T 
cells, mast cells, 
endothelia 
Stem/progenitor cells: development, 
proliferation, differentiation into 
granulocytes, monocytes and 
macrophages 
Metcalf (1973); 
Burgess and Metcalf 
(1980); Shi et al. 
(2006) 
 
APC: Antigen-presenting cells; BM: bone marrow; DCs: Dendritic cells; G-CSF: Granulocyte 
colony-stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating factor; IFN: 
Interferon; IL: Interleukin; M-CSF: Macrophage colony-stimulating factor; MIP-1: Macrophage 
inflammatory protein-1; NK: Natural killer cells; TC: cytotoxic T lymphocyte; TGF: Transforming 
growth factor; TH: helper T lymphocyte; TNF: Tumour necrosis factor; TReg: T regulatory cell 
 
1.3.2 Cells of the innate immune system 
Specialised populations of leukocytes comprise the cellular component of immunity, which 
is the next key phase of inflammation after non-cellular innate immunity. These populations 
originally develop from primitive progenitors located in blood islands of the embryonic yolk sac 
(Palis et al., 1999). Progenitor cells migrate to the foetal liver and eventually seed out the thymus, 
spleen and bone marrow (Fernández and de Alarcón, 2013). Bone marrow haematopoiesis, the 
process of blood cell generation, becomes more prominent during the second trimester and is the 
major haematopoietic site throughout post-natal life (Fig. 1.6). Since mature blood cells are 
senescent, the ability of multi-potent haematopoietic stem cells (HSCs) to self-renew and replenish 
their more differentiated progeny is crucial for sustaining life and accommodating increased 
leukocyte demand after injury or infection (Reya, 2003). Long-term self-renewing HSCs are 
identified as the Lin
-
CD34
+
CD38
-
CD90
+
CD45RA
-
 population in the human, and the Lin
-
Sca1
+
Kit
+
Flt3
-
Thy1.1
-
CD34
-
CD48
-
CD150
+
 population in the mouse (Spangrude et al., 1988; 
Passegue et al., 2003; Zhang et al., 2003; Weissman and Shizuru, 2008; Wang and Wagers, 2011). 
Key molecular signals in haematopoiesis are the transcription factors PU.1 and GATA-1 (Song et 
al., 2004; Orkin and Zon, 2008), as well as signalling of stem cell factor (SCF), and thrombopoietin 
(TPO) (Robb, 2007). These signals induce HSC differentiation into Lin
-
CD34
+
CD38
+IL3Rα-
CD45RA
-
 common myeloid progenitors (CMPs) (mouse CMPs: Lin
-
Sca1
-
Kit
+
CD34
+
CD16/32
-
) 
(Weissman and Shizuru, 2008; Wang and Wagers, 2011). 
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Figure 1.6: All immune cells are originally derived from a small population of haematopoietic 
stem cells (HSCs). HSCs include the long-term reconstituting HSCs (LT-HSCs), which self-renew 
to maintain pulripotency, the short-term reconstituting HSCs (ST-HSCs), and the multipotent 
progenitors (MPP), which have more restricted potential for self-renewal. These precursors 
differentiate into lineage-committed oligopotent progenitors (indicated by *), known as the common 
myeloid progenitors (CMP) and common lymphoid progenitors (CLP). These lineage-committed 
cells form all the mature haematogenous cells (depicted toward the bottom of the diagram). Dotted 
lines indicate less predominant pathways. For simplicity, only one type of each cell subset is shown. 
CD135: FLK2 and Flt3; IL-7R: interleukin-7 receptor; lin: lineage markers; NK: natural killer; 
SCA1: stem cell antigen 1 (Figure adapted from Wang and Wagers, 2011). 
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1.3.2.1 Granulocytes 
In response to granulocyte-macrophage colony-stimulating factor (GM-CSF), CMPs 
differentiate into Lin
-
CD34
+
CD38
+IL3Rα-CD45RA+CD135+ granulocyte-monocyte progenitors 
(GMPs) (mouse GMPs: Lin
-
Sca1
-
Kit
+
CD34
+
CD16/32
+
) (Weissman and Shizuru, 2008; Wang and 
Wagers, 2011; van Galen et al., 2014). The presence of granulocyte colony-stimulating factor (G-
CSF), SCF, IL-3, IL-5 (Ihle, 1992; Okuda et al., 1999; Robb, 2007; Hamilton, 2008), and activation 
of CEBPα (Orkin and Zon, 2008), GMPs proliferate and differentiate into granulocytes of the innate 
immune system, thus called because of their cytoplasmic granules. Basal granulopoiesis in humans 
occurs at a rate of 0.5-1 x 10
11
 cells per day (Dancey et al., 1976), which live on average 5.4 days 
under homeostatic conditions (Pillay et al., 2010). Emergency granulopoiesis is elicited in response 
to pathogen-associated molecular patterns (PAMPs), or injury/stress elicited danger associated 
molecular patterns (DAMPs), which are detected by pattern recognition receptors (PRRs) on 
immune and BM cells (Manz and Boettcher, 2014). There are four principal populations of 
granulocytes, which differentiate according to transcriptional regulation by GATA-1, Gfi-1, and 
CEBPα and CEBPε (Lekstrom-Himes, 2001; Orkin and Zon, 2008). 
Neutrophils are by far the most abundant granulocyte, and identified as the 
polymorphonuclear population that is CD45
+
CD16/32
+
CD11b
+
CD14
lo
CD31
+
CD66
-
CXCR2
l+ 
in 
both mice and humans, as well as CD15
+
CXCR1
+
 in humans (Fujimoto et al., 2000; Murdoch et al., 
2008) and Ly6C
+
Ly6G
+
Ly6b.2
+
VEGFR1
+
 in mice (Hestdal et al., 1991; Daley et al., 2008; 
Murdoch et al., 2008; Rosas et al., 2010). They are highly motile, phagocytic cells that are the first 
to arrive at inflammatory sites in both the periphery and CNS (Segal, 2005; Kigerl et al., 2006; 
Beck et al., 2010; Amulic et al., 2012). In response cytokine cues such as IL-1β, IL-6, IL-8 and 
TNFα, neutrophils adhere to the vascular endothelium by anchoring to selectins (e.g. E-selectin) 
and integrins (e.g. intracellular adhesion molecule (ICAM)-1/CD54). They can extravasate through 
capillary walls by secreting matrix metalloproteinsases (MMPs) and utilising endothelia molecules 
(e.g. platelet endothelial cell adhesion molecule (PECAM)-1/CD31), then rapidly chemotax toward 
the site of inflammation (Wright et al., 2010; Kolaczkowska and Kubes, 2013).  
Neutrophils utilise a broad array of PRRs that scan for PAMPS/DAMPS in the extracellular 
and endosomal compartments (e.g. toll-like receptors (TLRs), C-type lectin receptors (CLRs), and 
receptor for advanced glycation end products (RAGE)), as well as intracellular compartments (e.g. 
nucleotide-binding oligomerisation domain (NOD)-like receptors (NLRs) and absent in melanoma 2 
(AIM2)) (Collison et al., 2002; Hayashi et al., 2003; Frutuoso et al., 2010; Thomas and Schroder, 
2013). Neutrophils also target pathogens and abnormal host material by degranulating and releasing 
antimicrobial molecules such as neutrophil elastase, cathepsin-G, defensins, proteases, lysozyme, 
neutrophil extracellular traps (NETs), and reactive oxygen species (ROS) through myeloperoxidase 
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activity (Brinkmann et al., 2004; Eyles et al., 2006; Nathan, 2006; Bardoel et al., 2014). Surface 
expression of CD16/32 facilitates binding of the Fc region of antibodies, and thereby enhances 
opsonisation, complement activation, and phagocytosis (Hazenbos et al., 1996; Nimmerjahn and 
Ravetch, 2008). Finally, neutrophils also signal other immune cells into action, such inducing 
macrophages to produce TNFα by TLR4 signalling (Ribeiro-Gomes et al., 2007), and recruiting T 
lymphocytes via IL-17 synthesis (Borregaard, 2010; Kolaczkowska and Kubes, 2013).  
The three other granulocyte subsets, eosinophils, basophils, and mast cells, comprise a very 
small percentage of the granulocyte population, but are important for host defence against a myriad 
of unicellular and multicellular pathogens (Schroeder, 2009; Bystrom et al., 2011; Sullivan et al., 
2011; Muniz et al., 2012). 
 
1.3.2.2 Dendritic cells 
Rather than proceeding toward a granulocytic fate, in response to GM-CSF, and 
transcription factors such as C/EBPα and PU.1, bone marrow GMPs can become Lin-
CX3CR1
+
CD117
lo
CD115
+ 
CD135
+
 macrophage-dendritic cell (DC) precursors (MDP) (Dahl et al., 
2003; Wang et al., 2006; Auffray et al., 2009). MDPs give rise to two main cell types. The first is 
the common DC progenitors (CDPs) via Flt3 activation (Onai et al., 2007), which then differentiate 
to become one of the DC lineage subsets through transcriptional control of Irf2, Irf4, Irf8, Notch2, 
Batf3, Id2, and CSF1-R activation (Heinz et al., 2006; Satpathy et al., 2012). These subsets include 
plasmacytoid DCs, or one of at least five CD45
+
CD11c
hi
MHCII
+
 tissue-resident subsets: the 
CDllb
hi
CD4
+CD8α- and CDllbloCD4-CD8α+ populations in lymphoid tissue, and CD11bloCD103+, 
CDllb
hi
CD103
+
 and CD11b
hi
CD103
-
 DCs in non-lymphoid tissues (Naik et al., 2007; Hashimoto et 
al., 2011). These subsets capture and process antigen, take up residence in or migrate to lymphoid 
organs, express costimulatory molecules, and secrete cytokines to initiate adaptive immune 
responses (see section 1.3.3). They also tolerise T cells to host antigens, a crucial step in preventing 
autoimmunity (Banchereau and Steinman, 1998).  
 
1.3.2.3 Monocytes 
The second MDP progeny, monocytes, arise from M-CSF activation of CD115 on MDPs  
(Wiktor-Jedrzejczak and Gordon, 1996; Dai et al., 2002), as well as PU.1 and Irf8 signalling 
(Hromas et al., 1993; Scott et al., 1994; Tamura et al., 2000; Nagamura-Inoue et al., 2001). These 
cells are non-granulocytic with a unilobed nucleus and express CD45, CD115 and CD11b in both 
mice and humans (Gordon and Taylor, 2005; Ziegler-Heitbrock et al., 2010). After exiting the bone 
marrow, they circulate in the blood with a half-life of approximately three days in humans 
(Whitelaw, 1972) and 17 hours in mice (van Furth and Cohn, 1968; van Furth, 1989), before 
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undergoing spontaneous apoptosis (Fahy et al., 1999; Savill and Fadok, 2000) or differentiating into 
tissue-resident DCs or macrophages (see Section 1.3.2.4) (Ebert and Florey, 1939; Gonzalez-Mejia 
and Doseff, 2009; Hashimoto et al., 2011).  The fate of tissue-resident monocyte progeny is largely 
driven by anatomical location. For example, marginal zone macrophages adjacent to the marginal 
sinus of the spleen, through which the circulation passes, are CD45
+
CD11c
hi
MHCII
+ 
CD11b
hi 
CD103
-
, and express many other PRRs and scavenger receptors. This phenotype supports antigen 
sampling and presentation to splenic lymphocyte populations, and clearance of blood-borne 
pathogens (Kraal, 1992; Geijtenbeek et al., 2002; Kang et al., 2003). In comparison, monocyte 
precursors recruited to the bone surface can differentiate into highly phagocytic, multinucleated, 
bone-resorbing osteoclasts upon activation by M-CSF and receptor activator of nuclear factor κB 
ligand (RANKL) (Kurihara et al., 1990; Udagawa et al., 1990; Arai et al., 1999). Mature monocytes 
also take up residence in the subcapsular red pulp of the spleen, ready for rapid deployment in 
response to inflammatory cues (Swirski et al., 2009). Recruited to sites of inflammation by 
cytokines and neutrophils, monocytes constitute the second major wave of immune cell infiltration 
following trauma (Beck et al., 2010; Swirski and Robbins, 2013).  
The specific contribution of recruited monocytes to inflammation is complex due to the 
heterogeneity of monocyte phenotypes and functions. In humans, the classically activated 
monocytes are CD14
++
CD16
-
, and comprise 95% of circulating human monocytes; the alternatively 
activated population is CD14
+
CD16
+ 
(Passlick et al., 1989; Ziegler-Heitbrock, 2007; Gonzalez-
Mejia and Doseff, 2009). The mouse counterpart to the classically activated human monocytes are 
Ly6C
hi
 cells, which comprise approximately 50% of mouse blood monocytes (Geissmann et al., 
2003; Qu et al., 2004; Sunderkotter et al., 2004; Tacke and Randolph, 2006). The Ly6C
lo
 subset in 
mice is very similar to alternatively activated human monocytes (Gordon and Taylor, 2005; Tacke 
and Randolph, 2006; Ziegler-Heitbrock, 2007). These two major mouse subsets also share 
similarities in cell diameter and other phenotypic markers of human monocytes (Geissmann et al., 
2003). Notably, CCR1 and CCR2 are more highly expressed on classically activated monocytes 
from both species, whereas CX3CR1 is more highly expressed on CD14
+
CD16
+
 human monocytes 
and Ly6C
lo
 mouse monocytes (Palframan et al., 2001; Gordon and Taylor, 2005; Tacke et al., 2007; 
Ingersoll et al., 2010a). Studies demonstrate that classically activated monocytes arrive earlier and 
initiate inflammatory activities, whereas alternatively activated monocytes patrol blood vessels, 
stimulate tissue repair, remodelling, and angiogenesis (Arnold et al., 2007; Nahrendorf et al., 2007; 
Zhao et al., 2009; Ley et al., 2011). 
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1.3.2.4 Macrophages 
As indicated in Section 1.3.2.3, monocytes are also the progenitor cells to another major 
immune population, the macrophages. Like their precursors,  blood-borne macrophages  have 
diverse roles in maintenance of tissue homeostasis through clearance of senescent cells and the 
remodelling and repair of damaged tissues after infection or injury (Gordon, 1998). In the presence 
of an inflammatory stimulus, haematogenous monocytes mobilised from the bone marrow (van 
Furth and Cohn, 1968) or spleen (Swirski et al., 2009) polarise to one of two major subsets of 
macrophages. These subsets have distinct phenotypes and functions, thought to be governed by the 
nature of the inflammatory stimulus, timing  of activation, and the cytokine microenvironment 
(reviewed by Martinez et al. (2008); Murdoch et al. (2008); Lawrence and Natoli (2011)). The 
classically activated/M1 macrophages (CD14
+
MHCII
+
CD80/86
+
CD16/32
+
) can be induced in vitro 
by stimulation with IFNγ and lipopolysaccharide (LPS) (Gensel et al., 2009; Durafourt et al., 2012; 
Jaguin et al., 2013; Ying et al., 2013). These early arriving cells exhibit high microbicide activity, 
phagocytosis, and pro-inflammatory cytokine production (i.e. inducible nitric oxide synthase 
(iNOS), TNFα). Comparably, monocyte/macrophage polarisation using IL-4 or IL-13 in culture 
results in an alternatively activated/ M2 macrophage phenotype (CD206
+
Arg-1
+
Lyve-1
+
Fizz1
+
Ym-
1
+
). When the inflammatory stimulus subsides, the production of growth factors such as platelet-
derived growth factor (PDGF), and anti-inflammatory cytokines (e.g. IL-10), is thought to promote 
a switch in dominance of macrophage subsets from M1 to M2; this stage of inflammation is also 
associated with lymphocyte proliferation and collagen synthesis by fibroblasts (Raes et al., 2005; 
Kigerl et al., 2009; Porta et al., 2009; Murray and Wynn, 2011; Jaguin et al., 2013; Shechter et al., 
2013; Ying et al., 2013).  
The expression of CD16/32 by macrophages (and monocyte-derived DCs) supports the 
opsonisation of pathogens by antibodies, pathogen killing, and complement activation via formation 
of immune complexes in the classical pathway (Ricklin et al., 2012; Guilliams et al., 2014). 
Macrophages and DCs also function as professional antigen-presenting cells (APCs), which engulf 
and process foreign material, and present epitopes on MHCII molecules to cells of the adaptive 
immune system. This interaction, in addition to costimulatory molecule signals (e.g. CD80/86, 
CD70 and OX40L) (Sugamura et al., 2004), and cues from cytokines and complement factors C3a 
and C5a (Strainic et al., 2008), equips naïve adaptive immune cells to survive and become effector 
immune cells (see Section 1.3.3.1) (Murphy et al., 2008). In sum, the MDP progeny, which includes 
DCs, monocytes, and macrophages, adopt distinct and more specialised phenotypes, and have active 
immunological roles including: migration to sites of inflammation, phagocytosis, antigen-
presentation, production of cytokines, and stimulation of the adaptive immune system (section 
1.3.3) (Auffray et al., 2009).  
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1.3.2.5 Platelets 
Alternative to the GMP lineage, the upregulation of GATA-1, along with stem cell factor 
(SCF), thrombopoietin (TPO), erythropoietin (EPO), IL-3 and IL-9 signalling, (Donahue et al., 
1990; Fujiki et al., 2002; Orkin and Zon, 2008), CMPs are directed to become megakaryocyte-
erythroid progenitors (MEP), which are Lin
-
CD34
+
CD38
+
IL3Ra
-
CD45RA
-
 in humans and Lin-
Kit
+
Sca1
-
CD34
-
CD16/32
-
 in mice (Weissman and Shizuru, 2008). MEPs subsequently produce 
platelets or erythrocytes. Platelets contribute factor V and acidic phospholipids which are important 
for blood coagulation during haemorrhagic injury (Murphy et al., 2008). Although not immune cells 
themselves, platelets secrete antimicrobial products such as defensins, growth factors and cytokines 
(Mantovani and Garlanda, 2013; Wong et al., 2013), thereby critically facilitating monocyte 
chemotaxis through platelet-monocyte adhesion interactions, such as P-selectin:sialyl-Lewis
x
, 
CXCL4/CCL5:CCR5, and CXCL4, which facilitates CCL2-dependent chemotaxis  (Burger and 
Wagner, 2003; Koenen et al., 2009; Sahin et al., 2010; Kuckleburg et al., 2011). Thrombin and 
fibrinogen synthesis resulting from platelet activation also links the coagulation system to the 
complement system through the extrinsic protease pathway (Huber-Lang et al., 2006; Amara et al., 
2008; Rittirsch et al., 2008a) (see Section 2.2). Erythrocytes are enucleated cells that are important 
for transporting oxygen in hypoperfused tissues after ischaemic attack. In inflamed tissues, they are 
important in scavenging excess ROS (Minetti et al., 2007), and may be involved in production of 
complement component C3 (Hostetter and Johnson, 1989). 
 
1.3.3 The adaptive immune system 
The second major lineage arising from HSC differentiation is the lymphoid lineage, which 
gives rise to cells of the adaptive immune system, namely T lymphocytes, Natural killer (NK) cells, 
and B lymphocytes. These cells form the final wave of leukocytes recruited to sites of 
inflammation. In response to PU.1, GATA-3, Flt3 and IL-7 (Robb, 2007), HSCs differentiate into 
common lymphoid progenitors (CLP), identified as the Lin
-
CD34
+
CD38
+
CD10
+
CD16/32
lo
  
population in humans, and the Lin-Sca1
lo
c-Kit
loIL7Rα+Flt3+ CD34+CD16/32lo population in mice 
(Weissman and Shizuru, 2008). CLPs can take up residence in the thymus, where they give rise to 
naïve CD3
+
 T lymphocytes expressing a T cell receptor (TCR). Interaction between the TCR with 
antigen presented by MHCII on APCs (namely DCs, macrophages, and subsets of B cells and 
epithelial cells), with simultaneous interaction between costimulatory molecules (e.g. T cell CD28 
with APC CD80/86), results in naïve T lymphocytes to become effector T cells (Sugamura et al., 
2004; Murphy et al., 2008). T lymphocytes that recognise and respond to self-antigens are 
eliminated during thymic development.  
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1.3.3.1 T lymphocytes 
T cell subsets include the CD4
+
 helper T cells (TH1, TH2, TH17 subsets), CD8
+
 cytotoxic T 
cells (TC), and Foxp3
+ 
regulatory T (TReg) cells. TH1 cells (T-bet
+
STAT4
+
) are induced by IL-12 and 
IFNγ (Hsieh et al., 1993; Bradley et al., 1996), as well as complement factors C3a and C5a (Sacks, 
2010). TH1 cells secrete IFNγ, TNFα and IL-2 to remove intracellular pathogens and cancer cells 
(Zhu and Paul, 2008). TH2 cells (STAT5
+
GATA-3
+
) are induced by IL-2 and IL-4 (Le Gros et al., 
1990; Cote-Sierra et al., 2004). They synthesise IL-4 and IL-10 to target multicellular extracellular 
parasites and stimulate antibody-mediated immunity (Zhu et al., 2003; Zhu and Paul, 2008). TH17 
cells (STAT3
+RORγt+) are produced as a result of TGFβ, IL-23 and IL-6 signalling (Mangan et al., 
2006; McGeachy et al., 2007). These cells produce IL-17, IL-21 and IL-22 to target extracellular 
bacteria and fungi (Szabo et al., 2000; Park et al., 2005; Tato and O'Shea, 2006).  
TC cells recognise epitopes presented by MHCI molecules and mediate target cell removal 
through production of TNFα, granzyme B, perforin, IFNγ (which promotes Caspase-1 activation), 
and death receptor engagement (Fas-Ligand(CD96L):CD95) (Andersen et al., 2006). The 
complement activation fragment C5a is also important in generating antiviral TC responses (Kim et 
al., 2004). TReg cell production is favoured by IL-2 and TGFβ (Chen et al., 2003; Sakaguchi, 2005). 
This population produces IL-10 (Jankovic et al., 2007) and maintains immunological tolerance to 
self antigens by suppressing overactive immune responses that are deleterious to the host 
(Sakaguchi et al., 2008).  
T cell subsets have the specialised ability to undergo clonal expansion and ultimately persist 
for a lifetime, a process known as immunological memory. Effector T memory (TEmem) cells that 
recall a previously encountered antigen mediate protective memory and produce a stronger and 
faster immune response than the first time. Comparably, central memory T cells (TCmem) have little 
effector function but can mediate reactive memory by homing to secondary lymphoid organs then 
proliferating and differentiating into effector T cells (Sallusto et al., 2004).  
 
1.3.3.2 Natural killer cells 
 Alternative to T cells, CLPs can differentiate into specialised CD3
+
 natural killer (NK) cells 
(Greenberg et al., 1973). Within the bone marrow, immature NK progenitors express inhibitory 
Ly49 receptors that engage autologous MHCI molecules (Fernandez et al., 2005). This ‘licensing’ 
process results in the generation of functional NK cells which express a sophisticated repertoire of 
activating and inhibitory receptors for recognition of host and pathogen-associated markers (Sun, 
2010). Importantly, NK cells do not require prior sensitisation by MHCII or costimulation to have 
cytolytic effects. They are thus constitutively poised to eliminate stressed, virally infected, or 
transformed cells, while minimising damage to healthy cells, in the periphery (Lanier, 2005; Marcus 
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and Raulet, 2013). Given NK cells also have immunological memory, they are often viewed as 
bridging cells between innate and adaptive immunity (Vivier et al., 2011). 
 
1.3.3.3 B lymphocytes 
In response to IL-4, CLPs differentiate into CD19
+
 pre-B cells (Dorshkind and Montecino-
Rodriguez, 2007). Immature B cells must generate a functional B cell receptor (BCR) and overcome 
clonal deletion (resulting from reactivity with autoantigens) to emerge from the bone marrow as 
mature but naïve B cells expressing surface immunoglobulin (Ig) M (IgM) and IgD (Forster and 
Rajewsky, 1990; Hartley et al., 1991). They then migrate to extrafollicular regions of lymphoid 
organs, where they can become activated. The activation process involves BCR recognition of 
antigen, followed by CD40/CD40L interactions with follicular TH cells, proliferation and germinal 
centre formation (Cerutti et al., 2012). B cell maturation in germinal centres involves negative 
selection by T cells, clonal expansion, hypermutation of the variable region of Ig genes and class 
switching to change the  B cell Ig repertoire (MacLennan, 1994). This process ultimately results in 
production of specialised extrafollicular plasma cells, as well as memory B cells (MacLennan, 
1994; Nutt and Tarlinton, 2011; McHeyzer-Williams et al., 2012). Surface markers including 
CD20, CD27, B cell activating factor (BAFF) receptor, CD38 and CD138, identify the stages of 
differentiation from immature B cells to Ig-producing plasma cells (Sims et al., 2005). 
Ig (ie. antibodies) released by plasma cells consist of a fragment antigen binding (F(ab’)2) 
portion, with heavy and light chain regions that recognise and bind a specific epitope (Murphy et 
al., 2008). This portion opsonises membrane-bound and soluble antigen, which promotes antibody-
dependent cell-mediated cytotoxicity (ADCC), immune complex formation, and antigen clearance 
by phagocytes. The fragment crystallisable (Fc) region of Ig contains two heavy chains, which bind 
specific Fc receptors on immune cells, thereby ensuring an appropriate immune response, such as 
degranulation, is produced (Heyman, 1996). The Fc region can also bind other molecules, such as 
complement proteins, which sets into motion the classical complement cascade, further signalling 
recruitment of phagocytic innate immune cells (Casali and Schettino, 1996). In addition to antibody 
production, effector B cells recognise antigen in their native form, making them exceptionally 
potent APCs. B cells therefore significantly boost T cell expansion and systemic T cell responses at 
low antigen concentrations (Rivera et al., 2001). Finally, effector B cells produce high levels of 
TNFα, IL-6, and lymphotoxin. However, B cells activated by CD40 alone produce IL-10 to prevent 
inappropriate autoimmune responses (Duddy et al., 2004; Fillatreau et al., 2008).  
Through these activities, the innate and adaptive immune systems are highly efficient in 
executing tailored responses that neutralise or eliminate general and specific inflammatory stimuli 
and recalling previously encountered antigen whilst avoiding damage to host tissue. 
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1.3.4 Detrimental roles for inflammation in the CNS  
Despite the critical and tightly-regulated roles of the mammalian immune system in host 
protection, the role of inflammation in neurotrauma is more complex (Anderson, 2002; Jones et al., 
2005b; Donnelly and Popovich, 2008). Rather than culminating in tissue repair, persisting 
inflammation after SCI is characterised by a non-resolving, growth-inhibitory microenvironment 
that contributes neuropathology and poor functional prognosis (Popovich and Longbrake, 2008; 
Popovich and McTigue, 2009; Cregg et al., 2014). The following section will focus on the features 
of CNS inflammation thought to contribute to poor injury resolution and associated secondary 
injury. The differences in nature and timing of the inflammatory response in the periphery and CNS 
are summarised in Fig. 1.7. 
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Figure 1.7: Diagram showing the kinetics of classical wound healing in the periphery (top 
panel) and in the context of CNS injury (bottom panel). The x axis represents time post-injury 
and the y axis represents the magnitude of the response. Blue lines represent events unique to the 
CNS. Normally, disruption to homeostasis elicits coagulation, immune cell infiltration and 
proliferation, scar formation, tissue remodelling, matrix reorganisation, and culminates in repair and 
regeneration of tissues (indicated by green). In the injured CNS, the scar persists (indicated by red) 
as a result of ongoing pathological neuroinflammatory processes (bold lines). BBB: blood-brain 
barrier; CNS: central nervous system; CSPG: chondroitin sulfate proteoglycan; MQ: macrophages 
(Figure adapted from Shechter and Schwartz, 2013).  
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Compared to peripheral tissues, neurons and membranes of the CNS are particularly 
vulnerable to damage by non-cellular immune mediators. Eicosanoids (Mitsuhashi et al., 1994; 
Hains et al., 2001) and cytokines (Pineau and Lacroix, 2007; Rice et al., 2007; Pineau and Lacroix, 
2009) are expressed in the injured spinal cord within minutes of trauma by resident glia (Pineau and 
Lacroix, 2007). Among these products, IL-1β is neurotoxic (Allan et al., 2005; Wang et al., 2005; 
Ye et al., 2013) and disrupts vascular stability (Zhu et al., 2012). TNFα also augments neuron and 
oligodendrocyte apoptosis and demyelination (Chen et al., 2011; Ye et al., 2013). TGFβ potentiates 
fibrosis (Logan et al., 1994; Logan et al., 1999) and axonal damage (Kohta et al., 2009), whilst IL-6 
is implicated in excitotoxicity (Spooren et al., 2011) and positive feedback to increase levels of IL-
1β and TNFα (Romano et al., 1997). Reactive oxygen species (ROS) are also rapidly generated by 
reperfusion of ischaemic or hypoperfused tissue, and by resident and infiltrating immune cells (Liu 
et al., 1998; Liu et al., 2000; Bao and Liu, 2004). The CNS is particularly vulnerable to oxidative 
damage, as it is rich in polysaturated fatty acid chains and expresses limited antioxidant defence 
mechanisms, including low catalase, superoxide dismutase and glutathione peroxidase activity 
(Lewen et al., 2000; Vaziri et al., 2004). Copious levels of ROS are associated with impaired 
mitochondrial activity within one hour of SCI (Azbill et al., 1997), and the resulting irreversible 
damage to lipids, proteins and nucleic acids that leads to cell death (Thery et al., 1991; Lifshitz et 
al., 2004; Xu et al., 2005; Xiong et al., 2007). 
These mediators activate resident CNS cells in SCI (Laping et al., 1994; Bruce et al., 1996; 
Basu et al., 2002; Okada et al., 2004), highlighting another key difference between the 
inflammatory response in the CNS and periphery: the involvement of specialised CNS glia. 
Microglia are the immunosurveillance cells of the brain and spinal cord, and among the first cells to 
respond to changes in CNS homeostasis (see Section 1.1.3), including contusive SCI (Popovich et 
al., 1997; Sroga et al., 2003; Farrar et al., 2012). After activation by cytokines, microglia in turn 
produce IL-1β (Yang et al., 2004; Pineau and Lacroix, 2007), TNFα (Yang et al., 2005; Low et al., 
2014), and ROS (Kaushal et al., 2007; Kaushal and Schlichter, 2008), which has been associated 
with exacerbated neuronal death (Beattie et al., 2000; Low et al., 2014). Microglia activated by 
inflammatory stimuli promote axon retraction in vitro (Horn et al., 2008; Kigerl et al., 2009), and 
secrete axon growth-inhibiting molecules such as repulsive guidance molecule A (RGMA), which 
has been associated with axonal dieback after in vivo contusive SCI (Kitayama et al., 2011). 
Furthermore, unlike injury to peripheral, non-neural tissues, Wallerian degeneration and myelin 
debris persist chronically (Vargas and Barres, 2007), likely contributing to failure of axonal 
regeneration due to the presence of myelin-associated growth-inhibitory molecules (e.g. NogoA) 
(Filbin, 2003; Schwab, 2004), and impaired remyelination (Kotter et al., 2005; Kotter et al., 2006). 
Evidence suggests that insufficient microglial phagocytosis of myelin debris, partly as a result of 
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aberrant cytokine activation (Bruck et al., 1992), potentiates a poor regenerative response in SCI 
(Neumann et al., 2009). 
Similar to microglia, resident CNS astrocytes also play key roles in the neuroinflammatory 
response to SCI. Reactive astrogliosis is initiated in response to inflammatory signals such as IL-1, 
IL-6, TGFβ TNFα, IFNγ, ROS and PRR ligands (Giulian et al., 1988; Yong et al., 1991; Asher et 
al., 2000; Pineau and Lacroix, 2007; Schachtrup et al., 2010; Sofroniew and Vinters, 2010; Heneka 
et al., 2014). These signals increase expression of structural filament molecules including glial 
fibrillary acidic protein (GFAP) (Bignami and Dahl, 1974; Barrett et al., 1981), nestin and vimentin 
(Yang et al., 1994), promote astrocyte hypertrophy, proliferation (Faulkner et al., 2004; Erturk et 
al., 2012), and migration toward the inflammatory stimulus (Silver and Miller, 2004; Cregg et al., 
2014). Here, astrocytes form a glial border which sequesters necrotic pathology from intact 
neuronal tissue. Complete elimination of this process through astrocyte ablation results in diffuse 
inflammatory pathology and further impaired functional recovery (Bush et al., 1999; Faulkner et al., 
2004; Myer et al., 2006; Okada et al., 2006). Outside these neuroprotective properties, once formed, 
the persisting glial scar is also regarded as a physical barrier to normal tissue remodelling (Silver 
and Miller, 2004; Wanner et al., 2008; Cregg et al., 2014). Reactive astrocytes also chemically 
hamper axonal regeneration through the continued deposition of growth-inhibiting molecules, 
particularly the chondroitin sulfate proteoglycans (CSPG) neurocan, brevican, phosphacan, and 
versican (McKeon et al., 1999; Jones et al., 2003; Tang et al., 2003). These molecules further 
augment the production of pro-inflammatory cytokines, thus perpetuating the cycle of secondary 
injury. In line with this, suppression (rather than elimination) of astrocyte reactivity through 
blockade of NFκB (Brambilla et al., 2005) or IL-6 signalling (Okada et al., 2004), is associated with 
improved functional recovery. 
Another major difference between peripheral and CNS inflammation is immune cell access; 
the spinal cord is normally anatomically separated from the blood and circulating immune cells by 
the BSB. Trauma-induced BSB breakdown leads to prominent haemorrhage into the meningeal 
spaces and parenchyma, with the BSB remaining abnormally permeable for at least 3-4 weeks post-
SCI (Popovich et al., 1996b; Whetstone et al., 2003). Tissue injury and BSB disruption lead to 
infiltration of granulocytes within the first hour of SCI; these cells peak in number at approximately 
24 hours post-injury (Dusart and Schwab, 1994; Carlson et al., 1998; Beck et al., 2010). 
Granulocytes are thought to further compromise vasculature through excessive secretion of 
proteases such as MMP9 (Mautes et al., 2000; Noble et al., 2002) and neutrophil elastase (Tonai et 
al., 2001). Although categorically determining the role of neutrophils in SCI has been somewhat 
hindered by a lack of highly specific depletion strategies (Plemel et al., 2014), the majority of 
studies which have used pharmacological techniques designed to deplete neutrophil populations or 
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suppress their infiltration, mostly report improved functional and/or histopatholocial outcomes 
(Table 1.2).  
Monocytes are the next haematogenous immune cells to enter the injured spinal cord 
(Stirling and Yong, 2008; Pineau et al., 2010). The pro-inflammatory (Ly6C
hi
CX3CR1
lo
) population 
is preferentially recruited at 7 days post-injury (Blomster et al., 2013a), and reducing the infiltration 
of these cells via splenectomy was associated with improved recovery. Once recruited, blood 
monocytes also differentiate and integrate into the pool of activated macrophages at the site of SCI 
(Donnelly et al., 2011; Blomster et al., 2013a). 
In peripheral inflammation, monocyte/macrophage subsets precisely coordinate the timing 
of their infiltration, with each other and other immune cells, to promote wound resolution (see 
section 1.3.2). However, after their recruitment, activated macrophages chronically persist in spared 
white matter and as a central scar of lipid-filled phagocytes (Popovich and Jones, 2003; Profyris et 
al., 2004), which is a hallmark non-resolving inflammation in both human (Fleming et al., 2006) 
and rodent SCI (Kigerl et al., 2006; Beck et al., 2010). Despite the challenges in delineating blood-
derived from microglial-derived macrophages, a wealth of literature has reported adverse roles for 
activated macrophages in secondary SCI pathology. Specifically, they have been shown to promote 
axonal retraction and dieback (Horn et al., 2008; Busch et al., 2009), production of pro-
inflammatory cytokines (including TNFα, IL-1α, and IL-1β) that promote excitotoxicity (Takahashi 
et al., 2003) and demyelination through myelin phagocytosis (Shamash et al., 2002), 
oligodendrocyte apoptosis (Shuman et al., 1997), and production of large molecular weight 
inhibitors of neurite outgrowth, such as including chondroitin sulfate proteoglycans (CSPGs) (Zuo 
et al., 1998; Jones et al., 2002a; Martinez et al., 2006) Furthermore, there is an aberrant 
preponderance of M1-polarised, classically activated macrophages which are neurotoxic (Kigerl et 
al., 2009; Hu et al., 2012), and are thought to contribute to the self-perpetuating cycle of 
inflammatory events (David and Kroner, 2011). In line with this, neurological improvements from 
SCI have been repeatedly observed when macrophages are eliminated or their functions are 
suppressed (Table 1.2). 
Adaptive immune lymphocytes are the final subsets of blood-derived cells to infiltrate the 
injured spinal cord. Although tight regulatory mechanisms eliminate autoreactive lymphocytes at 
every stage of immunological development, evidence indicates that trauma triggers an endogenous 
repertoire of autoreactive lymphocytes that persist chronically in the injured parenchyma (Popovich 
et al., 1996a; Jones et al., 2002b; Popovich and Jones, 2003; Ankeny et al., 2006; Beck et al., 2010; 
Vaughn et al., 2013). T lymphocytes that are autoreactive to MBP have been shown to exacerbate 
axonal injury, demyelination, and functional deficits in rat (Jones et al., 2004) and mouse SCI 
(Jones et al., 2002b). T cells isolated from spinal injured rats elicit neurological deficits and 
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histopathological changes reminiscent of experimental autoimmune encephalomyelitis (EAE) 
pathology when transferred into naive animals (Popovich et al., 1996a). Mechanisms thought to 
contribute to these detrimental effects include: direct neuron apoptosis via engagement of with 
FasL, LFA-1, and CD40 (Giuliani et al., 2003; Aktas et al., 2005), producing high levels of 
neuronal Ca
2+
 influx (Nitsch et al., 2004), blocking action potential propagation (Yarom et al., 
1983), and oligodendrocyte lysis (Antel et al., 1994). Autoreactive T cells are also associated with 
pro-inflammatory cytokine synthesis (including IFNγ, TNFα, IL-1β, IL-12), and thus M1 
macrophage polarisation (Gimsa et al., 2000; Jones et al., 2002b; Jones et al., 2004). Lastly, B cells 
potentiate immunopathology by enhancing T cell functions (Lund and Randall, 2010), generating 
pathogenic autoantibodies, and fixing classical complement components (Ankeny et al., 2006; 
Ankeny et al., 2009; Ankeny and Popovich, 2010). 
Collectively, for reasons not fully understood, infiltrating humoral and cellular immunity 
elicits chronic, non-resolving inflammation that impedes tissue repair and worsens functional 
recovery from SCI. Whether these deleterious aspects can be manipulated to reduce secondary 
injury and/or promote wound healing more reminiscent of peripheral inflammation, is the main 
focus of SCI research on neuroinflammation, and of this thesis. 
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Table 1.2. Summary of experimental SCI studies which aimed to improve injury 
outcomes by manipulating the cellular inflammatory response 
Target cell/s 
(overall role) 
 
Intervention strategy 
 
SCI Model 
 
Outcome 
 
Comments 
 
Reference 
Neutrophils 
(injurious) 
Blockade of neutrophil 
infiltration via administration 
of a monoclonal antibody 
(mAb) to intracellular adhesion 
molecule-1 (ICAM-1) (1 mg/kg 
i.v.) administration 30 minutes 
after SCI. 
T11-T12 compression 
SCI (25 g or 30 g 
weight placed 
extradurally for 5 or 15 
mins) in Wistar rats. 
Improved: Improved 
motor recovery (Tarlov’s 
scoring, inclined plane 
test, footprint analysis 
metrics), reduced MPO 
presence, cord oedema 
and spinal blood flow. 
ICAM-1 expressed by 
endothelia binds integrins of 
the type CD11a/CD18 or 
CD11b/CD18, which are 
expressed by other leukocyte 
populations (Rothlein et al., 
1986). Hence, the results are 
unlikely due to suppressed 
infiltration of neutrophils alone. 
 
Hamada 
et al. 
(1996) 
Neutrophils 
(injurious) 
1) Depletion of neutrophils 
using nitrogen mustard (1.75 
mg/kg i.v.) 48 hours prior to 
SCI. 
 
2) Reduce neutrophil-
endothelial cell interaction and 
thus migration into the injured 
spinal cord using anti-P-
selectin mAb (1.5 mg/kg, i.v.) 
prior to compression injury.  
 
T12 laminectomy and 
compression SCI (20 g 
weight placed 
extradurally for 20 
mins) in Wistar rats. 
Improved: Increased 
motor recovery (Tarlov’s 
scoring, inclined plane test 
and climbing ability), 
reduced MPO activity and 
haemorrhage in both 
treatment groups. 
It would be of interest to 
establish the precise 
mechanism of action of these 
treatments, and their 
effectiveness when 
administered post-injury. 
Taoka et 
al. (1997) 
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Neutrophils 
(injurious) 
1) Administration of BIO5192, 
a blocker of the α4β1 integrin 
(10 mg/kg i.v.) at 2, 12, 24 and 
48 hours after SCI. This group 
was used to assess leukocyte 
infiltration and oxidative 
damage. 
 
2) Administration of BIO5192 
(10 mg/kg. i.v.) 2 hours post-
injury and implantation of a 
cannula (8 hours post-injury) 
into the subaxillary space, 
connected to an osmotic 
minipump delivering 8 µl/h of 
BIO5192 for 24 hours and 
injection of BIO5192 at 48 h 
and 60 h after SCI (10 mg/kg 
i.v.). This group was used to 
assess mechanical allodynia 
and motor recovery. 
 
T4 laminectomy and 60 
second clip 
compression (35 g clip) 
in Wistar rats. 
Improved: Decreased 
myeloperoxidase staining, 
indicating less granulocyte 
activity, and reduced EP-1 
(marker of recruited 
monocytes, macrophages, 
and microglia) at the 
lesion site 24 and 72 hours 
after SCI, reduced 
oxidative enzymes 
(gp91
phox
, COX-2, iNOS), 
free radical formation, 
lipid peroxidation, 
mechanical allodynia, 
demyelination, and 
improved motor recovery 
(BBB scoring) from 28 
days until 42 days post-
injury. 
BIO5192 is a selective inhibitor 
of both inactivated and 
activated forms of the human, 
mouse and rat α4β1 integrin and 
has a slow dissociation rate, 
with substantial binding 
remaining in the absence of 
circulating plasma levels of the 
compound (Leone et al., 2003).  
 
BIO5192 can also bind 
fibronectin and potentially also 
reduce fibronectin-mediated 
leukocyte migration (Lobb and 
Hemler, 1994). 
Bao et al. 
(2008) 
Neutrophils 
(beneficial) 
Deplete early-arriving 
neutrophils with anti-Gr-1 
antibody (4 mg/kg i.p.) 
administered 2 and 24 hours 
after SCI. 
Moderate (60 kdyne) 
T9/10 contusion SCI 
(IH impactor) in 6-8 
week old CD-1 and 
lysozyme-eGFP 
C57BL6/J mice. 
Worsened: Reduced 
motor recovery (BMS 
scoring), astrocyte 
reactivity, spared white 
matter and axonal 
preservation. 
The anti-Gr-1 antibody used is 
this study does not only 
recognise neutrophils, as it can 
also bind Ly6C, expressed on 
dendritic cells and Gr-1
+
 
monocyte subsets (Daley et al., 
2008). 
 
Stirling et 
al. (2009) 
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Neutrophils, 
Monocytes 
(injurious 
when 
combined) 
1) Neutrophil depletion group: 
administration of anti-Ly6G 
mAb (RB6-8C5 clone) (100 μg 
i.p.) at 1 day before injury 
(neutrophil depletion group). 
 
2) Monocyte depletion group: 
liposome-encapsulated 
clodronate (100 μl i.v.) at 1, 3 
and 6 days post-injury. 
 
3) Double depletion group: 
combination of above 
treatments. 
T9 laminectomy and 
moderate contusion 
injury (2 g weight 
dropped from 5 cm) in  
C57BL/6 mice.  
1) Slightly improved. 
Decreased BSB disruption 
(MMP-9 measurements), 
but no difference in other 
parameters. 
 
2) Slightly improved. 
Decreased oxidative stress 
markers but no difference 
in other parameters. 
 
3) Improved: increased 
functional recovery (BMS 
scoring, rotarod), myelin 
sparing, decreased   
oxidative stress markers, 
and increased BSB 
integrity (MMP-9, Evans 
blue immunoreactivity) 
compared to control mice. 
The anti-Ly6G mAb clone 
RB6-8C5 also recognises 
Ly6C, which is expressed on 
dendritic cells and 
inflammatory monocytes, and 
can be induced on macrophages 
stimulated with IL-3 and GM-
CSF. Thus, the neutrophil-
depletion group may have also 
depleted other cell types. 
 
Global depletion of monocytes 
likely also depleted the tissue-
reparative M2 macrophage 
subset, thereby resulting in the 
monocyte depletion group 
having no difference compared 
to control mice.  
Lee et al. 
(2011) 
Neutrophils, 
macrophages 
(injurious) 
Reduce neutrophil infiltration 
and delay entry of 
haematogenous monocyte-
derived macrophages with anti-
CD11d mAb (1 mg/kg i.v.) 
administered 2, 24 and 48 
hours after SCI. 
1) T4 clip compression 
injury (8.3 g clip 
sustained for 60 
seconds) in Wistar rats 
(mechanical allodynia 
group). 
 
2) T12 clip 
compression injury (35 
g clip) in Wistar rats 
(autonomic dysreflexia 
group). 
Improved: Increased 
motor recovery (BBB 
testing), reduced 
mechanical allodynia and 
autonomic dysreflexia, 
increased myelin and axon 
sparing. 
Anti-CD11d mAb selectively 
blocks the CD11d/CD18 
integrin, critical for leukocyte 
adhesion to endothelial cells 
and extravasation, though 
dissociates relatively quickly. 
Gris et al. 
(2004) 
Chapter 1: General introduction                         38 
Neutrophils, 
monocytes, 
macrophages 
(injurious) 
Reduce neutrophil and 
monocyte/macrophage 
infiltration by administering 
anti-α4 mAb (clone TA-2) (2.5 
mg/kg, i.v.), at 2 hours after 
SCI, or at 2 and 24 hours after 
SCI. 
T4 laminectomy and 60 
second clip 
compression (35 g clip) 
in Wistar rats. 
Improved: More motor 
recovery and reduced 
mechanical allodynia, 
demyelination, 
serotonergic axon 
degeneration and 
oxidative damage. 
The anti-α4 mAb binds 
endothelial VCAM-1 (Alon et 
al., 1995) and fibronectin 
(Lobb and Hemler, 1994), 
thereby reducing intraspinal 
migration of inflammatory cells 
without cell depletion.  
 
Fleming 
et al. 
(2008) 
Neutrophils, 
macrophages 
(injurious) 
Reduce neutrophil and 
macrophage infiltration using 
CD11d mAb (clone 205C) (1 
mg/kg i.v.) at 2, 24 and 48 
hours after injury.  
T4 clip compression 
injury (8.3 g clip 
sustained for 60 
seconds) in C57BL/6 
mice. 
Improved: Increased 
locomotor recovery (BMS 
scoring), myelin sparing, 
serotonergic input and 
axon growth, reduced 
collagenous scar 
formation, and reduced 
markers of oxidative 
damage (MPO activity, 
malondialedhyde 
presence, and 
Dichlorofluorescin 
diacetate oxidation) 
compared to control mice.  
 
The high level injury may have 
prevented infiltration of 
leukocytes derived from the 
splenic monocyte reservoir as 
well as the bone marrow 
reservoir. It would be of 
interest to examine the effects 
of this treatment in lower 
thoracic level injuries. 
Geremia 
et al. 
(2012) 
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Monocytes 
(injurious) 
Genetic ablation of the 
fractalkine receptor, CX3CR1, 
on microglia and monocyte 
derived macrophages, or on 
monocyte-derived macrophages 
alone via bone marrow 
chimeras. 
T9-10 laminectomy and 
moderate (0.5 mm over 
30 ms) contusion injury 
using the Ohio State 
University 
electromechanical 
device in C57BL/6 
mice (or Cx3cr1
gfp/gfp
 
mice). 
 
2) Moderate (75 kdyne) 
contusion SCI using the 
IH impactor (75 kdyne) 
in C57BL/6 mice (or 
Cx3cr1
gfp/gfp
 mice). 
Improved: higher BMS 
scores and reduced white 
matter loss in Cx3cr1
gfp/gfp
 
mice and in 
[Cx3cr1
gfp/gfp→WT] bone 
marrow chimeras, 
compared to their control 
groups. 
Deficiency of CX3CR1 was 
associated with predominance 
of CCR2
+
Ly6C
hi 
MHCII
-
CD11c
+
 macrophages, whereas 
in WT mice, the Ly6C
lo 
iNOS
+
MHCII
+
CD11c
-
 
macrophages dominated the 
monocyte-derived macrophage 
population. The skewing of 
monocytes towards an anti-
inflammatory Ly6C
hi
 
phenotype was the mechanism 
for the improvements. 
Donnelly 
et al. 
(2011) 
Monocytes 
(injurious) 
2) Genetic ablation of the 
fractalkine receptor, CX3CR1, 
on microglia and monocyte 
derived macrophages, or on 
monocyte-derived macrophages 
only via bone marrow 
chimeras.  
 
2) Splenectomy to deplete 
monocytes and their progeny. 
T9 laminectomy and 
moderate (70 kdyne) 
contusion injury using 
the IH impactor in 
C57BL/6 mice (or 
Cx3cr1
gfp/gfp
 mice). 
1) Worsened: 
[Cx3cr1
gfp/gfp→ WT] bone 
marrow chimeras 
performed worse than 
[WT→WT] chimeras.  
 
2) Improved: Removal of 
monocytes via 
splenectomy improved 
functional recovery and 
myelin preservation 
1) Genetic ablation of CX3CR1 
was associated with increased 
presence of monocyte-derived 
macrophages.  
 
2) Removal of the main 
monocyte reservoir, the spleen, 
impaired monocyte infiltration.  
Adoptive transfer experiments 
showed that the Ly6C
hi
 pro-
inflammatory monocytes are 
preferentially recruited in the 
subacute phase of SCI, leading 
to worsened outcomes. 
 
Blomster 
et al. 
(2013a) 
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Macrophages 
(injurious) 
Macrophage depletion by 
administration of silica toxin 
(0.4 g/ml i.p.) administered 24-
48 hours before injury, or 
immediately after injury. 
T13 dorsal 
laminectomy and 
moderate (15 second) 
compression injury in 
Hartley guinea pigs. 
Improved: Improved 
functional outcome 
(cutaneous trunci muscle 
reflex, hindlimb toe-
spread response), 
increased number of 
myelinated axons, and 
decreased 
hypervascularity. 
The precise effect of silica on 
circulating leukocytes is not 
clearly defined. It is possible 
that it may have depleted 
polymorphonuclear 
phagocytes, as well as 
monocytes and macrophages. 
Blight 
(1994) 
Macrophages 
(injurious) 
Macrophage depletion by 
administration of clodronate 
liposomes injected 1, 3 and 6 
days post-injury (2.0 ml i.v.) . 
Partial laminectomy of 
T8 and moderate (0.9 
mm displacement) 
contusion SCI using the 
Ohio State spinal 
contusion injury device 
in Lewis rats. 
Improved: Reduced 
macrophage infiltration 
and cavitation, increased 
hindlimb motor recovery 
(BBB scoring), myelin 
sparing, and preservation 
of axons.  
Liposome-encapsulated 
clodronate induces selective 
apoptosis of monocytes and 
macrophages, without directly 
affecting other peripheral cells. 
Liposomes are normally unable 
to cross the BBB (van Rooijen 
and Sanders, 1994). 
Popovich 
et al. 
(1999) 
Macrophages 
(beneficial) 
1) Selective ablation of 
infiltrating CD11c
+
 monocyte-
derived macrophages using 
antibody-mediated depletion 
(MC-21, which blocks CCR2) 
injected i.p. immediately after 
SCI, and again at 1, 2, 4 and 6 
days post-SCI) 
 
2) Conditional macrophage 
ablation by diphtheria toxin 
injection (8 ng/g i.p.) 
repeatedly at 1 day intervals 
starting immediately after SCI 
in CD11c-DTR mice. 
T12 laminectomy and 
very severe (200 kdyne) 
contusion SCI using IH 
impactor device in 8-10 
week old mice. 
Worsened: Reduced 
functional recovery (BMS 
scoring) in monocyte 
derived macrophage-
depleted mice, more 
demyelination and larger 
lesion area compared to 
non-depleted mice.  
A more severe injury force than 
typically is typically reported 
was used in this study.  
 
Replenishing naïve monocytes 
by adoptive transfer or CNS-
specific vaccination increased 
the number of spontaneously 
recruited cells and improved 
recovery.  
 
The role of MDMs to 
spontaneous recovery was 
dependent on expression of 
arginase-I and IL-10. 
Shechter 
et al. 
(2009) 
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Macrophages 
(injurious) 
Macrophage depletion by 
administration of clodronate-
encapsulated liposomes (0.25 
mg/ml i.p.) injected 
immediately after SCI and 
again at 1, 3 and 6 days post-
injury. 
 
T9 laminectomy and 
moderate (10 g weight 
dropped 12.5 mm) 
contusion SCI at T8 
using the NYU 
impactor device in adult 
female Sprague-Dawley 
rats. 
Improved: Improved 
functional recovery (BBB 
scoring and subscoring), 
reduced lesion volume, 
increased grey and white 
matter tissue sparing, 
increased axonal sparing/ 
sprouting. 
Combining clodronate 
liposome treatment with 
rolipram, a phosphodiesterase 
inhibitor to promote axonal 
regeneration, resulted in even 
more marked effects than that 
observed with liposomes alone. 
 
Iannotti et 
al. (2011) 
Macrophages 
(beneficial) 
Inhibition of anti-inflammatory 
M2 monocyte-derived 
macrophage recruitment by:  
 
1) Blockade of VLA-4-VCAM-
1 interactions with anti-VLA-4 
or anti-VCAM-1 antibodies) 
 
2) Removing CD73 activity 
using α,β-methylene ADP or 
CD73
-/-
 mice. 
 
3) Injection of CD115
+
 
monocytes isolated from the 
bone marrow (>80% Ly6C
hi
). 
 
 
T9 laminectomy and 
moderate contusion 
injury (1.3 mm tip, 2 
mm height, 2 mm/s) 
using the IH device in 
mice.  
1) Worsened: lower BMS 
scores compared to control 
antibody-injected mice. 
 
2) Improved: Addition of 
monocytes by adoptive 
transfer increased 
functional recovery and 
decreased lesion size. 
VCAM-1-VLA-4 interactions 
and CD73 were determined to 
be important trafficking signals 
for M2 macrophages. Blockade 
of these signals or obstruction 
of CSF flow prevented 
alternatively activated 
monocyte recruitment and 
worsened functional recovery. 
An anti-inflammatory 
supporting microenvironment 
(including IL-10, IL-13, TGFβ-
2) was proposed to be a key 
mechanism for educating these 
cells before they infiltrated the 
injury site.  
 
Shechter 
et al. 
(2013) 
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T cells 
(injurious) 
Comparison of MBP-TCR 
transgenic mice in which >95% 
of T cells are autoreactive to 
MBP, with non-transgenic 
mice. 
T9-T10 laminectomy 
and severe (0.8 mm 
displacement) 
contusion SCI using the 
Ohio State University 
electromechanical 
device in mice.  
Worsened: Mice with 
autoreactive T cells had 
significantly impaired 
functional recovery (BMS 
scoring), white matter 
presence, and larger lesion 
expansion.  
Autoreactive T cells 
colocalised with regions of 
demyelination and axonal loss 
throughout the white matter in 
transgenic mice, but this was 
restricted to the dorsal columns 
in non-transgenic mice. 
Transgenic mice also had 
increased intraspinal pro-
inflammatory cytokine mRNA.  
Jones et 
al. 
(2002b) 
T cells 
(injurious) 
1) Passive immunisation: 
injection of MBP-reactive T 
cells (TMBP) (10
7
) or PBS at 1 
hour after injury (1 ml, i.p.) 
 
2) Active immunisation: 
injection at the tail base with 
either: 
- MBP (100 µg) + incomplete 
Freund’s adjuvant (IFA) 
- MBP + complete Freund’s 
adjuvant (CFA, containing 0.5 
mg/ml M. tuberculosis) 
- PBS + IFA 
- PBS + CFA 
 
 
T8 laminectomy and 
either: 
 
1) Moderate (1.1 mm 
displacement) 
contusion SCI using the 
OSU electromechanical 
device 
 
2) Severe (1.3 mm 
displacement) 
contusion SCI using the 
OSCU 
electromechanical 
device  
 
3) Complete transection 
using irridectomy 
scissors together with 
gentle aspiration. 
 
1) Worsened: Passive 
immunisation with TMBP 
worsened injury recovery 
after severe contusion SCI 
(but not moderate 
contusion or complete 
transection) based on BBB 
scoring and the inclined 
plane test. Passive 
immunisation also reduced 
the retrograde labelling of 
rubrospinal neurons. 
  
2) Worsened: Active 
immunisation with MBP 
delayed spontaneous 
recovery and exacerbated 
myelin loss and intraspinal 
inflammation beyond the 
site of injury (T cells and 
ED1
+
 macrophages).  
Functional recovery was 
enhanced in the chronic period 
by the presence of 
immunological adjuvants (PBS 
+ IFA/PBS + CFA). PBS + 
CFA animals also displayed an 
increase in the number of 
activated T cells and 
macrophage/microglia 
activation, suggesting that an 
undefined constituent of CFA 
caused activation of 
endogenous T cells, but does 
not adversely affect lesion size 
or functional recovery.  
Jones et 
al. (2004) 
B cells 
(injurious) 
Comparison WT mice to mice 
with IGH-6 mice, which do not 
express functional B cells.  
T9-10 laminectomy and 
T9 moderate-severe 
(0.5 mm, 25 ms) 
Improved: Mice deficient 
in functional B cells 
incapable of antibody 
Injection of 1 µl of purified B 
cell IgG and IgM antibodies 
from spinal injured into naive 
Ankeny et 
al. (2009) 
Chapter 1: General introduction                         43 
contusive SCI using the 
Ohio State University 
electromechanical 
device in mice. 
production had improved 
functional recovery (BMS 
scoring), reduced lesion 
volumes, and more grey 
matter and greater white 
matter sparing compared 
to WT mice.  
mice 0.9 mm into the ventral 
horn resulted in hindlimb 
paralysis and neuropathology. 
These effects were shown to be 
mediated via complement (C1q 
and C3) and FcγR-dependent 
mechanisms. Thus, B cells, via 
autoantibody production and 
complement activation, 
promote secondary SCI 
pathology. 
 
B and T cells 
(injurious) 
Comparison of WT mice with 
Rag2
-/-
 mice, which lack 
functional B and T cells. 
Laminectomy at T7-T9 
and compression SCI 
induced by time-
controlled (1 second) 
current flow through an 
electromagnetic device. 
Improved: Rag2
-/-
 mice 
showed improved 
functional recovery (BMS 
scoring and stepping 
angle) and less tissue 
pathology (increased 
neurofilament staining, 
myelination, number of 
cholinergic terminals 
present, and number of 
S100β/GFAP+ astrocytes, 
and reduced number of 
microglia). 
Results suggest that 
lymphocytes have an overall 
negative role in locomotor 
recovery, possibly via 
modulating microglia/ 
macrophage activation and 
demyelination. 
Wu et al. 
(2012) 
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1.3.5 Rodent models for investigating SCI 
Researchers have developed a number of animal models of human SCI in order to study the 
mechanisms of secondary injury. Rodents have been by far the most commonly utilised species in 
SCI research due to their small size, abbreviated life span, reproductive affluence, ease of 
procurement, handling, housing, and the availability of genetically engineered strains to study 
specific pathways or proteins (Kwon et al., 2002). There are three main models of mechanically-
induced spinal trauma used in rodents: transection, compression, and contusion.  
Transection SCI involves opening the dura and cutting all or part of the spinal cord with a 
scalpel or microscissors. Transection injuries disconnect specific ascending and/or descending 
axonal pathways at designated spinal levels, allowing the comparison of responses in the ipsilateral 
and contralateral spinal cord (Neumann and Woolf, 1999). This technique has led to the 
identification of molecules that inhibit, guide or promote growth of axons (Bradbury et al., 2002; 
Jones and Tuszynski, 2002; Kim et al., 2004), and enabled clear demonstrations of anatomical 
regeneration (Ruitenberg et al., 2003; Ruitenberg et al., 2005; Lu et al., 2012; Yao et al., 2013). 
Transection SCI, however, produces very severe damage to vascular, neural and glial networks, 
with consequent differences in the invasion of peripheral and meningeal cells. It is also rarely 
presented clinically. Thus, while useful for the study of axonal regeneration, this model is not ideal 
for studying the inflammatory dynamics which occur in human SCI (Hausmann, 2003). 
The most common mechanisms of human SCI are compression and contusion injuries. 
Hence, models of these types of injury are most clinically relevant (see section 1.2.2). Compression 
injuries can be produced in rodents by applying a weight or pressure on the spinal cord to produce 
ischaemia-associated tissue damage but with sparing of axons. More specifically, compression can 
be effected by applying aneurysm clips dorsoventrally or laterally for a pre-established period of 
time before decompression (Rivlin and Tator, 1978; von Euler et al., 1997; Poon et al., 2007). The 
main drawback of the clip compression method is the need to perform a complete laminectomy, 
including removal of the pedicles to permit extradural passage of the clip, without displacing the 
spinal cord (Khan and Griebel, 1983). Forceps crush injury has also been used to generate more 
severe compression with significant fibrosis (Blight, 1991a; Plemel et al., 2008), but can be 
restricted to certain anatomical regions (Evans et al., 2014). The use of an extradural balloon has 
also been utilised to produce compression. Initially developed in larger mammals (Tarlov et al., 
1953; Martin and Bloedel, 1973; Hansebout et al., 1975), this method involves inserting a balloon 
catheter into the epidural space through the lumbosacral junction, and inflating the balloon with a 
known quantity of gas at the desired spinal location. This technique is thought to simulate 
secondary injury in human SCI, particularly vascular pathology (Khan and Griebel, 1983; Chung et 
al., 2013; Leonard et al., 2013). Though now adapted for use in rats (Khan and Griebel, 1983; 
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Vanicky et al., 2001; Batchelor et al., 2010; Chung et al., 2013), balloon compression is not feasible 
in mice because of their smaller anatomy. Spinal cord compression has also been used in 
conjunction with contusion SCI, though there is a high incidence of infection and mortality 
associated with the severity of this type of injury (Batchelor et al., 2010). 
The third model of traumatic SCI is contusion; bruising of the spinal cord that imparts 
haemorrhage and tissue damage closely resembling that of vertebral fracture and/or dislocation. The 
earliest contusion injuries were produced by dropping a weight onto the exposed cord, with 
variations in the height from which the weight was dropped allowing grading of injury severity 
(Allen, 1911; Wrathall et al., 1985; Panjabi and Wrathall, 1988). However, early weight-drop 
devices had limited quality control, leading to variability in outcomes and the requirement of large 
group sizes to account for intrinsic variability. This led to the development of the more 
sophisticated New York University (NYU) device that provided information such as impact 
velocity and depth of injury (Gruner, 1992). Other devices that provided control over contusion 
biomechanics included use of a pneumatic cylinder mounted on a harness or a solenoid-controlled 
air cylinder (Anderson, 1982; Bresnahan et al., 1987; Noyes, 1987; Kearney et al., 1988). The most 
advanced contusion device is the Ohio State University (OSU) electromagnetic impactor, which has 
a probe sensitive to contact with the spinal dura (Stokes et al., 1992; Jakeman et al., 2000; Pearse et 
al., 2005). This device elicits an injury severity of user-defined tissue displacement, allowing high 
precision and reproducibility. A more recently developed and commercially available kinetic 
contusion device, known as the Infinite Horizon (IH) impactor, uses force rather than tissue 
displacement to set the contusion severity (Scheff et al., 2003). Both the OSU and IH devices 
require laminectomy to expose the dorsal surface of the spinal cord, as well as placement of clamps 
on the transverse processes of vertebrae rostral and caudal to the surgical site to stabilise the spinal 
column. The major advantage of the OSU and IH devices is the ability to monitor injury velocity, 
force, and tissue displacement from computer-generated impact graphs of inflicted injuries. This 
allows valid exclusion of animals that do not meet specified injury criteria. 
An important consideration when modelling SCI experimentally is the capacity for graded 
degrees of severity and functional outcomes. Very mild injuries result in spontaneous recovery, 
whereas very severe injuries result in restricted capacity for any neurological improvement; both 
extremes can mask the beneficial effects of potentially therapeutic strategies (Gruner et al., 1996; 
Basso et al., 2006). A moderately severe contusion SCI generates a primary mechanical trauma 
zone (the dorsal columns and grey matter), surrounded by a secondary penumbra region (the 
ventrolateral white matter) (Blight, 1991a; Scheff et al., 2003). Moderately severe contusion is thus 
most commonly used to study mechanisms of secondary neuroinflammatory pathology (David and 
Kroner, 2011). Indeed, this model has provided many of the insights regarding deleterious and 
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beneficial roles of immune cells in SCI (see Table 1.2). Importantly, the kinetics of immune cell 
infiltration in rodent SCI is very similar to the inflammatory cell dynamics observed in humans 
(Fleming et al., 2006; Kigerl et al., 2006; Beck et al., 2010). For these reasons, and the availability 
of genetically modified strains of mice, a mouse model of moderately severe (70 kdyne) contusion 
SCI, inflicted using the IH device, was selected for the experimental chapters of this thesis.  
 
1.4 Aims and outline of thesis 
 
Whether the beneficial roles of the inflammatory response can be manipulated to repair the 
injured spinal cord, or its deleterious roles suppressed, has been the subject of much research in the 
past three decades. Table 1.2 summarises the literature on experimental manipulation of immune 
cells to improve the outcomes from SCI. Although the majority of these studies indicate that 
inflammatory immune responses are deleterious to recovery, discrepancies remain regarding the 
role of certain cellular mediators of inflammation.  These disparities could be dependent on the 
differences in injury parameters, the timing and/or nature of intervention strategies. Developing a 
more detailed understanding of the molecular signals controlling cellular responses in SCI 
pathophysiology will undoubtedly expedite the development of effective therapeutics (Dumont et 
al., 2001).  
One critical component of the inflammatory response is the extremely potent and 
multifunctional innate immune complement system (see Chapter 2). This system is a cascade of 
membrane-bound and serum-derived proteins which literally complements the actions of antibody-
dependent and cell-mediated immunity. Specifically, complement greatly enhances opsonisation of 
pathogenic or damaged host cells, leukocyte recruitment, phagocytosis, and direct cell lysis by via 
membrane attack complex (MAC). All pathways of complement activation ultimately converge and 
result in MAC formation, except for the complement fragments C3a and C5a, which are involved, 
directly and indirectly, in leukocyte activation. Intriguingly, studies have also shown novel roles for 
the G protein-coupled receptors of these complement activation products, C3aR and C5aR, 
respectively, in CNS health and disease. Their precise role in secondary injury following SCI has, 
however, remained largely unknown. The overarching aim of the research in this PhD thesis has 
therefore been to better understand the role of the complement anaphylatoxin receptors C3aR and 
C5aR in SCI pathology, and to assess their potential as therapeutic targets in a mouse model of 
contusive SCI.  
Following on from this general introduction, Chapter 2 will provide a more detailed 
overview of the complement system, its activation pathways and the role of complement effectors, 
receptors and regulators in normal CNS physiology. The known roles of various complement 
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components in acquired CNS injury, specifically ischaemia-reperfusion (IR) injury/stroke, 
traumatic brain injury (TBI), and SCI, are reviewed here. 
Chapter 3, the first experimental study of this thesis, aimed to determine the role of C3aR in 
SCI using a variety of techniques, including genetic ablation of C3aR, bone marrow chimeras, and 
antibody-mediated neutrophil depletion. These studies revealed an unexpected and key regulatory 
role for C3aR in SCI. Specifically, C3aR appears to limit the mobilisation of neutrophilic 
granulocytes in response to SCI. By negatively regulating the magnitude of this response, C3aR 
controls the severity of secondary neuroinflammatory damage.  
Chapter 4 evaluated the role of the complement anaphylatoxin receptor C5aR in experimental 
SCI. It was determined that a lack of C5aR signalling, achieved either through genetic ablation or 
via pharmacological blockade, during the (sub)- acute phase significantly improved SCI outcomes. 
These early improvements were paralleled by dampened production of various pro-inflammatory 
cytokines in response to SCI. This improved phenotype was lost if C5aR was similarly and 
continuously targeted beyond the (sub)- acute phase of injury. A key role for the C5a-C5aR axis in 
astrocyte proliferation was identified, and impaired glial scar formation therefore likely contributed 
to the late worsening observed with sustained disabling of C5aR signalling.  
Chapter 5 explored the use of in vivo diffusion tensor imaging (DTI) to monitor and 
characterise pathological changes after experimental SCI. The spatial and temporal quantification of 
fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (λ||/AD) and radial diffusivity 
(λ⊥/RD) revealed that ventrolateral white matter may be salvageable for up to at least three days in 
the experimental model of contusive SCI that was used. Rostrocaudal asymmetry in axial diffusivity 
and FA were also found to be strong indicators of Wallerian degeneration in various white matter 
regions of the spinal cord. Demyelination and/or astrogliosis correlated with progressive increases 
in radial diffusivity in affected white matter tracts.  
The preliminary studies in Chapter 6 investigated whether DTI is sensitive enough to detect 
beneficial changes in diffusion indices as a result of a known immune-modulatory neuroprotective 
treatment for SCI, i.e. intravenous immunoglobulin (IVIG) therapy. 
Chapter 7 collates the findings of all preceding chapters, also highlighting outstanding 
questions and the therapeutic potential for targeting anaphylatoxin receptors in human SCI (or other 
acute neurological disorders). The promise of advanced magnetic resonance imaging techniques, 
such as DTI, in aiding translational research from the laboratory to the clinic is also discussed. 
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Abstract 
 
The complement system, a major component of the innate immune system, is becoming 
increasingly recognised as a key participant in physiology and disease. The awareness that 
immunological mediators support various aspects of both normal central nervous system (CNS) 
function and pathology has led to a renaissance of complement research in neuroscience. Various 
studies have revealed particularly novel findings on the wide-ranging involvement of complement 
in neural development, synapse elimination, and maturation of neural networks, as well as the 
progression of pathology in a range of chronic neurodegenerative disorders, and more recently, 
neurotraumatic events, where rapid disruption of neuronal homeostasis potently triggers 
complement activation. The purpose of this chapter is to summarise recent findings on complement 
activation and acquired CNS injury, i.e. ischaemic-reperfusion injury or stroke, traumatic brain 
injury (TBI) and spinal cord injury (SCI), highlighting the potential for complement-targeted 
therapeutics to alleviate the devastating consequences of these neurological conditions.   
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2.1 Introduction 
 
Injury to the central nervous system (CNS) elicits a complex series of pathophysiological 
events, including ischaemia, excitotoxicity, and inflammation. All of these factors adversely affect 
the integrity of spared neurons and thus accentuate tissue damage beyond the initial site of trauma. 
The cellular immune response in particular has received much attention as a key mediator of 
secondary injury, and strategies to manipulate the activation and recruitment of neutrophils (Taoka 
et al., 1997; Gris et al., 2004; Stirling et al., 2009; Beck et al., 2010; Geremia et al., 2012), 
monocytes and macrophages (Popovich et al., 1999; Mabon et al., 2000; Kigerl et al., 2009; 
Shechter et al., 2009), and lymphocytes (Popovich et al., 1996a; Schwartz and Hauben, 2002; 
Ankeny et al., 2009) after trauma have all been investigated, with the ultimate goal being to 
improve functional outcomes (reviewed in Hawthorne and Popovich (2011)). 
 Several recent studies have, however, put activation of the innate immune complement 
system into the spotlight as a perhaps sometimes-overlooked but potent mediator of secondary 
pathology (Anderson et al., 2004; Nguyen et al., 2008; Qiao et al., 2010). The particular aim of this 
chapter is to summarise the knowledge and understanding of complement activation in the injured 
CNS, specifically in relation to post-traumatic neuroinflammatory events and associated secondary 
damage. Several reviews have already provided a comprehensive overview of the role of 
complement in CNS development and chronic neurodegenerative disorders (Rutkowski et al., 2010; 
Woodruff et al., 2010; Veerhuis et al., 2011). 
 
2.2 The complement system: an introduction and effector mechanisms 
 
The predominant site of peripheral complement protein synthesis is the liver, where 
hepatocytes constantly produce and replenish circulating complement factors (Alper et al., 1969). 
Activation of these circulating complement proteins in response to an injurious or infectious 
challenge results in a self-amplifying cascade of proteolytic reactions through any one of four major 
identified pathways (Fig. 2.1).  
The classical pathway for complement activation is initiated by the binding of the recognition 
molecule C1q to pathogen antigens, C-reactive protein bound to bacterial polysaccharides, or 
antigen-antibody complexes (Gaboriaud et al., 2004). It is of interest to note in this context that 
pathogen opsonisation and antibody ligation by C1q also provides a bridge to activation of the 
adaptive immune system, which includes an enhancement of antigen retention in lymphoid tissues, 
a decrease in the B cell activation threshold and increased memory B cell survival (Carroll, 2004; 
Holers and Kulik, 2007; Carroll, 2008). T cell proliferation, differentiation, activation and antigen-
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presenting cell (APC) function can also be significantly influenced by complement (Dunkelberger 
and Song, 2010; Kwan et al., 2012). The lectin pathway for complement activation involves the 
recognition of pathogen carbohydrate antigens by mannose-binding lectin-associated serine proteins 
(MASP-1 and MASP-2) (Stahl and Ezekowitz, 1998), and the ficolins (Lu and Le, 1998). The 
alternative pathway of complement activation is initiated by spontaneous hydrolysis of complement 
component C3 in plasma, and the binding of factor B and D to C3(H2O) (Pangburn et al., 1981). All 
of the three aforementioned activation routes lead to the formation of C3 convertases and thus 
converge at this level. 
C3 convertases cleave the parental C3 molecule into two fragments, the larger C3b molecule 
and the smaller anaphylatoxin C3a. The C3b fragment opsonises pathogen- or danger-associated 
molecular patterns (PAMPs/DAMPs), which are small, conserved molecular motifs that are shared 
by classes of microbes and recognised by host cell pattern recognition receptors (PRRs), such as 
Toll-like receptors (TLRs) (Bianchi, 2007). C3b opsonises altered-self ligands, immune complexes 
and/or dead cells as well, which ultimately enhances their recognition and rapid phagocytosis by 
scavenging leukocytes that bear C3b receptors. The C3b fragment can also bind the C3 convertases, 
which leads to the formation of C5 convertases and the subsequent cleavage of the parental C5 
protein into C5b and the anaphylatoxin C5a. The amplification cascade then culminates in the 
association of C5b with C6, C7 and C8, which induces the polymerisation of 10–16 C9 molecules 
in order to assemble a transmembrane pore called the terminal ‘membrane attack complex’ (MAC), 
with subsequent lysis of the targeted pathogens or abnormal host cells as a result (Ricklin et al., 
2010). Importantly, components of the blood clotting and fibrinolysis pathways, as well as other 
cell-derived serine proteases, can also directly cleave and activate C3 and C5 proteins, and thus 
initiate the formation of complement end products independent of the C3 and C5 convertases, in a 
process now referred to as the extrinsic pathway (Huber-Lang et al., 2006; Amara et al., 2010; Perl 
et al., 2012). 
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Figure 2.1: Common pathways for complement activation. Recognition of antigen-antibody 
complexes by C1q initiates the classical pathway. Binding of carbohydrate antigens by mannose-
binding lectin (MBL) or MBL-associated serine proteases (MASPs) initiates the lectin pathway. 
Both pathways lead to the formation of the C3 convertase, C4b2a. Complement activation through 
the alternative pathway involves the spontaneous hydrolysis of plasma C3, generating a second C3 
convertase, C3(H2O)Bb. Proteolysis of C3 then leads to production of the C3b fragment, which 
binds to C3 convertases to generate C5 convertases. After the cleavage of C5, the C5b fragment 
binds C6-C9 to generate the membrane attack complex (MAC). The coagulation cascade leads to 
complement activation via the extrinsic pathway, this route does not depend on the presence of C3 
convertases. Anaphylatoxins C5a, C3a and C4a are generated through cleavage of C5, C3 and C4, 
respectively. Soluble and membrane-bound negative regulators of complement and their site of 
action are indicated in green. The functional significance of certain activation steps is shown in red. 
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2.2.1 The complement anaphylatoxins 
As indicated above, cleavage of parental C3 and C5 proteins also leads to generation of 
smaller activation fragments that do not directly contribute to MAC formation, the anaphylatoxins. 
Of these, C3a and C5a have been most intensely researched because of their potent effects on the 
inflammatory response. The small cleavage product of the C3 protein, the C3a anaphylatoxin, is a 
77 amino acid peptide that signals through the seven-transmembrane domain receptor C3aR (Ames 
et al., 1996). C3aR is expressed ubiquitously on the surface of many leukocytes such as 
macrophages, neutrophils, and lymphocyte subsets (Glovsky et al., 1979; Klos et al., 1992; Daffern 
et al., 1995; Gasque et al., 1998; Zwirner et al., 1998a; Zwirner et al., 1999; Werfel et al., 2000; 
Gutzmer et al., 2004; Strainic et al., 2008),  as well as non-immune cells such as endothelia 
(Monsinjon et al., 2001), neurons and glia (Gasque et al., 1998; Ischenko et al., 1998; Davoust et 
al., 1999).  The binding of C3a to C3aR leads to activation of heterotrimeric G proteins, namely Gαi 
and Gα16 in leukocytes and Gα12 or Gα13 in endothelial cells (Norgauer et al., 1993; Crass et al., 
1996; Schraufstatter et al., 2002). The downstream signaling events include activation of protein 
kinase C (PKC), the mitogen activated protein (MAP) kinases Erk1 and Erk2, and the PI3K/Akt 
pathway (Langkabel et al., 1999; Sayah et al., 2003; Venkatesha et al., 2005). Activation of these 
pathways can produce a variety of cellular responses, including Ca
2+
 flux (Norgauer et al., 1993), 
survival (Strainic et al., 2008), degranulation and histamine release (Kretzschmar et al., 1993; el-
Lati et al., 1994), oxidative burst (Murakami et al., 1993; Elsner et al., 1994a; Elsner et al., 1994b), 
costimulation to T cells (Peng et al., 2008; Strainic et al., 2008), and regulating production of IL-6 
and TNFα by monocytes and B cells (Fischer and Hugli, 1997; Fischer et al., 1999). The biological 
activities of C3a are terminated by carboxypeptidases; plasma proteases that remove the C-terminal 
arginine from C3a (Campbell et al., 2002). The resultant C3a derivative, C3a-desArg, does no 
longer bind C3aR (Crass et al., 1996; Wilken et al., 1999) and is thus considered biologically 
inactive (Zwirner et al., 1998b; Sayah et al., 2003; Bajic et al., 2013).   
Like C3a, the C5a anaphylatoxin is a small pro-inflammatory peptide. Its 74 amino acids are 
arranged into 4 helical antiparallel segments that are stabilised by three disulfide bonds and three 
loop segments (Nettesheim et al., 1988; Zuiderweg and Fesik, 1989; Zuiderweg et al., 1989). There 
are two major receptors for C5a. The first of these, C5aR (CD88), binds C5a with a Kd of 1 nM 
(Boulay et al., 1991; Gerard and Gerard, 1991), and is coupled to Gαi2, Gαi3 (Rollins et al., 1991) or 
Gα16 ((Amatruda et al., 1993). Binding of C5a to C5aR leads to Ca
2+
 mobilisation and activation of 
a variety of intracellular signaling molecules, including PIP3 kinase/Akt (Perianayagam et al., 
2002), Ras/B-Raf/MAP kinase/Erk (Buhl et al., 1994), phospholipase D (PLD) (Mullmann et al., 
1990), PKC (Buhl et al., 1994), sphingosine kinase 1 (Melendez and Ibrahim, 2004), NFκB  (Kastl 
et al., 2006), and signal transducer and activator of transcription (STAT) factors (Gao et al., 2004; 
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Lee et al., 2008). As a result of this, C5aR signalling can promote cell survival (Perianayagam et al., 
2002; Strainic et al., 2008), phagocytosis (Mollnes et al., 2002; Brekke et al., 2007), oxidative burst 
(Mollnes et al., 2002; Brekke et al., 2007), degranulation and release of lysosomal enzymes 
(McCarthy and Henson, 1979), histamine (el-Lati et al., 1994), and eosinophil cationic protein 
(Takafuji et al., 1996), in addition to regulating integrin expression necessary for leukocyte 
adhesion to endothelial cells and subsequent extravasation (DiScipio et al., 1999). Whereas C3a 
only modestly chemoattracts eosinophils and mast cells  (Daffern et al., 1995; Hartmann et al., 
1997), activation of the C5a-C5aR axis potently induces chemotaxis of most myeloid-derived cells 
(Lett-Brown and Leonard, 1977; Fernandez et al., 1978; Aksamit et al., 1981; Ehrengruber et al., 
1994; Morelli et al., 1996; Hartmann et al., 1997) and lymphocyte subsets (El-Naggar et al., 1980; 
Nataf et al., 1999; Ottonello et al., 1999). Like C3a, C5a activity is also tightly controlled by 
carboxypeptidases, which similarly remove the C-terminal arginine residue from C5a (Bokisch and 
Muller-Eberhard, 1970; Matthews et al., 2004). The resultant C5a-desArg retains only 1-10% of the 
inflammatory activity of C5a (Klos et al., 2009).  
The role of the second receptor for C5a, the C5aR-like protein 2 (C5L2) (Cain & Monk, 
2002), is less clear. Its inability to couple to G proteins has resulted in an enigmatic functional 
significance and controversy still surrounds its biological roles. Knowledge of C5L2 in context of 
the CNS is very limited but, in general, this C5a receptor appears to serve multiple roles in different 
species, organs and pathophysiological states (Chen et al., 2007; Lee et al., 2008; Rittirsch et al., 
2008b; Scola et al., 2009; Bamberg et al., 2010; Li et al., 2013); (see also Chapter 7). 
 
2.3 Physiological functions for complement in the CNS 
 
Although circulating complement proteins in blood plasma do not normally have access to 
the CNS because of the blood-brain and blood-spinal cord barriers (BBB and BSB, respectively), 
several studies have demonstrated that virtually all of the components of complement can be 
synthesised within the CNS (Perry and O'Connor, 2008; Woodruff et al., 2010; Veerhuis et al., 
2011). Accordingly, various non-immune physiological roles for complement have been identified, 
including synaptic remodelling during development, cell survival and neurogenesis.  
A seminal study by Stevens and colleagues (Stevens et al., 2007) showed that components 
of the classical complement pathway are key mediators of synapse elimination in the developing 
retinogeniculate pathway in mice. Early in development, retinal ganglion cells (RGCs) from both 
eyes extend excessive, overlapping projections into the dorsal lateral geniculate nucleus (dLGN) of 
the thalamus. Weaker synaptic arborisations are then eliminated and more active connections 
strengthened, resulting in the adult pattern of segregated eye layers by postnatal day 20 (Jaubert-
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Miazza et al., 2005). This process is coordinated by astrocyte-driven deposition of C1q and C3 on 
immature or weaker RGC synapses, which then tags them for removal, most likely by activated 
microglia. RGC axons in C1q
-/-
 and C3
-/-
 mice have indeed a higher degree of overlap during and 
after the remodelling process, resulting in the persistent retention of excessive retinal innervations 
of lateral geniculate neurons (Stevens et al., 2007). The supernumerary inputs retained in C1q
-/-
and 
C3
-/-
 neurons were shown to be immature or dysfunctional as judged by the weak magnitude of the 
glutamate-mediated currents carried by their AMPA receptors (Stevens et al., 2007). Interestingly, 
the failure to prune excessive excitatory synapses during development has been positively 
correlated to enhanced synaptic connectivity and epileptogenesis in C1q
-/-
 mice compared to wild 
type (WT) controls (Chu et al., 2010). Our groups have also previously shown localised expression 
of C5aR, the C5a anaphylatoxin receptor, on presynaptic terminals of mossy fibres within the CA3 
region of the adult rat hippocampus (Crane et al., 2009); it remains to be determined whether 
physiological C5a signalling here could also be involved in synaptic plasticity or whether it serves 
different and yet unknown functions in this structure.  
In addition to a role in synaptic plasticity, complement proteins may play an important role 
in neuroprotection in the CNS. In the absence of other complement components, C1q has been 
shown to increase neuronal survival and arborisation (Pisalyaput and Tenner, 2008). These effects 
are mediated via the upregulation of genes associated with cytoskeleton function (syntaxin-3), 
cholesterol/lipid metabolism (CH25H, INSIG2) and neurotrophic factors (NGF, NT-3, NTN1) 
(Benoit and Tenner, 2011). 
Intriguingly, in vitro experiments have also revealed a functional role for the MAC. At 
sublytic concentrations, the MAC can be endocytosed by oligodendrocytes and cause them to re-
enter the cell cycle (Yanamadala and Friedlander, 2010). Sublytic MAC also reduces apoptotic cell 
death by increasing synthesis of Bcl-2, inhibition of Caspase-3 activation and upregulation of the 
anti-apoptotic factor FLIP (FLICE-like inhibitory protein), (Soane et al., 1999; Cudrici et al., 2006), 
which inhibits Caspase-8. 
Lastly, physiological roles for the anaphylatoxins C3a and C5a within the adult murine CNS 
have also emerged, specifically an involvement in cell survival and neurogenesis. In mixed cultures 
of neurons and astrocytes, C3a protected neurons against NMDA-induced excitotoxicity in a dose- 
and astrocyte-dependent manner (van Beek et al., 2001). The neuroprotective action of C3a 
signalling could be mediated through the induction of nerve growth factor (NGF) expression in 
microglia (Heese et al., 1998; Jauneau et al., 2006) as well as astrocytes (Jauneau et al., 2006). C5a 
exposure also caused an upregulation of NGF mRNA expression in astrocytes (Jauneau et al., 
2006), with similar neuroprotective effects against glutamate-mediated neuronal excitotoxicity. The 
neuroprotective effects of anaphylatoxins against glutamate-induced excitotoxicity were shown to 
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be mediated via MAPK-dependent inhibition of Caspase-3 (Osaka et al., 1999a; Mukherjee and 
Pasinetti, 2001), regulation of glutamate receptor subunit 2 (GluR2) expression (Mukherjee et al., 
2008), and increased glial expression of the glutamate transporter GLT-1, which enhances the 
removal of extracellular glutamate (Persson et al., 2009). Administration of C5a in vivo was also 
reported to protect against kainic acid-induced neuronal apoptosis (Osaka et al., 1999a).  
With regards to a role for anaphylatoxins in neurogenesis, the respective receptors for C3a 
and C5a, C3aR and C5aR were shown to be expressed on neural progenitor cells as well as 
immature neurons (Rahpeymai et al., 2006). Mice treated with a non-specific C3aR antagonist 
(SB290157) displayed decreased formation of new neurons in areas of adult neurogenesis 
(Rahpeymai et al., 2006). The cellular (or humoral) source of C3a and the mechanism via which 
C3aR activation influences the creation and/or survival of new neurons remain to be elucidated. 
However, in the post-natal developing cerebellum, C3aR and C5aR expressions are known to 
increase during granule cell maturation (Benard et al., 2004). Subdural injection of a non-specific 
C5aR agonist (MAP-C5a) into the cerebellum of young rats increased the proliferation of immature 
granule neurons, resulting in an enlarged external granule cell layer (Benard et al., 2008). This 
effect could be reversed through concurrent administration of PMX53, a specific C5aR antagonist 
(Benard et al., 2008; Woodruff et al., 2011). A C3a agonist (MAP-C3a), on the other hand, 
decreased the thickness of the EGL whilst increasing the thickness of the internal granule cell layer. 
Video microscopy revealed that C3a accelerated the migration process of granule cells from the 
EGL to the internal granule cell layer (Benard et al., 2008). 
 
2.4 Complement and acute CNS disorders 
 
Various regulators normally finely tune the complement activation repertoire so that healthy 
host tissue is discriminated against. However, a disturbed balance between activation and regulation 
can induce targeting of healthy host tissue, and excessive or inappropriate complement activation 
has been implicated in the pathogenesis of numerous autoimmune, ischaemic and vascular diseases 
(Ricklin et al., 2010; Wagner and Frank, 2010). Complement deregulation has also been proposed 
in a myriad of CNS inflammatory pathologies and, as a result, complement-targeted therapeutics are 
increasingly emerging into the spotlight of drug discovery endeavours for various chronic 
neurodegenerative diseases, including multiple sclerosis (Morariu and Dalmasso, 1978; Morgan et 
al., 1984; Nataf et al., 2000; Niculescu et al., 2004; Liu et al., 2005; Rus et al., 2006; Ingram et al., 
2009; Ramaglia et al., 2012), Alzheimer’s disease (Maier et al., 2008; Zhou et al., 2008; Fonseca et 
al., 2009; Veerhuis, 2011), Huntington's disease (Woodruff et al., 2006; Moller, 2010), Parkinson’s 
disease (Wang et al., 2007; Depboylu et al., 2011) and motor neuron disease (Rus and Niculescu, 
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2001; Woodruff et al., 2008b; Woodruff et al., 2008a; Heurich et al., 2011; Lee et al., 2013). 
Although breakdown of the BBB and BSB does not occur until very late in most neurodegenerative 
pathologies, a prominent role for complement is perhaps not surprising when one considers again 
that the CNS can endogenously synthesise virtually all components of the complement system 
under appropriate stimuli (Gasque et al., 2000). Furthermore, neurons and oligodendrocytes express 
only low levels of the surface complement regulatory protein decay activating factor (DAF/CD55) 
and membrane cofactor protein (MCP/CD46), which renders them particularly vulnerable to 
complement-associated death (Agoropoulou et al., 1998; Singhrao et al., 2000). 
In contrast to the aforementioned chronic neurological disorders, CNS trauma is unique in 
that it involves a rapid and dramatic breakdown of the BBB/BSB. As a result, the immune-
privileged CNS parenchyma, with relatively low endogenous expression of complement and 
associated negative regulators, is exposed to the full force of both innate and adaptive components 
of the immune system, which includes a massive influx of serum complement as well as the 
invasion of circulating and activated leukocytes. Epitopes exposed by cellular injury, including 
phosphatidylserine, DNA and myelin, are highly vulnerable to complement recognition, 
opsonisation, and MAC deposition (Alexander et al., 2008) (Fig. 2.2). Although this process is 
important for the clearance of cellular and myelin debris as well as other molecules that may be 
inhibitory to wound healing and repair, over-activation of complement can compromise the 
integrity of neurons and oligodendrocytes in neighbouring tissue that was originally spared at the 
time of impact, thus exacerbating and widening neuropathology (Galvan et al., 2008; Arumugam et 
al., 2009). Lastly, since microhaemorrhaging is a hallmark of most neurotraumatic events, 
prominent complement activation through the extrinsic pathway can also be expected as a result of 
protease activity in the blood clotting and fibrinolysis pathways (Huber-Lang et al., 2006; Amara et 
al., 2010). The following sections of this review will now examine the multifarious roles that 
complement plays in stroke (i.e. ischaemia-reperfusion injuries), traumatic brain injury (TBI) and 
spinal cord injury (SCI).  
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Figure 2.2: Schematic diagram showing the role of complement activation in the 
pathophysiology associated with traumatic spinal cord injury (SCI). Mechanical damage to the 
spinal cord causes neuronal cell death and disruption of the blood-spinal cord barrier (BSB). This 
primary damage triggers a potent inflammatory response and initiates complement activation. 
Although complement activation may aid the clearance of cellular debris through opsonisation, it is 
also known to potentiate injury beyond the site of trauma through e.g. the opsonins C1q, C3b, and 
MAC, which can promote attack and clearance of only mildly compromised cells, thus contributing 
to secondary demyelination and apoptosis. Known functions of complement in the pathology of SCI 
are shown in italics; a green font indicates a putative reparative role, whereas a red font points 
towards an injurious role. 
1
(Qiao et al., 2006); 
2
(Ankeny et al., 2009); 
3
(Anderson et al., 2004); 
4
(Galvan et al., 2008); 
5
(Qiao et al., 2010); 
6
(Guo et al., 2010); 
7
(Beck et al., 2010; Guo et al., 2010). 
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2.4.1 Complement and cerebral ischaemic-reperfusion (IR) injury 
Macroscopically, cerebral IR injury is described as an arterial occlusion preceded by a 
thromboembolic event. Dynamic changes in cerebral blood flow produce a severe ischaemic core in 
the territory that is normally supplied by the affected artery, surrounded by a poorly perfused 
‘penumbra’ region (Kato and Kogure, 1999; Mocco et al., 2006c). Recanalisation of the occluded 
artery leads to reperfusion of blood and the induction of a series of excitotoxic and inflammatory 
events, which results in microvascular failure and neural cell death  (Kato and Kogure, 1999). 
Analysis of blood from human patients with ischaemic stroke showed significant alterations in 
complement levels, including elevation of the anaphylatoxins C3a and C5a, and depression of the 
MAC (Mocco et al., 2006b). Moreover, immunohistochemical staining of human brains revealed 
expression of C1q, C-reactive protein C3 and C4d (classical pathway), MASP-2 and factor B (lectin 
pathway), as well as C9 (terminal pathway) in ischaemic lesions (Pedersen et al., 2009). Staining 
for CD59 and CD55 was identified in normal brains, but these complement regulators were absent 
from lesioned brains, supporting that deregulation of complement contributes to IR pathology 
(Pedersen et al., 2009).  
To address whether complement activation products are simply a byproduct of injury or 
directly contribute to pathology in human stroke patients, one study analysed the influence of 
genetic polymorphisms in the MBL-2 and MASP-2 genes, which render the lectin pathway 
dysfunctional, on injury outcome. A logistic regression adjusted for age, gender and initial stroke 
severity determined that an unfavourable outcome at 3 months post-injury was more likely 
associated with a normally functioning lectin pathway (Cervera et al., 2010).  
This finding was further substantiated in a mouse model of middle cerebral artery occlusion 
(MCAO) in which MBL
-/-
 mice displayed smaller  infarct penumbra around the striatum, cortex and 
hippocampus, better behavioural outcomes, as well as less C3 deposition and leukocyte infiltration, 
compared to WT mice (Cervera et al., 2010). Reconstitution of MBL
-/-
 mice with recombinant 
human protein annulled the beneficial effects of MBL deficiency (Cervera et al., 2010). A 
detrimental role for the lectin pathway in IR injury was, however, not fully reproduced in an 
independent study where MBL-deficient mice subjected to cerebral IR reportedly showed no 
difference in systemic neutrophil activation, C3 deposits and only modest tissue sparing in a 
subcortical brain region compared to their WT counterparts  (Morrison et al., 2011). It must be 
noted, however, that occlusion of the middle cerebral artery in the latter study lasted only for 
60 minutes (Morrison et al., 2011) as opposed to 2 hours, as in the earlier mentioned investigation 
(Cervera et al., 2010). Injury severity and the resulting degree of complement activation may thus 
have been an influencing factor in the outcome that could explain the seeming discrepancy between 
these two studies. The contribution of the lectin pathway to secondary pathology was further 
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studied using a human recombinant C1 inhibitor (rhC1-INH), which binds MBL with high affinity 
(Gesuete et al., 2009). RhC1-INH reduced cerebral damage when given up to 18 h after transient 
ischaemia and up to 6 hours after permanent ischaemia, demonstrating a relatively wide therapeutic 
window for this treatment (Gesuete et al., 2009). It must be noted, however, that this inhibitor also 
influences activity of the classical pathway (vide infra).  
The significance of classical pathway activation has also been investigated in rodent models 
of IR injury. One of the subunits of the C1 protease, C1q, accumulates on neuronal cell bodies as 
well as necrotic cellular debris during the period of greatest infarct evolution (Schafer et al., 2000; 
Mack et al., 2006). Interestingly, C1q deficiency was shown to be neuroprotective in neonatal (p7) 
mouse hypoxic-ischaemic brain injury (Ten et al., 2005), predominantly by attenuating oxidative 
damage (Ten et al., 2005). However, no beneficial effects of C1q deficiency on stroke outcomes 
were observed when adult C1q
-/-
 mice were compared with their WT counterparts (Mocco et al., 
2006c), suggesting that the presence of C1q during the acute phase does not directly mediate 
neuronal injury. While it could be argued that a possible detrimental role for C1q in secondary 
immunopathology following hypoxic-ischaemic brain injury may only become more apparent 
during the post-acute phase when CNS autoantibodies are likely to be present, this does not explain 
the discordance between acute neonatal and adult studies. Although speculative at present, an 
alternative explanation for this apparent discrepancy may lie in age-related differences in 
complement protein expression and the general maturity of the complement system in neonatal 
versus adult mice. Known age-related increases in the expression of factor B, C3, C4 and C5  
(Reichwald et al., 2009) may have masked or overshadowed any neuroprotective effects of C1q 
deficiency in adult mice through non-classical routes of complement activation.  
The therapeutic potential of a C1 inhibitor (C1-INH) that binds and inactivates C1r, C1s, 
MASP1 and MASP2, thus blocking both the classical and lectin pathways, has also been assessed 
(De Simoni et al., 2004). These investigators reported a reduction in ischaemic volume (to as low as 
10.8% of that of vehicle-treated mice), alongside ameliorated neurological impairments, neuronal 
degeneration and reduced infiltration of CD45
+
 leukocytes (De Simoni et al., 2004). Similar effects 
were observed in Wistar rats following a 60 minute MCAO, after which animals that were treated 
with C1-INH had smaller infarct volumes and less granulocyte accumulation  (Akita et al., 2003). 
This neuroprotective effect was later shown to be mediated by upregulation of the anti-
inflammatory cytokine IL-10 as well as IL-6, which is known to be able to exert both pro- and anti-
inflammatory effects (Kishimoto et al., 1995; Xing et al., 1998), in addition to a down-regulation of 
leukocyte adherence molecules P-selectin and ICAM-1, and known inducers of apoptosis like TNF, 
IL-18 and pro-Caspase-3 (Storini et al., 2005). When C1q
-/-
 mice were treated with C1-INH, the 
ischaemic volume was reduced to 31.4% of that of saline-treated mice (De Simoni et al., 2004), 
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indicating the protective effects of C1-INH are indeed independent of C1q. Together, these findings 
indicate that the lectin pathway and subcomponents of the C1 complex, but not C1q, contribute to 
IR pathology.  
An inhibitor of both the classical and alternative pathways, soluble complement receptor-1 
(sCR1), led to a significant reduction in neutrophil and platelet aggregation and improved 
neurological function in mouse MCAO (Huang et al., 1999; Huang et al., 2008). This finding was, 
however, not reproduced in a non-human primate model of stroke (Mocco et al., 2006a). It would 
be of interest to more specifically pinpoint the contribution of the alternative pathway to cerebral IR 
injury as targeted inhibitors of this pathway have shown therapeutic benefits in both cardiac 
(Atkinson et al., 2010) and intestinal (Huang et al., 2008)  IR injury. This could be achieved using 
factor B null mice or the targeted inhibitor of the alternative pathway, CR2-fH (Huang et al., 2008).  
As illustrated in Fig. 2.1, the classical, alternative and lectin activation pathways of 
complement converge at the level of C3 convertase, making this cascade centrepiece an ideal target 
to assess the overall impact of complement activation in IR injury. In line with the above mentioned 
studies, which largely indicate a detrimental role for complement activation following injury, C3
-/-
 
mice have significantly smaller infarct volumes, improved neurological deficit scores, and reduced 
granulocyte infiltration and oxidative stress in a mouse model of transient focal cerebral ischaemia. 
These effects were reversed by reconstitution with C3 protein (Mocco et al., 2006c).  
The precise role of C5, the next downstream intersection in the cascade, in IR pathology is 
still uncertain. C5 deficiency reduced the neurological deficit and lesion size in the MCAO model 
in mice (Arumugam et al., 2007), while C5 inhibition with a monoclonal antibody yielded similarly 
positive results in rats (Costa et al., 2006). A more recent in vitro study showed that oxygen-glucose 
deprivation can induce the proteolytic cleavage of neuronally expressed C5, which in turn increased 
apoptotic cell death through a C5a-dependent mechanism (Pavlovski et al., 2012). The benefits of 
C5 deficiency on stroke outcome in mice were, however, not observed in an independent study by 
Mocco et al. (2006c). Although we cannot fully reconcile these differences, it was noted that a later 
study from the same laboratory did report improved recovery when blocking C5a signalling (vide 
infra). Further research is therefore warranted to better characterise the role of C5 and its activated 
cleavage products, C5a and C5b, in the context of IR injury.  
Interestingly, C6
-/-
 mice have a similar degree of hypoxic-ischaemic pathology compared to 
WT mice (Ten et al., 2010), which appears to suggest that inhibiting MAC formation may not 
necessarily yield beneficial effects. However, a pathological role of excessive MAC deposition has 
been supported by studies of CD59a
-/-
 mice. Deficiency in CD59a was associated with increased 
infarct volume, worse neurological deficits and brain swelling following a 30 minute MCAO and 72 
hour reperfusion as compared to WT mice (Harhausen et al., 2010). Importantly, however, there 
Chapter 2: Complement activation in the injured CNS     62 
was no difference in these outcome measures when these mice were subjected to 1 hour of MCAO 
with 48 hours reperfusion, although increased apoptosis was detected in CD59a-/- mice (Harhausen 
et al., 2010). This highlights that the detrimental effects of excessive MAC formation relative to 
secondary pathology are probably concentration- and model-specific, and perhaps most amenable to 
therapeutic intervention for mild IR injury.  
Investigation of the complement system following cerebral IR would not be complete 
without having determined the role of the anaphylatoxins C3a and C5a. Although these peptides do 
not contribute to MAC formation, as described earlier, they potently mediate inflammation (Ricklin 
et al., 2010). Expression of both C3aR and C5aR is increased in mouse models of cerebral 
ischaemia (Nishino et al., 1994; Barnum et al., 2002; Arumugam et al., 2007). Pharmacological 
antagonism of C3aR produced smaller stroke volumes, less ICAM-1 on endothelial cells and fewer 
C3aR
+
 granulocytes in mice subjected to a transient (60 minutes), but not permanent, MCAO 
(Ducruet et al., 2008). It should be taken into account, however, when interpreting these findings 
that the compound used in this study, SB290157, reportedly has off-target effects, including 
neutropenia in vivo (Proctor et al., 2004), and full agonist activity in a variety of cell systems in 
vitro (Mathieu et al., 2005; Therien, 2005). In comparison, mice administered a specific C5aR 
antagonist (PMX53, 5 mg/kg i.v.) 30 minutes prior to ischaemia exhibited only moderately 
improved outcomes when subjected to 60 minutes of MCAO (Arumugam et al., 2007). Others have 
reported, however, that C5aR inhibition in the same model 45 minutes prior to ischaemia with the 
same compound, but at a lower dose (1 mg/kg i.v.), yielded dramatically beneficial effects, both in 
terms of neurological deficits and infarct volume (Kim et al., 2008). These findings suggest that 
anaphylatoxin signalling may be more complex than previously thought, with concentration-
specific, time-dependent and model-specific effects.  
 
2.4.2 Complement activation in traumatic brain injury (TBI) 
A substantial body of evidence points toward a similarly prominent role for complement 
activation in the secondary post-injury sequelae following brain injury. In human TBI patients that 
underwent frontal or temporal lobe resection for intractable intracranial hypertension (2-82 h post-
injury), resected tissue was analysed for complement factors (Bellander et al., 2001). 
Immunoreactivity against C1q, C3, C4 C3b, C3d and C5b-9 was detected on neurons in the 
penumbra region of the contused brain area (Bellander et al., 2001). In the CSF of TBI patients, C3 
as well as classical (C1q, C4)  (Stahel et al., 1998) and alternative pathway components (factor B)  
(Kossmann et al., 1997b) were also elevated, and thus likely involved in secondary injury  
(Kossmann et al., 1997b). Furthermore, the concentration of MAC in CSF of TBI patients is up to 1 
800 fold higher than in control CSF, and there is a significant correlation between intrathecal MAC 
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levels and post-traumatic BBB dysfunction (Stahel et al., 2001). In animal models, 
immunoreactivity for C3 was found around the lesion but not in the uninjured contralateral 
hemisphere, while deposition of C9, a key component of the MAC, was also observed on damaged 
neurons after an experimental cerebral contusion (Bellander et al., 1996). Collectively, these 
findings indicate that all four complement pathways are activated in response to TBI, and it is the 
widely held view that complement deregulation contributes to nerve cell death.  
A number of studies have attempted to address the relative contribution of specific 
complement activation pathways to secondary injury following TBI. Factor B null (fB
-/-
) mice, 
which lack a functional alternative pathway, show significantly attenuated complement activation 
and neuronal death in addition to upregulation of Fas receptor and Bcl-2 in response to TBI 
compared to brain homogenates of fB
+/+
 (i.e. WT) littermates (Leinhase et al., 2006b). In a follow-
up study, administration of a monoclonal anti-factor B antibody (mab1379), which strongly inhibits 
alternative pathway activation, at 1 and 24 hours post-injury, significantly attenuated C5a levels in 
serum, in addition to general inflammation and neuronal apoptosis, whilst also yielding a 
neuroprotective pattern of intracerebral gene expression  (Leinhase et al., 2007). Importantly, 
however, no difference was detected in neurological grade relative to controls. This was attributed 
to a combination of the short half-life of mab1379, compensatory inflammatory effects (i.e. release 
of TNF, IL-1β, IL-8, IL-12,and  IL-18), and the need to apply more sensitive neurological testing 
systems (Leinhase et al., 2007). Further experiments are therefore required to determine the optimal 
dosage, injection route and time points of mab1379 to fully determine the feasibility and therapeutic 
merit of targeting the alternative pathway. One option may also be to use alternative pathway-
targeted therapies in combination with those targeting other complement activation routes.  
Another study evaluated the combined influence of the classical and lectin pathways on the 
outcome from TBI by administering C1-INH to mice that underwent controlled cortical impact 
(Longhi et al., 2009). The investigation revealed attenuation in motor deficits and cognitive 
dysfunction as well as reduced contusion volumes in the group given C1-INH at 10 minutes post-
injury. When C1-INH treatment was delayed to 60 minutes post-injury, only improvements in 
recovery of motor function were observed compared to the saline-treated group (Longhi et al., 
2009). Although a more potent recombinant C1 inhibitor has been developed (Gesuete et al., 2009), 
as of yet, there are no reports detailing the efficacy of this compound in TBI or SCI models.  
Unequivocal evidence that complement activation contributes to secondary damage in TBI 
has come from C3
-/-
 mice, which showed less brain oedema, lower haemeoxygenase-1 levels, along 
with reduced microglia activation and neutrophil infiltration around the clot following intracerebral 
haemorrhage; usage of the affected forelimb was also improved compared to WT controls (Yang et 
al., 2006). In a cryoinjury model, C3
-/-
 mice again showed fewer infiltrating immune cells, less 
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haemorrhage and better preservation of cytoplasm compared to injured WT brains (Sewell et al., 
2004). Targeted overexpression in the CNS of complement receptor type 1-related protein y (Crry), 
a functional homologue of the human complement-regulatory proteins CD55 and CD46, that 
inhibits complement activation at the C3 convertase level, also significantly improved neurological 
outcome for up to 4 weeks after trauma compared to WT mice (Rancan et al., 2003). Although this 
model is perhaps less clinically relevant, its findings led to a follow-up study that used systemic 
administration of the recombinant Crry molecule (Crry-Ig) in a standardised mouse model of closed 
head injury (Leinhase et al., 2006a). When given 1 and 24 hours after trauma, significant 
neurological improvements and tissue preservation were observed, and this phenotype was 
associated with upregulation of neuroprotective genes (Bcl-2, C1-Inh, CD55, CD59) in the injured 
hemisphere compared to the vehicle-treated control group (Leinhase et al., 2006a).  
The role of the MAC in focal closed head injury was investigated using CD59
-/-
 mice, which 
have excessive MAC deposition because of a lack of this negative complement regulator (Stahel et 
al., 2009). As anticipated, CD59
-/-
 mice had significantly exacerbated neurological severity scores 
and displayed increased neuronal cell death. Interestingly, there was no difference in Fas, FasL, Bax 
or Bcl-2 expression between CD59
-/-
 mice and WT littermates (Stahel et al., 2009).  
The role of the anaphylatoxins in the pathophysiology of TBI has also been explored. A 
reduction in secondary damage after traumatic brain cyroinjury was observed in C5
-/-
 mice or in 
mice treated with a C5aR antagonist (Sewell et al., 2004). Similarly, treatment with a C5aR 
antagonist [hexapeptide-derived macrocycle AcF(OPdChaWR)] in a mouse model of intracerebral 
haemorrhage significantly improved neurological function as assessed by spatial memory retention 
in the Morris water maze test, corner turn test and a 28 point neurological scale at 24, 48 and 
72 hours post-injury, and decreased oedema and granulocyte infiltration relative to vehicle-treated 
animals (Garrett et al., 2009). These effects were more marked when combined with a C3aR 
antagonist, although this result should again be interpreted with some caution as the compound 
SB290157 can display full agonist activity in certain cell types as mentioned earlier (Mathieu et al., 
2005; Therien, 2005). Thus, anaphylatoxin signalling also appears to negatively influence TBI 
outcomes, at least acutely. It is, however, necessary to determine whether the beneficial effects of 
anaphylatoxin antagonism are dependent on timing of the treatment and if they can be sustained 
long-term without producing deleterious side effects to the host, as observed in other models of 
neurotrauma (vide infra Beck et al. (2010)).  
In summary, the above mentioned studies demonstrate that complement is potently activated 
following TBI and that targeted interventions can rescue neighbouring intact tissue after brain 
injury with the potential to improve functional outcomes.  
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2.4.3 Dual roles for complement activation in spinal cord injury (SCI)? 
Following traumatic SCI, a robust and complex inflammatory response is initiated through 
the recruitment and activation of infiltrating leukocytes and resident microglia. It is the widely held 
view that this inflammatory cascade again exacerbates the primary injury by damaging 
neighbouring neurons that were originally spared (Dumont et al., 2001; Hausmann, 2003) (see 
Chapter 1). A prominent role for complement activation in post-SCI inflammation and associated 
secondary damage is becoming increasingly clear.  
Early studies on complement activation in a rat weight-drop model of SCI established that 
the classical (C1q and C4), alternative (Factor B) and terminal (C5b-9) pathways are strongly 
activated within 1 day post-injury, and that activation fragments remain on neurons and 
oligodendrocytes for up to 6 weeks as far as 20 mm rostral to the site of injury  (Anderson et al., 
2004). Complement inhibitor proteins such as factor H and clusterin are also reportedly expressed at 
elevated levels on both neurons and oligodendrocytes after SCI in rats, perhaps in an endogenous 
attempt to constrain inflammation to the primary injury area (Anderson et al., 2004; Qiao et al., 
2006). These findings led to several studies in which the therapeutic potential of complement 
pathway inhibition was tested via pharmacological agents.  
The effect of inhibiting the classical/alternative pathway (Reynolds et al., 2004) and 
C3b/C4b activity (Li et al., 2010) was investigated in Sprague-Dawley rats subjected to moderate 
weight-drop SCI. In these studies, treated animals had decreased complement deposition and 
leukocyte infiltration, which was paralleled by increased tissue sparing and improved locomotor 
recovery compared to vehicle-treated animals subjected to SCI.  
In mouse models of contusive SCI, genetic deficiency of factor B (Qiao et al., 2010), C1q 
(Galvan et al., 2008), and C3 (Qiao et al., 2006; Guo et al., 2010) resulted in improved sensory and 
locomotor outcomes as well as increased tissue sparing in comparison to WT mice. Blocking the 
alternative pathway with the CR2 inhibitor, Crry (Qiao et al., 2006) or a factor B neutralising 
antibody (Qiao et al., 2010) similarly improved histological and functional parameters as compared 
to untreated mice. It has also been shown that SCI potently activates B cells, resulting in the 
production of pathogenic autoantibodies that bind CNS antigens (Ankeny et al., 2009). Such 
immune complexes serve as a substrate for ligation by C1q and phagocytic/cytolytic cells bearing 
IgG receptors (Fc receptors). Indeed, injection of purified antibodies into uninjured spinal cord 
consistently produced paralysis and pathology, involving the activation of C1q and cells bearing Fc 
receptors. Conversely, in B cell deficient mice, which lack antibody production and thus cannot 
form immune complexes, minimal C1q deposition was observed at and near the lesion site, which 
in turn was associated with improved recovery of locomotor function  (Ankeny et al., 2009). 
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Although the above detailed studies point to a prominent role for complement-mediated 
pathology after SCI, particularly via the MAC, the precise role of other activation fragments such as 
the anaphylatoxins is yet to be conclusively determined. A recent study illustrated these 
complexities in a rat model of contusive SCI. Antagonism of the high-affinity C5a receptor, C5aR, 
from 14 days post-SCI onwards worsened locomotor recovery, demyelination and altered 
macrophage/microglia recruitment (Beck et al., 2010). We have now independently confirmed these 
results in C5ar
-/-
 mice, while a similarly novel anti-inflammatory role for C3aR in SCI was also 
determined in our laboratory. These intriguing findings suggest that activation of these receptors, at 
least during certain phases post-injury, serve a regulating and perhaps positive role in repair 
processes, which may be by aiding in the elimination of toxic proteins and debris  (Beck et al., 
2010). With other studies having demonstrated clearly detrimental roles for general complement 
activation following CNS injury, most likely through formation of the MAC, it is at present difficult 
to judge the true importance of anaphylatoxin signalling following neurotraumatic events, and 
whether or not the above detailed findings are specific to SCI. It would therefore be of interest to 
further study the role of C3a and C5a under conditions where MAC assembly is prevented but 
anaphylatoxins can still be generated, e.g. through the use of C6 deficient mice (Banda et al., 2012). 
 
2.5 Conclusion and future outlook 
 
Although complement activation is a necessary part of normal wound healing in the body, 
its deregulation or excessive activation following neurotraumatic events has emerged as a major 
contributor to secondary tissue damage. All available lines of evidence suggest that targeting 
complement may represent a novel and effective strategy for attenuating or ameliorating acute CNS 
trauma. However, because of the multifarious roles of complement in the normal CNS, non-
selective and chronic anti-complement therapies may be a less favourable option when aiming to 
translate complement-directed therapeutics into the clinic. Detrimental outcomes have already been 
observed in SCI following long-term interference with anaphylatoxin receptor signalling and 
similar effects could perhaps be anticipated with other approaches, particularly when one considers 
that, similar to development, complement activation may play vital roles in post-injury plasticity; 
particularly the rewiring of local neural circuits following SCI (Rossignol and Frigon, 2011). As 
such, it will be critical to elucidate the precise spatiotemporal function of specific complement 
activation fragments in future years. This will allow the design of novel and optimally effective 
therapeutic strategies that can harness ameliorative factors and neutralise or regulate toxic 
components in an appropriate and timely manner.  
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As progress is being made towards the translation of complement-based therapeutics into the 
clinic, consideration should also be given to the fact that there are known functional differences in 
complement system activity between species that could influence the efficacy of the intervention 
and thus trial outcomes. Although studies in genetically modified mice have greatly advanced our 
understanding of complement activation in neurotrauma, unlocking a number of promising avenues 
for therapeutic intervention, certain strains of mice are also known to have lower complement 
activity compared to other mammals such as rats, rabbits, guinea pigs and humans (Rice, 1950; 
Drake et al., 1973; Grant, 1976; Ong and Mattes, 1989; Ebanks and Isenman, 1996). These 
observations highlight the importance of understanding the limitations of experimental models and, 
where appropriate, the need to consider using intermediate animal models between mice and 
humans in translational complement research. 
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Abstract 
 
Activation of the innate immune complement system is thought to significantly exacerbate 
inflammatory pathology after spinal cord injury (SCI). The role of complement peptide C3a therein 
is, however, poorly understood. This study thus investigated the role of C3a and its G protein-
coupled receptor, C3aR, in a mouse model of contusive SCI. We demonstrate rapid complement 
activation in response to SCI, with tissue C3a levels peaking at 1 day post-injury. C3ar
-/-
 mice, 
which lack the signalling receptor for C3a, displayed significantly more impaired functional 
recovery, larger lesion volumes, reduced white matter content and an increased inflammatory 
infiltrate compared to wild type (WT) mice after SCI. Blood analysis revealed significantly 
increased Gr-1
+
 granulocyte numbers in C3ar
-/-
 mice at 2 hours post-SCI, suggesting that absence of 
C3aR leads to acute granulocytosis in response to neurotrauma. These findings could not be 
explained by altered expression of key factors involved in granulocyte mobilisation/chemotaxis 
(SDF-1, CXCL1, G-CSF, C5a and C5aR). In vitro experiments did, however, indicate that C3a is 
able to block C5a-induced chemotaxis of bone marrow (BM) granulocytes in a C3aR-dependent 
manner. BM chimera experiments further suggested that expression of C3aR on circulating cells 
was key in determining SCI outcomes. The specific influence of neutrophils was revealed through 
treatment with an anti-Ly6G antibody (clone 1A8), which alleviated the C3ar
-/-
 phenotype. 
Collectively, these findings indicate that C3aR negatively regulates granulocyte mobilisation in 
response to neurotrauma and thereby limits post-SCI inflammatory pathology. 
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3.1 Introduction 
 
Spinal cord injury (SCI) evokes a major inflammatory response, aspects of which exacerbate 
damage caused by the initial mechanical trauma (Donnelly and Popovich, 2008). One of the earliest 
effectors of inflammation following SCI is the complement system, which comprises a cascade of 
over 30 soluble and membrane-bound components and regulators (Makrides, 1998; Anderson et al., 
2004). This complex cascade can be activated through multiple biochemical induction routes, which 
all intersect at the C3 convertase level where factor C3 is cleaved into C3a and C3b (Ricklin et al., 
2010). The C3b fragment functions as an opsonin and also leads to C5 convertase formation, which 
results in production of the lytic membrane attack complex (MAC). MAC formation and 
complement-mediated opsonisation of CNS cells are thought to contribute significantly to 
secondary immunopathology in SCI (Anderson et al., 2004; Reynolds et al., 2004; Galvan et al., 
2008; Ankeny et al., 2009; Guo et al., 2010; Qiao et al., 2010). Much less is known, however, about 
the role of the smaller C3 proteolysis product, C3a, in local and systemic inflammation following 
SCI. 
C3a is a 77 amino acid polypeptide that signals through the G protein-coupled receptor 
C3aR, expressed on most myeloid cells (Goers et al., 1984; Kretzschmar et al., 1993; Zwirner et al., 
1998a; Zwirner et al., 1998b). The C3a-C3aR axis mediates numerous immunological functions in 
the periphery, including: histamine release from basophils and mast cells (Glovsky et al., 1979; 
Kretzschmar et al., 1993; el-Lati et al., 1994), mast cell chemotaxis (Hartmann et al., 1997), 
retention of haematopoietic stem cells (Ratajczak et al., 2004; Wysoczynski et al., 2009) and 
neutrophils (Wu et al., 2013) in the bone marrow (BM) niche, regulation of oxidative burst in 
macrophages and eosinophils (Murakami et al., 1993; Elsner et al., 1994a), and pro-inflammatory 
cytokine production (Takabayashi et al., 1998; Fischer et al., 1999; Monsinjon et al., 2001). C3aR is 
also expressed on B and T lymphocyte subsets (Fischer and Hugli, 1997; Werfel et al., 2000), where 
it is required for survival, costimulation, and expansion of T and B cells (Strainic et al., 2008; 
Dutow et al., 2014); C3aR is further thought to support TH1 immune responses (Cravedi et al., 
2013; Ghannam et al., 2014) and suppress TH2 (Kawamoto et al., 2004), TH17 (Lim et al., 2012), 
and Foxp3
+
 TReg cell activity (Kwan et al., 2013; Strainic et al., 2013; van der Touw et al., 2013). 
In the CNS, C3aR expression has been reported on neurons (Davoust et al., 1999; 
Rahpeymai et al., 2006), microglia (Davoust et al., 1999), and astrocytes (Gasque et al., 1998; 
Ischenko et al., 1998; Davoust et al., 1999). Deleterious roles for C3aR signalling have been 
identified in the context of CNS disorders based on correlative clinical studies (Mocco et al., 2006b; 
Mack et al., 2007), and animal models of neurological disease (Boos et al., 2004; Mocco et al., 
2006c; Garrett et al., 2009; Rynkowski et al., 2009; Ingersoll et al., 2010b). Intriguingly C3a 
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reportedly also protects against NMDA-induced neuron death in vitro (van Beek et al., 2001), and 
endotoxin-induced shock in vivo (Boos et al., 2005). These seemingly opposing findings point 
towards highly context and/or disease-specific functions, which are most likely driven by 
differences in the nature and timing of the inflammatory response. 
Despite a putatively key role in the inflammatory response to neurotrauma, the contribution 
of the C3a-C3aR axis to SCI outcomes has not been explored to date. Using a variety of 
approaches, including C3ar
-/-
 (i.e. knockout) mice, BM chimeras, antibody-mediated cell depletion, 
and in vitro assays, we provide direct evidence that C3aR is critical for limiting granulocyte 
mobilisation in response to trauma and, in doing so, controls neurological recovery from SCI.    
 
3.2 Materials and Methods 
 
3.2.1 Animals 
Adult female C57BL6/J (wild type (WT); n = 125), C3ar
-/- 
(n = 69) (Kildsgaard et al., 
2000), C5ar
-/- 
(n = 14) (Hollmann et al., 2008), and Cx3cr1
gfp/+
 mice (n = 3) (Jung et al., 2000) were 
used for this investigation. All mice were obtained from local breeding colonies at The University 
of Queensland Biological Resources facility. C3ar
-/-
, C5ar
-/-
, and Cx3cr1
gfp/+
 mice had all been 
backcrossed for more than 10 generations onto a C57BL6/J genetic background prior to 
experimentation. All animals were housed under conventional conditions in clean holding facilities 
on a 12 hour light-dark cycle with ad libitum access to food and water. Experimental mice were 
always age-matched and weight-matched within experiments. All experimental procedures were 
approved by The University of Queensland’s Animal Ethics Committee and conducted in 
accordance with the relevant guidelines of the National Health and Medical Research Council of 
Australia. 
  
3.2.2 Spinal cord injury  
Mice were anaesthetised with a mixture of tiletamine/zolezepam (50 mg/kg; Virbac) and 
xylazine (20 mg/kg; Troy Laboratories) and subjected to contusive SCI. This involved identification 
of the ninth thoracic (T9) vertebra based on anatomical landmarks (Harrison et al., 2013), followed 
by a dorsal laminectomy of T9 as described previously (Scheff et al., 2003; Blomster et al., 2013b). 
Next, a severe (70 kdyne) contusion injury was inflicted on the spinal cord using the Infinite 
Horizon impactor device (Precision Systems and Instrumentation). The muscle and skin were 
closed separately using 6-0 polyglactin dissolvable sutures (Ethicon) and Michel wound clips (Kent 
Scientific), respectively. Post-operatively, animals received a single injection of buprenorphine (0.5 
mg/kg s.c.) in Hartmann's sodium lactate solution for analgesia, and were administered antibiotics 
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(1.0 mg/kg gentamicin s.c.) for the first 5 days post-injury. Bladders were manually voided twice 
daily for the duration of the experiments.  
 
3.2.3 Assessment of functional recovery  
Open field locomotor performance was assessed using the 10 point Basso Mouse Scale 
(BMS), specifically designed for murine models of SCI (Basso et al., 2006). Two investigators 
observed individual mice for 4 minutes, during which time various aspects of locomotion, including 
ankle movements, stepping, coordination, paw position, trunk, and tail position were assessed. BMS 
subscores were also determined to assess the finer aspects of locomotion (Basso et al., 2006). 
Experimental animals were assessed at 1, 3, 7, 10, 14, 21, 28, and 35 days post-injury. All assessors 
were blinded to the genotypes of mice being scored to avoid experimenter bias. For experiments 
with WT and conventional C3ar
-/-
 mice, the actual applied force was 71.64 ± 0.65 kdyne (mean ± 
SEM) and 71.4 ± 0.50 kdyne, with an average tissue displacement of 586.5 ± 7.6 μm and 588.8 ± 
19.1 μm, respectively. There were no significant differences in injury parameters between 
experimental groups (p > 0.05). 
 
3.2.4 Tissue processing and magnetic resonance imaging (MRI)  
Mice were sacrificed at 1, 10, or 35 days post-injury as specified. Animals were 
anaesthetised with sodium pentobarbitone (100 mg/kg i.p., Virbac) and transcardially perfused with 
20 ml of saline (0.9% NaCl) containing 10 IU/ml heparin (Pfizer) and 2% NaNO3, followed by 30 
ml of phosphate-buffered Zamboni’s fixative (2% picric acid, 2% formaldehyde, pH 7.2-7.4). The 
perfused vertebral column was then dissected out and post-fixed overnight at 4 ̊C. 
 For MRI analysis, post-mortem samples of the vertebral column, dissected from mice that 
were perfused at 35 days post-SCI, were washed extensively in 0.1 M phosphate-buffered saline 
(PBS), followed by immersion for 48 hours in PBS containing gadolinium contrast agent (0.2% 
Magnevist, Bayer HealthCare Pharmaceuticals). Vertebral columns with the spinal cord in situ were 
imaged on a 16.4 T small animal MRI (Bruker BioSpin) as detailed elsewhere (Blomster et al., 
2013b). A stack of 256 two dimensional T2 slices was generated for each imaged specimen. MRI 
datasets were analysed using AVIZO 6.2 software (Visualisation Sciences Group), using an 
orthoslice along the sagittal plane and two user-defined (oblique) slices along the coronal and 
transverse planes, respectively. The Apply-Transform function was used to set these axes as the 
reference points for further analyses. A 3D image of the lesion core was reconstructed by manually 
outlining the hypo-intense core in the coronal plane of every slice using the three dimensional Lasso 
tool; the sagittal and transverse planes were also viewed to confirm that the complete lesion core 
was highlighted. As areas of demyelination were at times difficult to distinguish from remnants of 
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spared grey matter, only the hypo-intense lesion core was outlined for three dimensional 
reconstruction and calculation of lesion volumes. The analyser was at all times blinded to the 
experimental group during image analysis.   
 
3.2.5 Histological analysis  
Spinal cords were dissected out from the vertebral column and cryoprotected over two 
nights via subsequent incubations in 10% then 30% sucrose in PBS. Next, the lesioned segment of 
the spinal cord was embedded in Optimal Cooling Temperature (OCT) compound (ProSciTech), 
snap-frozen using dry ice-cooled isopentane and stored at -80 ̊C until sectioning. Coronal sections 
(20 μm thick) were cut on a Leica cryostat CM3050-S, collected on Superfrost Plus slides (1:5 
series; Lomb Scientific) and stored at -80 ̊C until staining. 
 Nissl staining was performed to examine gross morphology of the injured spinal cords. For 
this, slides were washed in PBS (3 x 10 minutes) and incubated in 0.25% Cresyl Violet (Sigma-
Aldrich) for 1 minute at room temperature (RT). Slides were then washed once more in PBS, 
dehydrated in graded ethanol and xylene series and coverslipped using Depex mounting media 
(Electron Microscopy Sciences). The area of abnormal granular tissue was outlined in ImageJ for 
each section containing lesion pathology. The volume of granular tissue was then estimated by 
multiplying the calculated area by the section thickness. 
Immunofluorescent staining was employed to assess the expression and distribution of C3aR 
in the injured spinal cord using a chicken anti-C3aR antibody (1:200; Bachem). C3aR 
immunofluorescent staining was combined with rat anti-Ly6b.2 (1:400; BD Biosciences) to identify 
neutrophils (and a subset of inflammatory monocytes (Rosas et al., 2010)); or with rat anti-CD11b 
(1:200; BD Biosciences), which is expressed by granulocytes and cells of monocytic lineage; or 
with anti-ionised Ca
2+
 binding adaptor molecule 1 (rabbit anti-Iba1; 1:500; Wako Pure Chemical 
Industries) to visualise microglia/macrophages and anti-glial fibrillary acidic protein (mouse anti-
GFAP, 1:1000; BD Biosciences) to identify astrocytes. Tissue from injured Cx3cr1
gfp/+
 mice was 
used to confirm that Ly6b.2 staining was mostly confined to neutrophils in the injured spinal cord 
and not early arriving monocytes/macrophages. In brief, slides were allowed to defrost for 1 hour at 
RT, followed by washes in PBS (3 x 10 minutes). Where applicable, HistoMouse kit (Life 
Technologies) was used as per the manufacturer’s instructions to allow for the use of mouse 
primary antibodies on mouse tissue. Next, slides were incubated in blocking solution (0.2% Triton 
X-100 (Sigma-Aldrich), 2% bovine serum albumin (BSA; Sigma-Aldrich) in PBS) for 1 hour at RT 
to permeabilise the sections and prevent non-specific labelling. This solution was also used as the 
antibody diluent in all incubation steps. Spinal cord sections were incubated overnight at 4 ̊C with 
primary antibodies in a humidified chamber. The following day, slides were washed in PBS (3 x 10 
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minutes) to remove any unbound antibody, followed by incubation for 1 hour at RT with an 
appropriate combination of biotinylated donkey anti-rat IgG (1:200; BD Biosciences), goat anti-
chicken IgG-Alexa Fluor 555 (1:500; Invitrogen), goat anti-rabbit IgG-Alexa Fluor 647 (1:250; 
Molecular Probes), and/or goat anti-mouse IgG-Alexa Fluor 488 (1:200; Invitrogen). Where 
biotinylated secondaries were used, an additional incubation step with streptavidin-Alexa Fluor 488 
(1:200; BD Biosciences) was carried out. After a final set of washes in PBS, slides were 
coverslipped using fluorescent mounting medium containing Hoechst nuclear dye (1:1000; Sigma-
Aldrich). Specificity of C3aR staining was confirmed on spinal cord tissue from injured C3ar
-/-
 
mice. Stained sections were captured on an Olympus BX61 confocal microscope and analysed 
using Imaris software (v. 7.7.0; Bitplane) to assess colocalisation. 
FluoroMyelin Red staining (1:150; Molecular Probes) was performed as per the 
manufacturer’s instructions to assess white matter myelin content at and around the lesion site. 
Stained spinal cord sections were photographed using an Olympus SZX12 Research Fluorescence 
Stereo Microscope (Spectra Services). Next, proportional area measurements were obtained using 
the freehand selection tool in ImageJ for measuring section area and the thresholding function for 
measuring FluoroMyelin signal. The analyser was at all times blinded to the experimental group 
during image analysis. The lesion epicentre was defined as the section with the least FluoroMyelin 
Red staining relative to the section area ratio as described previously (Blomster et al., 2013a).  
To compare and contrast the magnitude of the inflammatory response between genotypes, 
immunohistochemical staining procedures were used to identify granulocytes/inflammatory 
monocytes (rat anti-Ly6b.2; 1:400; BD Biosciences), macrophages/microglia (rabbit anti-Iba1; 
1:500; Wako Pure Chemical Industries) and T cells (rat anti-CD3; 1:400; AbD Serotec) at the injury 
site. Sections were dried for 1 hour at RT, washed in PBS (3 x 10 minutes), followed by incubations 
in PBS containing 10% methanol and 0.3% H2O2 for 20 mins to quench endogenous peroxidase 
activity. Slides were then washed again and incubated with blocking solution for 1 hour at RT. 
Slides were incubated overnight with primary antibody in a humidified chamber at 4 ̊C. The next 
day, slides were washed extensively in PBS and incubated for 1.5 hours with a biotinylated 
secondary antibody (donkey anti-rat IgG; 1:250; AbD Serotec) or goat anti-rabbit IgG (1:250; AbD 
Serotec). Sections were then washed again and incubated with Vectastain Elite ABC reagent (1:200; 
Vector Laboratories) for 1 hour at RT. After another set of 3 x 10 minute washes, stains were 
developed by incubating the sections with 3,3-diaminobenzidine (DAB; Sigma-Aldrich) for 5 
minutes at RT. Stained sections were dehydrated through graded series of ethanol (70-100%), 
washed twice in xylene and coverslipped using Depex mounting media (Electron Microscopy 
Sciences). Slides were digitised using a ScanScope XT scanner (Aperio) with ImageScope software 
(Leica Biosystems). For quantitative analysis, Ly6b.2
+
 and CD3
+
 cell numbers per section were 
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counted using the manual tag function in ImagePro Plus Version 6.3 (Media Cybernetics) and 
expressed as the number of cells per mm
2
, based on the section area that was outlined in ImageJ. As 
phagocytic microglia/macrophages tend to form dense clusters in regions of inflammation, 
haemorrhage, and necrosis, it is difficult to reliably distinguish individual cells. For this reason, 
proportional area (PA) measurements were used as described previously (Kigerl et al., 2006). 
Analysers were again at all times blinded to the experimental condition and/or genotype during 
counting and image analysis.  
 
3.2.6 Flow cytometry 
For quantification of blood granulocyte numbers in response to SCI, blood samples (exactly 
50 μl per time point) were obtained from WT (n = 6) and C3ar-/- mice (n = 6) via retroorbital eye 
bleeds at 1 week prior to SCI, then again at 2 hours post-SCI and 1 day after SCI. For each time 
point, an equal number of biological replicates from each genotype were always processed side by 
side. Mice were euthanised with sodium pentobarbitone (100 mg/kg i.p., Virbac) immediately after 
their final eye bleed at 1 day post-SCI. Blood samples were immediately diluted 1:3 in 
anticoagulant buffer (DPBS with 4 mM EDTA, pH 7.2) and stored on ice. Samples were then 
diluted 1:5 with red blood cell lysis buffer (0.85% NH4Cl, pH 7.2) and incubated for 5 minutes at 
RT. Cells were retrieved via low speed centrifugation (300 x g for 10 minutes). Zombie Green 
(FITC-conjugated) viability dye (BioLegend) was used for the exclusion of dead cells as per the 
manufacturer’s instructions. Cells were resuspended to a concentration of 1 x 107 cells/ml in 
cytometry blocking buffer (0.5% BSA, 2 mM EDTA, in DPBS, pH 7.2), then incubated with rat 
anti-CD16/32 (1:200; BD Biocience) for 10 mins on ice to block Fc receptors. Biotinylated rat anti-
Gr-1 (1:400; BD Biosciences) was then added to cells for 10 mins, followed by addition of 
streptavidin-Alexa Fluor 546 (1:200; BD Biosciences). Next, cells were collected via low speed 
centrifugation (300 x g for 10 minutes), washed with cytometry blocking buffer and resuspended in 
395 μl DPBS with 2 mM EDTA. Fluorosphere counting beads (Beckman Coulter) were added prior 
to analysis to allow for quantification of absolute cell numbers within each experimental sample. 
All samples were analysed using an LSRII flow cytometer (BD Biosciences) and BD FACS Diva 
software. After acquisition, compensation was applied to remove Zombie Green/Gr-1 spectral 
overlap. Doublets were excluded based on FSC-A/FSC-H linearity. Biotinylated rat IgG2bκ isotype 
and unstained controls were used to confirm staining specificity and determine gate placement. 
Granulocytes were gated as the Gr-1
+
SSC
hi
 population (see Suppl. Fig. S3.1).   
Similar procedures were used to determine surface expression of C5aR in WT (n = 5) and 
C3ar
-/-
 (n = 5) mice, before and 2 hours after SCI. An Alexa Fluor 647-conjugated rat anti-mouse 
C5aR antibody (1:20; BD Biosciences) was used to identify C5aR. Alexa Fluor 647-conjugated 
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IgG2α isotype and unstained controls, as well as blood samples from C5ar-/- mice (n = 6), were 
used to confirm staining specificity and to determine gate placement. 
 
3.2.7 Enzyme linked immunosorbent assays (ELISAs) 
At 2 hours post-SCI, WT (n = 5) and C3ar
-/-
 (n = 5) mice were anaesthetised with sodium 
pentobarbitone (100 mg/kg i.p., Virbac), after which 0.5 ml of blood was collected from the heart 
with a syringe containing 30 μl of 4 mM EDTA. Obtained blood samples were mixed immediately 
with 10 μl of the complement inhibitor FUT175 (5 mg/ml; BD Biosciences) and stored on ice. 
Samples were centrifuged at 13 000 x g for 10 minutes at 4 ̊C, after which the supernatant was 
collected, aliquoted and stored at -80 ̊C. Spinal cord segments T11-T13 (vertebral level T8-T10) 
were also dissected at this time, snap frozen in liquid nitrogen and stored at -80 ̊C. Frozen spinal 
cord segments were ground to a fine powder using a mortar and pestle on dry ice then dissolved in 
200 µl of NP-40 lysis buffer (Invitrogen) containing 1 mM PMSF (reconstituted in DMSO) (Sigma-
Aldrich), 92.6 M FUT175 (BD Biosciences), and 5 l of protease inhibitor cocktail (Sigma-
Aldrich; #P8340). Samples were vortexed for 1 minute, incubated on ice for 1 hour and then 
centrifuged at 3000 x g for 30 minutes at 4 ̊C, after which the supernatants were collected and 
stored as 20 l aliquots at -80 ̊C. These procedures were also used for collection of plasma and 
spinal cord samples from sham-operated (i.e. laminectomy only) WT (n = 5) and C3ar
-/-
 (n = 5) 
controls. 
Commercially available Quantikine ELISA kits were used to determine the protein levels of 
SDF-1α (R&D Systems; #MCX120), G-CSF (R&D Systems; #MCS00), C5a (R&D Systems; 
#DY2150) and CXCL1 (R&D Systems; #MM200) in plasma and spinal cord samples, according to 
the manufacturer’s instructions. All samples were diluted appropriately, such that they were 
detected within the linear aspect of the standard curve. For spinal cord samples, the concentration of 
these factors was normalised to the total protein content of the sample, determined using a BCA 
protein assay kit (Thermo Scientific) according to manufacturer’s instructions.   
An additional cohort of WT mice (n = 28) were injured to determine the time course of 
complement activation (Liu et al., 2004) and C3a generation in spinal cord and plasma after SCI. 
These mice were subjected to SCI as detailed earlier, and then sacrificed at 30 mins, 2 hours, 6 
hours, 1 day, 4 days, 7 days, or 35 days post-SCI (n = 4 per time point). Laminectomised mice (n = 
4) were used to determine baseline C3a levels in spinal cord (Fig. 3.1A, ‘time point 0’). Another 35 
mice underwent laminectomy to determine the impact of laminectomy on plasma C3a levels at 30 
mins, 2 hours, 6 hours, 1 day, 4 days, 7 days, or 35 days post-SCI (n = 5 per time point). Naïve mice 
(n = 4) were used to determine baseline C3a levels in plasma (Fig. 3.1B, ‘time point 0’). Blood 
plasma and spinal cord samples were collected from all of these mice as described above. The 
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amount of C3a in samples was quantified by ELISA (BD Biosciences; #I87-1162, #558251, and 
#558618; no cross-reactivity with mouse C3 or C5a). The amount of C3a in spinal cord 
homogenates was again normalised to the amount of protein in the sample. 
 Haemoglobin levels in spinal cord samples were also measured to determine the level of 
tissue haemorrhaging. For this, spinal cord samples were diluted 1:30 in Drabkin’s reagent (Sigma-
Aldrich) and analysed alongside a standard curve that was generated using purified bovine 
haemoglobin (Sigma-Aldrich). All samples were run in duplicate and the absorbance of each well 
measured at 540 nm using a Tecan Sunrise 96 well plate reader. Spinal cord haemoglobin 
concentrations were also normalised to protein content of each sample. 
 
3.2.8 Bone marrow chimeras 
To distinguish the effect of C3aR deletion on CNS cells from circulating cells on SCI 
outcomes, three groups of bone marrow (BM) chimeric mice were generated: [WT → WT] (n = 15), 
[WT → C3ar-/-] (n = 9), and [C3ar-/- → WT] (n = 7), as detailed previously (Chinnery et al., 2010). 
These mice were allowed to recover for 8 weeks after chimerisation before undergoing 
laminectomy, SCI surgery and behavioural assessment as described in Section 3.2.2 and 3.2.3. For 
these experiments, the actual applied force was 72.58 ± 0.56 kdyne (mean ± SEM) for [WT → WT] 
BM chimeras, 71.57 ± 0.65 kdyne for [C3ar
-/-
 → WT] BM chimeras, and 71.86 ± 0.83 kdyne for 
[WT → C3ar-/-] BM chimeras, with an associated tissue displacement of 570.2 ± 19.5 μm, 573.4 ± 
17.9 μm, and 579.1 ± 15.7 μm, respectively. There were no significant differences in injury 
parameters between experimental groups (p > 0.05). 
 
3.2.9 Ly6G
+
 cell depletion 
 To directly assess the role of neutrophils in SCI outcomes and the C3ar
-/-
 phenotype, WT 
and C3ar
-/-
 mice were injected with a rat α-Ly6G antibody (clone 1A8; 2.5 mg/kg i.p; Bioxcell), or 
isotype control antibody (IgG2α, clone 2A3; 2.5 mg/kg i.p; Bioxcell; hereafter referred to as ‘Iso’), 
at 3 hours before injury. Both antibody batches were custom-made to ensure they contained < 0.5 
endotoxin units (EU)/mg.  Contusive SCI, BMS scoring and perfusion fixation were performed as 
described above. For these experiments, the actual applied force was 71.86 ± 0.14 kdyne (mean ± 
SEM) for WT + Iso, 71.25 ± 0.45 kdyne for WT + α-Ly6G, 71.50  ± 0.62 kdyne for C3ar-/- + Iso, 
and 71.83 ± 0.54 kdyne for C3ar
-/- 
+ α-Ly6G, with an associated tissue displacement of 541.3 ± 
14.28 μm, 546.6 ± 20.13 μm, 552.3 ± 38.48 μm, and 541.8 ± 20.79 μm, respectively. There were no 
significant differences (p > 0.05) in injury parameters between the four groups of mice. The 
efficacy of α-Ly6G injection in depleting neutrophils was first tested in a pilot experiment (Fig. 
3.6C-H). This involved processing cells from the blood at 24, 48 or 72 hours post-SCI as described 
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above. The cellular immunophenotype of the spleen and BM at 48 or 72 hours post-SCI was also 
analysed as reported elsewhere (Lagasse and Weissman, 1996), along with the T11-13 spinal cord 
segment at 72 hours post-SCI as described previously (Beck et al., 2010). Neutrophils were gated as 
the Ly6C
+
SSC
hi
 population (Ly6C-Alexa Fluor-647; BD Biosciences). The efficacy of α-Ly6G 
injections was again confirmed as part of the main study that compared SCI outcomes between 
genotypes (72 hours post-SCI, n = 3 per genotype and experimental condition; Fig. 3.6I-K), which 
showed that Ly6C
+
SSC
hi
 cells were also significantly reduced in the blood of C3ar
-/-
 mice for at 
least 72 hours after SCI. 
 
3.2.10 Chemotaxis assays  
BM neutrophils were isolated from the femurs of WT (n = 12), C5ar
-/-
 (n = 8) and C3ar
-/- 
(n 
= 8) mice using the anti-Ly6G microbead kit and magnetic MiniMACS cell separation system 
(Miltenyi Biotec) as per the manufacturer’s instructions using a total of 5 independent repeat 
experiments. The migration plate (Neuroprobe, 101-3) consisted of a 3 µm pore filter in a 96 well 
format. RPMI medium (29 µl) with or without recombinant mouse C5a (50 nM; BioVision Inc.) or 
the selective C3aR agonist WWGKKYRASKLGLAR (EP141, 10 µM; Wu et al. (2013)), or a 
combination of C5a and EP141, was pipetted in the wells below the filter. The filter was then 
snapped into place, and 5 x 10
4
 neutrophils in 25 µl of RPMI pipetted onto the hydrophobic rings on 
top of the filter, allowing contact with the media below the filter. For pre-activation of C3aR, 
Ly6G-enriched cells from either WT, C5ar
-/-
 and C3ar
-/- 
BM were stimulated with EP141 (10 µM) 
15 mins prior to being added to the migration plate. Once loaded, plates were incubated for 6 hours 
under standard cell culture conditions (37 ̊C, 5% CO2). Following this, the filter was carefully 
removed and the number of transmigrated cells in the bottom compartment counted after dilution in 
trypan blue solution (1:1) using a Neubauer haemocytometer.  
 
3.2.11 Statistical Analysis  
GraphPad Prism (GraphPad Software Inc.) was used for data visualisation and statistical 
analyses. Behavioural datasets were analysed using repeated-measures two-way ANOVA followed 
by Bonferroni post hoc tests. Differences in lesion volumes, histological data, flow cytometry, and 
protein concentrations and cell migration between experimental conditions and/or genotype were 
determined using a two-sided Student’s t test, one-way ANOVA or two-way ANOVA with post hoc 
test as specified in Figure legends. All datasets are presented as mean ± SEM, with statistical 
significance set as p < 0.05. 
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3.3 Results  
 
3.3.1 C3a production and expression of C3aR after SCI 
To ascertain the level of complement activation (Liu et al., 2004), and putative involvement 
of C3a in the pathophysiological response to SCI, tissue and plasma levels of C3a were measured at 
various time points after injury using ELISA. SCI resulted in rapid activation of complement and 
production of C3a in the spinal cord itself (Fig. 3.1A). Tissue levels of C3a were significantly 
increased at 6 hours (16.5 fold; p < 0.05), and peaked at 1 day post-SCI (29.3 fold; p < 0.001) 
compared to sham-operated control mice. In the plasma, C3a levels rose sharply within the first 30 
minutes after SCI and remained significantly higher up to 1 day post-injury compared to sham-
operated mice (Fig. 3.1B). C3ar
-/-
 mice had similar levels of C3a compared to their WT 
counterparts at baseline in both the plasma (p = 0.81) and spinal cord (p = 0.96), as well as at 2 
hours post-SCI in the plasma (p = 0.91) and spinal cord (p = 0.89), suggesting a similar magnitude 
of complement activation between genotypes.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Contusive SCI leads to rapid complement activation and production of C3a. Spinal 
cord and blood plasma samples were collected from WT mice at 30 mins, 2 hours, 6 hours, 1 day, 4 
days, 7 days, and 35 days following SCI. A: C3a levels in the injured spinal cord (T11-T13 
segment) rapidly increased in response to injury, peaking at 1 day post-SCI. Data points represent 
mean ± SEM; n = 4 per time point; *, p < 0.05; ***, p < 0.001; one-way ANOVA with Newman-
Keuls post hoc tests compared to sham-operated cord (time point 0). B: Circulating C3a levels 
significantly increased within 2 hours of SCI (blue line), and remained at peak levels up to 1 day 
post-injury; they then decreased to levels comparable to sham-operated levels (grey line) from 4 
days post-SCI onwards. Data points represent mean ± SEM; n = 4-5 per time point; *, p < 0.05; **, 
p < 0.01; two-way ANOVA with Newman-Keuls post hoc tests comparing spinal injured to sham-
operated mice at matching time points. 
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Immunofluorescent staining revealed widespread expression of C3aR in the injured spinal 
cord across the various experimental time points. At 1 day post-injury, C3aR-expressing Ly6b.2
+
 
cells were abundant at and around the lesion site, particularly in the dorsal horns and dorsal 
columns (Fig. 3.1C). The majority of these infiltrating Ly6b.2
+
 cells appeared to be neutrophils, as 
very little colocalisation was observed between Ly6b.2 and GFP fluorescence in injured Cx3cr1
gfp/+
 
mice (Fig. 3.1D). A high degree of colocalisation was also observed between C3aR and CD11b
+
 
cells at this time point (Fig. 3.1E). These findings are generally consistent with the timing of 
neutrophil recruitment to the injured spinal cord (Dusart and Schwab, 1994; Carlson et al., 1998; 
Beck et al., 2010), as well as previous reports that C3aR is expressed on granulocytic neutrophils 
and induces Ca
2+
 mobilisation in these cells (Norgauer et al., 1993; Martin et al., 1997). At 35 days 
post-injury, widespread expression of C3aR remained at the lesion site, including strong expression 
on GFAP
+
 astrocytes and Iba1
+
 microglia/macrophages (Fig. 3.1F). No C3aR staining was observed 
on lesioned C3ar
-/- 
mouse spinal cord tissue (Fig. 3.1F’), indicating antibody specificity. C3aR is 
thus present on infiltrating leukocytes as well as resident CNS cells after SCI.  
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Figure 3.1 (cont.) C: Representative image showing that C3aR (red) colocalises to infiltrating 
Ly6b.2
+
 cells (green) in the injured dorsal grey matter of the spinal cord, as also evident from the 
merged image (see arrow) and surface reconstruction of the merged image using Imaris (r
2
 value  = 
square of Pearson’s correlation for colocalisation). D: Ly6b.2 staining (red) shows minimal overlap 
with GFP fluorescence (green) in the injured spinal cord of Cx3cr1
gfp/+ 
mice. An Imaris surface 
reconstruction of the merged image is shown on the right, along with the r
2
 value. E: A high degree 
of colocalisation between C3aR (red) and CD11b (green) staining was observed, as evident from 
the merged image (see arrow) and Imaris analysis (right). F: Representative image showing C3aR 
staining (red) in WT spinal cord (lateral funiculus) at 35 days after injury. C3aR colocalises to 
amoeboid-shaped Iba1
+
 microglia/macrophages (blue; closed arrowhead, r
2
 = 0.39) and fibrous 
GFAP
+
 astrocytes (green; arrow, r
2
 = 0.79). Small round, nucleated (i.e. DAPI
+
) C3aR
+
Iba1
-
GFAP
-
 
cells can also be observed (open arrowhead), most likely representing Ly6b.2
+
 immune cell 
infiltrate. F’: No specific staining for C3aR was observed in C3ar-/- spinal cord.   
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3.3.2 Genetic ablation of C3aR worsens the outcome from SCI 
Prior to injury, WT and C3ar
-/-
 mice displayed normal overground locomotion, achieving a 
maximum BMS score of 9. At 1 day after SCI, near complete paralysis of the hindlimbs was 
observed in WT and C3ar
-/-
 mice (BMS scores 0-1). Following the resolution of spinal shock, 
gradual spontaneous recovery of locomotor function was observed for all mice. Intriguingly, the 
recovery of C3ar
-/-
 mice stalled in the post-acute phase and started to diverge from WT mice from 
day 10 post-injury onwards. Statistical analysis showed that BMS locomotor scores for C3ar
-/-
 mice 
were significantly less than those of WT mice at 21, 28, and 35 days post-SCI (Fig. 3.2A). BMS 
subscores of C3ar
-/-
 mice were also significantly lower than WT mice at the endpoint (p = 0.008; 
Fig. 3.2B). Consistent with the functional data, C3ar
-/-
 mice had significantly larger lesion core 
volumes compared to WT mice as determined by MRI analysis (p = 0.02; Fig. 3.2C, D). 
Quantitative assessment of Nissl staining further revealed that there was a greater volume of 
granular tissue in C3ar
-/-
 mice compared to WT mice (p = 0.008; Fig. 2E, F). As there is normally a 
high correlation between
 
white matter preservation at the lesion epicentre and behavioural deficits 
after contusive SCI (Bresnahan et al., 1987; Noble and Wrathall, 1989), we also quantified myelin 
content at the injury site. In line with both the functional and MRI data, a significant reduction in 
myelin content was observed at the lesion epicentre in C3ar
-/-
 mice compared to WT mice at 35 
days post-SCI (p = 0.0024; Fig. 3.2G, H). 
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Figure 3.2: SCI outcomes in WT and C3ar
-/-
 mice. A: WT mice recovered more hindlimb 
locomotor function compared to C3ar
-/-
 mice, trending from 10 days post-injury onwards. C3ar
-/-
 
mice had significantly lower BMS scores at 21, 28 and 35 days post-SCI. Data points represent 
mean ± SEM; n = 13-15 per group; *, p < 0.05; **, p < 0.01; two-way ANOVA with Bonferroni 
post hoc tests comparing WT to C3ar
-/-
 mice at matching time points. B: BMS subscores were also 
significantly lower in C3ar
-/-
 mice compared to WT mice at 35 days post-SCI. Bars represent the 
mean ± SEM; n = 13-15 per group; **, p < 0.01; student’s two-sided t test. C: Representative 
images from post-mortem MRI showing the injured spinal cord from a WT (top) and C3ar
-/-
 mouse 
(bottom row) at 35 days post-injury. Representative three dimensional reconstructions of the lesion 
core, as derived from the hypointense signal in MR images, are shown on the right in yellow. D: 
Quantitative analysis of the number of voxels occupied by the hypointense lesion core revealed that 
C3ar
-/-
 mice had significantly larger lesion core volumes compared to WT mice. Bars represent the 
mean ± SEM; n = 5-8 per group; *, p < 0.05; student’s two-sided t test.  
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Figure 3.2 (cont.) E: Representative cresyl violet-stained coronal sections of WT (top row) and 
C3ar
-/-
 spinal cord (bottom row) showing granular tissue presence at and around the lesion 
epicentre. F: Quantitative analysis showed that C3ar
-/-
 mice had a significantly increased granular 
tissue volume compared to WT mice. Bars represent the mean ± SEM; n = 5-8 per group; **, p < 
0.01; student’s two-sided t test. G: Representative images of the lesion epicentre for WT and C3ar-/- 
mice at 35 days post-SCI, showing myelin content (red; left) and GFAP immunoreactivity (green, 
middle); a merged image is shown on the right. A decreased presence of myelin was observed in the 
lateral and ventral margins of the spinal cord in C3ar
-/-
 mice. H: Quantitative analysis confirmed 
significantly decreased myelin content at the lesion epicentre revealed in C3ar
-/-
 mice compared to 
WT mice. Bars represent the mean ± SEM; n = 5-8 per group; **, p < 0.01; student’s two-sided t 
test.  
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3.3.3 Genetic ablation of C3aR exacerbates the inflammatory response to SCI 
To better understand why the absence of C3aR resulted in a worsened outcome from SCI, 
we next characterised the inflammatory infiltrate at the lesion site. Consistent with previous 
observations in WT mice (Kigerl et al., 2006), there was an abnormal presence of Ly6b.2
+
 cells at 
the lesion epicentre up to 35 days post-SCI. Importantly, however, quantitative analysis revealed 
that there were significantly more Ly6b.2
+
 cells across the injured spinal cord segment of C3ar
-/-
 
mice at every time point investigated (p < 0.05; Fig. 3.3A, B). Additional endpoint analysis also 
revealed an increased presence of Iba1
+
 microglia/macrophages (p = 0.03; Fig. 3.3C) and CD3
+
 T 
cells (p = 0.04; Fig. 3.3D) at the lesion epicentre of C3ar
-/-
 mice. Thus, absence of C3aR augments 
the inflammatory response to SCI, beginning with an increased presence of Ly6b.2
+
 cells early after 
injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Genetic ablation of C3aR augments the cellular inflammatory response to SCI. A: 
Representative photomicrographs showing the Ly6b.2
+
 infiltrate in the injured spinal cord of a WT 
mouse (top) and C3ar
-/-
 mouse (bottom) at 1 day post-SCI; the boundary between the dorsal horns 
and dorsal columns is indicated by a dashed red line. B: Quantitative cell counts in the section 
defined as the lesion epicentre revealed a significantly greater number of Ly6b.2
+
 cells in C3ar
-/-
 
mice compared to WT mice at 1, 10 or 35 days post-SCI. Data points represent the mean ± SEM; n 
= 5-8 per group; *, p < 0.05; ***, p < 0.001; two-way ANOVA with Newman-Keuls post hoc tests 
comparing WT to C3ar
-/-
 mice at matching time points. C: Proportional area measurements 
determined Iba1
+
 macrophages/microglia presence at the lesion epicentre was also increased in 
C3ar
-/-
 mice at 35 days post-SCI. Bars represent the mean ± SEM; n = 5 per group; *, p < 0.05; 
student’s two-sided t test. D: CD3+ T cell numbers were also significantly increased at the lesion 
epicentre of C3ar
-/-
 mice at 35 days post-injury. Bars represent the ± SEM; n = 5 per group; *, p < 
0.05; student’s two-sided t test. 
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3.3.4 C3ar
-/-
 mice exhibit granulocytosis in the blood acutely after SCI  
Having established that absence of C3aR leads to increased presence of Ly6b.2
+
 cells at the 
lesion site acutely after injury, we aimed to determine if this phenotype could have resulted from 
increased neutrophil mobilisation following SCI. Flow cytometric analysis of circulating 
granulocyte numbers revealed no differences between WT and C3ar
-/-
 mice under homeostatic 
conditions (WT: 0.64 ± 0.12 x 10
6
 cells/ml vs. C3ar
-/-
: 0.51 ± 0.12 x 10
6
 cells/ml; p = 0.47). 
Significantly higher numbers of SSC
hi
Gr-1
+
 granulocytes were, however, observed in the blood of 
C3ar
-/-
 mice at 2 hours post-SCI (WT: 0.91 ± 0.18 x 10
6
 cells/ml vs. C3ar
-/-
: 1.6 ± 0.17 x 10
6
 
cells/ml; p = 0.037; Fig. 3.4A, B). This early effect of C3aR deficiency on leukocyte mobilisation 
appeared specific for granulocytes, as no differences were observed in the total number of 
circulating lymphocytes (WT: 3.9 x 10
6
 ± 1.0 x 10
6
 cells/ml vs. C3ar
-/-
: 4.2 x 10
6
 ± 0.81 x 10
6
 
cells/ml; p = 0.88) and SSC
lo
Gr-1
+
 inflammatory monocytes (WT: 2.1 ± 0.55 x 10
5
 cells/ml vs. 
C3ar
-/-
: 2.5 ± 0.66 x 10
5 
cells/ml; p = 0.67) at this point in time. These findings therefore suggest 
that genetic ablation of C3aR leads specifically to increased mobilisation of granulocytes from their 
reservoirs into the circulation in response to SCI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: C3ar
-/-
 mice exhibit granulocytosis acutely after SCI. A: Representative blood 
contour plots showing granulocytes (blue) and inflammatory monocytes (green) in the blood of WT 
(top row) and C3ar
-/-
 (bottom row) mice; the gating strategy is shown in Suppl. Fig. 3.1. Blood 
samples were collected 1 week prior to SCI (left), and again at 2 hours (middle) and 1 day post-SCI 
(right). B: Quantitative analysis of blood granulocyte numbers in WT and C3ar
-/-
 mice as a function 
of post-injury time. A significant increase in circulating granulocyte numbers was observed in C3ar
-
/-
 mice at 2 hours post-SCI compared to WT mice. Data points represent the mean ± SEM; n = 6 per 
genotype; *, p < 0.05; two-way repeated-measures ANOVA with Newman-Keuls post hoc tests 
comparing WT to C3ar
-/-
 mice at matching time points.  
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Haemoglobin levels in the spinal cord were also measured to indicate intraparenchymal 
haemorrhage after injury. Haemoglobin levels were significantly increased in both WT (p = 0.013) 
and C3ar
-/-
 mice (p = 0.035) as a result of SCI (Fig. 3.5A), but were not affected by C3aR 
deficiency (prior to SCI p = 0.38; 2 hours post-SCI: p = 0.88). The degree of microhaemorrhaging 
thus appeared similar between genotypes.  
 
3.3.5 C3aR elimination does not affect granulocyte mobilising and chemotactic factors 
Levels of a select number of key proteins known to be involved in granulocyte mobilisation 
and/or recruitment, specifically SDF-1α, G-CSF, C5a, and CXCL1 were also examined. No 
differences in plasma SDF-1α levels were observed between WT and C3ar-/- mice following sham 
surgery (WT: 8.19 ± 1.2 ng/ml vs. C3ar
-/-
: 8.92 ± 1.88 ng/ml; p = 0.77), or at 2 hours post-SCI (WT: 
3.47 ± 0.67 ng/ml vs. C3ar
-/-
: 3.27 ± 1.36 ng/ml; p = 0.92); SDF-1α protein levels were significantly 
reduced in the plasma of SCI mice compared to sham-operated controls (p < 0.05). SDF-1α levels 
within the spinal cord were below the detection threshold under the experimental conditions used. 
G-CSF levels were significantly increased in the blood in the SCI condition (p < 0.05; Fig. 3.5B), 
and a trend towards elevated G-CSF expression was also evident in the spinal cord after injury (Fig. 
3.5C). No differences in G-CSF protein levels were, however, observed between genotypes under 
comparable conditions (p = 0.38). C5a levels were significantly increased in the plasma of both WT 
(p < 0.05) and C3ar
-/-
 (p < 0.01) mice (Fig. 3.5D), and in the spinal cord at 2 hours post-injury 
compared to sham-operated controls (p < 0.05; Fig. 3.5E). No differences in C5a levels were 
observed between the respective genotypes in plasma (p = 0.10 at baseline; p = 0.32 at 2 hours) nor 
spinal cord (p = 0.17 at baseline; p = 0.34 at 2 hours). CXCL1 levels were significantly increased in 
blood plasma and spinal cord samples of both WT and C3ar
-/-
 mice at 2 hours post-SCI compared 
that of sham-operated controls (p < 0.05), but no differences were observed between genotypes 
(Fig. 3.5F, G; p > 0.05). Analysis of C5aR levels on circulating granulocytes revealed that cell 
surface expression of this receptor was significantly increased at 2 hours post-injury (Fig. 3.5H, I), 
suggesting a possible increase in responsiveness to C5a. There was, however, no difference in the 
level of C5aR expression between WT and C3ar
-/-
 mice at matching time points. Data from in vitro 
migration assays also indicated that BM neutrophil chemotaxis towards C5a was not different 
between genotypes (Fig. 3.7). Collectively, these results suggest that C3aR deficiency does not 
increase the levels of expression of granulocyte mobilising and chemotactic factors, or the 
responsiveness of granulocytes to C5a. 
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Figure 3.5: SCI leads to intramedullary haemorrhage and increased presence of granulocyte 
mobilising/chemotactic factors. Blood plasma and spinal cord (T11-13) samples were collected 
from sham-operated and SCI mice (at 2 hours post-injury). A: Haemoglobin content of the spinal 
cord was elevated in response to injury but was not different between WT and C3ar
-/-
 mice, 
indicating that microhaemorrhaging was not influenced by genetic ablation of C3aR. B, C: G-CSF 
levels were significantly increased in the plasma in response to SCI (B), while a consistent trend 
towards increased expression was also observed in the spinal cord (C). D, E: C5a levels were also 
increased in the plasma (D) and spinal cord (E) after injury. F, G: Levels of CXCL1, another potent 
granulocyte chemotactic factor, were also significantly increased in the plasma (F) and spinal cord 
(G) in response to SCI. No differences were detected between genotypes for matching time points. 
H, I: Surface expression of C5aR appeared elevated on circulating granulocytes in response to SCI, 
as evident from a significant increase in the mean fluorescence intensity (MFI) of C5aR staining, 
but was not affected by C3aR elimination. Bars represent the mean ± SEM; n = 5 per group; *, p < 
0.05; **, p < 0.01; ***, p < 0.001; one-way ANOVA with Newman-Keuls post hoc tests.  
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3.3.6 Absence of C3aR on circulating but not CNS cells worsens recovery from SCI.  
We theorised that if C3aR expression within the peripheral immune compartment is 
necessary to constrain the inflammatory response to SCI, then reinstating the expression of this 
receptor on leukocytes should rescue, at least in part, the worsened functional phenotype of C3ar
-/-
 
mice. We tested this hypothesis by generating [WT → C3ar-/-] as well as [WT → WT] and [C3ar-/- 
→ WT] BM chimeras. BMS scoring revealed that transplantation of WT BM into C3ar-/- recipients 
rescued the functional phenotype of genetic C3aR ablation, with [WT → C3ar-/-] BM chimeras 
recovering equally well from SCI as their [WT → WT] counterparts (Fig. 3.6A, B). In contrast, 
[C3ar
-/-
 → WT] BM chimeras phenocopied C3ar-/- mice and displayed significantly impaired 
recovery from SCI (Fig. 3.6A, B). These experiments demonstrate that expression of C3aR on 
circulating cells (but not within the CNS) is a critical determinant for the functional outcome from 
SCI. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: C3aR controls the outcome from SCI through negative regulation of granulocyte 
mobilisation in the peripheral immune compartment. A: [WT → C3ar-/-] (WT → KO) BM 
chimeras recovered equally well from SCI compared to [WT → WT] BM chimeras as determined 
by BMS scoring. [C3ar
-/-→WT] (KO → WT) BM chimeras recapitulated the phenotype of 
conventional C3ar
-/-
 mice, displaying significantly worsened recovery of locomotor function 
relative to [WT → WT] BM chimeras. Data points represent mean ± SEM; n = 7-15 per group; *, p 
< 0.05; **, p < 0.01; ***, p < 0.001; two-way ANOVA with Bonferroni post hoc tests comparing 
[WT → KO] and [WT → WT] with [KO→WT] mice. B: Dot plot showing individual BMS scores 
for experimental animals within each group at the study endpoint (35 days post-SCI). For this 
experiment, two cohorts of [WT → WT] BM chimeras were generated as control groups for 
[KO→WT] and [WT → KO] BM chimeras. BMS scores for these animals were pooled as the 
recovery of these two control groups was similar; the statistical outcome of the experiment was not 
affected by this. The black line represents the mean; n = 7-15 per group; ***, p < 0.001; one-way 
ANOVA with Newman-Keuls post hoc tests. 
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3.3.7 Specific depletion of Ly6G
+
 cells improves motor recovery in WT and C3ar
-/-
 mice 
Based on the outcome of our blood analysis and BM chimera experiments, we hypothesised 
that if augmented neutrophil mobilisation was driving the exacerbated immune response and 
worsened recovery from SCI in C3ar
-/-
 mice, then targeted ablation of these cells should restore 
functional recovery to a level that was at least comparable to WT mice. We directly tested this by 
selectively depleting neutrophils with α-Ly6G antibody treatment (neutrophil-specific clone 1A8). 
We first confirmed the efficacy of this antibody in depleting neutrophils in the blood, spleen, BM, 
and injured spinal cord for up to 72 hours post-SCI (Fig. 3.6C-H). Of note, significant 
granulocytosis was observed at this time point in C3ar
-/-
 + Iso mice compared to WT + Iso 
counterparts (C3ar
-/-
 + Iso: 0.94 ± 0.79 x 10
6
 cells/ml vs. WT + Iso: 0.20 ± 0.10 x 10
6
 cells/ml; p = 
0.0025). Regardless, α-Ly6G antibody treatment effectively depleted circulating Ly6C+ 
granulocytes in both genotypes (WT + α-Ly6G: 3.21 ± 1.71 x 103 cells/ml vs. C3ar-/- + α-Ly6G: 
2.42 ± 1.18 x 10
3
 cells/ml; p = 0.7409). Consistent with our earlier observations, blinded BMS 
scoring showed that C3ar
-/-
 + Iso mice recovered significantly worse than their WT + Iso 
counterparts at 28 (p < 0.05) and 35 (p < 0.01) days post-SCI (Fig. 3.6I, J). When treated with α-
Ly6G antibody, both WT and C3ar
-/-
 mice recovered significantly better than WT + Iso mice from 
21 days post-SCI onwards (p < 0.05 for day 21 and 28; p < 0.01 for day 35), highlighting the 
injurious role of Ly6G
+
 cells in this condition. Importantly, there were no differences in the 
recovery of WT + α-Ly6G and C3ar-/- + α-Ly6G groups; both groups regained significantly more 
locomotor function compared to C3ar
-/-
 + Iso mice from 14 days post-SCI onwards (p < 0.01 for 
day 14; p < 0.0001 for days 21, 28 and 35). Quantification of myelin content with experimenter 
blinding also indicated significantly improved SCI outcomes of WT and C3ar
-/-
 mice as a result of 
α-Ly6G treatment (Fig. 3.6K). Thus, selective depletion of Ly6G+ cells alleviates the C3ar-/- 
phenotype following SCI. 
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Figure 3.6 (cont.) C, D: Representative flow cytometry plots showing that Ly6C
+
SSC
hi
 cells (blue) 
are present in the blood (C) and spinal cord (D) after injection of an Isotype control antibody (Iso; 
top row) in both WT and C3ar
-/-
 mice, but are depleted at 72 hours following α-Ly6G treatment (α-
Ly6G; bottom row). E-H: Quantification of Ly6C
+
SSC
hi
 cells in various tissue compartments. The 
α-Ly6G treatment led to a dramatic reduction in the number of circulating Ly6C+SSChi cells present 
in the blood of WT mice up to 72 hours after SCI (E). Ly6C
+
SSC
hi
 cells were also significantly 
reduced in the spinal cord (F), spleen (G) and bone marrow (BM) (H). Bars represent the mean ± 
SEM; n = 3-5 per group; *, p < 0.05; ***, p < 0.001; ****, p < 0.0001; one-way ANOVA with 
Newman-Keuls post hoc tests. I: Depletion of Ly6G
+
 cells improves recovery from SCI and 
alleviates the functional phenotype of C3ar
-/-
 mice. Data points represent mean ± SEM; n = 5-9 per 
group; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; repeated measures two-way ANOVA with 
Bonferroni post hoc tests comparing indicated groups to C3ar
-/-
 + Iso group. J, K: Dot plots 
showing BMS scores (J) and myelin content (K) of individual animals within each experimental 
group at the study endpoint (35 days post-SCI). The black line represents the mean; n = 5-9 per 
group; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; one-way ANOVA with 
Newman-Keuls post hoc tests. 
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3.3.8 C3aR activation reduces cellular responsiveness to C5a gradients  
We lastly used an in vitro chemotaxis assay system to test whether C3aR signalling could act to 
antagonise the actions of neutrophil mobilising factors. We first established that C5a induced a 
significant but comparable chemotactic response of Ly6G-enriched WT and C3ar
-/-
 BM cells (Fig. 
3.7, left columns; p < 0.01). This effect was specific for C5aR, as C5ar
-/-
 cells did not respond to 
C5a (p = 0.37). Migration in the absence of C5a was similar between all genotypes (p = 0.42; data 
not shown). The selective C3aR peptide agonist WWGKKYRASKLGLAR (EP141; Wu et al., 
2013) alone did not induce a chemotactic response from Ly6G-enriched BM neutrophils (Fig. 3.7, 
middle columns; p = 0.23). Chemotactic responses to C5a were not different when C5a was added 
in combination with EP141 to the lower chamber (p = 0.44; data not shown). In contrast, addition 
Ly6G-enriched neutrophils, which had been incubated with EP141 just prior to the start of the 
migration assay, to the upper compartment completely counteracted the normal chemotactic 
response of WT cells to C5a (p = 0.003), down to levels that were not significantly different from 
baseline migration in the absence of C5a (p = 0.45; Fig. 3.7, right columns). No such effect of 
EP141 was observed for C3ar
-/-
 cells, which still showed a clear chemotactic response to C5a (p = 
0.01) that was not different from the normal migration of WT and C3ar
-/-
 cells towards C5a only (p 
= 0.72). Baseline migration (i.e. in the absence of C5a) was not affected by pre-exposure of the cells 
to EP141 for any genotype (p = 0.29; data not shown). Collectively, these findings demonstrate that 
activation of C3aR can oppose C5aR-mediated chemotaxis of Ly6G-enriched BM neutrophils.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: C3aR activation counteracts migration of Ly6G-enriched BM neutrophils toward 
C5a in vitro. WT and C3ar
-/-
 cells showed a significant but comparable chemotactic response to 
C5a over baseline conditions (left). C5ar
-/- 
cells did not respond to C5a, indicating that the 
migratory effect was specifically mediated via C5aR. Addition of the specific C3aR agonist EP141 
(10 μM) to the lower (L) compartment did not induce a chemotactic response (middle). Addition of 
EP141 to the upper (U) compartment completely abrogated the migration of WT but not C3ar
-/-
 
cells toward C5a. Bars represent mean ± SEM; n = 8-12 per group; *, p < 0.05; **, p < 0.01; one-
way ANOVA with Newman-Keuls post hoc tests. 
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3.4 Discussion 
 
3.4.1 Complement activation peaks in the acute phase of SCI  
Previous immunohistochemical studies have documented widespread presence of 
complement products in response to SCI (Anderson et al., 2004). Increased expression of negative 
complement regulators, factor H and clusterin, have also been observed, perhaps representing an 
endogenous attempt to restrain the amplification of damaging complement-mediated inflammatory 
responses in the injured spinal cord (Anderson et al., 2005). The precise temporal profile of 
complement activation following SCI has, however, not been quantified to date.  Complement split 
products, including the anaphylatoxins, are only present when complement activation occurs, and 
are not altered by acute phase responses, allowing a static appraisal of an extremely dynamic 
process (Liu et al., 2004). We therefore first measured C3a levels in blood and spinal cord to obtain 
a more detailed, quantitative insight into the magnitude of complement activation and C3a 
generation at various time points after SCI. We show that rapid and robust complement activation 
occurs in response to SCI, with C3a tissue levels peaking at 1 day post-injury. The pattern of 
complement activation at the lesion site thus closely aligns with the dynamics of neutrophil 
infiltration (Kigerl et al., 2006; Beck et al., 2010). Levels of C5a, another complement activation 
product, were also elevated acutely after SCI.  
As neural cells naturally express relatively small amounts of complement regulatory 
proteins on their surface (Agoropoulou et al., 1996; Singhrao et al., 2000), the prevailing view has 
been that excessive and deregulated activation of the complement system is harmful and contributes 
significantly to secondary immune-mediated pathology following SCI (Brennan et al., 2012). 
Indeed, previous studies using gene knockout and/or pharmacological approaches to inhibit C1q 
(Galvan et al., 2008; Ankeny et al., 2009), factor B (Qiao et al., 2010), C3 (Dyer et al., 2005; Qiao 
et al., 2006; Guo et al., 2010), C3 convertase formation (Reynolds et al., 2004), C3b/C4b (Li et al., 
2010), and iC3b (Qiao et al., 2006), have all reported improved outcomes from SCI. However, a 
variety of complement effector mechanisms, including opsonisation and MAC formation, may have 
contributed to such outcomes, and the specific roles of signalling through the C3a-C3aR axis cannot 
be inferred from these findings.  
 
3.4.2 Absence of C3aR increases inflammation and worsens recovery from SCI 
Only a few studies have attempted to more directly probe the role of C3aR in acquired CNS 
injuries, but these mainly utilised a small molecule ligand, SB 290157, to pharmacologically inhibit 
C3aR (Ducruet et al., 2008; Garrett et al., 2009; Rynkowski et al., 2009). Importantly, full agonist 
activity on C3aR has also been reported for this compound (Mathieu et al., 2005; Therien, 2005), 
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leaving an unclear picture in relation to the interpretation of these findings. To resolve this issue, we 
used C3ar
-/-
 mice to more precisely define the role of this receptor in SCI pathology. In doing so, 
we uncovered a protective role for C3aR in the outcome from neurotraumatic events, with C3ar
-/-
 
mice showing impaired hindlimb locomotor function and increased tissue damage. This phenotype 
was accompanied by a significantly increased presence of Ly6b.2
+
 cell infiltrate, more Iba1
+
 
macrophages/microglia, and a greater CD3
+
 T lymphocyte infiltrate at the site of SCI compared to 
WT animals. These observations strongly argue against a dominant pro-inflammatory role for 
activation of the C3a-C3aR axis following traumatic SCI; rather, they point towards more immune-
regulatory and/or tissue-protective functions of C3aR in the context of SCI pathogenesis.  
Although previous reports have implicated the C3a-C3aR axis in neuroprotection (van Beek 
et al., 2001; Jarlestedt et al., 2013), neurotrophic factor expression from astrocytes and microglia 
(Heese et al., 1998; Jauneau et al., 2006), neurogenesis (Rahpeymai et al., 2006), migration and 
differentiation of neural progenitor cells (Shinjyo et al., 2009), and regeneration of the embryonic 
chick retina (Haynes et al., 2013), our experiments in BM chimeric mice showed that a lack of 
C3aR expression on CNS resident cells does not alter SCI outcomes. On the other hand, and 
consistent with the results of our Ly6G
+
 cell depletion experiments, select absence of this receptor 
within the peripheral immune compartment led to a phenotype that mirrored conventional C3ar
-/-
 
mice. These findings do not necessarily preclude a role for C3aR within the CNS and/or 
neuroimmune interactions following SCI. They do, however, demonstrate that the absence of C3aR 
activation on CNS cells is not the main mechanism for the exacerbated C3ar
-/-
 phenotype, and point 
towards a critical role for C3aR expression on circulating leukocytes in relation to SCI outcomes.  
 
3.4.3 C3aR regulates mobilisation and/or chemotaxis of Ly6C
+
SSC
hi
 cells following SCI 
Blood analysis revealed that C3ar
-/-
 mice have normal levels of circulating white blood cells 
under homeostatic conditions, but display acute granulocytosis in response to SCI. This phenotype 
could not be explained by altered expression of chemotactic signals, as the key mobilising factors 
G-CSF (Wang et al., 1988; Semerad et al., 2002), CXCL1 (Huber et al., 1991; Watanabe et al., 
1999), and C5a (Lee et al., 2009), were similarly increased in the circulation and spinal cord 
parenchyma of WT and C3ar
-/-
 mice after SCI. Elimination of C3aR also did not affect expression 
of the C5a receptor, C5aR, on the surface of circulating granulocytic neutrophils in the blood, nor 
the migration of these cells towards C5a in vitro. The acute increase in the number of circulating 
granulocytes in C3ar
-/-
 mice could also not be explained by differences in severity of the primary 
injury, as impact parameters were always comparable between genotypes based on analysis of the 
actual applied force and associated tissue displacement. Lastly, haemoglobin levels within the 
injured spinal cord parenchyma were also similar between WT and C3ar
-/-
 mice at 2 hours post-
Chapter 3: C3aR ablation leads to granulocytosis and exacerbates SCI   96 
injury. With platelet coagulation and fibrin deposition normally occurring within minutes of 
contusive SCI (Goodman et al., 1979), it also seems unlikely that the C3ar
-/-
 phenotype could have 
resulted from increased microhaemorrhaging as a result of C3aR absence (Fukuoka and Hugli, 
1988; Sauter, 2012). We therefore postulate that C3aR normally exerts a protective effect in SCI by 
negatively regulating the mobilisation of granulocytic neutrophils. 
Using a gut ischaemia-reperfusion injury model, we previously showed that C3aR indeed 
appears to promote retention of granulocytic neutrophils in the BM (Wu et al., 2013), although the 
actual mechanism pertaining to this has remained unclear. The in vitro chemotaxis experiments in 
the present study now provide direct evidence that C3a can act as a physiological antagonist of the 
C5a-C5aR axis, which is an important pathway for granulocyte egress and mobilisation (Kajita and 
Hugli, 1990). Polymorphonuclear leukocytes are the first white blood cells to enter the injured 
spinal cord (Kigerl et al., 2006; Beck et al., 2010), and their increased presence in C3ar
-/-
 mice 
likely generated a microenvironment that amplified all ensuing inflammatory responses, with the 
ultimate result being an exacerbated secondary immunopathology and worsened functional and 
anatomical outcomes from SCI. Targeted depletion of Ly6G
+
 neutrophils indeed alleviated the 
C3ar
-/-
 phenotype and improved overall recovery. These observations are consistent with previous 
studies suggesting injurious effects of these cells in SCI pathology (Taoka et al., 1997; Fleming et 
al., 2008), although it must also be acknowledged that other studies have reported only slight 
improvements (Lee et al., 2011; Saiwai et al., 2013) or a worsened functional outcome (Stirling et 
al., 2009; Saiwai et al., 2013) following granulocyte depletion. It is important to note, however, that 
in the latter study, an α-Gr-1 antibody (clone RB6-8C5) was used, which recognises Ly6G and 
Ly6C and thus also depletes Ly6C
+
 monocytes. As far as direct comparisons can be made, other 
notable differences with previous reports include a more severe injury used in the present study, 
which may have meant that a treatment effect observed here would not been detected previously 
due to the non-linearity of the BMS scale. Indeed, a trend towards improved functional recovery 
(Saiwai et al., 2013) and myelin sparing (Lee et al., 2011) appeared to have been present following 
anti-Ly6G antibody (clone 1A8) treatment.  
In summary, C3aR signalling has been mostly regarded as a classical pro-inflammatory 
pathway in CNS disease. The present findings do, however, point towards a key immune-regulatory 
role for the C3a-C3aR axis in the context of SCI, where it can restrain granulocyte mobilisation in 
response to injury-induced chemotactic signals such as C5a. The importance of C3aR in 
suppressing the magnitude of the peripheral inflammatory response in acute SCI should therefore 
not be overlooked, and targeted activation of this receptor on neutrophils thus warrants 
consideration as a possible treatment option during the acute management of neurotraumatic events. 
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Figure 3.8: Schematic diagram showing a working model for the proposed regulatory role of 
the C3a-C3aR axis in the cellular inflammatory response to SCI. Traumatic injury to the spinal 
cord leads to robust complement activation and increased C3a and C5a levels. C5a, along with other 
mobilising/chemotactic factors such as G-CSF and CXCL1 promote the release of granulocytes into 
the circulation. These cells then migrate to the lesion site where they contribute to 
neuroinflammatory processes associated with secondary injury. Interaction of C3a with its receptor 
C3aR reduces the sensitivity of granulocytic neutrophils to mobilising/chemotactic signals, which 
limits the release of these cells and thus controls the severity of the inflammatory response to SCI. 
Information obtained from the current chapter, as well as: Ward and Newman (1969); Wang et al. 
(1988); Kajita and Hugli (1990); Huber et al. (1991); Watanabe et al. (1999); Semerad et al. (2002); 
Anderson et al. (2004); Suratt et al. (2004); Lee et al. (2009); Kohler et al. (2011); Wu et al. (2013). 
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Supplementary Material 
 
 
 
 
 
 
 
 
 
 
Figure S3.1: Gating strategy for circulating granulocytes. A:  A defined number of fluorescent 
counting beads (Beckman Coulter) were added to each sample to allow for accurate determination 
of absolute cell counts. B: Single cells were gated and doublet cells excluded with FSC-A and FSC-
H linearity. C: Characteristic FSC/SSC plot of the single cell population gated in A and B. D: Dead 
cells were excluded based on positive Zombie Green staining (BioLegend); live cells do not stain 
with this dye. Live Gr-1+ cells (D
1
) were then gated into granulocytes (Gr-1
+
SSC
hi cells, blue 
population) and inflammatory monocytes (Gr-1
+
SSC
lo cells, green population) based their position 
in SSC-A/Gr-1 plots (E). F: Characteristic FSC/SSC contour plot of granulocytes (blue) and Gr-1
+
 
inflammatory monocytes (green). Isotype control antibodies (BD Biosciences) were matched for 
fluorophores and used to determine gate placement. Compensation was applied after data 
acquisition to remove spectral overlap between Zombie Green and Alexa Fluor 546 (Gr-1 staining).  
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Abstract 
 
This study investigated the role of the complement activation fragment C5a in secondary 
pathology following contusive spinal cord injury (SCI). C5ar
-/-
 mice, which lack the signalling 
receptor for C5a, displayed signs of improved locomotor recovery and reduced inflammation during 
the first week of SCI compared to wild type mice. Intriguingly, the early signs of improved 
recovery in C5ar
-/-
 mice deteriorated from day 14 onward, with absence of C5aR ultimately leading 
to poorer functional recovery, larger lesion volumes, reduced myelin content and more widespread 
inflammation at 35 days post-SCI. Pharmacological blockade of C5aR with a selective antagonist 
(C5aR-A) during the first 7 days post-SCI improved recovery compared to vehicle-treated mice, 
and this phenotype was sustained up to 35 days after injury. Consistent with observations made in 
C5ar
-/-
 mice, these improvements were, however, lost if C5aR-A administration was continued into 
the more chronic phase of SCI. Signalling through the C5a-C5aR axis thus appears injurious in the 
acute period but serves a protective and/or reparative role in the post-acute phase of SCI. Further 
experiments in bone marrow chimeric mice suggested that the dual and opposing roles of C5aR on 
SCI outcomes primarily relate to its expression on CNS-resident cells and not infiltrating 
leukocytes. Additional in vivo and in vitro studies provided direct evidence that C5aR signalling is 
required during the post-acute phase for astrocyte hyperplasia, hypertrophy, and glial scar 
formation. Collectively, these findings highlight the complexity of the inflammatory response to 
SCI and emphasise the importance of optimising the timing of therapeutic interventions.  
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4.1 Introduction 
 
The complex inflammatory response to traumatic spinal cord injury (SCI) contains elements 
that are known to be required for successful wound healing in other tissues; in  context of central 
nervous system (CNS) injury these can, however, also cause additional damage to spared neural 
tissue (Donnelly and Popovich, 2008). A more in-depth understanding of these seemingly opposing 
roles of inflammation is therefore required, such that new and effective immune-modulatory 
therapies can be developed to improve recovery from SCI, and potentially other acquired CNS 
injuries. The innate immune complement system, composed of more than 30 soluble and 
membrane-bound proteins, receptors and regulators, is a major component of trauma-induced 
neuroinflammation (Anderson et al., 2004; Brennan et al., 2012). Previous studies have already 
shown that SCI outcomes can be improved through genetic deletion or pharmacological blockade of 
complement opsonins (Ankeny et al., 2009), the lytic membrane attack complex (MAC; Li et al., 
2009), as well as more general interference with the main (i.e. classical, lectin and alternative) 
pathways for complement system activation (Reynolds et al., 2004; Qiao et al., 2006; Guo et al., 
2010; Qiao et al., 2010). The role of the C5a activation fragment in the immune response to SCI 
remains, however, uncertain.  
C5a is a 74 amino acid peptide that is generated by the proteolysis of complement protein 
C5. It is known to be a potent chemoattractant molecule through interaction with its G protein-
coupled receptor C5aR (CD88) (Ward and Newman, 1969), which is present on most leukocytes 
(Chenoweth and Hugli, 1978; Chenoweth et al., 1982). In the CNS, C5aR expression has been 
reported on neurons (Stahel et al., 1997; O'Barr et al., 2001; Benard et al., 2004; Woodruff et al., 
2006; Humayun et al., 2009), astrocytes (Gasque et al., 1995; Lacy et al., 1995; Woodruff et al., 
2008b), microglia (Lacy et al., 1995; Griffin et al., 2007), oligodendrocytes (Nataf et al., 2001), and 
neural progenitor cells (Farkas et al., 1999; Rahpeymai et al., 2006).  
Previous in vivo studies have shown that parenchymal C5a/C5aR expression is increased in 
models of traumatic brain injury (Stahel et al., 1997), intracerebral hemorrhage (Xi et al., 2001), 
and ischemic injury (van Beek et al., 2000; Pavlovski et al., 2012), as well as in the plasma of 
human patients with stroke (Mocco et al., 2006b) and subarachnoid haemorrhage (Mack et al., 
2007). More importantly, acute inhibition of the C5a-C5aR axis improves outcomes from 
experimental ischemic stroke (Kim et al., 2008; Pavlovski et al., 2012) and intracerebral 
haemorrhage (Garrett et al., 2009). Intriguingly, while acute C5aR blockade is thought to attenuate 
inflammation, delayed antagonism of this receptor, starting 2 weeks post-injury, led to significantly 
exacerbated SCI outcomes (Beck et al., 2010). These findings suggest a novel 
neuroprotective/reparative role for C5aR signalling in the post-acute phase of neurotrauma, 
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although the mechanisms behind these observations are poorly understood. In the present study, we 
used C5aR knockout (C5ar
-/-
) mice, pharmacological targeting of C5aR, bone marrow chimeras, 
and in vitro studies to better understand the role of the C5a-C5aR axis in SCI.  
 
4.2 Materials and Methods 
 
4.2.1 Animals 
Adult female age- and weight-matched C57BL6/J (wild type (WT); n = 147), C5ar
-/- 
(n = 
62) (Hollmann et al., 2008) and Macgreen (Csf1r-EGFP, n = 24) (Sasmono et al., 2003) mice were 
used in this study. C5ar
-/-
 and Macgreen mice had been backcrossed for more than 10 generations 
onto the C57BL6/J genetic background. All animals were obtained from local breeding colonies at 
The University of Queensland’s Biological Resources facility. Mice were maintained in 
individually ventilated cages (IVCs) under standard conditions on a 12 hour light-dark cycle with 
ad libitum access to food and water. All experimental procedures were approved by The University 
of Queensland’s Animal Ethics Committee and conducted in accordance with the relevant National 
Health and Medical Research Council of Australia policies. 
 
4.2.2 Spinal cord injury 
Mice were anaesthetised with a mixture of tiletamine/zolezepam (50 mg/kg; Virbac) and 
xylazine (20 mg/kg; Troy Laboratories), after which they underwent contusive SCI. In brief, this 
involved identification of the ninth thoracic (T) vertebra based on anatomical landmarks (Harrison 
et al., 2013), followed by dorsal laminectomy of T9 as described previously (Scheff et al., 2003; 
Blomster et al., 2013a). Next, a severe (~ 70 kdyne) contusion injury was inflicted on the spinal 
cord using the Infinite Horizon impactor device (Precision Systems and Instrumentation). 
Following this, muscle and skin were closed separately using 6-0 polyglactin dissolvable sutures 
(Ethicon) and Michel wound clips (Kent Scientific), respectively. Investigators performing surgery 
were blinded to the genotype and/or treatment condition of the animals. Postoperatively, animals 
received a single injection of buprenorphine (0.5 mg/kg s.c.) in Hartmann's sodium lactate solution 
for analgesia, and were administered antibiotics (1.0 mg/kg gentamicin s.c.) for the first 5 days 
post-injury. Bladders were manually voided twice daily for the duration of the experiments.  
 
4.2.3 C5a Enzyme-linked immunosorbent assay (ELISA) 
To determine the time course of C5a generation following SCI, WT mice were subjected to 
either SCI or sham surgery and then euthanized with sodium pentobarbitone (100 mg/kg i.p., 
Virbac) at either 30 mins, 2 hours, 6 hours, 12 hours, 1 day, 4 days, 7 days, or 35 days post-injury 
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(n = 4-5 per time point). An additional 4 unoperated (i.e. naïve) mice were used to assess C5a levels 
under normal homeostatic conditions (time point ‘0’).  
At the appropriate time point, 0.5 ml volume of blood collected directly from the heart via 
cardiac puncture using a syringe containing 30 μl of 4 mM EDTA. Blood samples were mixed 
immediately with 10 μl of the complement inhibitor FUT175 (5 mg/ml; BD Biosciences) and stored 
on ice. Samples were centrifuged at 13 000 x g for 10 minutes at 4 ̊C, after which the supernatant 
was collected, aliquoted, and stored at -80 ̊C. The T11-T13 spinal cord segment was also dissected 
immediately after the cardiac bleed, snap frozen in liquid nitrogen and then stored at -80 ̊C. Spinal 
cord samples were ground to a fine powder using a mortar and pestle on dry ice, then dissolved in 
200 µl of NP-40 lysis buffer (Invitrogen) containing 1 mM PMSF (reconstituted in DMSO) (Sigma-
Aldrich), 92.6 M FUT175 (BD Biosciences), and 5 l of protease inhibitor cocktail (Sigma-
Aldrich). Samples were vortexed for 1 minute, incubated on ice for 1 hour, then centrifuged at 13 
000 x g for 30 minutes at 4 ̊C. Supernatants were collected, aliquoted, and stored at -80 ̊C. An 
ELISA (R&D Systems, #DY2150) was then used to determine the concentration of C5a in blood 
plasma and spinal cord samples according to the manufacturer’s instructions; all samples were 
detected within the linear aspect of the standard curve. For spinal cord samples, the measured 
concentration of C5a was always normalised to the protein concentration of the sample, which was 
measured by a BCA protein assay (Thermo Scientific #23227) according to the manufacturer’s 
instructions.   
 
4.2.4 Tissue processing for magnetic resonance imaging (MRI) and histology 
Mice were anaesthetised with sodium pentobarbitone (100 mg/kg i.p., Virbac) at their 
specified endpoints (see Results section for details). Mice were then transcardially perfused with 20 
ml of saline (0.9% NaCl) containing 10 IU/ml heparin (Pfizer) and 2% NaNO3, followed by 30 ml 
of phosphate-buffered Zamboni’s fixative (2% picric acid, 2% formaldehyde, pH 7.2-7.4). The 
perfused vertebral column was then dissected out and post-fixed overnight at 4C. Spinal cord 
specimens were then imaged where applicable (MRI, see below), dissected out from the vertebral 
column and cryoprotected via subsequent overnight incubations in 10% and 30% sucrose solutions. 
Next, the lesion segment of the spinal cord was embedded in Optimal Cooling Temperature (OCT) 
compound (ProSciTech), snap-frozen using dry ice-cooled isopentane, and then stored at -80 ̊C until 
sectioning. Coronal sections (20 μm thick) were cut on a Leica cryostat CM3050-S, collected on 
Superfrost Plus slides (1:5 series; Lomb Scientific) and stored at -80 ̊C until staining. 
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4.2.5 Analysis of C5aR Expression 
Immunofluorescent staining techniques were used to assess the expression and distribution 
of C5aR in the injured spinal cord. A rat anti-C5aR antibody (clone 10/92, 1:200; Serotec) was used 
for these experiments. Antibody specificity was confirmed through staining of spinal cord tissue 
from injured C5ar
-/-
 mice, as well as omission of the primary antibody incubation step on WT 
tissue. Staining for C5aR was combined with immunolabelling for ionised calcium binding adaptor 
molecule 1 (rabbit anti-Iba1, 1:500; Wako Pure Chemical Industries) to label 
microglia/macrophages, or with glial fibrillary acidic protein (rabbit anti-GFAP, 1:1000; Dako) to 
identify astrocytes. Slides were defrosted for 1 hour at room temperature (RT) and then washed in 
PBS (3 x 10 minutes). Next, slides were incubated in blocking solution (0.2% Triton X-100 (Sigma-
Aldrich), 2% bovine serum albumin (BSA; Sigma-Aldrich) in PBS) for 1 hour at RT to 
permeabilise the sections and reduce non-specific antibody binding. This solution was also used as 
the antibody diluent. After blocking, spinal cord sections were incubated overnight at 4 ̊C with 
primary antibodies in a humidified chamber. The following day, slides were washed in PBS (3 x 10 
minutes) to remove unbound antibody, followed by incubation with secondary antibodies (goat anti-
rat IgG-Alexa Fluor 555 (1:500; Invitrogen) and goat anti-rabbit IgG-Alexa Fluor 488 (1:200; 
Molecular Probes) for 1 hour at RT. Slides were then washed again in PBS (3 x 10 minutes), cover-
slipped with Dako fluorescent mounting medium containing Hoechst 33342 nuclear dye (1:1000; 
Sigma-Aldrich), and imaged using an Olympus BX61 confocal microscope. 
 
4.2.6 Assessment of functional recovery  
Mouse hindlimb locomotor recovery in WT and C5ar
-/-
 mice was assessed at 1, 3, 7, 10, 14, 
21, 28 and 35 days post-injury using the ten point Basso Mouse Scale (BMS), which is specifically 
designed for mouse models of SCI (Basso et al., 2006). Two investigators assessed various aspects 
of each mouse’s locomotion in open field for four minutes. For mice that achieved a score of 
frequent plantar stepping (i.e. a BMS score 5), BMS subscores were also assigned to quantify the 
finer aspects of locomotion. For the initial experiments comparing the recovery of WT and 
conventional C5ar
-/-
 mice, the actual applied force was 71.9 ± 0.56 kdyne (n = 12, mean ± SEM) 
and 72.2 ± 0.52 kdyne (n = 8, mean ± SEM), with an average tissue displacement of 593.4 ± 6.57 
μm (mean ± SEM) and 597.4 ± 9.71 μm (mean ± SEM), respectively. There were no significant 
differences in injury parameters between experimental groups (p > 0.05). 
For pharmacological studies involving C5aR antagonism during the first week of injury (see 
below, C5aR-A treatment), ledged tapered beam walking was used as a second, independent 
measure to assess hindlimb locomotor ability. The beam itself, which was elevated 1 m above the 
floor, was 90 cm long and had a starting width of 3 cm that narrowed to 0.5 cm at the end. Mice 
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were trained to cross the beam for 5 consecutive times during 2 days of habituation trials prior to 
the testing day. On the test day itself (35 days post-SCI), each mouse was again required to cross 
the beam 5 times and videotaped while performing the task. The total number of steps, the number 
of footfalls, and the traversing time were recorded. For each animal, the mean data from the five 
crossings was calculated for each of these parameters. A group of sham-operated Macgreen mice (n 
= 6) was included to determine baseline performance for this functional task. Assessors were 
blinded to the experimental condition (genotype / treatment group) during all behavioural testing to 
avoid experimenter bias. 
 
4.2.7 MRI 
 For post-mortem MRI analysis at 35 days post-injury, spinal cord samples were washed 
extensively in 0.1 M phosphate-buffered saline (PBS) after overnight post-fixing, followed by 
immersion for 48 hours in PBS containing gadolinium contrast agent (0.2% Magnevist, Bayer 
HealthCare Pharmaceuticals). Vertebral columns with the spinal cord in situ were imaged on a  
16.4 T small animal MRI (Bruker BioSpin) as detailed elsewhere (Blomster et al., 2013b). A stack 
of 256 two dimensional T2 slices was generated for each imaged specimen. MRI datasets were 
analysed using AVIZO v6.2 software (Visualisation Sciences Group), with an orthoslice along the 
sagittal plane and two user-defined (oblique) slices along the coronal and transverse planes, 
respectively. The Apply-Transform function was used to set these axes as the reference points for 
further analyses. A three dimensional image of the lesion core was reconstructed by manually 
outlining the hypointense core in the coronal plane of every slice using the Lasso tool; the sagittal 
and transverse planes were also viewed to confirm that the complete lesion core was highlighted. As 
areas of demyelination can be difficult to distinguish from remnants of spared grey matter, only the 
hypointense core was outlined for reconstruction and calculation of lesion volumes. Image 
quantification was performed with the investigator blinded to the experimental group.   
 
4.2.8 General staining procedures and analysis of histopathology  
FluoroMyelin Red staining (1:150; Molecular Probes) was performed as per the 
manufacturer’s instructions to assess white matter myelin content at and around the lesion site 
(Blomster et al., 2013a). FluoroMyelin Red staining was combined with immunostaining for GFAP 
as detailed above, except for experiments that involved Macgreen mice, where a separate set of 
sections were stained for GFAP using a goat anti-rabbit IgG-Alexa Fluor 546 secondary antibody 
(1:250; Molecular Probes). Stained spinal cord sections were photographed using an Olympus 
SZX12 Research Fluorescence Stereo Microscope (Spectra Services). The proportional area of 
myelin and GFAP staining (relative to the section area) was measured using the freehand selection 
Chapter 4: C5aR controls inflammation and astrogliosis in SCI         106 
tool and threshold functions in ImageJ. The average pixel intensity for GFAP immunofluorescence 
was also determined as detailed previously (Schmid et al., 2013). For each experimental animal, the 
lesion epicentre was defined as the coronal section with the least amount of FluoroMyelin Red 
staining relative to the section area (Blomster et al., 2013a). Image acquisition and data analysis was 
again performed with experimenter blinding.  
To evaluate the cellular immune response in the injured spinal cord, immunohistochemical 
staining with rat anti-Ly6b.2 (1:400; AbD Serotec) was used to visualise infiltrating neutrophils 
(and a subset of inflammatory monocytes) (Rosas et al., 2010). Rat anti-CD11b (1:200; AbD 
Serotec) was used to label granulocytes, macrophages and microglia. Rat anti-CD3 (1:400; AbD 
Serotec) was used to stain T lymphocytes. For all of these stains, slides were first washed in PBS (3 
x 10 minutes). To quench endogenous peroxidase activity, slides were incubated at RT in PBS 
containing 10% methanol for 10 minutes, then incubated for 20 minutes at RT in PBS containing 
10% methanol and 0.3% H2O2. Slides were then washed again in PBS (3 x 10 minutes) and 
incubated with blocking solution for 1 hour at RT, before overnight incubation with primary 
antibody in a humidified chamber at 4 ̊C. The following day, slides were washed in PBS and 
incubated for 1.5 hours at RT with biotinylated donkey anti-rat IgG (1:250; AbD Serotec). Sections 
were then washed again in PBS (3 x 10 minutes) and incubated with Vectastain Elite ABC reagent 
(1:200; Vector Laboratories) for 1 hour at RT. After another set of 3 x 10 minute washes in PBS, 
the staining was developed by incubating each slide for 5 minutes at RT with 0.5 ml of 3,3-
diaminobenzidine (Sigma-Aldrich). Stained sections were dehydrated through graded series of 
ethanol (70-100%), washed twice in xylene, and cover-slipped using Depex mounting media 
(Electron Microscopy Sciences). Immunohistochemically stained slides were digitised using a 
ScanScope XT scanner (Aperio) and ImageScope (Leica Biosystems).  
For quantitative analysis, Ly6b.2
+
 and CD3
+
 cell numbers in the spinal cord were counted 
using the manual tag function in ImagePro Plus Version 6.3 (Media Cybernetics) and expressed as 
number of cells per mm
2
 based on the section area outlined in ImageJ. The CD11b
+
 immune 
infiltrate was quantified and expressed as a proportional area of the section (Kigerl et al., 2006). 
The analyser was blinded to the experimental condition during counting and image analysis.  
 
4.2.9 C5aR-A treatment 
A cohort of Macgreen mice was used for pharmacological inhibition of C5aR during the 
acute/sub-acute phase. These mice underwent SCI as described above, then administered either the 
cyclic C5aR peptide antagonist (C5aR-A; [hydrocinnamate-(OPdChaWR)], 1 mg/kg, i.p., n = 8) 
(Finch et al., 1999) or a vehicle solution (5% glucose, i.p., n = 10). Treatment started at 30 minutes 
post-injury and was repeated every 12 hours for the first 7 days post-injury. The actual applied force 
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for this experiment was 72.5 ± 0.65 kdyne and 72.5 ± 0.54 kdyne (mean ± SEM) for vehicle-treated 
and C5aR-A-treated mice, respectively. The associated tissue displacement was 539.2 ± 7.5m and 
528.7 ± 12.4 m (mean ± SEM), respectively. There were no differences in injury parameters 
between groups (p > 0.05). These mice were subjected to BMS scoring, ledged tapered beam 
walking and post-mortem analysis of histopathology, all as detailed earlier.  
In a separate experiment, WT mice were subjected to SCI and treated with either C5aR-A (n 
= 4) or vehicle (n = 5) as detailed above, every 12 hours until the experimental endpoint of 21 days 
post-SCI. The actual applied force here was 72.0 ± 1 kdyne (mean ± SEM) for C5aR-A-treated 
mice and 72.60 ± 0.68 kdyne (mean ± SEM) for vehicle-treated controls; the associated tissue 
displacement was 534.7 ± 25.9 m and 522.7 ± 29.7m (mean ± SEM), respectively. A cohort of 
C5ar
-/-
 mice (n = 5) was also included in this experiment; the applied force for these animals was 
72.8 ± 0.8 kdyne (mean ± SEM), with an associated tissue displacement of 521.6 ± 33.4 m (mean 
± SEM). There were no differences in injury severity parameters between experimental groups (p > 
0.05). All of the animals in this experiment were also injected with the thymidine analog 5-bromo-
2’-deoxyuridine (BrdU; BD Biosciences, 50 mg/kg, i.p.), every 24 hours for the first 7 days post-
SCI to label proliferating cells (see below). This period was chosen for BrdU injection as it is 
thought to capture the onset of oligodendrocyte precursor cell and astrocyte proliferation after 
rodent CNS trauma (Bush et al., 1999; Zai and Wrathall, 2005; Lytle and Wrathall, 2007; Tripathi 
and McTigue, 2007; Wanner et al., 2013). Functional recovery in this experiment was monitored 
via BMS scoring with investigator blinding.  
 
4.2.10 Cytokine quantification  
For analysis of cytokine levels in acute SCI, the injured spinal cord segment (vertebral 
levels T8-T10) from both WT and C5ar
-/-
 mice was collected at 12 hours post-SCI (n = 5 per group) 
and processed as detailed (see C5a Enzyme-linked immunosorbent assay (ELISA) section). This 
segment of spinal cord was also collected from sham-operated (i.e. laminectomy with no 
subsequent SCI) WT and C5ar
-/-
 mice to establish baseline cytokine levels (n = 4 per group).  
The concentrations of CXCL1 and IL-1β in spinal cord supernatants were determined using 
cytokine Flex Sets (BD Biosciences #558340 and #560232, respectively). Levels of IL-12p70, 
TNFα, IFNγ, MCP-1, IL-10 and IL-6 were also determined using a Cytometric Bead Array (BD 
Biosciences #552364) as per the manufacturer’s instructions. The latter samples were analysed on 
an LSRII flow cytometer (BD Biosciences), and concentrations computed using FCAP array v3.0 
software. For all assays, samples were appropriately diluted, such that they were always detected 
within the linear aspect of the standard curves. The calculated cytokine concentrations were 
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normalised to the total protein content of each sample, which was measured by a BCA protein assay 
(Thermo Scientific #23227) according to the manufacturer’s instructions.   
 
4.2.11 Flow cytometry 
Flow cytometry was used to quantify the inflammatory infiltrate in the injured spinal cord at 
7 days post-SCI. In brief, injured spinal cord of WT and C5ar
-/-
 mice (T11-13 segments) were 
dissociated as reported elsewhere (Beck et al., 2010; Blomster et al., 2013a). Cells were then 
resuspended in flow cytometry blocking buffer (0.5% BSA, 2 mM EDTA, in DPBS, pH 7.2), 
followed by incubation with rat-anti-CD16/32 (1:200; BD Biocience) for 10 mins at 4 ̊C to block Fc 
receptors. Cells were immunolabelled with rat anti-Ly6G-Alexa 647 (1:200, BD Bioscience), rat 
anti-Ly6C-V450 (1:200; BD Bioscience), and rat anti-CD45-PE (1:200; BD Bioscience). For the 
exclusion of dead cells, samples were also incubated with near infrared-conjugated viability dye 
(Zombie NIR, 1:100; Biolegend). Stained samples were then analysed using an LSR II flow 
cytometer (BD Biosciences) and BD FACS Diva software. After acquisition, compensation was 
applied to remove Zombie NIR/Ly6G-Alexa 647 spectral overlap; cell doublets, triplets, etc. were 
excluded based on FSC-A/FSC-H linearity. Inflammatory monocytes/macrophages were defined as 
the CD45
hi
Ly6C
+
Ly6G
-
 population, and neutrophils as the CD45
+
Ly6C
+
Ly6G
+
 population. 
Propidium iodide-fluorescing counting beads (5 μl; Beckman Coulter) were added as an internal 
control to enable quantification of absolute cell numbers according to the manufacturer's 
instructions. 
 
4.2.12 Bone marrow (BM) chimeras 
To assess the impact of selective C5aR deletion within the peripheral immune compartment 
on recovery from SCI, [WT → WT] (n = 6), and [C5ar-/- → WT] (n = 7) BM chimeric mice were 
generated as detailed previously (Chinnery et al., 2010). These mice were allowed to recover for 8 
weeks after chimerisation before being subjected to SCI surgery as detailed above. For this 
experiment, the actual applied force was 72.86 ± 0.80 kdyne vs. 72.29 ± 0.87 kdyne (mean ± SEM), 
with an associated tissue displacement of 518.6 ± 14.9 μm and 511.1 ± 12.18 μm (mean ± SEM) for 
[WT → WT] and [C5ar-/- → WT] BM chimeras, respectively. There were no significant differences 
in injury parameters between experimental groups (p > 0.05). SCI outcomes for these mice were 
assessed via BMS scoring and post-mortem analysis of histopathology as detailed earlier. 
 
4.2.13 Assessment of glial cell proliferation and apoptosis 
Spinal cord tissue from mice that were chronically treated with C5aR-A, and also 
administered BrdU during the first week following SCI, was used to determine whether C5aR 
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targeting influenced the proliferative response(s) of oligodendrocyte precursor cells and astrocytes 
(study endpoint: 21 days post-SCI). Immunofluorescent staining of spinal tissue was employed 
using similar procedures as described above, but with the inclusion of a denaturing step (20 minutes 
incubation in 2 N HCl at 37 ̊C) to expose the BrdU epitope within the nuclear DNA. After blocking, 
sections were probed with rat anti-BrdU antibody (1:100; Serotec) in combination with rabbit anti-
GFAP (1:1000; Dako) for astrocytes, or mouse anti-CC1 (1:100; Abcam) for oligodendrocytes. For 
the latter, the HistoMouse kit (Life Technologies) was used as per the manufacturer’s instructions to 
allow for the use of mouse primary antibodies on mouse tissue. An incubation with biotinylated 
donkey anti-rat IgG (1:200; Vector Laboratories) secondary antibody (1 hour at RT) was followed 
by a 1 hour incubation with streptavidin-Alexa Fluor 546 (1:200; BD Biosciences), combined with 
either goat anti-rabbit IgG-Alexa Fluor 488 (1:200; Invitrogen) for GFAP staining, or with goat 
anti-mouse IgG-Alexa Fluor 488 (1:200; Molecular Probes) for CC1 staining. Tiled optical sections 
were captured on a Zeiss fluorescence microscope with ApoTome attachment, after which the total 
BrdU
+
GFAP
+
 or BrdU
+
CC1
+
 cell numbers were counted in spinal cord cross-sections at regular 
intervals away from the lesion epicentre, with the analyser being blinded to the experimental 
condition. Section areas were measured in ImageJ (up to 1 mm in rostral and caudal directions), 
allowing the cell count to be expressed as number of cells per mm
2
. Lesion volumes in these 
animals were estimated by outlining the lesion core area (delineated by GFAP staining) in every 
relevant section using ImageJ; obtained values were then multiplied by the section thickness and 
totalled for each animal.  
 To also compare and contrast oligodendrocyte cell death between the various genotypes 
and/or experimental conditions at the study endpoint, a separate set of sections were stained for 
CC1 and active Caspase-3 (anti-Cleaved Caspase-3 rabbit polyclonal; 1:200; BD Pharmingen). The 
number of CC1
+ 
Cleaved Caspase-3
+
 cells were then counted within each section and expressed as 
the number of cells per mm
2
 based on the section area outlined in ImageJ. The analyser was again 
blinded to the experimental condition during analysis.  
 
4.2.14 In vitro astrocyte proliferation 
Astrocyte cultures were established from the brains of WT or C5ar
-/-
 pups (P1-P3; n = 8 per 
culture) (Gordon et al., 2011)). In brief, brains were harvested, the meninges removed, and the 
tissue placed in ice-cold Dulbecco's modified Eagle's medium/F-12 nutrient mixture (DMEM-F12, 
GIBCO, #11320) supplemented with 10% heat-inactivated foetal bovine serum (FBS), 50 U/ml 
penicillin, 50 μg/ml streptomycin, 2 mM l-glutamine, 100 μM non-essential amino acids, and 2 mM 
sodium pyruvate (Invitrogen). The tissue was then incubated in 0.25% trypsin (Sigma-Aldrich) at 
37 ̊C for 30 minutes with gentle agitation. Trypsinization was stopped by adding an equal volume of 
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DMEM/F12 complete media, followed by three washes in the same media. A single cell suspension 
of the tissue was prepared by gentle trituration and passing of the solution through a 70 μm nylon 
mesh cell strainer to remove tissue debris and aggregates, after which the remaining cell suspension 
was seeded into two T-75 flasks per mouse brain. Primary astrocytes were purified by daily media 
changes for three days and residual microglial cells were maximally depleted by treatment with the 
lysosomotropic agent leucine methylester (5 mM) for 6 hours to obtain ~98% pure astrocytes. The 
purity of astrocyte cultures was routinely verified by immunocytochemistry for GFAP and Iba1.  
For the proliferation assay, purified astrocytes were plated out at a density of either 0.5 or 1 
x 10
4
 cells per well in a 48 well plate with media containing DMEM/F12, 10% FBS, 1% non-
essential amino acids, 1% penicillin/streptomycin, 1% L-glutamine, and 1% sodium pyruvate. The 
next day, cells were switched to media containing 2% FBS and recombinant mouse C5a (Hycult 
Biotech) was added at a concentration of 0 nM, 5 nm, 10 nm, 50 nM, 100 nM or 200 nM in 
triplicate. For experiments that aimed to determine if phosphorylation of Signal Transducer and 
Activator of Transcription 3 (STAT3) was involved in astrocyte proliferation in the presence of 
C5a, 5 μM of the STAT3 inhibitor (BP-1-102, Millipore) was added 10 minutes prior to C5a (50 
nM) exposure; BP-1-102 disrupts STAT3-STAT3 dimerisation and STAT3-phospho-tyrosine 
(pTyr) peptide interactions (Zhang et al., 2012b). Plates were then incubated for 48 hours under 
standard cell culture conditions (37 ̊C, 5% CO2). The extent of astrocyte proliferation under the 
various experimental conditions was measured using a CyQUANT assay (Life Technologies) 
according to the manufacturer’s instructions.  
 
4.2.15 Western blotting 
Separate sets of astrocyte cultures were established and randomly allocated to one of the 
following groups: 1) no treatment, 2) 50 nM C5a only, 3) 50 nM C5a + 10 µM BP-1-102 (STAT3-
inhibitor), and 4) 10 µM BP-1-102 only. Astrocytes were exposed to C5a for 1 hour; where 
applicable, BP-1-102 was added to the culture medium 10 minutes prior C5a exposure. After 
incubation, cells were scraped off the flasks and collected via (low speed) centrifugation at 300 x g 
for 6 minutes. Supernatants were removed and the cell pellets stored at -80 ̊C until lysis in 150 μl of 
modified RIPA buffer containing: 10 mM Tris, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM 
NaF, 20 nM Na4P2O7, 2 nM Na3VO4, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton-X 100, 
10% glycerol, and 10 μl/ml Halt protease/phosphatase inhibitor cocktail (Thermo Scientific). Cell 
lysates were vortexed for 1 minute at RT, incubated on ice for 30 minutes, and then centrifuged for 
30 minutes at 4 ̊C to remove debris. The protein concentration in the supernatant was determined 
using a standard BCA protein assay (Thermo Scientific).  
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The Bio-Rad electroblotting system was used for western blotting experiments. To 
determine the ratio of phosphorylated STAT3 (P-STAT3) to STAT3, 30 µg of protein was diluted 
1:3 in loading buffer (250 mM Tris HCl, 8% SDS, 0.008% bromophenol blue, 20% β-
mercaptoethanol 40% glycerol, pH 6.8), heated to 96 ̊C for 4 minutes, then stored on ice for 5 
minutes.  Samples and dual colour protein standards (Bio-Rad) were separated on 10% SDS-
polyacrylamide gels using a 3 A (114 V) current in running buffer (0.19 M Tris, 1.92 M glycine, 
0.35 M SDS in ddH2O) for 1 hour. Immobilon polyvinylidene difluoride (PVDF) membranes 
(Millipore) were primed with a 15 second wash in methanol, followed by a 2 minute wash in ddH2O 
and a 5 minute wash in transfer buffer (4.68 M methanol in running buffer). Proteins were then 
transferred over 1 hour onto the membranes using a 3 A (100 V) current in transfer buffer. After the 
transfer, membranes were washed (3 x 10 minutes) in Tris-buffered saline (TBS)-Tween (TBST; 50 
mM Tris, 150 mM NaCl, 0.05% Tween-20), followed by blocking in Odyssey blocking buffer (LI-
COR) for 1 hour at RT on a rotator. Membranes were then cut and probed with primary antibodies 
against β-actin (1:1000; Cell Signalling Technology; #4967) and anti-STAT3 (79D7) (1:2000; Cell 
Signalling Technology; #4904) overnight at 4 ̊C on a rotator. The following morning, membranes 
were washed on a rotator at RT (3 x 10 minutes in TBST). Next, membranes were incubated with 
secondary antibody (goat anti-rabbit IgG-IRDye 800CW (1:20 000; LI-COR; #926-32211) for 1 
hour at RT on a rotator. After 3 x 10 minute washes in TBST, blots were imaged using the Odyssey 
Infrared Imaging System (LI-COR). Bound antibodies were then stripped from the membrane using 
Newblot PVDF stripping buffer (LI-COR; #928-40032) as per the manufacturer’s instructions, and 
the membranes incubated again for 10 minutes on a rotator in Odyssey blocking buffer (LI-COR). 
Membranes were then washed (3 x 10 minutes in TBST) and probed for β-actin (1:1000; Cell 
Signalling Technology; #4967) and P-STAT3 (1:1000; Cell Signalling Technology; #9131) 
overnight at 4 ̊C. The next morning, blots were washed (3 x 10 minutes in TBST) and incubated 
with secondary antibody (goat anti-rabbit IgG-IRDye 800CW (1:20 000; LI-COR #926-32211) for 
1 hour at RT on a rotator. After another series of washes in TBST, blots were imaged again using 
the Odyssey Infrared Imaging System (LI-COR). The ratio of P-STAT3 to STAT3 in each lane was 
calculated after normalisation to the β-actin band using the Analyse Gel function in ImageJ.  
To confirm C5aR expression by cultured astrocytes, 40 µg of protein was loaded into the 
Bio-Rad electroblotting system. Rat anti-C5aR antibody (clone 10/92; 1:1000; Hycult Biotech 
#HM1077), in combination with goat anti-rat IgG IRDye-700CW (1:10 000; LI-COR; #926-
32219), was used to detect C5aR using similar procedures as detailed above. After stripping, blots 
were probed for β-actin (1:1000; Cell Signalling Technology; #4967) followed by goat anti-rabbit 
IgG-IRDye 800CW (1:20 000; LI-COR #926-32211) to control for loading and confirm appropriate 
protein transfer. WT mouse brain homogenate was used as a positive control. Protein homogenised 
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from C5ar
-/-
 mouse brain was also included to confirm again the specificity of the antibody that was 
used to detect C5aR. 
 
4.2.16 Statistical Analysis  
GraphPad Prism (GraphPad Software Inc.) was used for all data visualisation and statistical 
analyses. In vivo BMS data was analysed using two-way repeated measures ANOVA with 
Bonferroni post hoc tests. Two-sided Student’s t tests were used to directly compare differences in 
lesion size and/or histological data (myelin, GFAP, Ly6b.2, CD11b, and CD3 staining) at the lesion 
epicentre. Data from the narrowing beam walk, in vitro cell culture and western blot experiments 
were analysed using one-way ANOVA with Newman-Keuls post hoc tests. For the comparison of 
C5a levels in the spinal cord and blood plasma, in vivo glial cell proliferation/survival, Ly6b.2
+
 and 
CD3
+
 cell numbers along the length of the injured cord, and cytokine levels between experimental 
groups/conditions, two-way ANOVA with Newman-Keuls post hoc test was used. Pearson’s 
correlation test was used to examine the relationship between astrocyte proliferation and lesion size, 
and for correlating lesion volume, myelin or GFAP staining with BMS scores. All data is presented 
as mean ± SEM, with statistical significance determined at p < 0.05. 
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4.3 Results 
 
4.3.1 C5a production and expression of C5aR  
C5a levels in homogenised spinal cord and plasma samples were measured by ELISA to 
determine the temporal profile of complement activation after SCI. Baseline C5a levels were low 
(2.6 ± 0.25 pg/µg protein) in spinal cord samples from unoperated mice (time point 0). C5a levels in 
samples from naïve mice were not different to samples from sham-operated mice at any time point 
after surgery (p > 0.05). Following SCI, a rapid and dramatic increase in tissue C5a levels was 
observed, which peaked at 1 day post-injury (9.3 ± 1.4 pg/µg protein, a 4.5 fold increase over sham-
operated controls). Spinal cord C5a levels were still significantly higher in SCI mice compared to 
sham-operated controls at 4 (7.0 ± 1.1 vs. 2.2 ± 0.68 pg/µg protein) and 7 days (6.1 ± 0.85 vs. 1.8 ± 
0.63 pg/µg protein) after surgery (Fig. 4.1A). Tissue C5a levels remained slightly elevated at 35 
days post-SCI, but this was not statistically significant compared to sham-operated mice when using 
ANOVA. In the plasma, a rapid increase in circulating C5a levels was observed following SCI, with 
these being significantly elevated above the amount of C5a present in matching samples from sham-
operated mice at 30 mins, 2 hours, 6 hours, 12 hours, and 1 day after surgery (Fig. 4.1B). Although 
still elevated, C5a levels were no longer different between sham and SCI mice from 4 days post-
injury onwards.  
Immunofluorescent staining was used to examine the pattern and distribution of C5aR 
expression in the injured spinal cord. At 1 day post-SCI, prominent C5aR staining was observed on 
surviving Iba1
+
 microglia and population of smaller, round/ovoid Iba1
-
 cells that are most likely 
infiltrating neutrophils (Fig. 4.1C). At 7 days post-SCI, C5aR staining was apparent on cells with 
amoeboid and ramified morphology. Staining with Iba1 indicated that many of these cells were 
activated microglia and clustered macrophages (Fig. 4.1D). C5aR staining also localised to a subset 
of GFAP
+
 astrocytes in the rim of spared white matter surrounding the lesion core (Fig. 4.1E). No 
C5aR staining was present on injured spinal cord tissue from C5ar
-/-
 mice (Fig. 4.1F), indicating 
antibody specificity. Expression of C5aR by astrocytes was also confirmed in vitro through western 
blotting (Fig. 4.1G).  
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Figure 4.1: Production of C5a and expression of C5aR in the injured spinal cord. A: C5a 
protein concentration in injured WT spinal cord is significantly increased compared to both naïve 
(time point 0) and sham levels at 2 hours, 6 hours, 12 hours, 1 day, 4 days, and 7 days post-SCI (n = 
4-5 per time point, one-way ANOVA with Newman-Keuls post hoc tests, *p < 0.05; **p < 0.01, 
****p < 0.0001). B: WT C5a levels are also increased in the plasma in response to SCI, exceeding 
levels observed in sham-operated mice at 30 mins, 2 hours, 6 hours, 12 hours, and 1 day post-injury 
(n = 4-5 per time point, one-way ANOVA with Newman-Keuls post hoc tests, *p < 0.05; **p < 
0.01). C-E:  Representative confocal images showing C5aR expression in the injured spinal cord at 
1 and 7 days post-injury. C: At 1 day post-injury, C5aR appeared present at the lesion epicentre on 
nucleated Iba1
+
 cells (arrow) as well as numerous smaller circular/ovoid cells that did not express 
Iba1 (arrowheads). Scale bar = 6.0 μm. D: At 7 days post-injury, C5aR is present on cells with 
amoeboid morphology in WT mice, which appear to be clustered Iba1
+
 macrophages/microglia 
(arrow). Scale bar = 10 μm. E: C5aR expression was also observed on more elongated GFAP+ 
astrocytes (arrows), alongside C5aR
+
GFAP
-
 cells with macrophage-like morphology (arrowhead). 
Scale bar = 13 μm.  F: Only a very low level of non-specific background fluorescence was observed 
following C5aR staining of lesioned C5ar
-/-
 spinal cord tissue. Scale bar = 35 μm. G: 
Representative western blots demonstrating C5aR expression by astrocytes in vitro. The left and 
middle lanes contain WT and C5ar
-/-
 whole mouse brain homogenates, respectively; the right lane 
contains protein sample from cultured WT astrocytes.  
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4.3.2 Genetic ablation of C5aR reveals a dual role for C5a signalling in SCI 
BMS locomotor scoring with experimenter blinding was performed on C5ar
-/-
 and WT mice 
for 5 weeks after injury to determine the contribution of C5aR to SCI outcomes. Prior to SCI, all 
mice displayed normal overground locomotion, achieving BMS scores of 9. SCI produced near-
complete paralysis (BMS scores 0-1) in all mice at 1 day post-SCI. By 7 days post-SCI, C5ar
-/-
 
mice displayed significantly more hindlimb motor function than WT mice (p < 0.05) (Fig. 4.2A, B).  
These early improvements were, however, not sustained and no longer present by 10 days post-SCI. 
In fact, by 21 days post-SCI, C5ar
-/-
 mice now showed signs of impaired functional recovery and 
their BMS scores were significantly below those of WT mice at 28 and 35 days after injury (Fig. 
4.2A, C). Endpoint post-mortem analysis of lesion volume and histopathology provided additional 
support of an ultimately poorer outcome as a result of C5aR ablation. Specifically, a reconstruction 
of the lesion site from ex vivo magnetic resonance imaging (MRI) datasets revealed significantly 
larger lesion core volumes in C5ar
-/- 
mice as compared to WT mice at 35 days post-SCI (Fig. 4.2D, 
E; p = 0.023). Lesion core volumes in WT and C5ar
-/- 
mice were negatively correlated with the 
BMS scores of individual animals at the study endpoint (r
2
 = 0.71; p = 0.002). 
In addition, FluoroMyelin Red staining revealed a reduction in myelin content in C5ar
-/-
 
mice (Fig. 4.2F, G; p = 0.012). GFAP
+
 immunoreactivity (Fig. 4.2F) was also found to be reduced 
in C5ar
-/-
 mice at 35 days post-injury with regards to both the immunoreactive area (Fig. 4.2H; p = 
0.0073) and the intensity of GFAP staining (Fig. 4.2I; p = 0.017). FluoroMyelin and GFAP staining 
at the lesion epicentre of WT and C5ar
-/- 
mice were also both negatively correlated with BMS 
scores at the study endpoint (r
2
 = 0.73 and r
2
 = 0.51, respectively; p < 0.003). Lastly, a more 
widespread presence of Ly6b.2
+
 cells (Fig. 4.2J; p = 0.0007), and CD3
+
 T cells (Fig. 4.2K; p = 
0.0057), was observed along the length of the spinal cord at the study endpoint.  
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Figure 4.2: C5ar
-/-
 mice have a dual phenotype after SCI. A: BMS locomotor scoring revealed 
that C5ar
-/-
 mice have significantly improved hindlimb motor function at 7 days post-injury 
compared to WT mice. This trend reversed with time, such that at 28 and 35 days post-SCI, WT 
mice had regained significantly more motor function than C5ar
-/-
 mice (two-way ANOVA with 
Bonferroni post hoc tests, n = 8-12). B: Pooled BMS scores for individual mice from various 
experiments at 7 days post-injury (Student’s two-sided t test, n = 18-21). C: Graph showing the 
BMS scores for individual mice at 35 days-post injury from longitudinal scores plotted in A; 
Student’s two-sided t test, n = 8-12). D: Post-mortem T2*-weighted MRI images showing lesion 
sites in WT and C5ar
-/-
 mice. Scale bar (top left image) = 400 μm for coronal images; 1 mm for 
sagittal images. E: Quantitative analysis revealed significantly larger lesion core volumes in C5ar
-/-
 
mice. Representative reconstructions of lesion cores for each genotype are shown in grey. F, G: A 
reduction in myelin content was observed in C5ar
-/-
 mice at 35 days post-SCI. (Student’s two-sided 
t test, n = 8 per group). Scale bar, F (top left image) = 200 μm. H, I: Reductions in the proportional 
area (H) and intensity (I) of GFAP staining were also observed in C5ar
-/-
 mice (Student’s two-sided 
t tests, n = 8 per group).  J, K: A more widespread presence of Ly6b.2
+
 cells (J) and CD3
+
 T cells 
(K) was observed in C5ar
-/-
 mice at 35 days post-injury (two-way ANOVA with Newman-Keuls 
post hoc tests, n = 5 per group), as also confirmed by area under the curve analysis (Student’s two-
sided t test, n = 5 per group).*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. 
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4.3.3 Acute but not sustained C5aR antagonism improves SCI outcomes  
Since the genetic ablation of C5aR appeared beneficial during the (sub-) acute period of 
SCI, it was hypothesised that transient pharmacological blockade of C5aR during only the first 7 
days post-SCI would lead to sustained improvements in SCI recovery. Similar to C5ar
-/-
 mice, 
administration of C5aR-A to Macgreen mice with SCI during the first week of injury resulted in a 
clear trend for improved recovery compared to vehicle-treated Macgreen mice. This improvement 
was sustained into the more chronic phase of injury and significantly different from vehicle-treated 
controls at 21, 28 days, and 35 days after injury (p < 0.05) (Fig. 4.3A, B). The ledged tapered beam 
walk test was also used at the study endpoint as a second, independent measure of the efficacy of 
(sub-) acute C5aR-A treatment. Sham-operated control mice had no difficulty mastering this task, 
making very few mistakes and crossing the beam relatively fast (Fig. 4.3C, D). Although SCI 
consistently led to impaired performance in this test, C5aR-A-treated mice made significantly less 
stepping mistakes (p = 0.0024; Fig. 4.3C) and also traversed the beam faster (p = 0.017) (Fig. 4.3D) 
compared to vehicle-treated mice with SCI. Histological assessment of injured spinal cords at 35 
days post-SCI confirmed attenuated pathology as a result of (sub-) acute C5aR-A treatment, with 
C5aR-A-treated mice having significantly more myelin content compared to the vehicle-treated 
animals (Fig. 4.3E, F; p = 0.0088). The GFP
+
 infiltrate in the lesion core was also significantly 
reduced (p = 0.0061; Fig. 4.3E, G). There was, however, no difference in the GFAP
+
 area (p = 0.67; 
Fig. 4.3H, I) or staining intensity (p = 0.48; Fig. 4.3H, J) between groups. Collectively, these data 
indicate that C5aR antagonism, when limited to a 7-day window during the (sub-) acute period of 
SCI, leads to improvements in neurological recovery that are sustained into the chronic phase of 
injury.  
Importantly, continued antagonism of C5aR beyond the first week of injury in WT mice 
produced a phenotype similar to that of C5ar
-/-
 mice. Specifically, an early trend towards improved 
recovery after C5aR-A treatment was again observed at 7 days post-SCI, but this did not persist into 
the more chronic phase (Fig. 4.3K). Thus, the benefits of therapeutically targeting C5aR are 
annulled if blockade is maintained beyond the first week of spinal trauma. 
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Figure 4.3: Acute but not sustained antagonism of C5aR improves SCI outcomes in Macgreen 
mice. A: BMS locomotor scores of mice treated with a C5aR antagonist (C5aR-A) for 7 days post-
SCI have significantly higher BMS scores than vehicle (Veh)-treated mice at 21, 28 and 35 days 
after injury (*p < 0.05; two-way ANOVA with Bonferroni post hoc tests, n = 8-10). B: A scatter 
plot depicting the BMS scores of individual mice at 35 days post-SCI (*, p = 0.029; Student’s two-
tailed t test, n = 8-10). C, D: Data from the ledged tapered beam walk task also indicated that C5aR 
blockade during the acute period improved long-term recovery, with C5aR-A-treated mice making 
significantly fewer stepping mistakes (C), and also traversing the beam faster (D) than vehicle-
treated SCI controls (*, p < 0.05, **, p < 0.01; ***, p < 0.001, ****, p < 0.0001; one-way ANOVA 
with Newman-Keuls post hoc tests, n = 6-10). E, F: (Sub-) acute C5aR-A treatment resulted in 
significantly more myelin being present at the lesion epicentre at 35 days post-SCI compared to 
vehicle-treated mice (**, p = 0.0088, Student’s t test, n = 5 per group). Scale bar, E (top left image) 
= 200 μm. E, G: The GFP+ infiltrate in the lesion core of Macgreen mice was also significantly 
reduced following the C5aR-A treatment regimen (**, p = 0.0061, Student’s two-sided t test, n = 5 
per group). H-J: GFAP immunoreactivity at 35 days post-SCI was not significantly different 
between treatment groups based on analysis of both proportional area (I) and staining intensity (J). 
Scale bar, H (top left image) = 200 μm. K: Improved recovery from SCI was not sustained with 
continued C5aR-A administration (*, p < 0.05 for C5ar
-/-
 + vehicle vs. WT + vehicle, two-way 
ANOVA with Bonferroni post hoc tests, n = 4-5). 
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4.3.4 C5ar
-/-
 mice have reduced levels of pro-inflammatory cytokines and attenuated 
macrophage recruitment early after SCI 
To begin exploring why there were consistent signs of improved recovery during the (sub-) 
acute phase in the absence of C5aR signalling, we first investigated if the inflammatory response to 
SCI was altered by C5aR ablation. We theorised that a dampened production of pro-inflammatory 
cytokines acutely after SCI may have yielded neuroprotection, which in turn underpinned the early 
functional improvements seen in C5ar
-/-
 mice. A cytometric bead array (BD Biosciences) was 
therefore used to measure the concentration of a panel of cytokines within the injured spinal cord of 
WT and C5ar
-/-
 mice at 12 hours post-SCI. This time point was specifically selected because 
various key pro-inflammatory cytokines are elevated or at peak concentrations here (Pineau and 
Lacroix, 2007); it also precedes the peak of the first wave of peripheral immune cell infiltration, i.e. 
neutrophils (Kigerl et al., 2006; Beck et al., 2010), thereby allowing some differentiation between 
leukocyte-derived and glial/neuronally-derived cytokines. There was no difference in baseline (ie. 
sham-surgery) levels of any cytokine between WT and C5ar
-/-
 mice (p > 0.05). In both genotypes, 
SCI elicited significant increases in spinal cord levels of MCP-1 (Fig. 4.4A), TNF (Fig. 4.4B), 
CXCL1 (Fig. 4.4C), IL-6 (Fig. 4.4D), IL-1β (Fig. 4.4E), and IL-10 (Fig. 4.4F) over baseline. IL-
12p70 and IFNγ levels were not increased in response to SCI at this time point in either genotype 
(data not shown). Notably, many SCI-induced changes in cytokine levels were attenuated in the 
absence of C5aR, with significant reductions observed in CXCL1 (40%, p < 0.05), IL-6 (33%, p < 
0.01), and IL-1β (75%, p < 0.0001) levels within the injured spinal cord.  
We also quantified the number of granulocytes and inflammatory monocytes/macrophages 
at 1 and 7 days post-injury, i.e. time points that represent the respective peak recruitment/infiltration 
times for these cells. Immunolabelling of Ly6b.2
+
 cells (which predominantly represent neutrophils 
acutely after injury) revealed no statistically significant reduction in the recruitment of these cells 
between genotypes at 1 day post-SCI (Fig. 4.4G; p = 0.11). Flow cytometric analysis of the spinal 
cord at 7 days post-SCI also showed no significant difference in the Ly6G
+
 infiltrate between 
genotypes (p = 0.07; Fig. 4.4H). There was, however a clear reduction in the number of 
CD45
hi
Ly6C
+
Ly6G
-
 cells (inflammatory monocytes/macrophages) in C5ar
-/- 
mice at this time point 
(p = 0.002) (Fig. 4.4I). In summary, these findings indicate that acute disabling of the C5a-C5aR 
axis significantly reduces local pro-inflammatory cytokine production and the recruitment of 
inflammatory monocytes/macrophages.  
 
 
 
Chapter 4: C5aR controls inflammation and astrogliosis in SCI    120 
Figure 4.4: Inflammation in the (sub-) acute period of SCI is reduced with C5aR elimination. 
A-F: Levels of MCP-1 (A), TNF (B), CXCL1 (C), IL-6 (D), IL-1β (E) and IL-10 (F) were all 
significantly increased at 12 hours post-SCI compared to sham-operated controls, regardless of 
genotype. Note that C5aR deficiency did, however, result in significant reductions in CXCL1, IL-6, 
and IL-1β in the injured spinal cord compared to WT mice (*p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001, two-way ANOVA with Newman-Keuls post hoc tests, n = 4-5). G-H: No 
significant differences in the Ly6b.2
+
 inflammatory cell infiltrate were observed between WT and 
C5ar
-/-
 mice at 1 day (G) and 7 days (H) post-SCI. Scale bar, G (bottom image) = 40 μm. I: A 
significant reduction in the number of inflammatory monocytes/macrophages was observed in 
injured C5ar
-/-
 spinal cord at 7 days post-SCI (*p < 0.05; Student’s two-sided t test, n = 5 per 
group). 
 
Chapter 4: C5aR controls inflammation and astrogliosis in SCI    121 
4.3.5 Lack of C5aR in the peripheral immune compartment does not affect SCI outcomes 
Having observed a clear dual and time-dependent role for C5aR in the response to SCI, we 
next aimed to better understand the mechanisms resulting in this phenotype. To this end, BM 
chimeric mice were generated to better appreciate the role of C5aR expression within the peripheral 
immune compartment (i.e., circulating leukocytes) with regards to SCI outcomes (Fig. 4.5A). BMS 
locomotor scoring with experimenter blinding revealed that transplantation of C5ar
-/-
 BM into 
conditioned WT hosts ([C5ar
-/-
 →WT] BM chimeras) did not lead to altered recovery from SCI 
compared to [WT→WT] chimeras mice for up to at least 35 days post-SCI (Fig. 4.5B, C). There 
were also no statistically significant differences in lesion histopathology, including the amount of 
myelin at the lesion epicentre (Fig. 4.5D), Ly6b.2
+
 cellular infiltrate (Fig. 4.5E), CD11b
+
 
immunoreactivity (Fig. 4.5F), and CD3
+
 T cell numbers (Fig. 4.5G). Taken together, these data 
suggest that both the early injurious role of C5aR and its more delayed neuroprotective/reparative 
actions in the post-acute phase are mostly mediated through resident CNS cells and not circulating 
immune cells. 
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Figure 4.5: C5aR deficiency in the peripheral immune compartment does not alter the 
outcome from SCI. A: Flow cytometry data showing chimerisation efficacy. [C5ar
-/-
 → WT] bone 
marrow (BM) chimeras, i.e. WT mice that received a C5ar
-/-
 bone marrow transplant, only express 
background levels of C5aR on circulating granulocytes, equivalent to the amount of non-specific 
staining observed on C5ar
-/- 
cells (***, p < 0.001, one-way ANOVA with Newman-Keuls post hoc, 
n = 3-7). B: BMS locomotor scoring revealed no significant differences in functional recovery as a 
result of select C5aR deficiency in the peripheral immune compartment compared to [WT → WT] 
controls (two-way ANOVA with Bonferroni post hoc tests, n = 6-7). C: Scatter plot showing main 
BMS scores for individual mice at 35 day post-SCI. D: No difference was observed between the 
experimental groups in the amount of myelin within the ventrolateral white matter at 35 days post-
SCI (Student’s two-sided t test, p > 0.05, n = 6-7). Scale bar, D (top) = 200 μm. E-G: Quantification 
of the inflammatory infiltrate also showed no differences between the experimental groups in the 
number of Ly6b.2
+
 cells (E), the proportional area of CD11b
+
 immunoreactivity (F), and the 
number of CD3
+
 lymphocytes (G) present at the lesion epicentre (Student’s two-sided t tests, p > 
0.05, n = 6-7).  
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4.3.6 C5aR regulates astrocyte proliferation and glial scar formation in vivo 
Our next aim was to understand why genetic ablation or continued pharmacological 
blockade of C5aR adversely affected recovery in the more chronic period of SCI. Based on one of 
our initial observations that C5ar
-/-
 mice had reduced myelin content at 35 days post-SCI (Fig. 4.2F, 
G), we first explored whether C5aR signalling may be required for oligodendrocyte precursor cell 
proliferation (and/or survival) in response to SCI. To test this, BrdU was administered daily for the 
first 7 days post-SCI to WT mice that were treated for 21 days with either C5aR-A or vehicle, as 
well as to a cohort of vehicle-treated C5ar
-/-
 mice. The experimental endpoint of 21 days post-SCI 
was chosen based on a previous study showing that deficiency in C5 (i.e. the parental protein from 
which C5a is generated) leads to impaired remyelination in experimental autoimmune encephalitis 
at this stage (Weerth et al., 2003). 
Quantification of the total (CC1
+
) and newly generated (CC1
+
BrdU
+
) oligodendrocytes in 
spared white matter at and around the lesion epicentre at 21 days post-SCI revealed no significant 
differences between any of the experimental groups (p = 0.93). Specifically, a total of 27 ± 7 
newborn oligodendrocytes were observed at the lesion epicentre in vehicle-treated WT mice 
compared to 29 ± 4 cells in C5aR-A-treated WT mice and 26 ± 3 cells for C5ar
-/-
 mice. Total CC1
+
 
cell numbers were also not different between the experimental groups (p = 0.94), with 356 ± 46 
cells counted in vehicle-treated controls compared to 351 ± 65 cells for C5aR-A-treated WT mice 
and 328 ± 57 cells for C5ar
-/-
 mice. We also observed no differences in the number of apoptotic 
(Cleaved Caspase-3
+ 
CC1
+
) oligodendrocytes between the experimental groups at the lesion 
epicentre (p = 0.87). Specifically, a total of 10 ± 3 cells were counted here in vehicle-treated WT 
mice, as compared to 9 ± 2 cells in C5aR-A-treated WT mice and 11 ± 2 cells in C5ar
-/-
 mice. 
Similar results for each of the above quantitative analyses were obtained between experimental 
groups for distances up to at least 600 μm in both rostral and caudal directions (data not shown).  
Given that neither genetic nor pharmacological disabling of the C5a-C5aR axis appeared to affect 
oligodendrocyte generation and survival, we next investigated whether astrocyte proliferation was 
impaired under C5aR-deficient conditions. Quantification of BrdU
+
GFAP
+
 cells revealed that there 
was a significant reduction in the number of newly generated astrocytes present at the lesion 
margins in the absence of C5aR signalling at 21 days post-SCI (Fig. 4.6A; p < 0.05). These findings 
are in agreement with the observation that C5ar
-/-
 mice had less GFAP
+
 immunoreactivity at 35 
days post-SCI (Fig. 4.2F, H, I), and indicate that impaired formation of the glial scar may have led 
to a greater spread of secondary injury due to a failure to effectively seal off the lesion site 
(Faulkner et al., 2004; Herrmann et al., 2008). Consistent with that, the total number of 
BrdU
+
GFAP
+
 astrocytes across the analysed segment of the lesioned spinal cord was strongly and 
negatively correlated with the lesion volume (Fig. 4.6B; p < 0.0001).    
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Figure 4.6 Signalling through the C5a-C5aR axis promotes astrocyte proliferation in vivo and 
in vitro. A: Quantification of BrdU
+
GFAP
+
 astrocytes at the lesion site of WT SCI mice that were 
chronically administered C5aR-A (orange) or vehicle (Veh, blue) solution, and vehicle-treated 
C5ar
-/- 
mice (red). Note the significantly reduced presence of newly generated astrocytes along the 
rostral and caudal margins of the lesion in the absence of C5aR signalling (two-way ANOVA with 
Newman-Keuls post hoc tests, n = 4-5 per group, *p < 0.05; **p < 0.01). B: A significant, negative 
correlation was observed between the total number of BrdU
+
GFAP
+
 cells and lesion volumes 
(Pearson’s correlation, p < 0.0001) C: C5a stimulates the proliferation of WT astrocytes in vitro in a 
dose-dependent manner at concentrations greater than 10 nM (one-way ANOVA with Newman-
Keuls post hoc tests, *p < 0.05; ***p < 0.001; graph representative of 3 experimental repeats). D: 
C5ar
-/-
 astrocytes did not proliferate in response to high dose C5a (50 nM; Student’s two-sided t 
test, p > 0.05). E: Exposure of cultured astrocytes to C5a (50 nM) resulted in a significant increase 
in the ratio of P-STAT3 to STAT3. Addition of the STAT3 Inhibitor BP-1-102 (10 µM) just prior to 
C5a stimulation blocked this increase in STAT3 phosphorylation (one-way ANOVA with Newman-
Keuls post hoc tests, **p < 0.01). F: Stimulation of C5ar
-/-
 astrocytes with 50 nM of C5a did not 
lead to a significant change in STAT3 phosphorylation (Student’s two-sided t test, p > 0.05). G: 
Addition of BP-1-102 (5 µM) blocked C5a-induced astrocyte proliferation in vitro (one-way 
ANOVA with Newman-Keuls post hoc tests, **p < 0.01; ***p < 0.001). Dotted line represents the 
initial number of cells plated. All data is presented as mean ± SEM, with n = 6 biological replicates 
for D-F. 
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4.3.7 C5a promotes astrocyte proliferation and STAT3 phosphorylation in vitro  
Given the observation that interference with C5aR signalling reduced astrocyte proliferation 
in vivo, we next directly tested the premise that C5a promotes the proliferation of these cells in 
vitro. Exposure of cultured astrocytes to C5a indeed elicited a dose-dependent proliferative 
response, with significantly more astrocytes being present in the cultures following stimulation with 
C5a concentrations of 10, 50 100 and 200 nM compared to baseline (Fig. 4.6C). Having already 
established that cultured astrocytes express C5aR (Fig. 4.1G), we next examined whether the 
proliferative effect of C5a was mediated via activation of this particular receptor. Exposure of C5ar
-
/-
 astrocytes to C5a failed to induce a proliferative response (Fig. 4.6D), thereby confirming that this 
effect requires the presence of C5aR. 
Based on previous demonstrations that activation of the STAT3 pathway plays a critical role 
in astrocyte proliferation and the neuroprotective properties of the glial scar (Okada et al., 2006; 
Herrmann et al., 2008; Wanner et al., 2013), we next investigated whether STAT3 phosphorylation 
in astrocytes occurs downstream of C5aR following C5a stimulation. The amount of 
phosphorylated STAT3 (P-STAT3) was found to be markedly (2.5 fold) increased in response to 
C5a stimulation (50 nM), an effect that could be blocked if the STAT3 inhibitor BP-1-102 was 
added just prior to C5a exposure (Fig. 4.6E). No increase in STAT3 phosphorylation was observed 
in C5ar
-/- 
astrocytes following exposure to C5a (Fig. 4.6F). In the final experiment, we tested 
whether activation of the STAT3 pathway was driving astrocyte proliferation in response to C5a. 
Treatment with BP-1-102 indeed annulled the proliferative effect of C5a on astrocytes (Fig. 4.6G). 
Collectively, these findings indicate that C5a-induced phosphorylation of STAT3 occurs 
downstream of C5aR, which in turn drives astrocyte proliferation. 
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4.4 Discussion 
Complement activation in CNS injury is predominantly considered deleterious to recovery. 
Specifically, complement proteins are thought to contribute to secondary injury through 
opsonisation and MAC formation (reviewed by Brennan et al., 2012). Other complement activation 
products appear to have more complex or even biphasic roles (Beck et al., 2010). We report that 
eliminating C5aR signalling attenuates pro-inflammatory cytokine expression at the lesion site 
acutely after injury. This was followed by reduced macrophage recruitment and improved recovery 
of hindlimb function at 7 days post-SCI. Importantly, and consistent with Beck et al. (2010), lack of 
C5aR signalling in the post-acute period was detrimental to recovery. Experiments in BM chimeric 
mice suggested that these dual and opposing roles of C5aR are predominantly mediated via CNS 
cells and not infiltrating immune cells. Additional in vivo and in vitro studies demonstrated that 
C5aR signalling regulates astrocyte proliferation, at least partly by STAT3 phosphorylation. We 
therefore postulate that while acute/sub-acute blockade of C5aR improves recovery, prolonged 
interference with C5aR signalling leads to impaired scar formation and reduced ability to confine 
pathology, as evidenced by poorer neurological recovery, larger lesion volumes and more 
widespread presence of immune cells along the spinal axis. 
 
4.4.1 Time course of complement activation in SCI 
Previous studies clearly demonstrated the occurrence of complement system activation 
following SCI, with abnormal expression and/or deposition of C1q, Factor B, C3, C4, C7, and 
MAC on neurons, glia and infiltrating immune cells (Anderson et al., 2004; Qiao et al., 2006; 
Nguyen et al., 2008; Ankeny et al., 2009). The present data show that complement activation peaks 
locally at 12-24 hours post-SCI based on C5a levels. Extrinsic pathway activity  likely plays a 
major role in C5a generation during this early phase due to microhaemorrhaging (Huber-Lang et al., 
2006). C5a levels remained significantly elevated up to 7 days post-SCI but decreased thereafter to 
concentrations that were only slightly elevated from baseline. SCI also elicited a sharp rise in 
plasma C5a levels, which were significantly elevated over sham-operated controls up to 1 day post-
injury. Thus, robust increases in C5a levels occur in the blood and spinal cord during first week of 
injury.    
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4.4.2 C5aR inhibition in the acute/sub-acute phase improves SCI recovery 
Characterisation of the cellular infiltrate showed that recruitment of CD45
hi
Ly6C
+
Ly6G
+ 
granulocytes was not affected by C5aR deficiency at both 1 and 7 days post-SCI. There was, 
however, a clear and significant reduction in the CD45
hi
Ly6C
+
Ly6G
- 
infiltrate at 7 days post-SCI in 
C5ar
-/-
 mice, suggesting reduced recruitment of inflammatory monocytes/macrophages (Blomster et 
al., 2013a). Overall, these findings are in agreement with previous observations that C5aR 
antagonism in an equivalent rat model does not dramatically alter granulocyte presence but 
markedly reduces the number of ED1
+
 microglia/macrophages at 7 days post-injury Beck et al. 
(2010). Collectively, these data suggest that blocking C5aR signalling attenuates activation and/or 
recruitment of select inflammatory cell populations, which coincides with improved recovery early 
on.  
As C5aR is expressed in the CNS and peripheral immune compartment (Woodruff et al., 
2010), BM chimera experiments were performed to determine the impact of C5aR deficiency 
exclusively on circulating leukocytes in relation to SCI outcomes. The outcome of these 
experiments suggested that the dual and opposing roles of C5aR in SCI are predominantly mediated 
via CNS-resident cells. Consistent with this, injury-induced expression of IL-6, IL-1β and CXCL1 
within the spinal cord was significantly abrogated in absence of C5aR signalling at 12 hours post-
SCI, a time point that coincides with high complement activation but precedes the first major wave 
of leukocyte infiltration (Kigerl et al., 2006; Beck et al., 2010).  
IL-1β has previously been shown to promote injurious local inflammation, which correlates 
with impaired functional recovery (de Rivero Vaccari et al., 2012; Boato et al., 2013). Similarly, IL-
6 polarises macrophage towards a pro-inflammatory ‘M1’ phenotype, and treatment with anti-IL-6 
antibody leads to a predominance of tissue-reparative ‘M2’ macrophages and improved recovery 
(Mukaino et al., 2010; Guerrero et al., 2012). Although we did not identify the precise cell 
population(s) responsible for pro-inflammatory cytokine production, astrocytes and microglia are 
likely candidates as they express C5aR (Fig. 4.1C) and rapidly respond to trauma (Pineau and 
Lacroix, 2007; Donnelly and Popovich, 2008; Pineau et al., 2010). We therefore postulate that the 
benefits of C5aR blockade during the acute/sub-acute phase of SCI are primarily mediated through 
reduced pro-inflammatory cytokine production and associated neuroprotection (Farkas et al., 1998; 
Humayun et al., 2009; Pavlovski et al., 2012), with reduced recruitment of inflammatory Ly6C
+
 
monocytes/macrophages at 7 days post-SCI as a direct reflection of attenuated secondary injury. 
Targeting the C5a-C5aR pathway during the first hours to days post-SCI is thus a credible 
therapeutic avenue to promote SCI recovery (Fig. 4.7).  
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Figure 4.7: Diagram showing the proposed dual and time-dependent role of C5aR in SCI. In 
the (sub-) acute period (0-7 days post-SCI), activated astrocytes and microglia proliferate and/or 
migrate to the site of injury. Activation of these cells occurs in part through increased C5a levels as 
a result of complement activation, which in turn augments their production and release of pro-
inflammatory cytokines at the lesion site. Release of CXCL1 is a key signal for neutrophil 
recruitment to the site of SCI. IL-1β and IL-6 aid in the recruitment of blood monocytes and 
macrophages, which promote secondary injury if adopting an M1 phenotype. In the post-acute to 
chronic period of SCI (7 days post-SCI onwards), C5aR signalling is critically required for STAT3-
mediated astrocyte proliferation and glial scar formation, which seals the injury site and prevents 
the spread of secondary injury. Through its regulation of IL-6 levels, C5aR may also be involved 
IL-6R-dependent astrocyte proliferation. 
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4.4.3 C5aR activation regulates astrocyte proliferation and glial scarring  
Although our findings clearly demonstrate that C5aR activation is deleterious to recovery in 
the acute/sub-acute period of SCI, lack of C5aR signalling in the chronic phase ultimately led to 
exacerbated injury outcomes. Specifically, C5ar
-/- 
mice exhibited lower BMS scores, larger lesion 
volumes, less white matter myelin and reduced glial scarring at 35 days post-injury. Improvements 
obtained through pharmacological blockade of C5aR were also lost if treatment was extended 
beyond the acute phase. Although a recent study by Li et al. (2014a) did not report such a dual role 
for C5aR, our findings are consistent with earlier observations by Beck et al. (2010), who 
independently showed that chronic C5aR-A treatment similarly impairs recovery in rats. 
Unfortunately, Li et al. (2014a) did not report lesion volumes or axonal/myelin sparing as an 
independent accompaniment to functional testing, making a direct comparison between our studies 
difficult; additional differences in the lesion model of choice (computer-controlled impact vs. 
manual compression with forceps) and mouse strains used (C57BL/6J vs. BALB/c; Kigerl et al., 
2006) are likely contributors to this disparity. Regardless, the mechanism(s) contributing to the 
reparative/neuroprotective role of C5aR in contusive SCI had remained unclear. Although previous 
studies suggested a possible role for C5a in reparative remyelination following cuprizone treatment 
(Ingersoll et al., 2010b), oligodendrocyte survival and/or proliferation of oligodendrocyte precursor 
cells appeared unaffected by disabling C5aR signalling in the context of SCI.  
As we observed a reduction in GFAP
+
 immunoreactivity in C5ar
-/- 
mice at the study 
endpoint, we investigated whether C5aR signalling had any effect on astrocyte proliferation. Our in 
vivo data revealed that both genetic ablation and pharmacological blockade of C5aR inhibits 
astrocyte proliferation. This finding was supported by additional in vitro data showing that 
activation of C5aR by C5a induces astrocyte proliferation in a dose-dependent manner.  
With previous research indicating a key role for STAT3 in protective glial scar formation 
(Okada et al., 2006; Herrmann et al., 2008; Wanner et al., 2013), we evaluated whether C5aR 
signalling in astrocytes promotes STAT3 pathway activation. Exposure of cultured astrocytes to 
C5a indeed leads to STAT3 phosphorylation via C5aR, an event that is critical for initiating 
downstream transcriptional events and cell proliferation. Intriguingly, Okada et al. (2004) 
demonstrated that IL-6 also promotes astrocyte proliferation via STAT3, which could be inhibited 
with anti-IL-6R antibody treatment (Okada et al., 2004). As we observed reduced IL-6 levels in 
C5ar
-/- 
mice, it is likely that this may have further impaired astrocyte proliferation in vivo. 
Activation of the C5a-C5aR axis may thus stimulate astrocyte proliferation directly, as well as 
indirectly via IL-6 release from astrocytes and/or microglia.  
Importantly, pleiotropic roles for astrocytes and the glial scar have been ascribed, i.e. 
inhibitory from a regeneration perspective but neuroprotective with regards to secondary injury 
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(Bush et al., 1999; Faulkner et al., 2004; Silver and Miller, 2004; Rolls et al., 2009; Pineau et al., 
2010; Cregg et al., 2014; Pekny et al., 2014). On the latter, demarcation of the lesion is achieved 
through astrocyte hypertrophy, which increases cell density up to four fold in spinal white matter 
(Erturk et al., 2012). By separating the injury core from neighbouring intact neural tissue, astrocytes 
limit the spread of immune cells along the spinal axis, as previously reported (Okada et al., 2006), 
and observed here for the Ly6b.2
+
 and CD3
+ 
infiltrate. We therefore postulate that the 
reparative/neuroprotective functions attributed to C5aR signalling in the post-acute phase of SCI 
(Beck et al., 2010) include its role in glial scar formation. Whether exogenous stimulation of 
astrocyte proliferation via C5aR agonism during the post-acute phase could in fact benefit recovery 
remains an outstanding question. It is also worth mentioning that our findings do not necessarily 
exclude a role for the alternate C5a receptor, C5L2, in SCI. They do, however, show that, at least 
for the induction of pro-inflammatory cytokine expression and astrocyte proliferation, expression of 
C5aR is required.  
In summary, the present findings confirm C5aR as a promising therapeutic target in SCI, 
demonstrating that timely pharmacological inhibition of this receptor can reduce immune-mediated 
secondary damage and improve recovery. The identified key role for C5aR signalling in astrocyte 
proliferation and glial scarring during the chronic phase of SCI also highlights the importance, 
however, of fully understanding the dual and time-dependent functions that inflammatory mediators 
like C5a may have, such that adverse outcomes can be prevented by restricting treatments to critical 
windows.  
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Abstract  
 
This study examined the sensitivity of ultra-high field (16.4 T) diffusion tensor imaging (DTI; 
70 μm in-plane resolution, 1 mm slice thickness) to evaluate the spatiotemporal development of 
severe mid-thoracic contusive spinal cord injury (SCI) in mice. In vivo imaging was performed 
prior to SCI, then again at 2 hours, 1 day, 3 days, 7 days, and 30 days post-SCI using a 16.4 T small 
animal nuclear magnetic resonance spectrometer (Bruker BioSpin). Cross-sectional spinal cord 
areas were measured in axial slices, and various DTI parameters, i.e. fractional anisotropy (FA), 
mean diffusivity (MD), axial diffusivity (λ||) and radial diffusivity (λ⊥), were calculated for the total 
spared white matter (WM), ventral funiculi (VF), lateral funiculi (LF) and dorsal columns (DCs), 
and then correlated with histopathology. Cross-sectional area measurements revealed significant 
atrophy (32% reduction) of the injured spinal cord at the lesion epicentre in the chronic phase of 
injury. Analysis of diffusion tensor parameters further showed that tissue integrity was most 
severely affected in the DCs, i.e. the site of immediate impact, which demonstrated a rapid and 
permanent decrease in FA and λ||. In contrast, DTI parameters for the ventrolateral white matter 
changed more gradually with time, suggesting that these regions are undergoing more delayed 
degeneration in a manner that may be amenable to therapeutic intervention. Of all the DTI 
parameters, λ⊥ was most closely correlated to myelin content whereas changes in FA and λ|| 
appeared more indicative of axonal integrity, Wallerian degeneration, and associated presence of 
macrophages. We conclude that longitudinal DTI at 16.4 T provides a clinically relevant, objective 
measure for assessing white matter pathology following contusive SCI in mice that may aid the 
translation of putative neuroprotective strategies into the clinic. 
 
  
Chapter 5: Diffusion tensor imaging to assess SCI pathology in vivo    133 
5.1 Introduction 
 
The adult mammalian spinal cord has very limited inherent capacity for repair. 
Neurotraumatic events that affect this part of the central nervous system (CNS) thus lead to 
permanent motor, sensory and autonomic impairments, with the degree of physical debilitation 
determined by the anatomical level and severity of the spinal cord injury (SCI) (Bunge et al., 1993; 
Gonzalez et al., 2003; Park et al., 2004). CNS neurons that survive the initial mechanical insult 
become increasingly exposed during the acute and post-acute phases to an ischaemic and toxic 
microenvironment that includes increased levels of excitatory amino acids and ions (excitotoxicity), 
reactive oxygen species (oxidative stress) and potent inflammatory mediators. This produces further 
damage by propagating the loss of neural tissue beyond the initial impact site, a process collectively 
known as secondary injury (Dumont et al., 2001; Donnelly and Popovich, 2008). 
As most SCIs are anatomically incomplete contusion injuries, involving crushed or fractured 
vertebrae that bruise and/or compress the spinal cord (Bunge et al., 1993; Norenberg et al., 2004), 
the process of secondary injury is highly amenable to therapeutic intervention, and several putative 
therapies targeting these sequelae are currently being developed in animal models of SCI or 
undergoing clinical evaluation (Hawryluk et al., 2008; Kwon et al., 2010; Cadotte and Fehlings, 
2011; Gensel et al., 2011). The simultaneous development of non-invasive imaging methods to 
quantitatively assess the effectiveness of such therapeutic interventions will be an important step for 
successful translation of candidate therapies from the laboratory into the clinic. In particular, the 
incorporation of advanced magnetic resonance imaging (MRI) techniques in preclinical studies 
offers an objective and independent accompaniment that could be used alongside functional testing. 
Whilst informative, functional improvements seen in animal models, particularly rodents, may not 
be directly transferable to the human context because of differences in anatomical organization of 
the spinal cord and the amount of supraspinal control that is required for quadrupedal versus bipedal 
locomotion (Courtine et al., 2007). MRI is not hampered by these limitations. 
In the present study, we used diffusion tensor imaging (DTI) to chronologically assess SCI 
pathology in live mice at a microscopic scale. In uninjured spinal white matter, water molecules 
predominantly diffuse along the longitudinal plane (the ‘axial diffusivity’ λ||). Conversely, the 
Brownian motion at right angles to the direction of white matter tracts (the ‘radial diffusivity’ λ⊥) is 
more restricted by both axonal membranes and myelin sheaths (Stroman et al., 2012). The overall 
degree of directionality (anisotropy) of water diffusion in tissues can be measured as fractional 
anisotropy (FA) (Beaulieu and Allen, 1994). Tissues with a high degree of diffusion directionality, 
such as spinal white matter, are anisotropic and have FA values of ~ 0.8 (Underwood et al., 2011). 
Conversely, more isotropic tissues in which water diffusion is much less restricted, e.g. the grey 
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matter or cerebrospinal fluid (CSF), have an FA value of ~ 0.2 or lower (Sundgren et al., 2004; 
Mori and Zhang, 2006). The mean diffusivity (MD) provides an index of the overall magnitude of 
water molecule diffusion independent of direction (Maas and Mukherjee, 2005). 
Combined, these quantitative parameters enable the detection of subtle and/or progressive 
changes in the integrity of the spinal white matter as a result of pathology that cannot be detected 
through conventional MRI techniques (Huisman et al., 2001; Schwartz and Hackney, 2003; 
Hesseltine et al., 2006; Shanmuganathan et al., 2008; Chang et al., 2010; Rajasekaran et al., 2010; 
Yin et al., 2010; Mulcahey et al., 2011). Indeed, DTI parameters have statistically stronger 
correlations with clinical examination data (Chang et al., 2010; Mulcahey et al., 2011). A previous 
report by Kim et al. (2007) showed that DTI at a field strength of 4.7 Tesla (T) can also reveal and 
quantify developing pathology in mice. In the present study, we used ultra-high field (16.4 T) DTI, 
which allowed for stronger b values, to longitudinally assess gross pathology and region-specific 
changes in the various diffusion parameters for up to 30 days post-SCI. This was followed by a 
detailed assessment of the histopathological correlate. 
 
5.2 Materials and methods 
 
5.2.1 Animals 
All experiments were conducted in accordance with the Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes, with approval from The University of Queensland 
Animal Ethics Committee. Female C57BL6/J mice (n = 4) were used in this study; animals were 
12-16 weeks of age at the time of the pre-injury scan. Experimental mice were housed individually 
under conventional conditions, with a 12 hour light-dark cycle and ad libitum access to food and 
water. 
 
5.2.2 Experimental spinal cord injury 
Mice were anaesthetised with xylazine (10 mg/kg i.p.) and zolazepam (50 mg/kg i.p.) prior 
to undergoing surgical laminectomy and severe (~ 70 kdyne) contusive SCI. This involved making 
a dorsal incision along the midline of the lower thoracic region. Next, the underlying paravertebral 
muscles were carefully split and dorsal laminectomy performed at thoracic (T) vertebral level T9 to 
expose the animal's intact dura overlying the spinal cord. The vertebral column was stabilised by 
rostral and caudal clamping with Adson microforceps, after which the mice were subjected to 
severe force-controlled contusion SCI using the Infinite Horizon Impactor with 1.3 mm diameter 
probe (Precision Systems and Instrumentation) as described previously (Scheff et al., 2003; 
Blomster et al., 2013b). The average applied force was 71.3 ± 1.03 kdyne (mean ± SEM) and the 
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associated tissue displacement was 608 ± 51.1 μm (mean ± SEM). Following impact, the muscles 
and skin were sutured closed. Post-operative care involved a single dose of buprenorphine 
(0.05 mg/kg) diluted in 1 ml of Hartmann's solution, gentamicin (1 mg/kg) daily for 5 days post-
injury, and twice daily bladder expression for the duration of the experiment. 
 
5.2.3 In vivo DTI 
All data was collected at the Centre for Advanced Imaging (CAI, The University of 
Queensland, Australia) using a 16.4 T nuclear magnetic resonance scanner with a 89 mm vertical 
bore magnet (Bruker BioSpin) and a transmit/receive linear surface coil (1.5 × 3.0 cm). Gradients 
were maintained at 30 ̊C. Animals were anaesthetised using an isoflurane/oxygen mixture (0.5–
1.5%). Animal respiration rate was monitored using a Biotrig Animal Monitoring System (M2M 
Imaging). Mice heads were held in position via a tooth bar and nose/head cone; they were supported 
inferiorly by a foam pad (see Suppl. Fig. 5.1A). In this position, their dorsum was situated parallel 
to the coil. For each imaging session, the hypointense lesion core was identified and centred in pilot 
axial, sagittal and transverse T1-weighted MR images (see Suppl. Figs. 5.1B–E). Slice angles were 
always set perpendicular to the long axis of the spinal cord. Vertebral landmarks (Harrison et al., 
2013) were also used to further identify the relative position of the lesion core and to confirm that 
laminectomy was indeed performed at the level of T9. Images were acquired using respiratory 
gating, a DTI spin-echo sequence with interleaved slice acquisition using TR/TE = 2400/21 ms. 
Diffusion sensitising gradients were applied in 12 non-collinear, uniformly distributed directions 
with the gradient strength b = 1500 s/mm
2
, 2 ms diffusion encoding and 14 ms diffusion separation, 
and 1 image that was acquired with the b value set to ‘0’ (b0). The acquisition matrix was 128 × 170 
over the field of view 9 × 12 mm
2
 to produce final in-plane resolution of 70 × 70 μm2, with 1.0 mm 
slice thickness. The number of excitations and the partial Fourier encoding acceleration were both 
2, and the total acquisition time per imaging session was 2 hours. Sixteen axial images covering part 
of the thoracic and lumbar spine were acquired as previously reported (Underwood et al., 2011). 
Live imaging was performed prior to injury, then again at 2 hours, and 1, 3, 7 and 30 days after 
injury. The diffusion tensor eigenvalues (λ1, λ2, λ3) were computed using the Paravision 5.0 (Bruker 
BioSpin) diffusion tensor calculation module. The axial diffusivity (λ||) is a measure of the 
diffusivity along the principal axis of the diffusion tensor (λ|| = λ1). The radial diffusivity (λ⊥) was 
calculated using the two minor diffusion axes (λ⊥ = (λ2 + λ3) / 2). The fractional anisotropy (FA) 
was calculated using the equation: FA = √1/2(√((λ1 − λ2)
2
 + (λ1 – λ3)
2
 + (λ2 – λ3)
2) / √(λ1
2
 + λ2
2
 + 
λ3
2
)).    
Paravision 5.0 (Bruker BioSpin) was used for all image analysis. The cross-sectional areas 
of the spinal cord were defined by manually outlining the circumference of the spinal cord on 
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transverse b0 and FA scans for each time point. Of the sixteen diffusion axial images acquired, the 
ten axial slices centred on the lesion core were used for subsequent analyses (see Suppl. Fig. 5.1). 
Regions of interest (ROI), specifically the total spared white matter (WM), ventral funiculi (VF), 
lateral funiculi (LF) and dorsal columns (DCs), were manually outlined on transverse DTI FA 
images as shown in Suppl. Fig. 5.2. 
 
5.2.4 Tissue preparation for ex vivo DTI 
At 30 days post-injury, animals were anaesthetised with sodium pentobarbitone (150 mg/kg 
i.p.) and transcardially perfused with 20 ml of 0.9% saline solution containing 0.1% heparin and 2% 
NaNO2, followed by 30 ml fixative (4% paraformaldehyde in phosphate-buffered saline (PBS: 
1.7 mM NaH2PO4, 9 mM Na2HPO4, 0.15 M NaCl, pH 7.4)). The vertebral column was dissected 
out and submerged in fixative for 48 hours at 4 ̊C. Next, samples were washed in PBS containing 
gadolinium contrast agent over 2 weeks (0.2% v/v Magnevist, Bayer). 
 
5.2.5 Ex vivo DTI and tractography 
Fixed specimens of the lower thoracic vertebral spine were trimmed in such a way that they 
fitted tightly into a glass tube, and immersed in fomblin oil (Solvay Solexis). The tube was then 
placed inside a 15 mm surface acoustic wave (SAW) linear coil (M2M Imaging). Spinal cords were 
imaged using a three dimensional DTI spin-echo sequence with the parameters: 
TR/TE = 400/20.8 ms, 2.5 ms diffusion encoding and 10 ms diffusion separation, 12 non-collinear 
directions, 2 b0 images, and the gradient strength b = 3000 s/mm
2
. The data was acquired with 1 
excitation and 1.2 partial Fourier phase encoding acceleration factor. The sweep width was 50 kHz 
over a field of view of 3.07 × 0.48 × 0.54 mm with 512 × 80 × 90 matrix to produce 60 μm 
isotropic resolution. The total scan time was 12 hours and 40 minutes. Diffusion data were 
processed using the DTI module of Diffusion Toolkit software (v. 0.6.2.1). 
Fibertracks were visualised using TrackVis (v. 0.5.2.1) by drawing ROIs (as shown in 
Suppl. Fig. 5.2) on transverse slices (ex vivo b0 maps), 1 mm rostral and caudal to the lesion 
epicentre; FA and angle thresholds were 0.1 and 45˚, respectively. A three dimensional 
reconstruction of the lesion site was produced by manually outlining the hypointense regions of the 
lesion core on transverse and sagittal b0 slices in the same program. 
 
5.2.6 Tissue preparation for histological analysis 
Following the conclusion of imaging, spinal cords were dissected out of the vertebral 
column and washed extensively in PBS. Tissue specimens were cryoprotected through two 
subsequent overnight incubations in PBS containing 10% and 30% sucrose, respectively. Spinal 
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cords were then snap-frozen in dry ice-cooled isopentane and stored at -80 ̊C until further 
processing. Samples were cut into 20 μm thick transverse sections using a Leica cryostat CM3050-
S and collected in 1:5 series on Superfrost Plus slides (Menzel-Gläser). Slides were air-dried for 
2 hours and stored at -80 ̊C until further processing. 
 
5.2.7 Assessment and quantification of histopathology 
For quantification of myelin content, spinal cord sections were stained with FluoroMyelin 
Red (1:150; Molecular Probes) in combination with immunofluorescent labelling of astrocytes 
(rabbit anti-GFAP; 1:1000; Dako) as described previously (Blomster et al., 2013a). Images were 
captured using Olympus SZX12 Research Fluorescence Stereo Microscope (Spectra Services) with 
NIS-Elements 3.0 software (Nikon Instruments Inc.) and analysed using the Java-based program 
ImageJ v1.43. The total section area and myelin-containing regions in the spared white matter were 
outlined using the freehand selection tool. The image was converted to an 8 bit file and the level of 
FluoroMyelin signal in the white matter determined using the threshold function. Myelin content 
was calculated by dividing the FluoroMyelin-positive area by the total area of the section. Similar 
procedures were followed for the analysis of GFAP staining. A separate set of sections was stained 
for neurofilament (NF200) (rabbit anti-NF200; 1:200; Sigma-Aldrich) in combination with 
FluoroMyelin Red and Hoechst nuclear dye (1:1000; Sigma-Aldrich). A third set of sections from 
each animal was stained for ionised Ca
2+
 binding adaptor molecule 1 (rabbit anti-Iba1; 1:500; Wako 
Pure Chemical Industries), which labels all microglia/macrophages, the activation marker CD68 (rat 
anti-CD68; 1:200; Serotec), and Hoechst nuclear dye. Stained sections were captured using an Axio 
Imager Azure (Zeiss). Immunopositive areas for NF200 and Iba1 were measured through 
thresholding in ImageJ for the relevant ROIs, i.e. the DCs and ventrolateral white matter. 
 
5.2.8 Statistical analysis 
Data was analysed using GraphPad Prism 4.0 software (GraphPad Software Inc.). Two-way 
ANOVA with Bonferroni post hoc was used to analyse the changes in cross-sectional area of the 
spinal cord after injury, with the within group factor being the slice number and the between group 
factor being time. One-way ANOVA with Newman-Keuls post hoc analysis was used to compare 
lesion core data with time. Two-way ANOVA with Bonferroni post hoc was used to analyse DTI 
parameters along the injured spinal cord for detection of Wallerian degeneration. Datasets were 
considered to be significantly different at p < 0.05. All experimental data is presented as 
mean ± standard error of the mean (SEM). 
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5.3 Results 
 
5.3.1 A reduction in spinal cord area in the chronic phase indicates tissue atrophy 
Longitudinal assessment of lesion development showed shrinkage of the cross-sectional area 
(atrophy) at 30 days post-injury. Compared to pre-SCI, significant decreases in cord area were 
observed up to 2 mm away from the lesion epicentre at the endpoint (Figs. 5.1A, B). The mean 
cross-sectional areas of the spinal cord (at and around the lesion epicentre) were slightly higher in 
the acute period (2 hours post-SCI) compared to pre-injury data. This suggested some minor tissue 
swelling but this did not reach statistical significance. Nonetheless, the MD of the identified white 
matter (WM) was measured to determine the possible effect of oedema on injured spinal cord 
anatomy (Fig. 5.1C). For WM, a significant reduction in MD was observed at the 2 hour, 1 day, 
3 day and 7 day time points compared to pre-injury measurements, indicating the possible presence 
of some intracellular and axonal oedema. At 30 days post-injury, MD values were similar to pre-
injury values, which would be consistent with the view that tissue oedema should have largely 
resolved in the more chronic phase of SCI (Norenberg et al., 2004). Regional analysis showed that 
the decline in MD in the acute phase was most pronounced in the more dorsal aspects of the spinal 
cord, that is, the immediate site of impact. No significant change in MD was observed for other 
specific ROIs, i.e. the ventral funiculi (VF) and lateral funiculi (LF) of the spinal cord, although 
these values were generally lower during the first week post-SCI (data not shown). We must note, 
however, that the changes in MD appeared to be mostly driven by a reduced λ||, as no clear 
reduction in λ⊥ was observed for the various ROIs during the acute phase (see also below), which 
thus appears to argue against a significant presence of cytotoxic oedema in the various white matter 
regions analysed. 
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Figure 5.1: The change in appearance of the lesion core with time after injury indicates general tissue atrophy and early cytotoxic oedema. A: 
In vivo serial images of the same mouse spinal cord lesion core, showing the FA, MD, λ∥ and b0. For simplicity, only the pre-injury, 2 hour, 7 day and 
30 day scans are shown. The grey matter and white matter of the spinal cord can still be clearly distinguished in the pre-injury scans as well as 2 h after 
SCI but the normal anatomical appearance progressively deteriorates thereafter. The cross-sectional area of the spinal cord decreases with time, which 
is particularly evident at 30 days post-SCI. Note the increased amount of fluid (CSF) around the spinal cord at this time point in the b0 map as a result 
of this tissue shrinkage. B: Quantification of the cross-sectional area of the spinal cord in transverse views confirmed the occurrence of spinal cord 
atrophy between 7 and 30 days post-injury. Of note, the rostrocaudal asymmetry that was observed at each time points resulted from a changing cross-
sectional area between the lumbar enlargement and lower thoracic region of the spinal cord. C: A significant reduction in MD values was observed 
during the first week post-SCI. Data points represent mean ± SEM (n = 4 per group); *, p < 0.05; **, p < 0.01; and ns, not significant compared to pre-
SCI (repeated measures two-way ANOVA with Bonferroni post hoc). 
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5.3.2 FA values at the lesion epicentre progressively decrease with time 
Fractional anisotropy (FA) values were calculated from diffusion tensor datasets for the total 
WM, VF, LF and DCs as outlined in Suppl. Fig. 5.2. A progressive decrease in FA was observed at 
the lesion epicentre as time progressed for the total WM, VF and LF following contusive SCI 
(Fig. 5.2). To best illustrate the progressive deterioration of FA values over time, we compared all 
earlier data points against 30 days post-SCI. FA values for each of the aforementioned regions were 
indeed significantly higher before injury as well as at 2 hours, 1 day and 3 days after injury as 
compared to the experimental endpoint of 30 days post-SCI (Table 5.1). The DCs, on the other 
hand, showed the most dramatic and rapid decline in FA over time. Specifically, although the FA in 
this region was still significantly higher before SCI and 2 hours after injury compared to endpoint 
values, values were already maximally diminished at 1 day post-injury for this ROI. Hence, there 
was no significant difference between the FA measured at 1, 3 and 7 days post-SCI compared to 
30 days post-injury for the DCs (Table 5.1 and Fig. 5.2D). These findings suggest that the VF and 
LF undergo more gradual degeneration and/or tissue remodelling after injury, which may be 
amenable to therapeutic intervention. In contrast, the rapid changes in diffusivity parameters for the 
DCs, i.e. within the first day of contusive SCI, indicate severe and likely irreversible damage. 
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Figure 5.2: SCI-induced changes in fractional anisotropy (FA) for the various regions of 
interest (ROIs) as a function of post-injury time. Note the gradual decline in FA for the spared 
white matter (A), ventral funiculi (B) and lateral funiculi (C). FA values were still significantly 
higher at 3 days post-injury compared to the experimental endpoint, 30 days post-SCI. In contrast, a 
much more dramatic and rapid decline in FA values was observed for the dorsal columns (D). FA 
values here already plateaued by 1 day post-injury. Data points represent mean ± SEM (n = 4 per 
group); *, p < 0.05; **, p < 0.01; and ***, p < 0.001 (repeated measures one-way ANOVA with 
Newman–Keuls post hoc). 
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Table 5.1: Summary of temporal changes at the lesion epicentre in fractional anisotropy (FA), axial diffusivity (λ||) (mm
2
sec
-1
) and radial diffusivity (λ⊥) 
(mm
2
sec
-1
) for the various regions of interest (ROIs), i.e. spared white matter (WM), ventral funiculi (VF), lateral funiculi (LF) and dorsal columns (DC).  
 
 
#
Denotes the time point for the indicated DTI parameter against which statistical comparisons were made, i.e. 30 days post-injury for FA and radial 
diffusivity (λ⊥), and pre-SCI for axial diffusivity (λ||). Repeated measures one-way ANOVA with Newman-Keuls post hoc tests; n = 4 per group; *, p < 
0.05; **, p < 0.01; ***, p < 0.001; ns, not significant. 
 
 
Time point  
 
Pre-SCI 2 hours post-SCI 1 day post-SCI 
DTI Parameter   FA λ|| (x10
-3
)  
#
 λ⊥ (x10
-3
) FA λ|| (x10
-3
) λ⊥ (x10
-3
) FA λ|| (x10
-3
) λ⊥ (x10
-3
) 
ROI  Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
WM 
0.75 
*** 
0.01 1.79 0.03 0.38 
*** 
0.03 0.60 
*** 
0.02 1.20 
* 
0.12 0.41 
*** 
0.04 0.53 
** 
0.05 0.99 
* 
0.09 0.39 
*** 
0.03 
VF 
0.74 
*** 
0.03 1.84 0.05 0.41 
** 
0.04 0.58 
*** 
0.04 1.16 
** 
0.12 0.39 
** 
0.02 0.51 
** 
0.05 1.03 
*** 
0.07 0.43 
** 
0.02 
LF 
0.76 
*** 
0.02 1.78 0.05 0.37 
*** 
0.02 0.60 
*** 
0.04 1.16 
** 
0.14 0.38 
*** 
0.01 0.52 
*** 
0.03 1.07 
** 
0.05 0.42 
*** 
0.01 
DC 
0.78 
*** 
0.01 1.86 0.04 0.35 
** 
0.01 0.49 
* 
0.02 0.72 
*** 
0.03 0.33 
** 
0.02 0.35 
ns 
0.04 0.88 
*** 
0.03 0.52 
* 
0.06 
 
Time point  
 
3 days post-SCI 7 days post-SCI 30 days post-SCI 
DTI Parameter   FA λ|| (x10
-3
) λ⊥ (x10
-3
) FA λ|| (x10
-3
) λ⊥ (x10
-3
) FA 
#
 λ|| (x10
-3
) λ⊥ (x10
-3
)
#
 
ROI   Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
WM 
0.46 
* 
0.05 1.07 
* 
0.19 0.48 
*** 
0.07 0.41 
ns 
0.03 1.06 
* 
0.25 0.48 
** 
0.06 0.31 0.02 1.16 
* 
0.06 0.75 0.05 
VF 
0.45 
* 
0.05 1.08 
** 
0.16 0.52 
** 
0.04 0.40 
ns 
0.02 0.88 
*** 
0.12 0.46 
** 
0.07 0.30 0.04 1.16 
*** 
0.14 0.76 0.11 
LF 
0.45 
** 
0.05 1.04 
** 
0.19 0.47 
*** 
0.06 0.37 
ns 
0.01 0.90 
*** 
0.08 0.49 
*** 
0.05 0.30 0.02 1.22 
** 
0.10 0.78 0.08 
DC 
0.33 
ns 
0.06 1.05 
*** 
0.15 0.58 
ns 
0.05 0.29 
ns 
0.03 0.74 
*** 
0.07 0.49 
* 
0.06 0.31 0.04 1.21 
*** 
0.14 0.78 0.15 
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5.3.3 SCI-induced changes in λ|| and λ⊥ at the lesion epicentre 
To gain a better understanding of what factors might be driving the progressive decline in 
FA values after SCI, changes in diffusion eigenvalues were subsequently examined. Overall, the 
axial diffusivity λ||, generally considered an indicator for axonal integrity (Kim et al., 2006; Budde 
et al., 2009), showed a profound and significant decline (~ 40%; p < 0.05) for identified WM at 
2 hours post-injury, with no obvious change thereafter (Fig. 5.3A and Table 5.1). Region-specific 
analysis showed that the λ|| was also significantly decreased for each of the respective ROIs, i.e. the 
VF, LF and DC, at 2 hours post-SCI compared to the pre-injury baseline values (Figs. 5.3B–D and 
Table 5.1). This decline was most marked for the DCs (p < 0.001), followed by the VF and LF 
(p < 0.01). The λ|| remained significantly below pre-injury values at all other time points analysed, 
i.e. up until 30 days post-SCI for each ROI (p < 0.01). Together, these findings indicate that DTI is 
able to detect acute axonal damage as a result of SCI. However, since the λ|| did not significantly 
change further as a function of post-injury time, the chosen imaging protocol appeared not sensitive 
enough to detect the more subtle loss of axons, if occurring, as part of secondary degeneration. All 
data points were therefore compared to pre-injury measurements for this parameter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Chapter 5: Diffusion tensor imaging can assess experimental SCI pathology in vivo  144 
 
 
 
 
Figure 5.3: SCI-induced changes in axial diffusivity (λ∥) for the various ROIs as a function of 
post-injury time. Note the rapid and sustained decrease in λ∥ at the lesion core at in all ROIs, 
including the spared white matter (A), ventral funiculi (B), lateral funiculi (C) and dorsal columns 
(D) all time points after SCI compared to pre-injury values. Data points represent mean ± SEM 
(n = 4 per group); *, p < 0.05; **, p < 0.01; and ***, p < 0.001 (repeated measures one-way 
ANOVA with Newman–Keuls post hoc). 
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In contrast to λ||, the radial diffusivity λ⊥, considered to be an indicator of myelination status 
(Song et al., 2002; Song et al., 2005) and possibly gliosis (Harsan et al., 2007), progressively 
increased as a function of time at the lesion epicentre (Fig. 5.4 and Table 5.1). As a result, this 
parameter was significantly higher at 30 days post-SCI for each ROI compared to all previous time 
points, including pre-injury (p < 0.05). Statistical comparisons here were made against the endpoint, 
i.e. 30 days post-SCI, to best illustrate the progressive increase in λ⊥ over time. Subsequent post-
mortem histological analysis confirmed decreased myelin content as well as astrogliosis at and in 
close proximity to the lesion epicentre (Fig. 5.5). The loss of myelin corresponded well with the 
drop in FA values in WM at the lesion site (Fig. 5.5A), whilst an inverse relationship was observed 
between myelin content and λ⊥, as anticipated (Fig. 5.5B). GFAP immunoreactivity, used as an 
indicator of astrogliosis, was prominently elevated at the lesion epicentre, in close correspondence 
with axial slices that showed the lowest FA values (Fig. 5.5C) and highest λ⊥ (not shown).  
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Figure 5.4: SCI-induced changes in radial diffusivity (λ⊥) for the white matter (WM) (A), 
ventral funiculi (VF) (B), lateral funiculi (LF) (C), and dorsal columns (DCs) (D) as a function 
of post-injury time. Note the progressive increase in λ⊥ after SCI, with significantly higher values 
obtained for this parameter at 30 days post-injury compared to all other experimental time points 
(except for the DCs at 3 days post-injury). Data points represent mean ± SEM (n = 4 per group); *, 
p < 0.05; **, p < 0.01; and ***, p < 0.001 (repeated measures one-way ANOVA with Newman–
Keuls post hoc). 
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5.3.4 Distal changes in FA and λ|| as indicators of Wallerian degeneration 
Region-specific analysis of FA along the injured spinal cord segment showed a significant 
rostrocaudal asymmetry, which was most pronounced for the DC area (Suppl. Fig. 5.3). Here, FA 
values returned to normal levels at a distance of ~ 3 mm caudal to the lesion epicentre. Rostral to 
the injury site, however, FA values remained significantly below baseline for a distance of at least 
up to 5 mm (Suppl. Fig. 5.3A; p < 0.05). We theorised that this rostrocaudal asymmetry may have 
resulted from Wallerian degeneration as this region mostly contains ascending sensory fibres. 
Therefore, severed axons that originated from dorsal root ganglia below the level of the spinal 
injury would no longer be connected to the neuronal cell body, and thus undergo degeneration. 
Consistent with this hypothesis, a similar degree of asymmetry was observed for λ || in the DCs 
(Suppl. Fig. 5.3D; p < 0.01). The opposite was observed for the ventrolateral white matter, where 
descending tracts dominate. Here, FA values were similar to pre-injury baseline measurements at 
≥ 2 mm rostral, but they did not return to normal for up to 4 mm caudal to the lesion epicentre 
(Suppl. Figs. 5.3B, C; p < 0.05). A loss of axonal integrity, resulting from degeneration of the distal 
portion of severed axons, appeared again evident based on a significantly decreased λ|| for at least 
5 mm caudal to the lesion epicentre (Suppl. Figs. 5.3E, F; p < 0.05). 
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Figure 5.5: Correlation between myelin content, GFAP immunoreactivity, and select DTI 
parameters for the spinal cord white matter (WM) at 30 days post-injury. A: Note that the 
reduction in FluoroMyelin Red staining (red line) is closely associated with the decline in FA (grey 
line); both are maximally reduced at the lesion epicentre. B: An inverse relationship was observed 
between myelin content (red line) and the radial diffusivity (λ⊥; grey line) across the injury site. C: 
Quantification of GFAP immunoreactivity revealed an inverse relationship between astrogliosis and 
FA. Note that the maximum decrease in FA (grey line) corresponds with the peak of GFAP 
immunoreactivity (green line) in proximity to the epicentre. D-F: Representative photomicrographs 
of the injured mouse spinal cord at 30 days post-SCI, showing relatively normal myelin staining 
(red) and low GFAP immunoreactivity (green) in more distant areas (D, F), but diminished myelin 
content and increased GFAP immunoreactivity at the lesion epicentre (E). Scale bar (in F): 300 μm. 
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A comparison with the relative density of neurofilament staining confirmed that the 
observed rostrocaudal asymmetry for the various ROIs was indeed reflective of Wallerian 
degeneration (Fig. 5.6). Specifically, the pattern of axonal loss for the DCs was most pronounced at 
and rostral to the lesion epicentre (Figs. 5.6A, D-F), closely correlating with the observed 
rostrocaudal asymmetry in FA (Fig. 5.6A) and λ|| (Fig. 5.6B). For the ventrolateral white matter, 
rostrocaudal asymmetry in the relative density of neurofilament staining again closely matched the 
pathology detected by DTI, with reduced FA values detected for up to 4 mm caudal to the injury 
site (Figs. 5.6C, D–F). 
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Figure 5.6: Correlation between neurofilament staining and select DTI parameters. A, B: The 
pattern of axonal loss for the dorsal columns, as detected by neurofilament staining (NF200; green 
line), closely correlated with observed rostrocaudal asymmetry in FA (A) and axial diffusivity (λ||) 
(B) (grey lines). C: For the ventrolateral white matter (WM), the observed rostrocaudal asymmetry 
in DTI parameters again correlated well with the pattern of axonal loss as detected by NF200 
staining and shown here for FA (grey line). D-F: Representative photomicrographs of the injured 
mouse spinal cord at 30 days post-SCI, showing NF200 (green) and FluoroMyelin (red) staining; 
cell nuclei are shown in blue (Hoechst nuclear dye). Images on the right show a higher 
magnification of the boxed areas in the left hand image. Note the loss of NF200 staining in the DC 
area (E) at and rostral to the lesion epicentre (D) as compared to caudal (F). For the ventral white 
matter, NF200 staining was highest rostral to the lesion epicentre (D), diminishing at the injury site 
(E) and caudal to it (F). Scale bars (in F): 300 μm (D-F) and 50 μm (insets). 
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Immunofluorescent staining for Iba1 and CD68 confirmed a prominent presence of 
macrophages at and around the lesion epicentre as expected (Fig. 5.7). However, a clear 
rostrocaudal asymmetry was again observed in identified ROIs undergoing Wallerian degeneration, 
with Iba1 staining being strongest in more distant areas where the greatest degree of axonal loss was 
observed based on neurofilament staining (compare with Fig. 5.6). Specifically, in the DC, the 
immunoreactive area for Iba1 was highest close to the lesion epicentre, as expected. However, a 
significantly greater presence of macrophages was observed in the rostral direction, for up to at least 
5 mm away from the lesion epicentre as compared to caudal (Figs. 5.7E-H; p < 0.05). In general, 
macrophage presence correlated inversely with FA (Fig. 5.7A) and λ|| (Fig. 5.7B). For the 
ventrolateral white matter, the Iba1
+
 immunoreactive area was higher caudal to the lesion site 
compared to rostral, as would be anticipated based on the pattern of Wallerian degeneration and the 
associated presence of macrophages (Figs. 5.7E-H). The observed asymmetry here again correlated 
inversely with FA data (Fig. 5.7C) and λ|| values (Fig. 5.7D).   
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Figure 5.7: Relationship between macrophage presence and select DTI parameters in areas 
undergoing Wallerian degeneration. The Iba1 immunopositive area (blue line) is greater for 
regions with reduced FA and λ|| (grey lines), in both the dorsal columns (DCs; A, B) and 
ventrolateral white matter (C, D). E-H: Representative photomicrographs of the injured mouse 
spinal cord at 30 days post-SCI, showing Iba1 (green) and CD68 (red) staining; cell nuclei are 
shown in blue (Hoechst nuclear dye). Images on the right show a higher magnification of the boxed 
areas in the left hand image. Note that for the DCs, there is an increased abundance of Iba1
+
CD68
+
 
macrophages rostral to the lesion epicentre (relative to caudal; compare E1, F1 with H1), which 
correlated inversely with the rostrocaudal asymmetry in FA and λ||. The opposite pattern was 
observed for the ventrolateral white matter. Of note, in contrast to the ventrolateral white matter, 
macrophage presence for the DC region appeared to peak just rostral to the lesion epicentre, as 
relatively fewer numbers of these cells occupied the fibrotic scar that replaced the severely damaged 
neural tissue in this ROI at 30 days post-injury (compare F1 to G1). Scale bars (in E): 250 μm (E-H) 
and 30 μm (insets).  
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The varying degree of damage to ascending and descending pathways in the DCs, VF and 
LF, along with the change in various DTI parameters, was further confirmed and visualised through 
ex vivo tractography (Fig. 5.8). Of note, the absolute values for λ⊥ have changed here compared to 
the preceding in vivo measurements due to tissue fixation.  
 
 
 
 
Figure 5.8: Representative tractography images from ex vivo DTI data at 30 days post-SCI. A 
three dimensional reconstruction of the lesion core is shown in yellow for each panel. Streamlines 
are colour-coded for FA (left) and λ⊥ (right), with blue and red representing the low- and high-end 
values of the scale, respectively. Note the dramatic loss of tissue anisotropy for the dorsal column 
(DC) area at the lesion site (A, B), indicating near complete damage to white matter tracts through 
this ROI. For the lateral (C, D) and ventral (E, F) funiculi, tract reconstructions still indicated 
substantial tissue damage, although some preservation of fibres was still evident for both these 
ROIs. Note also that FA values are decreased close to the lesion epicentre, whilst λ⊥ is increased. 
The rostrocaudal asymmetry in FA and λ⊥ can also be observed, most clearly for the DCs. Scale bar 
(in A): 1.0 mm. 
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5.4 Discussion 
 
Conventional MRI is the standard method for evaluating human SCI (Bozzo et al., 2011). 
MRI has also proved a valuable tool in various animal models of SCI, including dogs (Boekhoff et 
al., 2012) cats (Takahashi et al., 1996) rats (Kozlowski et al., 2008; Sandner et al., 2009; 
Martirosyan et al., 2010; Scholtes et al., 2011) and mice (Gonzalez-Lara et al., 2009; Tatar et al., 
2009), to identify tissue compression, oedema, haemorrhage and scarring (O'Beirne et al., 1993; 
Mhuircheartaigh et al., 2006; Blomster et al., 2013b). We demonstrate here that macroscopic 
assessment of longitudinal MRI data can also reveal the progression of atrophy in mice, with a 
significant tissue shrinkage detected between 7 and 30 days post-SCI. These observations are 
consistent with findings in human patients where spinal cord atrophy also occurs (Freund et al., 
2011). 
Although conventional MRI allows for macroscopic assessment of pathology, it is not 
normally an accurate predictor of functional outcomes as this technique does not provide 
quantitative information on the overall integrity and/or partial sparing of white matter tracts 
(Sundgren et al., 2004). Such information can, however, be obtained through DTI, which indeed 
provides a better correlation with clinical outcomes in SCI patients (Chang et al., 2010; Mulcahey et 
al., 2011). Yet, this imaging technique is not commonly applied to animal models of SCI, 
particularly mice. Technical challenges posed by the small size of the spinal cord, along with 
physiological motion and susceptibility artefacts, can make the acquisition of high quality images 
difficult (Cohen-Adad et al., 2008). Despite these obstacles, longitudinal in vivo DTI has the 
potential to considerably improve our understanding of secondary SCI pathology and to also 
identify potentially salvageable tissue through repeated imaging of the same animal. We show here 
that longitudinal assessment of specific DTI parameters reveals several key abnormalities following 
SCI in mice. 
MD values transiently declined during the acute period but returned to control levels at 
30 days post-SCI. This change is not likely the result of vasogenic oedema, i.e. leakage of plasma 
fluid into the extracellular space due to blood-spinal cord barrier dysfunction, as this would 
normally lead to an increased MD. Qualitative inspection of b0 (T2-weighted) images post-injury 
also did not reveal any obvious signs of fluid accumulation (hyperintensity) for the ROIs. Our 
experimental data also suggested minimal presence of cytotoxic oedema for the various white 
matter ROIs. After CNS injury, a variety of pathophysiological changes, including ischaemia, 
energy depletion, excitotoxicity and/or intracellular Ca
2 +
 accumulation, can all contribute to a 
decreased extracellular and increased intracellular fluid content. The resulting cell swelling (i.e. 
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cytotoxic oedema) has been associated with a decreased MD, particularly in grey matter 
(Loubinoux et al., 1997; Ellingson et al., 2007; Ellingson et al., 2010). However, whilst a rapid 
decline in λ|| was observed along with the drop in MD, we did not see a concomitant reduction in λ⊥, 
which thus appears to argue against this type of oedema being prominently present. 
A decrease in FA values at the lesion core became increasingly apparent over time for all 
ROIs. These findings are in line with clinical studies, which have reported reduced FA values near 
the injury site in SCI patients (Shanmuganathan et al., 2008; Rajasekaran et al., 2010; Kamble et al., 
2011; Petersen et al., 2012). As the FA correlates well with both the clinical completeness of SCI 
and electrophysiological measures (Petersen et al., 2012), this parameter thus likely also provides a 
relevant and translatable indicator to assess damage and possibly treatment efficacy in experimental 
animal studies. 
The drop in FA was most pronounced for the DCs. Given that this area was directly 
impacted and thus severely damaged, this dramatic decline in FA is perhaps not surprising. Indeed, 
tractography at 30 days post-injury failed to show any indications of pathway preservation in this 
region. Previous studies at 4.7 T indicated that axonal damage following contusive SCI in rodents is 
reflected by a decrease in λ|| (Budde et al., 2007), which most likely results from increased barriers 
to diffusion along the direction of axons, due to the collapse of axonal membranes and the 
accumulation of myelin debris within areas of necrosis (Loy et al., 2007). We therefore used this 
parameter to further assess pathway integrity in our model at 16.4 T. Reductions in λ|| confirmed 
that contusive SCI inflicted immediate and irreversible axonal damage for all ROIs, but particularly 
the DCs where the decline was greatest. The injury-induced reduction in λ|| at 2 hours post-SCI was 
less pronounced for regions more distant to the site of impact, i.e. the VF and LF, and a 
considerable level of anisotropic tissue was confirmed through tractography at the experimental 
endpoint, 30 days post-SCI. Of note, a slight increase in λ|| was observed here compared to the 7-
day time point, although values remained well below baseline in all ROIs. It remains to be 
determined if, and to what degree, axonal sprouting, gliosis and/or scarring contributed to this 
phenomenon. In this context, it is important to point out that the presumptive DC region (for the 
lesion epicentre only) had to be extrapolated based on proximal and distal slices for the subacute 
and late time points after injury as the normal tissue architecture was completely disrupted here; this 
may explain the greater level of variability in λ|| (relative to other ROIs) that was observed at the 
lesion epicentre. Thus, region-specific analysis of λ|| at 16.4 T can provide information on pathway 
integrity in a mouse model of SCI, and possibly detect more subtle loss of axons as part of ongoing 
secondary degeneration, at least up to 7 days post-injury. However, larger cohorts of mice, along 
with customised imaging protocols (Hui et al., 2010), are likely required to gain enough statistical 
power to reliably detect these latter changes. 
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Interestingly, a more comprehensive spatial analysis of SCI-induced changes in FA and λ|| 
revealed an ROI-dependent rostrocaudal asymmetry at the experimental endpoint. Similar 
observations were previously made at 4.7 T in mice (Kim et al., 2007) and, more recently, at 3 T in 
cats (Cohen-Adad et al., 2011). Consistent with previous findings after dorsal root axotomy (Zhang 
et al., 2009), we believe these changes to be indicative of Wallerian degeneration based on the post-
mortem histological correlate. Specifically, for the DCs, we observed reductions in FA and λ|| for up 
to at least 5 mm away from the lesion epicentre in the rostral but not the caudal direction. As the 
dorsal columns mostly contain ascending sensory fibres, a drop in FA, λ||, and fibre density as a 
result of Wallerian degeneration would be most notable rostral to the injury site, which was indeed 
the case. Increased macrophage presence was also noted here. We observed the opposite for the 
ventral and lateral funiculi where descending motor pathways dominate. Assessment of rostrocaudal 
asymmetry in FA and λ|| thus provides a non-invasive means to assess damage to ascending and 
descending tracts in SCI through region-specific analysis. 
As the FA takes into account both λ|| and λ⊥, any changes at the lesion site are likely not just 
reflective of axonal degeneration but also demyelination and possibly gliosis (Harsan et al., 2006; 
Harsan et al., 2007; Qin et al., 2012). The disruption of barriers to radial diffusion, particularly 
myelin sheaths, would permit greater movement of water in the perpendicular plane over time. 
Consistent with this, a progressive increase in λ⊥ was indeed observed at the lesion epicentre for all 
ROIs. These observations are in line with previous reports showing a close association between 
increased λ⊥ and demyelination in the diseased CNS (Song et al., 2002; Song et al., 2005; Harsan et 
al., 2006; Hofling et al., 2009). We confirmed the existence of a similarly inverse relationship 
between λ⊥ values and myelin content for our spinal cord samples through post-mortem histological 
analysis, although DTI appeared to be more sensitive for detecting subtle pathology at the lesion 
margins. The relatively quick spatial normalisation of λ⊥ (within ~ 2 mm of the lesion epicentre) 
also suggests that the established presence of tissue macrophages in more distant areas undergoing 
Wallerian degeneration exerts a minimal influence over this parameter. Assessment of λ⊥ thus 
provides important information on myelination status and, considering the close correlation between 
white matter preservation and functional deficits (Bresnahan et al., 1987; Noble and Wrathall, 
1989), may also likely yield translatable insights on the efficacy of targeted therapeutic 
interventions. 
In summary, this is the first longitudinal study to report on the use of ultra-high field 
(16.4 T) in vivo DTI to quantitatively monitor the progression of white matter damage following 
contusive SCI in mice for up to 30 days post-injury. We then conducted a detailed post-mortem 
microscopic analysis of key pathological changes, i.e. axonal loss, demyelination, astrogliosis and 
inflammation, to explain what factors might drive the observed changes in diffusion parameters 
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after SCI. Collectively, our findings suggest that the acute changes in FA are mostly driven by 
reductions in λ|| due to the disruption of tissue integrity as a result of impact. As pathology develops 
with time, a loss of myelin and the onset of glial scarring appear to contribute to a progressive 
increase in λ⊥, which in turn leads to further reductions in FA. Additional studies are, however, 
required to more directly correlate diffusion parameters with histopathology early after SCI to more 
definitively characterise this period. Only one other group has utilised in vivo DTI to 
chronologically examine SCI pathology in mice, although at a lower magnetic field strength (4.7 T), 
and only for up to 14 days post-injury (Kim et al., 2007). Consistent with our data, these authors 
reported a decreased FA and λ|| for the spared ventrolateral white matter in the injured spinal cord 
segment, whilst λ⊥ was increased (Kim et al., 2007; Tu et al., 2010); these SCI-induced changes 
reportedly plateaued between 7 and 14 days post-injury. In the present study, a continued increase 
in λ⊥ was, however, observed up until the late survival point of 30 days post-SCI, indicating 
ongoing and progressive demyelination. Differences in field strength and/or a more optimal b value 
to detect changes in λ⊥ (Hui et al., 2010) likely account for this seeming discrepancy. Our findings 
are also in general agreement with other in vivo and ex vivo DTI studies of SCI in different species 
such as rats (Krzyzak et al., 2005; DeBoy et al., 2007; Ellingson et al., 2008a; Zhang et al., 2009; 
Kim et al., 2012; Zhang et al., 2012a) and cats (Cohen-Adad et al., 2008; Ellingson et al., 2010; Qin 
et al., 2012). Most importantly, the changes in DTI parameters in mice with SCI closely match 
those observed in human patients (Chang et al., 2010; Cheran et al., 2011; Mulcahey et al., 2011; 
Bosma and Stroman, 2012; Petersen et al., 2012), highlighting its significance as a non-invasive, 
clinically relevant assessment tool to assess white matter integrity, and potentially treatment effects, 
for translational research. 
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Supplementary Figures 
 
 
Figure S5.1: Set-up for in vivo DTI and overview of methods for adjusting slice geometry 
between imaging sessions. A: Experimental mice were placed parallel to the coil, supported by 
foam pads and a head shield with tooth bar. Breathing rate was monitored using the Biotrig Animal 
Monitoring System (M2M Imaging). B-C: Pilot sagittal T1-weighted images of the injured mouse 
spinal cord at 1 day (B) and 30 days (C) post-SCI. Note that the lesion core can be clearly identified 
between time points based on a localised hypointensity (white arrows). Also note that the magenta 
rectangles, which indicate the field of view to be scanned, was adjusted between imaging sessions 
to appropriately align it with the spinal cord. D: A pilot T1-weighted transverse image confirming 
appropriate slice position and angle for DTI scanning. Of the 16 axial slices obtained, 10 slices 
centred on the lesion epicentre were used for analyses. E: A pilot axial T1-weighted image of the 
lesion site at 30 days post-SCI. Scale bars: B-C (in C) = 2.5 mm; D = 2.0 mm; and E = 1.0 mm. 
 
 
 
 
 
 
 
Figure S5.2: Overview of the various regions of interest (ROIs) overlayed on FA maps of the 
intact mouse spinal cord. A: White matter (WM), B: ventral funiculi (VF), C: lateral funiculi (LF), 
and D: dorsal columns (DCs). 
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Figure S5.3: Rostrocaudal asymmetry in FA and axial diffusivity (λ||) for the dorsal column 
(DC) area (A, D), ventral funiculi (VF) (B, E), and lateral funiculi (LF) (C, F) at 30 days post-
injury. Note the significant, persistent decrease for both FA and λ|| in the DC area for up to 5 mm in 
rostral (but not caudal) direction compared to pre-injury values (A, D). A similar asymmetry was 
observed for the VF (B, E) and LF (C, F), however, FA and λ|| values for these ROIs were 
persistently lower in the caudal (but not rostral) direction for up to at least 4 mm away from the 
lesion epicentre. Data points represent mean ± SEM (n = 4 per group); *, p < 0.05; **, p < 0.01; and 
***, p < 0.001 (repeated measures two-way ANOVA with Bonferroni post hoc). 
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Abstract 
 
Traumatic spinal cord injury (SCI) leads to immediate neural cell death and disruption of the 
blood-spinal cord barrier, which allows circulating immune cells and blood proteins to enter the 
spinal cord parenchyma. The resulting inflammatory response, which involves robust activation of 
complement system proteins, contributes to secondary injury and impairs neurological recovery. 
The aim of this study was to determine whether intravenous immunoglobulin (IVIG) therapy, which 
is already FDA approved for treating a variety of inflammatory and autoimmune conditions, is also 
effective in SCI. We report that IVIG administration attenuates complement system activation and 
improves the functional and histopathogical outcomes in a mouse model of contusive SCI. 
Importantly, the therapeutic effect of IVIG was detectable through non-invasive diffusion tensor 
imaging (DTI), with IVIG treatment counteracting the SCI-induced reduction in fractional 
anisotropy (FA) and progressive increase in radial diffusivity (RD) within white matter tracts during 
the post-acute phase. FA and RD values were significantly correlated with the functional 
performance of individual mice, with RD values also accurately predicting the degree of myelin 
preservation as assessed through post-mortem histological analysis. Together, these findings 
highlight the prospect of using IVIG as an anti-inflammatory treatment option for SCI, along with 
the potential for DTI to quantitatively assess both tissue damage and the efficacy of candidate 
intervention strategies in preclinical models of SCI. The ability to non-invasively detect treatment 
effects in live animals is a major step forward to screen and accelerate the translation of promising 
therapeutic interventions into the clinic. 
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6.1 Introduction 
 
 Traumatic spinal cord injury (SCI) is a catastrophic event that leads to severe and often 
permanent functional disabilities. Deregulated and chronically persisting inflammation in SCI is 
thought to significantly exacerbate the damage caused by the primary mechanical insult, also 
hampering endogenous repair processes (Bethea and Dietrich, 2002; Jones et al., 2005b; Donnelly 
and Popovich, 2008; Popovich and McTigue, 2009). Consequently, much of the research effort in 
relation to secondary damage in SCI has focused on inflammation in order to better understand its 
role and to define discrete therapeutic targets for intervention. Early studies showed that 
administration of immunosuppressant corticosteroids following experimental SCI confers 
neuroprotection and reduces spinal cord oedema (Ducker and Hamit, 1969; Ducker and Zeidman, 
1994).  As a result, steroid therapy has long been a standard practice for treating human patients. 
However, its efficacy in the clinical context is somewhat dubious (Hurlbert, 2001; Miller, 2008; 
Bydon et al., 2013). More effective immunomodulatory therapies that can target specific aspects of 
the complex neuroinflammatory response to SCI are thus urgently needed, alongside the 
development of sophisticated and clinically relevant assessment methods that can screen and select 
the most promising therapies for clinical trials based on their efficacy in animal studies.   
 One readily available candidate therapy for SCI that may be superior to corticosteroid 
treatment, based on its presumed mechanisms of action, is intravenous immunoglobulin (IVIG; 
Tzekou and Fehlings, 2014), a blood product that contains purified Ig from the pooled serum of 
thousands of healthy donors (Bayry et al., 2011). The benefits of IVIG therapy for SCI have indeed 
already been demonstrated in the rat, using both clip compression (Gok et al., 2009; Nguyen et al., 
2012) and weight drop (Gok et al., 2009; Nguyen et al., 2012) models of injury. Testing the efficacy 
of promising SCI therapeutics like IVIG in the clinic has, however, proved difficult due to the 
heterogeneity of the SCI patient population in terms of injury level and severity, as well as variation 
in spontaneous recovery (Fawcett et al., 2007; Lammertse et al., 2007; Steeves et al., 2007; 
Tuszynski et al., 2007; Lee et al., 2012; Dvorak et al., 2014). Furthermore, although rodent SCI 
models replicate much of the aetiology of human SCI, there are important intrinsic anatomical 
differences between species, and any improvements in recovery of locomotor function observed in 
quadruped mammals may not necessarily translate automatically to bipedal humans (Courtine et al., 
2007). The use of invasive tissue sampling procedures for histological assessment of pathology 
and/or treatment efficacy has also naturally been restricted to animal studies. There is thus an urgent 
need for non-invasive and transferable approaches that can be used to screen and assess treatment 
efficacy in both animals and human SCI patients.  
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 We previously reported that diffusion tensor imaging (DTI) can quantitatively document and 
assess the development of secondary SCI pathology in live mice (Brennan et al., 2013). Early 
changes in fractional anisotropy (FA) and axial diffusivity (AD) appeared to be mostly correlated to 
a loss of axonal integrity. Beyond the acute phase, the continued deterioration of FA values was 
mostly driven by a progressive increase in the radial diffusivity (RD), which in turn was correlated 
with both demyelination and glial scarring through post-mortem histological studies. The present 
study first established that IVIG improves recovery from SCI in mice. It was then investigated 
whether longitudinal DTI can be used as a quantitative tool to assess both treatment efficacy, and 
the possible mechanism(s) of action of IVIG based on observed changes in FA, AD and/or RD 
values. 
 
6.2 Materials and Methods 
 
6.2.1 Animals 
A total of 29 adult female age-matched and weight-matched C57BL6/J were used in this 
study. All experimental animals were obtained from local breeding colonies at The University of 
Queensland Biological Resources. Mice were maintained under standard conditions in clean 
holding facilities on a 12 hour light-dark cycle with ad libitum access to food and water. All 
experimental procedures were approved by The University of Queensland’s Animal Ethics 
Committee and conducted in accordance with the relevant policy guidelines for animal 
experimentation from the National Health and Medical Research Council of Australia.  
 
6.2.2 Spinal cord injury and IVIG therapy 
Mice were anaesthetised with a mixture of tiletamine/zolezepam (50 mg/kg; Virbac) and 
xylazine (20 mg/kg; Troy Laboratories), after which they were subjected to contusive SCI. This 
involved identification of the ninth thoracic (T) vertebra based on anatomical landmarks (Harrison 
et al., 2013), followed by dorsal laminectomy of T9 as described previously (Scheff et al., 2003; 
Blomster et al., 2013b). Next, a severe (~ 70 kdyne) contusion injury was inflicted on the spinal 
cord using the Infinite Horizon impactor (Precision Systems and Instrumentation). The muscle and 
skin were closed using 6-0 polyglactin dissolvable sutures (Ethicon). Post-operatively, animals 
received one injection of buprenorphine (0.5 mg/kg s.c.) in Hartmann's sodium lactate solution for 
analgesia, and were administered antibiotics (1.0 mg/kg gentamicin s.c.) for the first 5 days post-
injury. Bladders were manually voided twice daily for the duration of the experiment (i.e. up to 35 
days post-SCI) as part of general care.  
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Immediately after surgery, mice were randomly allocated to one of the following 
experimental groups: 1) no treatment (n = 7), 2) 1 g/kg human immunoglobulin (Ig; Privigen, CSL 
Behring; 0.4 cc i.v.; n = 7), 3) 2 g/kg Privigen (0.4 cc i.v.; n = 4), or 4) human albumin (Sigma-
Aldrich; 1 g/kg, 0.4 cc i.v.; n = 8). Albumin treatment was used to control for possible effects of 
protein loading following IVIG administration. The small pilot group (n = 4) given 2 g/kg Privigen 
was added to explore if a higher dose could augment any putative therapeutic benefits. All 
treatments were administered at 1 hour after SCI when the mice were still recovering from general 
anaesthesia. For treatment delivery, a small incision was made along the medial surface of the thigh 
to expose the femoral vein. A 30 G needle attached to a 1 ml syringe was then inserted into the vein 
and 0.4 cc of the treatment was slowly infused over a 2 minute time period. The needle was then 
withdrawn and a sterile cotton swab pressed gently against the vein for ~ 30 seconds to stop 
bleeding, after which the skin was sutured closed. Mice received a second dose of either IVIG or 
albumin at 14 days post-SCI via the lateral tail vein. All personnel involved in handling of the mice, 
data collection and analysis were at all times blinded to the treatment groups throughout the study to 
avoid experimenter bias. 
For mice that were given no treatment after SCI, the actual applied injury force and 
displacement was 72.3 ± 0.6 kdynes and 554.0 ± 13.6 µm (mean ± SEM), respectively. For those 
administered albumin, the applied force was 73.3 ± 0.9 kdynes of force and the associated 
displacement 533.0 ± 16.9 µm (mean ± SEM). For mice administered 1 g/kg IVIG, the applied 
force was 72.0 ± 1.1 kdynes and the tissue displacement 538.6 ± 12.8 µm (mean ± SEM); for those 
administered 2 g/kg IVIG, the applied force was 72.5 ± 2.2 kdynes, with an associated tissue 
displacement of 546.8 ± 26.1 µm (mean ± SEM). There were no significant differences in injury 
severity parameters between experimental groups (p > 0.05). 
 
6.2.3 Assessment of functional recovery  
Hindlimb locomotor recovery was assessed using the 10 point Basso Mouse Scale (BMS), 
specifically designed for murine models of SCI (Basso et al., 2006). Two investigators assessed the 
various aspects of hindlimb locomotor performance in open field for each experimental animal over 
a 4 minute period. For mice that achieved a score of frequent plantar stepping (i.e. a BMS score 5), 
BMS subscores were also assigned to quantify the finer aspects of locomotion. Animals were 
assessed at 1, 3, 7, 14, and 35 days post-SCI.  
 
6.2.4 In vivo DTI 
To determine whether DTI is capable of detecting the effectiveness of a treatment, a small 
cohort of untreated (n = 4) and IVIG-treated (2 g/kg; n = 4) mice with SCI were subjected to in vivo 
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DTI at 1, 7 and 35 days post-SCI. All data was collected at the Centre for Advanced Imaging (CAI, 
The University of Queensland, Australia) using a 16.4 T nuclear magnetic resonance scanner with 
an 89 mm vertical bore magnet (Bruker BioSpin) and a transmit/receive linear surface coil (1.5 x 
3.0 cm). Gradients were maintained at 30 ̊C. Animals were anaesthetised during imaging using an 
isoflurane/oxygen mixture (0.5–1.5%) at a flow rate of 1 L/min. Respiration rate was monitored 
using a Biotrig Animal Monitoring System (M2M Imaging), and maintained between 50-80 breaths 
per minute. Mice heads were held in position via a tooth bar and nose/head cone; they were 
supported inferiorly by a foam pad. In this position, their dorsum was situated adjacent to the coil. 
For each imaging session, the lesion site was identified and centred in pilot axial, sagittal, and 
transverse T1-weighted MR images. Slice angles were always set perpendicular to the long axis of 
the spinal cord. Vertebral landmarks were also used to confirm the anatomical position of the lesion 
and laminectomy site (Harrison et al., 2013). Images were acquired using respiratory gating, a two 
dimensional DTI spin-echo sequence with interleaved slice acquisition using TR/TE = 2400/21 ms. 
Diffusion sensitising gradients were applied in 12 non-collinear, uniformly distributed directions 
with the gradient strength b = 1500 s/mm
2
, 2 ms diffusion encoding and 14 ms diffusion separation, 
and 1 image being acquired with a b value of 0 (b0). The field of view was 9 × 12 mm
2
 with an 
acquisition matrix of 128 × 170, which yielded a final in-plane resolution of 70 × 70 μm2, with 
1.0 mm slice thickness. The number of excitations and the partial Fourier encoding acceleration 
were both 2, and the total acquisition time was 2 hours. Sixteen axial images covering part of the 
thoracic and lumbar spine were acquired as previously reported (Underwood et al., 2011; Brennan 
et al., 2013).  
The diffusion tensor eigenvalues (λ1, λ2, λ3) were computed using the Paravision 5.0 (Bruker 
BioSpin) diffusion tensor calculation module. The axial diffusivity (AD) was used to assess 
diffusivity along the principal axis of the diffusion tensor (λ1 = AD). The radial diffusivity (RD) 
was calculated using the two minor diffusion axes (RD = (λ2 + λ3) / 2). The fractional anisotropy 
(FA) was calculated using the equation: FA = √1/2(√((λ1 – λ2)
2
 + (λ1 – λ3)
2
 + √(λ2 – λ3)
2
) / 
√(λ1
2
 + λ2
2
 + λ3
2
)). Paravision 5.0 imaging software (Bruker BioSpin) was used for all image 
analysis. MRI datasets were de-identified to ensure investigator blinding during image analysis. 
Regions of interest (ROI), specifically the ventral funiculi (VF), lateral funiculi (LF) and dorsal 
columns (DCs) were outlined on transverse images as described previously (Brennan et al., 2013). 
 
6.2.5 Tissue preparation for histological analysis 
At 35 days post-injury, mice were anaesthetised with sodium pentobarbitone (150 mg/kg 
i.p.) and transcardially perfused with 20 ml of 0.9% saline solution containing 0.1% heparin and 2% 
NaNO2, followed by 30 ml of fixative (4% paraformaldehyde in phosphate-buffered saline (PBS: 
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1.7 mM NaH2PO4, 9 mM Na2HPO4, 0.15 M NaCl, pH 7.4)). The vertebral column was dissected 
out and submerged in fixative for 48 hours at 4 ̊C. Tissue specimens were cryoprotected through 
subsequent overnight incubations in PBS containing 10% and 30% sucrose, respectively. Spinal 
cords were then snap-frozen in dry ice-cooled isopentane and stored at -80 ̊C until further 
processing. Samples were cut into 20 μm thick transverse sections using a Leica cryostat CM3050-
S and collected as 1:5 series on Superfrost Plus slides (Menzel-Gläser). Slides were air-dried for 
2 hours and stored at -80 ̊C until further processing. 
 
6.2.6 Histology 
To determine whether intravenously administered Ig was able to access the spinal cord, 
immunofluorescent staining for human IgG (goat anti-hu-IgG, 1:100; Pierce Antibodies) was 
performed on tissue from 3 mice which had been subjected to sham surgery (i.e. laminectomy only; 
n = 1) or SCI (n = 2), and sacrificed at 24 hours post-surgery. Staining with primary antibody 
omission was used as the negative control. Hu-IgG staining was combined with immunofluorescent 
labelling of the neuronal marker NeuN (mouse anti-NeuN, 1:200; Millipore), or glial fibrillary 
acidic protein (rabbit anti-GFAP, 1:1000; Dako) to visualise astrocytes. Slides were first allowed to 
defrost for 1 hour at room temperature (RT), following by washes in PBS (3 x 10 mins). Where 
mouse primary antibodies were used, slides were also pre-treated with the HistoMouse kit (Life 
Technologies) as per the manufacturer’s instructions. Next, slides were incubated in blocking 
solution (0.2% Triton X-100 (Sigma-Aldrich) and 2% bovine serum albumin (BSA; Sigma-Aldrich) 
in PBS) for 1 hour at RT to permeabilise the sections and further reduce non-specific antibody 
binding; this solution was also used as the antibody diluent. Spinal cord sections were incubated 
overnight with primary antibodies at 4 ̊C in a humidified chamber. The following day, slides were 
washed in PBS (3 x 10 mins) to remove unbound primary antibody, followed by incubation for 1 
hour at RT with biotinylated horse anti-goat IgG (1:400; Vector Labs). Slides were then washed 
again in PBS (3 x 10 mins), after which the sections were incubated with an appropriate 
combination of streptavidin-Alexa Fluor 546 (1:200; BD Biosciences) and donkey anti-mouse-
Alexa Fluor 488 (1:200; Molecular Probes) or donkey anti-rabbit-Alexa Fluor 388 (1:200; 
Molecular Probes) secondary antibodies. Slides were then washed again in PBS (3 x 10 mins) and 
cover slipped with Dako fluorescent mounting medium. Sections were imaged using an Olympus 
BX61 confocal microscope. 
For quantification of myelin content, spinal cord sections were stained with FluoroMyelin 
Red (1:150; Molecular Probes) as described previously (Blomster et al., 2013a; Brennan et al., 
2013). Images were captured using an Olympus SZX12 Research Fluorescence Stereo Microscope 
(Spectra Services) with NIS-Elements 3.0 software (Nikon Instruments Inc.), followed by image 
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analysis using ImageJ v1.43. The total section area and the white matter were outlined using the 
freehand selection tool. The image was converted to an 8 bit file and the area of FluoroMyelin
+
 
staining determined using the threshold function. Myelin content was calculated by dividing the 
FluoroMyelin-positive area in the white matter by the total area of the section. A separate set of 
sections was stained for neurofilament (NF200) (rabbit anti-NF200; 1:200; Sigma-Aldrich), in 
combination with FluoroMyelin Red and Hoechst nuclear dye (1:1000; Sigma-Aldrich). Stained 
sections were captured using an Axio Imager Azure with Apotome attachment (Zeiss). 
Immunopositive areas for NF200 were again measured using the threshold function in ImageJ for 
dorsal columns (DC) and the ventrolateral white matter (VLWM). All sections were coded to 
ensure investigator blinding during image analysis.  
 
6.2.7 Statistical analysis 
Data was analysed using GraphPad Prism 6.0 software (GraphPad Software Inc.). A two-
way, repeated measures ANOVA with Bonferroni post hoc was used to analyse longitudinal BMS 
data and in vivo DTI data. A one-way ANOVA with Newman-Keuls post hoc was used to analyse 
35 day BMS scores and neurofilament data. Two-sided Student’s t tests were used to compare 
lesion volumes and myelin content between untreated and IVIG-treated (2 g/kg) groups at 35 days 
post-SCI. Linear regression analysis with Pearson’s r2 correlation coefficient was used to determine 
correlations between DTI parameters and BMS scores, and DTI parameters and myelin content, at 
35 days post-injury. Differences were considered to be significant at p < 0.05. All experimental data 
is presented as the group mean ± standard error of the mean (SEM). 
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6.3 Results 
 
6.3.1 IVIG is present at the site of SCI 
Immunofluorescent staining techniques were used to determine whether IVIG (administered 
one hour after SCI) entered the injured parenchyma in the acute phase of injury. For this, spinal 
cord tissue from sham-operated (i.e. laminectomy only) and injured mice was collected at 24 hours 
after surgery. In sham-operated mice, hu-IgG immunoreactivity appeared restricted to the 
meningeal border (Fig. 6.1A) and small capillary-like structures (Fig. 6.1A1). No staining was 
observed in the spinal cord parenchyma itself, suggesting that IVIG does not cross the blood-spinal 
cord barrier under normal conditions. In sharp contrast, hu-IgG in the spinal cord was clearly 
present within the cord parenchyma following SCI, with intense staining observed at and around the 
lesion epicentre (Fig. 6.1B). Dual colour immunofluorescent staining further revealed colocalisation 
of hu-IgG to NeuN
+
 neurons (Fig. 6.1C) and GFAP
+
 astrocytes (Fig. 6.1D).  
 
 
Figure 6.1: Intravenous immunoglobulin (IVIG) is present in the injured spinal cord. A: 
Representative image of a sagittal spinal cord section from a sham-operated (i.e. laminectomy only) 
mouse that was injected with 1 g/kg IVIG and perfused 24 hours later. IVIG (hu-IgG staining; red) 
is detectable near the GFAP
+
 (green) glia limitans/the meningeal border, but not within the spinal 
cord itself. A1: higher power magnification of the boxed region in A, showing hu-IgG 
immunoreactivity in association with capillary-like structures (arrow), but not the spinal cord 
parenchyma. B: Mid-sagittal section of an IVIG-treated animal with SCI. Note that there is 
widespread hu-IgG immunoreactivity across the injured segment, which diminishes in intensity in 
the rostral and caudal directions. C, D: Dual colour immunofluorescent staining showing 
colocalisation between hu-IgG and NeuN
+
 neurons (C, arrow), and GFAP
+
 astrocytes (D, arrow).  
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6.3.2 IVIG treatment improves neurological recovery from SCI 
To determine whether IVIG treatment could improve the functional outcome from SCI, 
BMS locomotor scoring with experimenter blinding was performed on injured, untreated controls, 
and injured mice treated with IVIG (1 g/kg and 2 g/kg) or albumin (1 g/kg; protein loading control) 
for up to 5 weeks after surgery (Fig. 6.2A, B). Prior to SCI, the entire cohort of mice displayed 
normal overground locomotion, achieving BMS scores of 9. Following SCI, all mice displayed 
near-complete paralysis (BMS scores 0-1) at 1 day post-SCI. By 7 days post-injury, mice had 
recovered from spinal shock and increased BMS scores were observed in all groups. At 14 days 
post-SCI, mice treated with 1 or 2 g/kg IVIG showed significantly improved locomotor 
performance compared to untreated mice. Albumin-treated mice showed an intermediate profile of 
recovery, with BMS scores not being significantly different from injured controls and IVIG-treated 
animals at this time point (p > 0.05). At the endpoint (35 days post-SCI), mice that were 
administered IVIG displayed significantly improved hindlimb locomotor function compared to both 
untreated (p < 0.0001) and albumin-treated (p < 0.05) mice. Albeit inferior to IVIG treatment, final 
BMS scores of albumin-treated mice were also significantly higher compared to injured controls at 
this time point (p < 0.05). In line with these functional observations, mice that were treated with 
IVIG (2 g/kg) had reduced lesion core volumes (Fig. 6.2C) and increased myelin content at the 
lesion epicentre (Fig. 6.2D, E). There was also a significant increase in the  number of NF200
+
 
axonal profiles in the dorsal columns (DC) as well as the ventrolateral white matter (VLWM) in 
IVIG treated mice (2 g/kg) compared to injured controls (Fig. 6.2F, G).  
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Figure 6.2: IVIG improves the outcome from experimental SCI. A: Mice administered IVIG (1 
g/kg or 2 g/kg) showed significantly improved functional recovery compared to untreated mice as 
early as 14 days post-SCI. IVIG therapy was also superior to protein loading control treatment at 35 
days post-SCI. Data points represent mean ± SEM; n = 4-8 per group; *, p < 0.05; ****, p < 0.0001; 
two-way ANOVA with Bonferroni post hoc. B: Scatter plot showing the spread of individual mouse 
BMS scores at 35 days post-SCI. The black line represents the mean of each group; *, p < 0.05; **, 
p < 0.01; ***, p < 0.001; ****, p < 0.0001; one-way ANOVA with Newman-Keuls post hoc. Mice 
administered IVIG (2 g/kg) also showed significantly reduced lesion volumes as determined by 
MRI analysis (C), and more myelin preservation (D, E) compared to untreated injured mice. Bars 
represent mean ± SEM; n = 4 per group; *, p < 0.05; Student’s two-sided t test. IVIG treatment also 
resulted in increased neurofilament (NF200) staining in the dorsal columns (DC) and ventrolateral 
white matter (VLWM) compared to untreated mice (F, G). Bars represent mean ± SEM; n = 4 per 
group; *, p < 0.05; one-way ANOVA with Newman-Keuls post hoc. 
  
S
C
I
S
C
I 
+
 I
V
IG
0 .0 0
0 .0 5
0 .1 0
0 .1 5
L
e
s
io
n
 v
o
lu
m
e
 (
c
m
3
) *
S
C
I
S
C
I 
+
 A
lb
u
m
in
S
C
I 
+
 I
V
IG
 [
1
 g
/k
g
]
S
C
I 
+
 I
V
IG
 [
2
 g
/k
g
]
0
3
6
9
* *
* * *
3
5
d
 B
M
S
 S
c
o
re
* * * *
n s
*
*
SCI + IVIG 
SCI 
VLWM DC 
S
C
I 
S
C
I 
+
 I
V
IG
 
Myelin / NF200 / Hoechst Myelin 
A B C 
D F G 
S
C
I 
S
C
I 
+
 I
V
IG
 
%
 M
y
e
li
n
S
C
I
S
C
I 
+
 I
V
IG
0
1 0
2 0
3 0
*
D C V L W M
0
1
2
3
4 *
*
%
 N
e
u
ro
fi
la
m
e
n
t
*
*
0 7 1 4 2 1 2 8 3 5
0
1
2
3
4
5
9
S C I
S C I +  A lb u m in
S C I +  IV IG  [1  g /k g ]
S C I +  IV IG  [2  g /k g ]
D a y s  P o s t- In ju ry
B
M
S
 l
o
c
o
m
o
to
r 
s
c
o
re
*
*
*
*
*
*
200 µm 
25 µm 
E 
Chapter 6: Intravenous immunoglobulin improves experimental SCI outcomes  171 
6.3.3 IVIG treatment attenuates the decline in FA following SCI 
Having established that IVIG treatment improves SCI outcomes, we next aimed to explore 
whether these improvements would be detectable through non-invasive diffusion tensor imaging 
(DTI) as improved DTI indices. Live imaging studies were restricted to injured, untreated control 
mice and SCI mice with 2 g/kg IVIG treatment. In untreated mice, there was a progressive 
deterioration of FA values between 1 and 35 days post-SCI for the ventral funiculi (VF) and lateral 
funiculi (LF). For the VF, FA values were significantly lower at 35 days after injury compared to 1 
day post-SCI (p < 0.01) (Fig, 6.3A). For the LF, FA values were significantly reduced at both 7 (p < 
0.05) and 35 days post-SCI (p < 0.01) compared to 1 day post-SCI (Fig. 6.3B). In sharp contrast, no 
such deterioration in FA was observed in IVIG-treated mice, although it must be noted that FA 
values were slightly lower in these animals at 1 day post-SCI. At the study endpoint, FA values 
were significantly higher for IVIG-treated mice in the VF (p < 0.01) and LF (p < 0.05) compared to 
injured, untreated controls. No time or treatment effect was seen for FA values in the dorsal 
columns (DCs), the site of direct impact (Fig. 6.3C).  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: Treatment with IVIG (2 g/kg) attenuates the SCI-induced changes in fractional 
anisotropy (FA). FA changes at the lesion epicentre in the ventral funiculi (A), lateral funiculi (B) 
and dorsal columns (C). In the VF and LF, non-treated animals showed a significant decrease in FA 
from 1 to 35 days post-SCI, which was significantly more pronounced than IVIG-treated mice at 35 
days post-injury. The FA in the DC slightly increased with time in the DC of IVIG-treated mice, but 
this was not different from untreated mice at any time point. Data points represent mean ± SEM; n 
= 4 per group; *, p < 0.05; **, p < 0.01; two-way repeated measures ANOVA with Bonferroni post 
hoc tests. 
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6.3.4 IVIG treatment attenuates SCI-induced increases in radial diffusivity (RD)  
Radial diffusivity (RD) values are generally regarded as a measure of myelin integrity, with 
high diffusion in the radial direction closely associated with demyelinating pathology (Ellingson et 
al., 2008b; Herrera et al., 2008). As demyelination as part of secondary  immunopathology appears 
to involve autoantibodies, complement activation and Fc receptors (Ankeny et al., 2009), we 
hypothesised that targeting these with IVIG treatment should attenuate the progressive increase in 
RD values that is normally observed in the post-acute phase of SCI (Brennan et al., 2013). Although 
IVIG administration did not completely prevent the progressive increase in white matter RD values 
over time, SCI-induced changes in RD were clearly attenuated compared to injured control mice 
that did not receive treatment, and were significantly lower at the study endpoint for both the VF 
and (p < 0.01; Fig. 6.4A) the LF (p < 0.05; Fig. 6.4B). There did not appear to be an effect of time 
or treatment group on RD values in the DC (p > 0.05; Fig. 6.3C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Treatment with IVIG (2 g/kg) attenuates SCI-induced changes in radial diffusivity 
(RD). RD changes at the lesion epicentre in the ventral funiculi (A), lateral funiculi (B) and dorsal 
columns (C). In the VF and LF, non-treated animals displayed a marked increase in RD with time 
after SCI. In both of these ROIs, the RD in untreated mice was significantly higher than the RD of 
IVIG-treated mice at 35 days post-injury. There was no effect of time or treatment on the RD in the 
DC. Data points represent mean ± SEM; n = 4 per group; *, p < 0.05; **, p < 0.01; two-way 
repeated measures ANOVA with Bonferroni post hoc tests. 
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6.3.5 The endpoint ventrolateral white matter FA and RD values significantly correlate with 
functional recovery 
Based on the observation that IVIG-treated mice displayed significantly more recovery of 
hindlimb function and improved DTI indices, we next explored whether FA and RD values were 
directly correlated with an improved neurological outcome at the study endpoint, 35 days post-SCI. 
Using linear regression, the relationship between BMS scores and the FA, AD or RD values was 
analysed. The degree of functional recovery was positively and significantly correlated to FA values 
in both the VF (p = 0.0005) and LF (p = 0.047), but not the DC region (p = 0.13) (Fig. 6.5A). AD 
values at the lesion epicentre did not correlate with the functional performance (i.e. BMS scores) of 
individual mice for any of the ROIs investigated under the imaging conditions used (Fig. 6.5B). On 
the contrary, RD values were strongly and inversely correlated with BMS scores for both the VF (p 
= 0.0009) and LF (p = 0.0086) (Fig. 6.5C). RD values for the DCs, the area mostly affected by the 
primary mechanical injury, were not significantly correlated with the hindlimb locomotor 
performance (p = 0.21). When plotting endpoint ventrolateral white matter FA, AD and RD 
measurements against the outcome of post-mortem myelin staining (Fig. 6.6A-C), only the RD was 
significantly correlated to myelin content at the lesion epicentre (p = 0.001).  Taken together with 
BMS correlations, these data suggest that both the FA and RD may be accurate prognostic markers 
for neurological recovery and/or treatment efficacy when measured in regions actively undergoing 
secondary degeneration, with the FA providing more general information on overall tissue integrity, 
and RD measurements being more indicative of myelination status.  
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Figure 6.5: The relationship between ROI diffusion parameters and BMS scores at 35 days 
post-injury. Data points represent individual mouse scores, with the black line representing the 
result of the regression analysis, showing the relationship between the x and y axis. A: An increased 
fractional anisotropy (FA) value in the ventral funiculi (VF) (left) and lateral funiculi (LF) (middle), 
but not the dorsal columns (DC) (right), was significantly correlated with improved functional 
recovery. B: The axial diffusivity (AD) did not correlate with BMS scores in any ROI. C: The 
radial diffusivity (RD) in the VF (left) and LF (middle), but not the DC (right), closely correlated 
with BMS scores. Linear regression with Pearson correlation coefficient (r
2
 value); n = 4 per group; 
*, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure 6.6: Correlation between the ventrolateral white matter diffusion parameters with 
myelin content at the lesion epicentre at 35 days post-SCI. Data points represent individual 
mouse scores, with the black line representing the result of the regression analysis, showing the 
relationship between the x and y axis. A: The fractional anisotropy (FA) in the ventrolateral white 
matter was not significantly associated (p = 0.16) with myelin content analysed through 
immunofluorescent staining. B: The axial diffusivity (AD) similarly showed no correlation to 
myelin status (p = 0.65). C: The radial diffusivity (RD), however, was highly correlated to 
myelination status. Linear regression with Pearson correlation coefficient (r
2
 value); n = 4 per 
group; *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
 
 
6.4 Discussion 
 
 A number of promising therapeutic interventions are currently being tested for the treatment 
of human SCI (Fehlings and Baptiste, 2005; Hawryluk et al., 2008; Gensel et al., 2011). All of these 
interventions have shown positive outcomes in preclinical animal studies, but assessing their 
efficacy in human trials is hampered by difficulties in study design (i.e. patient heterogeneity) 
(Dvorak et al., 2014); a paucity in transferable assessment methods between animal and human 
studies, and the intrinsic neuroanatomical differences between species (Schwab et al., 2006; Lee et 
al., 2012). The use of sophisticated, non-invasive assessment methods that can stratify injury 
severity and quantify treatment efficacy in both animal models and human SCI cases would 
overcome at least some of these challenges to translational research. There is now a growing body 
of evidence in support of diffusion tensor imaging (DTI) being one such technique (Fraidakis et al., 
1998; Loy et al., 2007; Kim et al., 2010; Rajasekaran et al., 2012). DTI can detect regions of 
oedema (Krzyzak et al., 2005), haemorrhage (Cheran et al., 2011), axonal damage and/or 
demyelination (Kim et al., 2007; Vargas et al., 2008), and Wallerian degeneration (Deo et al., 2006; 
Cohen-Adad et al., 2011; Brennan et al., 2013). However, no study to date has evaluated whether 
DTI is sensitive enough to reveal microstructural improvements in tissue integrity as a result of 
treatment and, if so, how quantifiable changes in diffusion indices correlate with the current gold 
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standard methods of assessing experimental treatment efficacy, i.e. functional performance in open 
field (BMS scores), and histopathology in post-mortem tissue samples. This study therefore 
explored whether in vivo DTI is capable of detecting beneficial effects of a promising therapeutic 
intervention, acute IVIG therapy. 
 IVIG therapy was originally designed as an antibody replacement strategy, but it is 
increasingly used to treat a myriad of inflammatory/autoimmune diseases because of its potent 
immune-modulatory properties (Durandy et al., 2009). These disorders include: idiopathic 
thrombocytopenic purpura (Qin et al., 2010), Kawasaki disease (Oates-Whitehead et al., 2003), 
myasthenia gravis (Schwendimann et al., 2005; Donofrio et al., 2009), Guillain-Barré syndrome 
(Korinthenberg, 2013), dermatomyositis (Bayry et al., 2011), and multiple sclerosis (Sorensen, 
2003; Achiron and Miron, 2005). IVIG therapy has also shown merit in a number of 
neurodegenerative conditions that are associated with marked inflammation, including acquired 
CNS injuries such as ischaemic stroke (Arumugam et al., 2007) and SCI (Nguyen et al., 2012). 
Potential mechanisms by which IVIG therapy improves neurological outcome in acquired CNS 
injuries are diverse and likely include the scavenging and neutralisation of complement activation 
products, reduced phagocytosis via Fc receptor blockade, along with neutralisation of pathogenic 
autoantibodies, pro-inflammatory cytokines and costimulatory molecules (Arumugam et al., 2007; 
Bayry et al., 2007; Hartung, 2008; Jacob and Rajabally, 2009), with the net result of these actions 
being attenuated endothelial cell dysfunction (Widiapradja et al., 2014) and increased neuronal 
survival (Widiapradja et al., 2012; Fann et al., 2013). With similar injurious inflammatory 
signalling events implied during the secondary injury phase of SCI, and the fact that IVIG already 
has an established safety profile (Katz et al., 2007), this promising treatment could thus rapidly 
enter clinical testing to explore its effectiveness for treating human SCI patients.   
 In this study, the therapeutic efficacy of IVIG was first confirmed in a mouse model of 
contusive SCI. Intravenously administered hu-IgG did not appear to enter the spinal cord following 
sham surgery, but was clearly present within the spinal cord parenchyma at 1 day post-SCI, when 
the integrity of the blood-spinal cord barrier is known to be disrupted (Popovich et al., 1996b; 
Tzekou and Fehlings, 2014). Apart from a more diffuse presence across the lesioned segment of the 
spinal cord, hu-IgG also appeared to directly localise to neurons and astrocytes, which can express 
Fc receptors (Nitta et al., 1992; Okun et al., 2010; van der Kleij et al., 2010), and therefore bind the 
Fc portion of hu-IgG (Anthony et al., 2008; Schwab and Nimmerjahn, 2013). With regards to SCI 
outcomes, IVIG-treated mice showed significantly improved hindlimb motor scores compared to 
(vehicle-treated and untreated) controls. The higher dose of IVIG (2 g/kg) did not appear to be 
significantly more effective compared to the 1 g/kg dose, although the small group size in the 2 g/kg 
group may have contributed to this outcome. A more extensive dose-response analysis should 
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therefore be conducted in follow-up studies across the spectrum that is most commonly used in the 
clinic (0.4-2 g/kg) to determine the most optimal dose for IVIG therapy in SCI. To further increase 
clinical relevance, future studies should also explore how long IVIG treatment can be delayed 
before its therapeutic efficacy is lost. Lastly, it must be noted that albumin treatment, which was 
used as a protein loading control, also led to improved SCI outcomes. These results are not 
inconsistent with previous reports that have described some immunosuppressive (Bar-Or et al., 
2006) and/or antioxidant properties (Belayev et al., 1999) of high dose albumin. Furthermore, it has 
also been suggested that the addition of a protein reserve in itself may be neuroprotective (Cain et 
al., 2007). Regardless, the efficacy of albumin still appeared inferior to IVIG treatment based on 
endpoint functional data. 
 To determine whether the established therapeutic effect of IVIG treatment could be detected 
non-invasively, longitudinal DTI was performed on the cohort of mice that was treated with 2 g/kg 
of IVIG, alongside a small group of non-treated SCI controls. Consistent with reports from both 
human patients and experimental animal studies (Renoux et al., 2006; Mulcahey et al., 2011; 
Brennan et al., 2013; Freund et al., 2013), FA values were reduced at the lesion epicentre at one day 
post-SCI but were not different between groups. Longitudinal monitoring (up to 35 days post-SCI) 
and quantification of SCI-induced changes in FA demonstrated, for the first time, the ability of DTI 
to detect favourable changes in diffusion characteristics as a result of IVIG therapy. Specifically, in 
untreated animals, and consistent with our previous observations (Brennan et al., 2013), FA values 
progressively deteriorated with time in the VF and LF. Importantly, this temporal decline in FA was 
partly countered in animals that were administered IVIG, with regional analysis revealing 
significantly higher FA in the VF of injured, IVIG-treated mice compared to injured, untreated 
controls. Endpoint FA measures here also demonstrated a direct correlation with the functional 
performance of individual animals, as determined by regression analysis. A similar trend was 
observed for the LF. These results indicate that FA values may be a useful biomarker for WM 
integrity and monitoring the extent of secondary degenerative changes over time, either in the 
presence or absence of a therapeutic intervention. Of note, FA values for the DC region, i.e. the part 
of the spinal cord that is directly impacted, did not further decrease between 1 and 35 days post-
SCI. These findings suggest that the damage inflicted by the initial mechanical trauma here is very 
severe, and highlight the fact that longitudinal DTI is most useful for monitoring regions that 
undergo secondary degeneration but were not completely destroyed by the primary injury.  
 An inherent advantage of DTI is that it provides insights into the diffusivity changes that 
drive disease-associated alterations in FA values, which in turn can provide valuable insights on the 
underlying pathological processes. In the present study, no significant differences were observed in 
AD values between experimental time points and/or groups. These findings are in line with our 
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earlier study, which showed an acute reduction in AD values following SCI but no significant 
change thereafter (Brennan et al., 2013). The present findings thus confirm that acute AD 
measurements are sensitive to the primary effects of SCI, most likely the axonal disruption early 
after injury (Donnelly and Popovich, 2008), but less so for detecting more subtle secondary 
degenerative changes (or an amelioration thereof), at least under the imaging conditions that were 
used. Future studies should, however, consider including additional b values, particularly towards 
the lower end of the spectrum, to ensure that the imaging protocol is optimised to detect possible 
changes in AD measurements (Ellingson et al., 2007; Hui et al., 2010). 
 More remarkably, the dramatic increase in RD values that is normally observed in the post-
acute phase (Brennan et al., 2013) and is linked to demyelination (Kim et al., 2007; Loy et al., 2007; 
Herrera et al., 2008; Fasano et al., 2009; Mulcahey et al., 2011), was significantly attenuated in 
IVIG-treated animals at the study endpoint. These findings suggest that IVIG treatment may 
mediate part of its therapeutic effect by protecting spared axons against secondary immune-
mediated demyelination (Stangel and Pul, 2006), which is consistent with the significantly 
increased myelin content that was observed in spared white matter of IVIG-treated animals. An 
additional contributing factor may have been enhanced reparative remyelination as a result of IVIG 
treatment (Stangel and Hartung, 2002; Ephrem et al., 2005). Importantly, in addition to myelin 
content, RD values were also highly correlated with the functional performance of individual mice, 
both within and between experimental groups. Thus, white matter RD values appear to be 
particularly useful and exquisitely sensitive as a biomarker for tissue damage, which may enable 
patient stratification, and objective assessment of treatment efficacy in longitudinal clinical studies.  
 In conclusion, the present findings highlight the potential of IVIG as a readily available and 
promising treatment option for acute SCI to improve the prospects of functional recovery. 
Furthermore, this study demonstrates the ability of DTI, a non-invasive and clinically relevant 
imaging technique, to detect microstructural improvements in the integrity of spinal cord white 
matter based on quantifiable changes in diffusion indices, in particular RD values. Routine 
incorporation of DTI techniques, both clinically and in translational SCI research, could thus be 
extremely advantageous, not only for characterising SCI pathology and stratification of patient 
cohorts, but also to expedite the selection of the most promising therapeutics, along with validation 
of their efficacy in clinical trials. 
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7.1 Summary of preceding chapters  
 
As overviewed in Chapter 1, the precise neuroanatomical organisation of the mammalian 
spinal cord confers its functionality as the critical structure for relaying information between the 
brain and body. Therefore, traumatic SCI causes neurological disabilities that are often permanent 
and devastating. It is now well established that the poor prognosis for functional recovery is partly 
attributable to a complex and insidious series of secondary injury events that follow the mechanical 
insult, principal among which is the neuroinflammatory response (Blight, 1991a; Dumont et al., 
2001). The standard treatment available for SCI-induced neuroinflammation has been the general 
anti-inflammatory drug methylprednisolone (Silva et al., 2014). However, methylprednisolone has 
questionable efficacy, thought to be due to its non-specific immunosuppressive actions (Baptiste 
and Fehlings, 2007; Miller, 2008; Bydon et al., 2013). This warrants further scrutiny regarding the 
roles of specific components and modulators of the inflammatory response in order to ultimately 
provide better treatment options for patients.  
To date, research targeting  mediators of neuroinflammation has mainly focused on cellular 
immunity, including granulocytes (Taoka et al., 1997; Bao et al., 2008; Fleming et al., 2008; 
Stirling et al., 2009; Lee et al., 2011; Geremia et al., 2012), monocytes (Mabon et al., 2000; Gris et 
al., 2004; Fleming et al., 2008; Abshire et al., 2011; Donnelly et al., 2011; Lee et al., 2011; 
Blomster et al., 2013a), macrophages (Blight, 1992; Blight, 1994; Popovich et al., 1999; Mabon et 
al., 2000; Bao et al., 2008; Fleming et al., 2008; Gensel et al., 2009; Kigerl et al., 2009; Shechter et 
al., 2009; Abshire et al., 2011; Donnelly et al., 2011; Iannotti et al., 2011; Shechter et al., 2013) and 
lymphocytes (Jones et al., 2002b; Jones et al., 2004; Jones et al., 2005a; Ankeny et al., 2009; Wu et 
al., 2012). However, both beneficial and detrimental roles have been identified for at least some of 
these aforementioned cells (Bethea, 2000; Conti et al., 2003; Hausmann, 2003; Chan, 2008; 
Donnelly and Popovich, 2008), highlighting the need to more precisely define the molecular cues 
pertaining to their activation, recruitment, and interactions with neurons and reactive glia, as 
indiscriminate immunosuppression could lead to adverse outcomes. 
One aspect of neuroinflammatory response that is crucial to immune cell activation is the 
innate immune complement system. As discussed in Chapter 2, complement can be activated by 
multiple induction routes, including the classical, alternative, mannan-binding lectin  (MBL) 
(Ricklin et al., 2010), and the extrinsic protease pathways (Muhlfelder et al., 1979; Huber-Lang et 
al., 2006; Amara et al., 2008; Amara et al., 2010). Complement proteins act in synchrony to protect 
against injury or infection through opsonisation of pathogens and abnormal host cells, direct cell 
lysis, and stimulating chemotaxis and/or activation of leukocytes (Ward, 1972; Ricklin et al., 2010; 
Sarma and Ward, 2011; Ricklin and Lambris, 2013). As well as forming the first line of host 
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defence, novel roles for this system have been discovered in CNS physiology (van Beek et al., 
2003; Benard et al., 2008; Woodruff et al., 2010; Brennan et al., 2012).  
However, in acute CNS trauma, pathological roles have been described for the classical 
(Rancan et al., 2003; Reynolds et al., 2004; Leinhase et al., 2006b; Gesuete et al., 2009; Longhi et 
al., 2009), alternative (Rancan et al., 2003; Reynolds et al., 2004; Huang et al., 2008; Qiao et al., 
2010), and MBL (Morrison et al., 2011; de la Rosa et al., 2014) induction pathways for complement 
system activation. Similarly detrimental roles have been identified for the complement opsonins 
(Huang et al., 1999; Ten et al., 2005; Ankeny et al., 2009), and the membrane attack complex 
(MAC) (Sewell et al., 2004; Costa et al., 2006; Leinhase et al., 2006a; Mocco et al., 2006c; Qiao et 
al., 2006; Yang et al., 2006; Arumugam et al., 2007; Li et al., 2009; Qiao et al., 2010). These 
components deposit on exposed intracellular epitopes and promote cell phagocytosis and lysis, 
thereby promoting the spread of damage into neighbouring intact parenchyma. In line with this, 
decreasing the activity of the complement regulatory factor CD59 exacerbates secondary pathology 
(Stahel et al., 2009; Harhausen et al., 2010). Intriguingly, Beck et al. (2010) observed that inhibition 
of the C5a anaphylatoxin receptor C5aR in the chronic phase of SCI worsened neurological 
recovery. Although the mechanisms driving this finding had remained unknown, it does highlight 
the importance of investigating and understanding the previously uncharacterised role of the 
complement anaphylatoxins in SCI, as these fragments do not contribute to opsonisation or MAC 
formation.  
 
7.1.1 The role of complement factor C3a in SCI 
 Chapter 3 aimed to explore the role of the complement C3a-C3aR axis in experimental SCI. 
An initial finding was that C3a is produced after SCI, peaking expression at 1 day post-injury in 
both the injured spinal parenchyma and in the plasma. These findings are in accordance with 
previous work describing SCI-induced complement activation (Anderson et al., 2004; Anderson et 
al., 2005; Nguyen et al., 2008). Expression of the C3a receptor (C3aR) was also observed on 
infiltrating granulocytes at 1 day post-SCI, and on resident glial cells up to 35 days post-SCI. This 
supports the previously demonstrated expression of C3aR on leukocytes (Kretzschmar et al., 1993; 
Murakami et al., 1993; Martin et al., 1997; Werfel et al., 2000) and CNS cells (Ischenko et al., 
1998; Davoust et al., 1999; Boos et al., 2005), as well as the observations that peak granulocyte 
infiltration occurs at ~ 1 day post-injury (Dusart and Schwab, 1994; Carlson et al., 1998; Beck et 
al., 2010), whereas glia remain chronically activated (Hains and Waxman, 2006; Donnelly and 
Popovich, 2008; Gwak et al., 2012). Our subsequent experiments revealed that C3ar
-/-
 mice, which 
are genetically deficient in C3aR, displayed an exacerbated neurological phenotype after injury 
compared to their wild type (WT) counterparts, in terms of functional recovery, injury morphology, 
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and histopathology. This phenotype was associated with an augmented inflammatory response, 
particularly in terms of Ly6b.2
+
 inflammatory infiltrate, which exceeded WT levels as early as 1 
day post-SCI. In order to determine whether this phenotype was due to increased recruitment of 
granulocytes to the injured spinal cord or increased mobilisation of cells from their reservoirs in 
response to injury, blood immunophenotyping was performed. In line with studies using models of 
peripheral tissue injury (Wu et al., 2013), C3ar
-/-
 mice exhibited granulocytosis as early as 2 hours 
after SCI. Experiments using bone marrow (BM) chimeras and granulocyte depletion ascertained 
that peripheral immune cells, specifically granulocytes, were the driving force behind the 
exacerbated phenotype in C3ar
-/-
 mice. Additional in vitro experiments revealed that C3aR can 
physiologically antagonise C5a-mediated granulocyte chemotaxis. These data therefore reveal a 
novel role for C3aR, indicating that signalling through the C3a-C3aR axis negatively regulates the 
mobilisation of granulocytes and/or granulocyte progenitor cells into the blood in response to SCI, 
at least in part by counteracting the C5a-C5aR axis. As recruitment of granulocytes, the earliest-
arriving leukocytes in the injured spinal cord, is mostly thought of as deleterious to recovery 
(Hamada et al., 1996; Taoka et al., 1997; Mautes et al., 2000; Tonai et al., 2001; Noble et al., 2002; 
Gris et al., 2004; Bao et al., 2008; Fleming et al., 2008; Lee et al., 2011; Geremia et al., 2012), the 
overall worsened phenotype in C3ar
-/-
 mice thus likely resulted from augmented granulocyte 
presence in the blood, enhanced recruitment and, ultimately, worsened secondary injury. This data 
led to the overall conclusion that the C3a-C3aR axis positively promotes recovery from SCI by 
limiting the granulocytic infiltrate. Activation of C3aR in the peripheral immune compartment may 
thus dampen granulocyte infiltration and represent a novel therapeutic strategy for SCI. 
 
7.1.2 The role of complement factor C5a in SCI 
The principal aim of Chapter 4 of this thesis was to evaluate the role of the C5a-C5aR axis 
in SCI. As C5a is classically known as a potent leukocyte activator and chemoattractant, it was 
initially hypothesised that C5ar
-/-
 mice, which lack the signalling receptor for C5a, would have 
reduced inflammation and thus improved neurological outcomes. C5ar
-/-
 mice indeed recovered 
better than their WT counterparts in the first 7 days after SCI, and this phenotype was associated 
with attenuated production of IL-1β, IL-6, and CXCL1, alongside reduced recruitment of pro-
inflammatory monocytes/macrophages. Administration of a specific C5aR antagonist (C5aR-A) in 
this acute period resulted in long-term improvements in functional recovery.  
Importantly, beyond this period, the improved phenotype of C5ar
-/-
 mice receded, and 
ultimately these mice recovered worse than WT mice by the study end point (35 days post-SCI). 
This was paralleled by reductions in myelin content and GFAP
+
 immunoreactivity, and more 
widespread inflammation. Prolonged administration of C5aR-A similarly annulled the beneficial 
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effects of early C5aR blockade. Subsequent experiments in bone marrow (BM) chimeric mice 
revealed that the dual and time-dependent phenotype of C5ar
-/- 
mice appeared mostly mediated by 
cells resident to the CNS, and not infiltrating leukocytes as originally predicted. In order to 
determine which CNS cells were mediating the late worsening in C5ar
-/- 
mice, additional in vivo 
and in vitro experiments were performed. From these, it was concluded that C5a has a direct role in 
promoting astrocyte proliferation via STAT3 phosphorylation, which is a critical step in the in 
formation of the astroglial border around pathology (Okada et al., 2006; Herrmann et al., 2008). 
Although astrogliosis forms a barrier for regeneration, it has been recognised previously that 
formation of the glial scar is important for limiting the spread of necrotic tissue into neighbouring 
parenchyma, and thus secondary injury (Rolls et al., 2008; Rolls et al., 2009; Shechter et al., 2011; 
Wanner et al., 2013). The newly identified role for the C5a-C5aR axis in astrocyte proliferation 
could therefore, at least in part, explain the late worsening of C5ar
-/-
 mice on the basis of impaired 
glial scarring.  
 
7.1.3 The use of in vivo diffusion tensor imaging (DTI) to assess SCI pathology  
One of the challenges to the translation of promising therapies is that the techniques used for 
assessing experimental SCI pathology and treatment efficacy in animal studies, such as histology 
and BMS scoring, are not directly transferable to human SCI. It is therefore important to develop 
clinically relevant, sensitive and specific techniques that can document the progression of secondary 
injury and detect treatment effects in experimental SCI. Such a method could, in theory, enable 
stratification of injury severity between patient groups and indicate the appropriate window of 
administration for intervention strategies. The aim of Chapter 5 of this thesis was therefore to 
evaluate whether DTI could be an effective technique for assessing pathological changes with time 
after injury. This technique relies on the principle that water molecules diffuse in equal directions 
when not restricted by anatomical barriers. Water diffuses in a preferential direction when confined 
within highly oriented anatomical structures, such as myelinated spinal white matter axons. Thus, 
the overall degree of diffusion directionality, or fractional anisotropy (FA), can be used to 
objectively quantify the integrity of spinal white matter. Its components, the axial diffusivity (AD) 
and radial diffusivity (RD), provide information about water diffusion in the rostrocaudal and 
mediolateral directions, respectively. 
From this study, it was initially observed that the spinal cord undergoes progressive atrophy, 
exhibiting significantly smaller cross-sectional area at and in close proximity to the lesion site at 30 
days post-SCI. This is consistent with fMRI studies showing atrophy and somatosensory 
reorganisation after injury (Rao et al., 2013). When diffusion parameters were subsequently 
analysed, it was determined that the FA decreases in a region-specific and time-dependent manner. 
Chapter 7: Summary and general discussion   185 
The FA was rapidly reduced in the dorsal columns (DC), whereas a more gradual decline in FA in 
the ventral funiculi (VF) and lateral funiculi (LF) indicated that these regions may be more 
amenable to therapeutic interventions targeting secondary degeneration. When the AD was 
quantified, a rapid reduction in all regions of interest was observed. This likely reflects the fact that 
axons are quickly compromised after injury (Budde et al., 2009). Assessment of AD along the 
length of the cord also revealed asymmetry. In particular, the DC displayed higher AD caudal to the 
injury site, but the ventrolateral white matter displayed higher AD rostral to the injury site. These 
findings correlate with the known patterns of Wallerian degeneration occurring in a region-specific 
manner, with ascending sensory fibers that dominate the mouse DC degenerating rostrally. 
Conversely, descending motor fibers that dominate the VF and LF are thought to degenerate 
caudally and, as a result, AD values were lower here compared to rostral. A close correlation 
between neurofilament staining and AD/FA supported the presumption that rostrocaudal asymmetry 
in axial diffusivity was indicative of Wallerian degeneration. These data are consistent with 
observations of AD signifying Wallerian degeneration in optic nerve degeneration (Song et al., 
2003; Sun et al., 2008), dorsal root axotomy (Zhang et al., 2009), experimental autoimmune 
encephalomyelitis (Budde et al., 2009), and cerebral hemisphere lesions (Righini et al., 2010). An 
inverse correlation between activated macrophages in areas of low axial diffusivity/fractional 
anisotropy similarly pointed toward Wallerian degeneration.  
The RD remained mostly stable over the first week of injury but significantly increased 
thereafter in all regions of interest. This increased RD was associated with a reduction in myelin 
content at the late time point, as determined through quantitative histological assessment. The 
endpoint reduction in myelin content is a culmination of oligodendrocyte death and the 
susceptibility of myelin to damaging secondary injury processes, which continues even after the 
acute period of SCI (Blight, 1985). The observation that elevated RD may be a marker of 
demyelination aligns with imaging studies of cuprizone-induced demyelination (Song et al., 2005; 
Sun et al., 2006), multiple sclerosis (Song et al., 2005; Klawiter et al., 2011), anterior temporal 
lobectomy (Liu et al., 2013), and schizophrenia (Seal et al., 2008; Scheel et al., 2013). Collectively, 
this study showed that the FA, AD and RD can be used to assess the development of experimental 
SCI pathology in a clinically relevant manner. 
 
7.1.4 The ability of in vivo DTI to detect treatment effects 
 Chapter 6 evaluated whether diffusion parameters could accurately predict treatment-
associated improvements in function. If this was the case, DTI may aid ascertaining the eligibility 
of patients for particular treatments, facilitating clinical trials in which patients and possible 
treatment effects can be better assessed based on injury stratification and individual follow up, 
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which may ultimately accelerate translational research. A preliminary study using intravenous 
immunoglobulin (IVIG) therapy, a known immune-modulatory and neuroprotective agent, was 
therefore conducted and animal recovery monitored through both conventional means and DTI. 
Although its mechanism of action is not completely understood, IVIG is thought to act as an anti-
inflammatory agent by blocking Fc receptors, limiting production of pro-inflammatory cytokines, 
and neutralising complement activation products (Bayry et al., 2006; Jacob and Rajabally, 2009; 
Baerenwaldt et al., 2010). In line with previous studies in rats (Gok et al., 2009; Fehlings and 
Nguyen, 2010; Nguyen et al., 2012), IVIG-treated mice exhibited improved functional and 
histological outcomes compared to the albumin- and vehicle-treated control mice following SCI. 
DTI studies showed that IVIG therapy resulted in less drastic SCI-induced changes in FA and RD, 
which are markers of tissue integrity and myelin status, respectively. Beneficial differences in 
diffusion indices were most evident in the ventrolateral white matter at the chronic time point, 
which are the regions most affected by secondary injury. Correlations between FA and RD with 
functional improvements and myelin preservation were similarly the strongest in regions affected 
by secondary injury in the chronic period. These observations are particularly encouraging, as they 
indicate DTI may be able to detect treatment effects in long-term follow up of SCI patients, 
particularly in clinical trials aimed at testing the efficacy of agents targeting secondary injury and/or 
demyelination. Overall, these findings suggest DTI is a sensitive technique for detecting the 
efficacy of therapies targeting secondary injury in in vivo experimental SCI, which could expedite 
translational research. 
 By increasing our understanding of the role of specific complement activation products in 
secondary injury, and developing clinically relevant methods for quantifying SCI pathology and 
secondary injury progression, the experimental chapters of this thesis have contributed to SCI 
research efforts as a whole, adding new insight to this complex disorder (Fig. 7.1). 
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Figure 7.1: Diagram showing the spectrum of SCI research stages and the path towards 
improving outcomes for SCI patients. SCI research is a field comprising multiple stages which 
require inter-disciplinary expertise and collaboration. Basic research in preclinical animal models 
has been invaluable for identifying the pathological mechanisms of SCI and novel strategies to 
promote repair. This thesis has helped to better understand the role of two molecules, the C3aR and 
C5aR complement anaphylatoxin receptors, in SCI, and how these could be targeted for clinical 
benefit. The use of IVIG was also demonstrated to improve injury outcomes in this thesis, but its 
precise mechanism of action is still being elucidated. Also in this thesis, the use of diffusion tensor 
imaging (DTI) was explored in experimental SCI to test its suitability for detecting the therapeutic 
activities of IVIG. As DTI is a clinically relevant, non-invasive method, it may provide a more 
accurate assessment of SCI upon clinical presentation in the future, and assist in the design and 
success of future clinical trials by providing a quantitative tool to assess pathology and treatment 
efficacy in experimental and human SCI. Outcomes from such studies should feed back into basic 
research, which continually contributes to a deeper understanding of pathophysiological and/or 
repair mechanisms in SCI, providing pathways to further refine promising candidate therapies.  
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7.2 Outstanding lines of enquiry for future research 
 
7.2.1 Potential additional activities for the C3a-C3aR axis in SCI 
Besides regulation of granulocyte mobilisation, there could be additional mechanisms 
through which C3a facilitates recovery from SCI which have not yet been explored. For example, 
the absence of C3aR is associated with augmented responsiveness of haematopoietic stem and 
progenitor cells (HSPC) to G-CSF-induced mobilisation from the bone marrow (Ratajczak et al., 
2004). This C3ar
-/-
 phenotype is thought to involve augmented production of matrix 
metalloproteinase-9 (MMP-9), which is an important mediator of detachment of cells from the bone 
marrow stroma (Wysoczynski et al., 2009). Given that HSPCs have been linked to tissue repair (Si 
et al., 2010), it is possible that altered chemotactic gradients and/or increased protease activity at the 
level of the bone marrow in absence of C3aR not only contributed to an augmented egress of 
granulocytes, but also increased HSPC egress in C3ar
-/- 
mice; whether or not these cells promote 
SCI repair remains under investigation, but benefits of G-CSF treatment have been claimed 
(Derakhshanrad et al., 2013). This could be investigated further through the use of conditional 
C3ar
-/-
 mice, as any putative benefits of increased HSPC mobilisation may have been masked by 
the presence of granulocytosis. It would also be of interest to quantify levels of C3a and the 
mobilising factors G-CSF and CXCL12/CXCR4, and key neutrophil proteases, such as MMP-9, 
neutrophil elastase and cathepsin G (Epstein, 2004), at the level of the bone marrow of uninjured 
and spinal cord injured WT and C3ar
-/-
 mice. Flow cytometry of bone marrow before and after SCI 
would further establish whether HSPC and/or granulocyte numbers vary substantially between 
genotypes in response to injury. 
 
7.2.2 Potential additional activities for C5a in SCI 
Similarly to C3a, outstanding questions remain regarding the role of C5a in SCI. In light of 
the therapeutic potential of targeting C5aR, these questions should be addressed in future 
investigations. An improved early phenotype of C5ar
-/-
 mice was associated with a reduction in 
levels of the pro-inflammatory cytokines IL-1β, IL-6 and CXCL1 at 12 hours post-SCI. As this time 
point is before immune cells entire the spinal cord in large numbers, it is likely that these cytokines 
are derived from resident CNS cells, in line with previous observations (Pineau and Lacroix, 2007). 
However, it would be of interest to identify the precise cellular source(s) of these cytokines in WT 
and C5ar
-/-
 mice so that potential therapies could be more specifically directed. Resident CNS 
microglia are perhaps the best candidate for cytokine production, being known to produce a myriad 
of cytokines in response to inflammatory stimuli, including IL-1β, IL-6, TNFα, IL-12, IL-23 (Glass 
et al., 2010; Saijo and Glass, 2011). Furthermore, microglial-derived IL-1β (Yang et al., 2004; 
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Pineau and Lacroix, 2007) is associated with exacerbated neuronal death (Beattie et al., 2000; Low 
et al., 2014), axon retraction in vitro (Horn et al., 2008), and in vivo (Kitayama et al., 2011). 
Abrogation of this response through genetic ablation of C5aR could thus have produced the early 
functional improvement observed in C5ar
-/-
 mice, which was also associated with reduced presence 
of activated microglia/macrophages. Comparing axonal retraction and/or neuronal death as a result 
of microglial activation in WT and C5ar
-/-
 mice could be further assessed in vitro through 
neuronal/microglial co-culture, ex vivo through immunohistochemistry, or in vivo through intravital 
microscopy (Evans et al., 2014). 
Although reduced microglial-derived cytokine production is a likely explanation for the 
early improved phenotype of C5ar
-/-
 mice, altered polarisation of activated microglia/macrophages 
in the absence of C5a-C5aR signalling could also, to some measure, explain our observations. There 
is some evidence that C5a mainly promotes microglia/macrophage polarisation towards a M1 
phenotype, hallmarked as pro-inflammatory and phagocytic (Schindler et al., 1990; Langer et al., 
2010; Phieler et al., 2013), which would also be in agreement with the pro-inflammatory cytokines 
that it appears to favour. M1-polarised macrophages are thought to exacerbate secondary SCI 
pathology by promoting pro-inflammatory cytokine production, neurotoxicity and axonal retraction 
(Gensel et al., 2009; Kigerl et al., 2009). Whether or not C5aR is directly involved in recruitment of 
pro-inflammatory monocytes/macrophages during peak infiltration (7 days post-SCI) also remains 
to be elucidated, although this may be complex and difficult to separate from reduced recruitment as 
a result of reduced secondary injury in C5ar
-/-
 mice. Interestingly, preferential polarisation of 
macrophages away from an M1 phenotype could have potentially contributed to the late worsening 
of C5ar
-/-
 mice, as insufficient microglial phagocytosis of myelin debris during the early period is 
thought impede regenerative responses in SCI (Neumann et al., 2009). Flow cytometric 
characterisation of microglia/macrophage phenotypes at various time points post-SCI could shed 
further light on whether this may indeed have contributed to a late worsening, as would studies in 
conditional C5ar
-/-
 mice and/or genetically modified strains that have a bias towards either M1 or 
M2 polarised macrophages. Administering C5aR-A to such mice would allow more precise 
evaluation of the mechanisms that underlie the early improvement and late worsening of 
conventiinal C5ar
-/-
 mice.  
Reactive astrocytes are also known to produce cytokines such as IL-1β and IL-6, making 
them another candidate source for production of the pro-inflammatory cytokines observed acutely 
after injury (Giulian et al., 1988; Yong et al., 1991; Asher et al., 2000; Pineau et al., 2010; 
Schachtrup et al., 2010; Sofroniew and Vinters, 2010; Heneka et al., 2014). Thus, during the very 
acute phase, limiting astrocyte-derived cytokine production may have reduced neurotoxicity, and 
consequently, improved functional recovery as observed in C5ar
-/-
 mice. Indeed, astrocyte-derived 
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IL-1 is thought to be a critical step in induction of inflammatory monocyte infiltration (Pineau et al., 
2010), which is generally seen as detrimental and associated with worsened functional recovery 
(Donnelly et al., 2011; Blomster et al., 2013a). Pro-inflammatory cytokines are, however, also 
important signals for astrogliosis, having been shown to increase expression of structural filament 
molecules GFAP (Bignami and Dahl, 1974; Barrett et al., 1981), nestin and vimentin (Yang et al., 
1994), promote astrocyte hypertrophy, proliferation (Faulkner et al., 2004; Erturk et al., 2012), and 
migration toward the inflammatory stimuli (Silver and Miller, 2004; Cregg et al., 2014). This thesis 
provided direct evidence that C5a promotes astrocyte proliferation through activation of the STAT3 
pathway. Disabling the C5a-C5aR axis did indeed lead to reduced glial scarring in vivo, most likely 
through its direct effect on astrocyte proliferation as well as indirectly through suppressing the 
production of cytokines like IL-6. Ultimately, inappropriate formation of the glial scar therefore 
likely mediated the late worsening of C5ar
-/-
 mice due to a lack of segregation between the necrotic 
lesion core and neighbouring intact tissue (Okada et al., 2006; Herrmann et al., 2008; Rolls et al., 
2009; Wanner et al., 2013). The use of a conditional C5ar
-/-
 mouse, with C5aR specifically ablated 
in astrocytes, could directly indicate the degree to which impaired astrocyte proliferation 
contributed to the late worsened phenotype of C5ar
-/-
 mice. 
Apart from astrocytes and microglia, C5aR has also been reported on oligodendrocytes 
(Nataf et al., 2001). Although C5a is thought to contribute to demyelination (Ingersoll et al., 
2010b), C5aR inhibition fails to protect against experimental autoimmune encephalomyelitis 
(EAE), the rodent model of multiple sclerosis (MS) (Morgan et al., 2004). In the SCI model, a 
reduction in myelin content was observed at the lesion site, but this was not associated with any 
significant differences in oligodendrocyte precursor cell proliferation or survival as a result of 
genetic C5aR elimination or chronic C5aR antagonism, as measured by immunolabelling of 
CC1
+
BrdU
+
 cells and CC1
+
Cleaved Caspase-3
+
 cells.  The observed reduction in FluoroMyelin Red 
staining thus likely reflected increased demyelination during the more chronic phase of injury in the 
absence of C5aR signalling, but not oligodendrocyte survival based on quantitative counting of the 
overall number of CC1
+
 cell bodies (Smith et al., 1993; Bhat et al., 1996). More advanced 
techniques, such as transmission electron microscopy, may enable more precise quantification of 
oligodendrocyte myelin content and provide more detailed insight as to how axonal demyelination 
and remyelination is affected by a lack of C5aR signalling (Penderis et al., 2003; Yuen et al., 2013; 
Mei et al., 2014). A recent study revealed that M2-polarised microglia and macrophages positively 
drive oligodendrocyte differentiation during reparative remyelination of the CNS (Miron et al., 
2013). As signalling through the C5a-C5aR axis is thought to control M1 responses rather than M2 
macrophage responses, an alteration of this process is not likely a major contributing factor 
explaining the reduced myelin content in C5ar
-/-
 mice. . 
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Various neuronal populations have also been reported to express C5aR (Stahel et al., 1997; 
Farkas et al., 1998; O'Barr et al., 2001). Thus, C5a signalling in neurons could have had a role in 
mediating the phenotype of C5ar
-/-
 mice after SCI. Indeed, C5aR is upregulated on neurons in a 
number of neurodegenerative disorders (Stahel et al., 1997; Singhrao et al., 1999; Humayun et al., 
2009; Lee et al., 2013), and has been shown to cause apoptosis of neurons in vitro (Farkas et al., 
1998; Farkas et al., 1999; Pavlovski et al., 2012). In vivo, C5aR has been shown to exacerbate 
traumatic brain injury (TBI) (Sewell et al., 2004), striatal degeneration (Woodruff et al., 2006), 
ischaemic stroke (Kim et al., 2008; Arumugam et al., 2009; Pavlovski et al., 2012), amyotrophic 
lateral sclerosis (Woodruff et al., 2008b), Alzheimer's disease (Fonseca et al., 2009; Ager et al., 
2010), and lupus cerebritis (Jacob et al., 2010b; Jacob et al., 2010a). This adds credence to the 
hypothesis that inhibition of C5aR on neurons may have contributed to the early improvement of 
C5ar
-/-
 mice through direct neuroprotection. In contrast, other studies have claimed that C5a also 
protects against glutamate-induced, serum-deprivation-induced, and K
+
-deprivation-induced neuron 
death in vitro, and kainic acid-induced neuronal death in vivo through inhibition of Caspase-3 and 
Caspase-9 activity (Osaka et al., 1999b; Osaka et al., 1999a; Mukherjee and Pasinetti, 2000; 
Mukherjee and Pasinetti, 2001; Benard et al., 2004). These opposing roles point to context, timing, 
or disease-specific mechanisms. Further studies could start by exploring the number of apoptotic 
neurons (eg. NeuN
+
Cleaved Caspase-3
+
 cells) in sections of WT and C5ar
-/-
 mice at both early and 
late time points after SCI. 
A vascular mechanism may also contribute to the early deleterious actions of C5a. 
Endothelial cells are known to express C5aR, and activation by C5a has been shown to cause NFκB 
translocation to the nucleus to induce endothelial cell apoptosis (Jacob et al., 2011). C5aR 
antagonism in a mouse model of lupus cerebritis preserved the integrity of endothelial cells and 
reduced neutrophil infiltration, which led to less neuronal apoptosis (Jacob et al., 2010b; Jacob et 
al., 2010a). Thus, it appears reasonable that C5a may cause early pathology after SCI by 
exacerbating endothelial dysfunction and BSB breakdown. An Evans Blue dye assay (Leonard et 
al., 2013; Harford-Wright et al., 2014) would be one method to explore whether the C5ar
-/-
 
phenotype is partly mediated by a vascular component. That said, conditional knockout approaches 
are required to demonstrate whether blocking C5a signalling directly reduces BSB leakiness, or 
whether this indirectly resulted from reduced breakdown due to attenuated inflammation. For 
example, genetic ablation of C5aR was shown to decrease CXCL1 levels, and the homologous 
human protein to IL-8 is known to elicit BBB dysfunction (Kossmann et al., 1997a).  
Finally, in order to fully appreciate the complex roles of C5a in SCI, it would be necessary 
to also investigate its alternate receptor, complement 5a receptor-like protein 2 (C5L2). C5L2 is a 
binding site for C5a. Unlike C5aR, C5L2 has a lower affinity for C5a and does not couple to G 
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proteins or any known intracellular signalling pathways (Li et al., 2013). It has been postulated that 
this enigmatic protein is an anti-inflammatory, C5a-sequestering site (Gerard et al., 2005; Scola et 
al., 2009; Bamberg et al., 2010), though pro-inflammatory roles have also been ascribed to C5L2 
(Zhang et al., 2010; Hao et al., 2013; Vijayan et al., 2014). Given that C5L2 is reportedly expressed 
in the CNS (Lee et al., 2001; Gavrilyuk et al., 2005; Woodruff et al., 2008b; Fonseca et al., 2013), 
and the fact that C5a has diverse and time-dependent roles in SCI pathology (see Chapter 4), it will 
be of great interest to better characterise this receptor in the context of neurotraumic events. This 
could be achieved through the use of C5l2
-/-
 mice (Chen et al., 2007). It would first be necessary to 
characterise the degree of complement activation and C5a production over time in C5l2
-/-
 mice with 
respect to WT mice. If C5L2 does have an important C5a-sequestering role in SCI, C5a levels 
might be expected to be elevated in C5l2
-/-
 mice compared to WT mice. Neurological outcomes 
would also expected to be worse than WT mice if C5L2 indeed normally curtails the deleterious 
functions of C5a signalling during the acute phase. ELISA could be used to measure C5a levels in 
plasma, and flow cytometric analysis could confirm whether there is increased C5aR internalisation 
on circulating leukocytes. If C5l2
-/-
 mice recover differently to WT mice, (sub)- acute-phase 
administration of a C5aR-A (or vehicle treatment) to both WT and C5l2
-/-
 mice could be used to 
determine whether deregulated C5aR signalling is involved in producing such a phenotype. In view 
of the dual phenotype of C5ar
-/-
 mice, and the fact that chronic C5aR antagonism was not 
beneficial, it would be critical to further optimise the treatment regimen for C5aR-A through a dose-
response assay, and to more precisely determine how long treatment can be delayed and/or 
extended (once initiated) without a loss of the therapeutic effect.  
 
7.2.3 Complement factors currently unexplored in SCI 
 In addition to more comprehensively characterising the roles of C3a and C5a in SCI, there 
remains uncertainty as to the role of additional complement components. The first is the extrinsic 
protease pathway of complement activation. This pathway is activated without the requirement of 
upstream components to generate C3 and C5 convertases (Huber-Lang et al., 2006; Amara et al., 
2010). It involves proteolytic enzymes released by neutrophils and macrophages, and factors such 
as kallikrein, plasmin and factor XIIa. The coagulation factor thrombin can then directly cleave C3 
and C5 into biologically active C3a and C5a, respectively. It is speculated that the complement 
activation observed in C3
-/- 
mice after SCI must occurred primarily through this pathway (Guo et 
al., 2010; Guo et al., 2013), and that this pathway substantially contributes to elevated complement 
levels and secondary injury. The contribution of this pathway in SCI could be tested using similar 
methodology to that used in experimental cerebral malaria (ECM). Ramos et al. (2012) reported that 
C4
-/-
 and fB
-/-
 mice are susceptible to ECM, whereas C5
-/-
 mice are protected from disease due to 
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reduced MAC formation. However, C3
-/-
 mice were also vulnerable to ECM, indicating that 
canonical C3 convertases are not necessary for MAC formation, ECM development and 
progression. Protection in C3
-/-
 mice could be generated through administration of an anti-C9 
antibody, and detection of C5a in serum of these mice confirmed that C5 proteolysis occurred 
independently of classical C3 convertase formation, most likely via the extrinsic protease pathway 
(Ramos et al., 2012).  
In addition, although it is known that excessive production of the MAC is detrimental to SCI 
recovery, the role of sublytic concentrations of MAC (sl-MAC) is not well understood. Several lines 
of evidence suggest a protective function for sl-MAC. Nucleated cells have resistance to sl-MAC 
via endocytosis (Carney et al., 1985; Morgan et al., 1987) and shedding of C5b-9-bearing 
membranes by exocytosis (Morgan, 1989; Scolding et al., 1989). Constitutive exposure to sl-MAC 
thereby confers MAC desensitisation and increases the threshold MAC concentration at which cells 
succumb to lytic attack, as determined by graded additions of antibodies and antibody-C3b 
complexes (Reiter et al., 1992). Apart from this complement-induced protection (Reiter et al., 
1992), sl-MAC assembly can also promote cell cycle entry, proliferation, growth and survival. Sl-
MAC is thought to activate the cell cycle in oligodendrocytes in a manner involving activation of 
Ras, Raf-1 and MEK1 (Niculescu and Rus, 2001), which are upstream kinases acting via JNK1, 
Erk1, PI3K (Rus et al., 1997), and PKC (Dashiell et al., 2000; Kraus and Fishelson, 2000). These 
pathways play a major role in inducing oligodendrocytes to enter the S phase of the cell cycle from 
the resting G1/G0 phase (Rus et al., 1997). An important ribosomal kinase in mitogenesis, p70 S6 
kinase, is also activated by sl-MAC (Rus et al., 1997). Thus, sl-MAC may be neuroprotective 
during the chronic phase of SCI through its capacity to promote oligodendrocyte proliferation, and 
by extension, remyelination of axons (Rus et al., 2005). Sl-MAC also promotes apoptotic rescue via 
activation of the PI3K/Akt pathway, inhibition of Bid cleavage, Caspase-8 activation, expression of 
FasL and Fas-induced apoptosis (Cudrici et al., 2006), and increasing expression of the survival 
factor Bcl-x(L) (Hila et al., 2001) and of the long isoform of cellular FLIP (Cudrici et al., 2006). 
Decreased sl-MAC and PI3K/Akt activity increases cytochrome c release, Bad phosphorylation, 
and Caspase-9 activation, initiating the mitochondrial pathway of apoptosis in oligodendrocytes 
(Soane et al., 2001). Thus, sl-MAC levels may actually be involved in protecting oligodendrocytes 
from death associated with secondary SCI pathology (Soane et al., 2001).  
In relation to studying low levels of MAC, it would also be of interest to evaluate the 
individual contribution of each MAC component in SCI. This could be done through the use of, for 
example, C6
-/-
 or C9
-/-
 mice. Additionally, the use of double knockout, conditional knockout mice, 
or selective complement antagonism could, in theory, allow determination of the role of specific 
complement pathways without the confounding effect of pathway redundancy. For example, studies 
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using fB
-/-
 mice in SCI showed improved neurological recovery (Qiao et al., 2010). Although this 
phenotype has mostly been attributed to impaired induction of the alternative pathway, fB
-/-
C6
-/-
 
mice would confirm whether the improved phenotype was due to elimination of the alternative 
pathway, dampened production of lytic MAC formation, or cooperative activity between the 
alternative and terminal pathways. Treatment of these mice with a C5aR-A would further determine 
whether reduced C5a anaphylatoxin signalling contributed to the improved phenotype of fB
-/-
 mice. 
Thus, the complexity of the complement cascade and functional redundancy could mean that more 
complex mouse genotypes and/or combinatorial therapies increasingly become used for future 
studies of complement-associated secondary injury. Conditional knockout mouse lines would also 
validate proposed mechanisms of complement action in SCI without the risk of abnormal mouse 
development. 
 
7.2.4 Feasibility of in vivo DTI for assessing human SCI pathology 
 There are a number of practical issues to consider before DTI could be routinely 
implemented for assessing human SCI. Firstly, the findings from Chapters 5 and 6 indicate that DTI 
does not detect changes in regions of primary mechanical injury with time or treatment, suggesting 
patients with anatomically complete SCI would not likely show changes in pathology and/or reveal 
a treatment effect, except for perhaps expansion of the injury along the length axis of the spinal 
cord. Comparing regions further away from the direct lesion site in these patients may thus still 
reveal whether such vulnerable tissue may still be amenable to therapy, which could manifest as 
level-dependent changes in the neurological deficit due to attenuated spread of secondary injury.  
Additionally, it is not uncommon for SCI patients undergo surgical decompression (Li et al., 
2014b; Silva et al., 2014). Although the role, nature and timing of decompression surgery is not 
standardised (Fehlings et al., 2012; Li et al., 2014b), it would be important to consider how 
decompression surgery could alter the interpretation of DTI parameters (if done at the time of 
admission), particularly as oedema and swelling can dramatically affect water diffusivity (De 
Belder et al., 2012; Newcombe et al., 2013). Furthermore, patients with surgically implanted metal 
devices for spine stabilisation (Cooper et al., 1988) would automatically be excluded from imaging. 
In these cases, DTI could only feasibly be performed prior to implantation and/or after device 
removal. There are also practical challenges in achieving quality images. For example, it would not 
be feasible to image human patients for as long as the mice were image even after patients were in a 
stable condition, as spasticity/autonomic dysreflexia could produce some motion artefacts. Spinal 
imaging of healthy control subjects prior to commencing SCI patient scanning would enable 
optimisation of scan sequences that are high in quality but low in duration. Imaging healthy controls 
would also assist in gauging the variability in spinal curvature and anterior-posterior diameter of 
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spinal canal, which can contribute to neurological outcome (Yamazaki et al., 2005). These 
anatomical factors should therefore also be taken into account when ascertaining injury severity. 
 
7.2.5 Optimising the dose of IVIG administration, and exploring its mechanism of action 
In Chapter 6 of the thesis, IVIG was the chosen immunotherapy for evaluating the ability of 
in vivo DTI to detect treatment effects. As this therapy is already in use clinically for other 
autoimmune diseases, has a good safety profile, and has shown promise in experimental SCI (Gok 
et al., 2009; Nguyen et al., 2012), these findings are particularly encouraging. For the current thesis, 
1 g/kg and 2 g/kg doses were chosen for functional assessment. Interestingly, the higher dose did 
not lead to any significant benefits in terms of recovery, indicating that perhaps even lower doses of 
IVIG could be used to elicit the same therapeutic efficacy, which would improve both safety and 
cost-effectiveness. Indeed, very high dose IVIG is known to bind complement receptor 1 (CR1) on 
red blood cells and cause erythrophagocytosis (Kessary-Shoham et al., 1999), and to form antigen-
antibody immune complexes that can mediate adverse side effects such as renal failure and 
thromboembolic events (Duhem et al., 1994; Orbach et al., 2005). A complete dose-response 
experiment in mice would determine if, and by how much, the dose of IVIG can be lowered without 
compromising its efficacy. Similarly, and from a clinical perspective, testing the timing of 
administration in relation to functional recovery would be valuable to determine how long treatment 
could be delayed before tissue can no longer be rescued from secondary pathology. In these future 
experiments, it would also be important to determine whether top-up doses of IVIG are actually 
required, and added to the degree of recovery that was observed. The magnitude of change required 
in tissue morphology that is detectable by DTI also requires further investigation and could be done 
as part of dose-response experiments.  
 In relation to the mechanism of action of IVIG, its primary function is thought to be the 
binding FcγRs on host cells; the competition with autoantibodies is thought to be central to its value 
in treating autoimmune disorders. IVIG is also thought to inhibit pro-inflammatory cytokine 
production and to neutralise complement activity (Bayry et al., 2006; Jacob and Rajabally, 2009; 
Baerenwaldt et al., 2010). More specific mechanisms of action are becoming recognised, and it is 
likely that more will be established in the future (Fig. 7.2). A greater understanding how IVIG 
mediates its therapeutic actions in SCI could lead to tailoring of treatment regimens and/or design 
of more targeted IVIG therapy. 
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Figure 7.2: A diagram of proposed mechanisms by which IVIG modulates innate and 
adaptive immunity. The F(ab’)2 portion is thought to kill target cells by antibody-dependent 
cytotoxicity (ACDD), block activating cell surface receptors such as CD95 and CD95 ligand 
(CD95L); neutralise pro-inflammatory cytokines, and scavenge complement anaphylatoxins. The Fc 
portion of IVIG is thought to saturate Fc receptors; promote expansion of T regulatory (TReg) cells; 
block the binding of immune complexes to FcγRs; and modulate immune effector functions of 
dendritic cells and B cells. (Figure adapted from Schwab and Nimmerjahn, 2013). 
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7.3 Concluding remarks 
 
 The studies performed as part of this thesis have provided new insights regarding the role of 
two key receptors of the complement system, C3aR and C5aR. It was shown that C3aR activation 
on granulocytes in the acute period, and C5aR activation on astrocytes in the chronic period, both 
facilitate recovery from SCI. In contrast, excessive granulocyte infiltration, and C5aR activation on 
CNS cells during the acute period, hampered neurological recovery. Pharmacological strategies 
were used to harness these processes. Depletion of neutrophils, short-term antagonism of C5aR, and 
IVIG therapy all improved SCI outcomes, offering new candidate therapies to be trialled in human 
SCI. Understanding the mechanisms, concentrations, and timing of these interventions is key to 
avoiding adverse effects of therapy. In addition to providing novel therapeutic targets for the 
treatment of SCI, the work presented in this thesis also showed that DTI is a feasible, clinically 
relevant strategy for measuring pathology and treatment efficacy in experimental SCI. The imaging 
studies conducted as part of this thesis provide insights on the spatiotemporal pattern of secondary 
degeneration, therapeutic windows for treatment, and an objective, non-invasive method to measure 
treatment efficacy in mouse contusion SCI. A more complete picture of SCI pathology, and a 
technique to more accurately quantify secondary degeneration, will potentially facilitate the 
development and implementation of effective SCI therapies in the future. 
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nervous system: another dual-edged sword?
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The complement system, a major component of the innate immune system, is becoming increasingly recognised
as a key participant in physiology and disease. The awareness that immunological mediators support various
aspects of both normal central nervous system (CNS) function and pathology has led to a renaissance of
complement research in neuroscience. Various studies have revealed particularly novel findings on the wide-
ranging involvement of complement in neural development, synapse elimination and maturation of neural
networks, as well as the progression of pathology in a range of chronic neurodegenerative disorders, and more
recently, neurotraumatic events, where rapid disruption of neuronal homeostasis potently triggers complement
activation. The purpose of this review is to summarise recent findings on complement activation and acquired
brain or spinal cord injury, i.e. ischaemic-reperfusion injury or stroke, traumatic brain injury (TBI) and spinal cord
injury (SCI), highlighting the potential for complement-targeted therapeutics to alleviate the devastating
consequences of these neurological conditions.Introduction
Injury to the central nervous system (CNS) elicits a com-
plex series of pathophysiological events, including ischae-
mia, excitotoxicity and inflammation. All of these factors
adversely affect the integrity of spared neurons and thus
accentuate tissue damage beyond the initial site of trauma.
The cellular immune response in particular has received
much attention as a key mediator of secondary injury, and
strategies to manipulate the activation and recruitment of
neutrophils [1-5], monocytes and macrophages [6-9], and
lymphocytes [10-12] after trauma have all been investi-
gated, with the ultimate goal being to improve functional
outcomes (reviewed in [13]).
Several recent studies have, however, put activation of
the innate immune complement system into the spot-
light as a perhaps sometimes-overlooked but potent me-
diator of secondary pathology [14-16]. The particular
aim of this review is to summarise current knowledge
and understanding of complement activation in the
injured CNS, specifically in relation to post-traumatic* Correspondence: m.ruitenberg@uq.edu.au
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reproduction in any medium, provided the orneuroinflammatory events and associated secondary
damage. Several other recent reviews have already pro-
vided a comprehensive overview of the role of comple-
ment in CNS development and chronic neurodegenerative
disorders [17-19].
The complement system: an introduction and effector
mechanisms
The predominant site of peripheral complement protein
synthesis is the liver, where hepatocytes constantly pro-
duce and replenish circulating complement factors [20].
Activation of these circulating complement proteins in
response to an injurious or infectious challenge results
in a self-amplifying cascade of proteolytic reactions
through any one of four major identified pathways
(Figure 1).
The classical pathway for complement activation is
initiated by the binding of the recognition molecule C1q
to pathogen antigens, C-reactive protein bound to bac-
terial polysaccharides or antigen-antibody complexes
[21]. It is of interest to note in this context that patho-
gen opsonisation and antibody ligation by C1q also pro-
vide a bridge to activation of the adaptive immune
system, which includes an enhancement of antigen re-
tention in lymphoid tissues, a decrease in the B cell acti-
vation threshold and increased memory B cell survivall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Common pathways for complement activation. Recognition of antigen-antibody complexes by C1q initiates the ‘classical pathway’.
Binding of carbohydrate antigens by mannose-binding lectin (MBL) or MBL-associated serine proteases (MASPs) initiates the ‘lectin pathway’. Both
pathways lead to the formation of the C3 convertase, C4b2a. Complement activation through the ‘alternative pathway’ involves the spontaneous
hydrolysis of plasma C3, generating a second C3 convertase, C3(H2O)Bb. Proteolysis of C3 then leads to production of the C3b fragment, which
binds to C3 convertases to generate C5 convertases. After the cleavage of C5, the C5b fragment binds C6-C9 to generate the membrane attack
complex (MAC). The coagulation cascade leads to complement activation via the ‘extrinsic pathway’; this route does not depend on the presence
of C3 convertases. Anaphylatoxins C5a, C3a and C4a are generated through cleavage of C5, C3 and C4, respectively. Soluble and membrane-
bound negative regulators of complement and their site of action are indicated in green. The functional significance of certain activation steps is
shown in red.
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and antigen-presenting cell (APC) function can also be
significantly influenced by complement [25,26]. The lectin
pathway for complement activation involves the recogni-
tion of pathogen carbohydrate antigens by mannose-
binding lectin-associated serine proteins (MASP-1 and
MASP-2) [27] and the ficolins [28]. The alternative
pathway of complement activation is initiated by spon-
taneous hydrolysis of complement component C3 in
plasma, and the binding of factor B and D to C3(H2O)
[29]. All of the three aforementioned activation routes
lead to the formation of C3 convertases and thus con-
verge at this level.
C3 convertases cleave the parental C3 molecule into
two fragments, the larger C3b molecule and the smaller
anaphylatoxin C3a. The C3b fragment opsonises
pathogen-associated molecular patterns (PAMPs), which
are small, conserved molecular motifs that are shared byclasses of microbes and recognised by host cell pattern
recognition receptors (PRRs), such as Toll-like receptors
(TLRs) [30]. C3b opsonises altered-self ligands, immune
complexes and/or dead cells as well, which ultimately
enhances their recognition and rapid phagocytosis by
scavenging leukocytes that bear C3b receptors. The C3b
fragment can also bind the C3 convertase, which leads
to the formation of a C5 convertase and the subsequent
cleavage of the parental C5 protein into C5b and the
anaphylatoxin C5a. The amplification cascade then cul-
minates in the association of C5b with C6, C7 and C8,
which induces the polymerisation of 10–16 C9 mole-
cules in order to assemble a transmembrane pore called
the terminal ‘membrane attack complex’ (MAC), with
subsequent lysis of the targeted pathogens or abnormal
host cells as a result [31]. Importantly, components of
the blood clotting and fibrinolysis pathways, as well as
other cell-derived serine proteases, can also directly
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the formation of complement end products, independent
of the C3 and C5 convertases, a process that is now re-
ferred to as the extrinsic pathway [32-34].
As indicated above, the cleavage of C3 and C5 also
leads to the generation of two smaller activation frag-
ments that do not directly contribute to MAC forma-
tion, the so-called anaphylatoxins. The small cleavage
product of the parental C3 protein, the anaphylatoxin
C3a, is a local mediator of inflammation that signals
through its G-protein coupled receptor, C3aR [35]. The
anaphylatoxin C5a, generated from C5, is one of the
most potent pro-inflammatory peptides known. It can
act as a phagocyte chemoattractant, and promote vascu-
lar permeability, platelet and leukocyte activation
through, for example, upregulation of the leukocyte ad-
hesion molecules necessary for transendothelial extrava-
sation to sites of infection or injury. It also induces
production of proinflammatory cytokines, chemokines,
leukotrienes, prostaglandins, oxidative burst and de-
granulation (reviewed in [31,36]). Similar to C3a, the
C5a molecule signals through a G-protein coupled re-
ceptor, which is known as C5aR or CD88 [37]. A second
receptor for C5a, known as C5L2, has been reported
[38], but its functional significance still remains contro-
versial; indeed, it could have multiple roles in different
species, organs and pathophysiological states [39-42].
Physiological functions for complement in the CNS
Although circulating complement proteins in blood
plasma do not normally have access to the CNS because
of the blood–brain and blood-spinal cord barriers (BBB
and BSB, respectively), several studies have demonstrated
that virtually all of the components of complement can be
synthesized within the CNS [18,19,43]. Accordingly, vari-
ous non-immune physiological roles for complement have
been identified, including synaptic remodelling during de-
velopment, cell survival and neurogenesis.
A seminal study by Stevens and colleagues [44]
showed that components of the classical complement
pathway are key mediators of synapse elimination in the
developing retinogeniculate pathway in mice. Early in
development, retinal ganglion cells (RGCs) from both
eyes extend excessive, overlapping projections into the
dorsal lateral geniculate nucleus (dLGN) of the thal-
amus. Weaker synaptic arborisations are then eliminated
and more active connections strengthened, resulting in
the adult pattern of segregated eye layers by postnatal
day 20 [45]. This process is coordinated by astrocyte-
driven deposition of C1q and C3 on immature or weaker
RGC synapses, which then tags them for removal, most
likely by activated microglia. RGC axons in C1q−/− and
C3−/− mice have indeed a higher degree of overlap dur-
ing and after the remodelling process, resulting in thepersistent retention of excessive retinal innervations of
lateral geniculate neurons [44]. The supernumerary
inputs retained in C1q−/− and C3−/− neurons were
shown to be immature or dysfunctional as judged by the
weak magnitude of the glutamate-mediated currents car-
ried by their AMPA receptors [44]. Interestingly, the fail-
ure to prune excessive excitatory synapses during
development has been positively correlated to enhanced
synaptic connectivity and epileptogenesis in C1q−/− mice
compared to wild-type (WT) controls [46]. Our groups
have also previously shown localized expression of
CD88, the C5a anaphylatoxin receptor, on presynaptic
terminals of mossy fibres within the CA3 region of the
adult rat hippocampus [47]; it remains to be determined
whether physiological C5a signalling here could also be
involved in synaptic plasticity or whether it serves differ-
ent and yet unknown functions in this structure.
In addition to a role in synaptic plasticity, complement
proteins may play an important role in neuroprotection
in the CNS. In the absence of other complement compo-
nents, C1q has been shown to increase neuronal survival
and arborisation [48]. These effects are mediated via the
upregulation of genes associated with cytoskeleton func-
tion (syntaxin-3), cholesterol/lipid metabolism (CH25H,
INSIG2) and neurotrophic factors (NGF, NT-3, NTN1)
[49].
A functional role for the MAC has also been demon-
strated. At sublytic concentrations, the MAC can be
endocytosed by oligodendrocytes and cause them to re-
enter the cell cycle [50]. Sublytic MAC can also reduce
apoptotic cell death by increasing synthesis of Bcl-2 and
inhibition of caspase-3 activation and caspase-8 proces-
sing and upregulating FLIP [51,52].
Lastly, a physiological role for the anaphylatoxins C3a
and C5a within the adult murine CNS has emerged, spe-
cifically an involvement in cell survival and neurogenesis.
In mixed cultures of neurons and astrocytes, C3a pro-
tected neurons against NMDA-induced excitotoxicity in a
dose- and astrocyte-dependent manner [53]. The neuro-
protective action of C3a signalling could be mediated
through the induction of nerve growth factor (NGF) ex-
pression in microglia [54,55] as well as astrocytes [55].
C5a exposure also causes an upregulation of NGF mRNA
expression in astrocytes [55], with similar neuroprotective
effects against glutamate-mediated neuronal excitotoxicity.
The neuroprotective effects of anaphylatoxins against
glutamate-induced excitotoxicity were shown to be
mediated via MAPK-dependent inhibition of caspase-3
[56,57], regulation of glutamate receptor subunit 2
(GluR2) expression [58], and increased glial expression of
the glutamate transporter GLT-1, which enhances the re-
moval of extracellular glutamate [59]. Administration of
C5a in vivo was also reported to protect against kainic
acid-induced neuronal apoptosis [56]. With regards to a
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receptors for C3a and C5a, C3aR and CD88 were shown
to be expressed on neural progenitor cells as well as im-
mature neurons [60]. Mice treated with a non-specific
C3aR antagonist (SB290157) displayed decreased forma-
tion of new neurons in areas of adult neurogenesis [60].
The cellular or humoral source of C3a and the mechanism
via which C3aR activation influences the creation and/or
survival of new neurons remain to be elucidated. However,
in the post-natal developing cerebellum, C3aR and CD88
expressions are known to increase during granular cell
maturation [61]. Subdural injection of a non-specific
CD88 agonist (MAP-C5a) into the cerebellum of young
rats increased the proliferation of immature granule neu-
rons, resulting in an enlarged external granule cell layer
[62,63]. This effect could be reversed through concurrent
administration of PMX53, a specific CD88 antagonist
[63,64]. A C3a agonist (MAP-C3a), on the other hand,
decreased the thickness of the EGL whilst increasing the
thickness of the internal granule cell layer. Video micros-
copy revealed that C3a accelerated the migration process
of granule cells from the EGL to the internal granule cell
layer [63].
Complement and CNS disorders
Various regulators normally finely tune the complement
activation repertoire so that healthy host tissue is discri-
minated and self-harm is avoided. However, a disturbed
balance between activation and regulation can induce
self-attack, and excessive or inappropriate complement
activation has been implicated in the pathogenesis of nu-
merous autoimmune, ischaemic and vascular diseases
[31,65]. Complement deregulation has also been pro-
posed in a myriad of CNS inflammatory pathologies and,
as a result, complement-targeted therapeutics are in-
creasingly emerging into the spotlight of drug discovery
endeavours for various chronic neurodegenerative dis-
eases, including multiple sclerosis [66-74], Alzheimer’s
disease [75-78], Huntington's disease [79,80], Parkinson’s
disease [81,82] and motor neuron disease [83-86]. Al-
though breakdown of the BBB and BSB does not occur
until very late in most neurodegenerative pathologies, a
prominent role for complement is perhaps not surpris-
ing when one considers again that the CNS can en-
dogenously synthesise virtually all components of the
complement system under appropriate stimuli [87]. Fur-
thermore, neurons and oligodendrocytes express only
low levels of the surface complement regulatory protein
decay activating factor (DAF/CD55) and membrane co-
factor protein (MCP/CD46), which renders them par-
ticularly vulnerable to complement-associated death
[88,89].
In contrast to the aforementioned chronic neurological
disorders, CNS trauma is unique in that it involves arapid and dramatic breakdown of the BBB/BSB. As a re-
sult, the immune-privileged CNS parenchyma, with rela-
tively low endogenous expression of complement and
associated negative regulators, is exposed to the full
force of both innate and adaptive components of the im-
mune system, which includes a massive influx of serum
complement as well as the invasion of circulating and
activated leukocytes. Epitopes exposed by cellular injury,
including phosphatidylserine, DNA and myelin, are
highly vulnerable to complement recognition, opsonisa-
tion and MAC deposition [90] (Figure 2). Although this
process is important for the clearance of cellular and
myelin debris as well as other molecules that may be in-
hibitory to wound healing and repair, over-activation of
complement can compromise the integrity of neurons
and oligodendrocytes in neighbouring tissue that was
originally spared at the time of impact, thus exacerbating
and widening neuropathology [91,92]. Lastly, since
micro-haemorrhaging is a hallmark of most neurotrau-
matic events, prominent complement activation through
the extrinsic pathway can also be expected as a result of
protease activity in the blood clotting and fibrinolysis
pathways [32,33]. The following sections of this review
will now examine the multifarious roles that comple-
ment plays in stroke (i.e. ischaemia-reperfusion injuries),
traumatic brain injury (TBI) and spinal cord injury
(SCI).
Complement and cerebral ischaemic-reperfusion (IR)
injury
Macroscopically, cerebral IR injury is described as an ar-
terial occlusion preceded by a thromboembolic event.
Dynamic changes in cerebral blood flow produce a se-
vere ischaemic core in the territory that is normally sup-
plied by the affected artery, surrounded by a poorly
perfused ‘penumbra’ region [95]. Recanalization of the
occluded artery leads to reperfusion of blood and the in-
duction of a series of excitotoxic and inflammatory
events, which results in microvascular failure and neural
cell death [95]. Analysis of blood from human patients
with ischaemic stroke showed significant alterations in
complement levels, including elevation of the anaphyla-
toxins C3a and C5a, and depression of the MAC [96].
Moreover, immunohistochemical staining of human
brains revealed expression of C1q, C-reactive protein C3
and C4d (classical pathway), while MASP-2 and factor B
(lectin pathway) and C9 (terminal pathway) were also
present in ischaemic lesions [97]. Staining for CD59 and
CD55 was identified in normal brains, but these comple-
ment regulators were absent from lesioned brains, sup-
porting that deregulation of complement contributes to
IR pathology [97].
To address whether complement activation products
are simply a by-product of injury or directly contribute
Figure 2 Schematic diagram showing the current understanding of the role of complement activation in the pathophysiology
associated with traumatic spinal cord injury (SCI). Mechanical damage to the spinal cord causes neuronal cell death and disruption of the
blood-spinal cord barrier (BSB). This primary damage triggers a potent inflammatory response and initiates complement activation. Although
complement activation may aid the clearance of cellular debris through opsonisation, it is also known to potentiate injury beyond the site of
trauma through e.g. the opsonins C1q, C3b and MAC, which can promote clearance of only mildly compromised cells and thus contribute to
secondary demyelination and apoptosis. Known functions of complement in the pathology of SCI are shown in italics; a green font colour
indicates a putative reparative role, whereas a red font points towards an injurious role, 1[93], 2[12], 3[14], 4[91], 5[16], 6[94], 7[4,94].
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lysed the influence of genetic polymorphisms in the
mannose-binding lectin (MBL) -2 and MASP-2 genes,
which render the lectin pathway dysfunctional, on injury
outcome. A logistic regression adjusted for age, gender
and initial stroke severity determined that an unfavour-
able outcome at 3 months post-injury was more likely
associated with a normally functioning lectin pathway
[98]. This finding was further substantiated in a mouse
model of middle cerebral artery occlusion (MCAO) in
which MBL-deficient mice displayed smaller infarctions
around the penumbra of the striatum, cortex and hippo-
campus, and better behavioural outcomes as well as less
C3 deposition and leukocyte infiltration compared to
WT mice [98]. Reconstitution of MBL−/− mice with re-
combinant human protein annulled the beneficial effects
of MBL deficiency [98]. A detrimental role for the lectin
pathway in IR injury was, however, not fully reproducedin an independent study where MBL-deficient mice sub-
jected to cerebral IR reportedly showed no difference in
systemic neutrophil activation, C3 deposits and only
modest tissue sparing in a sub-cortical brain region
compared to their WT counterparts [99]. It must be
noted, however, that occlusion of the middle cerebral ar-
tery in the latter study lasted only for 60 min [99] as
opposed to 2 h as in the earlier mentioned investigation
[98]. Injury severity and the resulting degree of comple-
ment activation may thus have been an influencing fac-
tor in the outcome that could explain the seeming
discrepancy between these two studies. The contribution
of the lectin pathway to secondary pathology was further
studied in a human recombinant C1 inhibitor (rhC1-
INH), which binds MBL with high affinity [100]. RhC1-
INH reduced cerebral damage when given up to 18 h
after transient ischaemia and up to 6 h after permanent
ischaemia, demonstrating a relatively wide therapeutic
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ever, that this inhibitor also influences activity of the
classical pathway (vide infra).
The significance of classical pathway activation has
also been investigated in rodent models of IR injury.
One of the subunits of the C1 protease, C1q, accumu-
lates on neuronal cell bodies as well as necrotic cellular
debris during the period of greatest infarct evolution
[101,102]. Interestingly, C1q deficiency was shown to be
neuroprotective in neonatal (p7) mouse hypoxic-
ischemic brain injury [103], predominantly by attenuat-
ing oxidative damage [103]. However, no beneficial
effects of C1q deficiency on stroke outcomes were
observed when adult C1q−/− mice were compared with
their WT counterparts [104], suggesting that the pres-
ence of C1q during the acute phase does not directly
mediate neuronal injury. While it could be argued that a
possible detrimental role for C1q in secondary immuno-
pathology following hypoxic-ischaemic brain injury may
only become more apparent during the post-acute phase
when CNS autoantibodies are likely to be present, this
does not explain the discordance between acute neonatal
and adult studies. Although speculative at present, an al-
ternative explanation for this apparent discrepancy may
lie in age-related differences in complement protein ex-
pression and the general maturity of the complement
system in neonatal versus adult mice. Known age-related
increases in the expression of factor B, C3, C4 and C5
[105] may have masked or overshadowed any neuropro-
tective effects of C1q deficiency in adult mice through
non-classical routes of complement activation.
The therapeutic potential of a C1 inhibitor (C1-INH)
that binds and inactivates C1r, C1s, MASP1 and MASP2,
thus blocking both the classical and lectin pathways, has
also been assessed [106]. These investigators reported a re-
duction in ischaemic volume (to as low as 10.8% of that of
vehicle-treated mice), alongside ameliorated neurological
impairments, neuronal degeneration and reduced infiltra-
tion of CD45+ leukocytes [106]. Similar effects were
observed in Wistar rats following a 60-min occlusion of
the middle cerebral artery, after which animals that were
treated with this C1 inhibitor had smaller infarct volumes
and less granulocyte accumulation [107]. This neuropro-
tective effect was later shown to be mediated by upregula-
tion of the anti-inflammatory cytokine IL-10 as well as
IL-6, which is known to be able to exert both pro- and
anti-inflammatory effects [108,109], in addition to a down-
regulation of pro-inflammatory P-selectin and ICAM-1,
and known inducers of apoptosis like TNF, IL-18 and
pro-caspase-3 [110]. When C1q−/− mice were treated
with C1-INH, the ischaemic volume was reduced to
31.4% of that of saline-treated mice [106], indicating the
protective effects of C1-INH are indeed independent of
C1q. Together, these findings indicate that the lectinpathway and subcomponents of the C1 complex, but not
C1q, contribute to IR pathology.
An inhibitor of both the classical and alternative path-
ways, soluble complement receptor-1 (sCR1), led to a
significant reduction in neutrophil and platelet aggrega-
tion and improved neurological function in mouse
MCAO [111,112]. This finding was, however, not repro-
duced in a non-human primate model of stroke [113]. It
would be of interest to more specifically pinpoint the
contribution of the alternative pathway to cerebral IR in-
jury as targeted inhibitors of this pathway have shown
therapeutic benefits in both cardiac [114] and intestinal
[112] IR injury. This could be achieved using factor B
null mice or the targeted inhibitor of the alternative
pathway, CR2-fH [112].
As illustrated in Figure 1, the classical, alternative and
lectin activation pathways of complement converge at
the level of C3 convertase, making this cascade
centrepiece an ideal target to assess the overall impact of
complement activation in IR injury. In line with the
above-mentioned studies, which largely indicate a detri-
mental role for complement activation following injury,
C3−/− mice have significantly smaller infarct volumes,
improved neurological deficit scores, and reduced gran-
ulocyte infiltration and oxidative stress in a mouse
model of transient focal cerebral ischaemia. These effects
were reversed by reconstitution with C3 protein [104].
The precise role of C5, the next downstream intersec-
tion in the cascade, is still uncertain. C5 deficiency
reduced the neurological deficit and lesion size in the
MCAO model in mice [115], while C5 inhibition with a
monoclonal antibody yielded similarly positive results in
rats [116]. A more recent in vitro study showed that
oxygen-glucose deprivation can induce the proteolytic
cleavage of neuronally expressed C5, which in turn
increased apoptotic cell death through a C5a-dependent
mechanism [117]. The benefits of C5 deficiency on
stroke outcome in mice were, however, not observed in
an independent study by Mocco et al. [104]. Although
we cannot fully reconcile these differences, it was noted
that a later study from the same laboratory did report
improved recovery when blocking C5a signalling (vide
infra). Further research is therefore warranted to better
characterise the role of C5 and its activated cleavage
products, C5a and C5b, in the context of IR injury.
Interestingly, C6−/− mice have a similar degree of
hypoxic-ischaemic pathology compared to WT mice
[118], which appears to suggest that inhibiting MAC for-
mation may not necessarily yield beneficial effects. How-
ever, a pathological role of excessive MAC deposition has
been supported by studies of CD59a−/− mice. Deficiency
in CD59a was associated with increased infarct volume,
worse neurological deficits and brain swelling following
a 30-min MCAO and 72-h reperfusion as compared to
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was no difference in these outcome measures when these
mice were subjected to 1 h of MCAO with 48 h reperfu-
sion, although increased apoptosis was detected in
CD59a−/− mice [119]. This highlights that the detrimental
effects of excessive MAC formation relative to secondary
pathology are probably concentration- and model-
specific, and thus most amenable to therapeutic interven-
tion in mild ischaemic-reperfusion injury.
Investigation of the complement system following cere-
bral IR would not be complete without having determined
the role of the anaphylatoxins C3a and C5a. Although
these proteins do not lead to MAC formation, as
described earlier, they potently mediate inflammation [31].
Expression of both C3aR and CD88 is increased in mouse
models of cerebral ischaemia [115,120,121]. Pharmaco-
logical antagonism of C3aR produced smaller stroke
volumes, less ICAM-1 protein on endothelial cells and less
upregulation of C3aR-positive granulocytes, but no differ-
ence in other inflammatory cell populations in mice sub-
jected to a transient (60 min), but not permanent, MCAO
[122]. It should be taken into account, however, when
interpreting these findings that the compound used in this
study, SB290157, reportedly has off-target effects, includ-
ing neutropenia in vivo [123], and full agonist activity in a
variety of cell systems in vitro [124,125]. In comparison,
mice administered a specific CD88 antagonist 30 min
prior to ischaemia (PMX53, 5 mg/kg i.v.) exhibited only a
moderately improved outcome when subjected to 60 min
MCAO [115]. Others have reported, however, that CD88
inhibition in the same model 45 min prior to ischaemia
with the same compound but at a lower dose (1 mg/kg i.v.)
yielded dramatically beneficial effects, both in terms of
neurological deficits and infarct volume [126]. These find-
ings suggest that anaphylatoxin signalling may be more
complex than previously thought, with concentration-
specific, time-dependent and model-specific effects.
Complement activation in traumatic brain injury (TBI)
A substantial body of evidence points towards a similarly
prominent role for complement activation in the sec-
ondary post-injury sequelae following brain injury. In
human TBI patients that underwent frontal or temporal
lobe resection for intractable intracranial hypertension
(2–82 h post-injury), resected tissue was analysed for
complement factors [127]. Immunoreactivity against
C1q, C3, C4 C3b, C3d and C5b-9 was detected on neu-
rons in the penumbra region of the contused brain area
[127]. In the CSF of TBI patients, C3 as well as classical
(C1q, C4) [128] and alternative pathway components
(factor B) [129] were also elevated, and thus likely to
contribute to secondary injury [129]. Furthermore, the
concentration of MAC in CSF of TBI patients is up to
1,800-fold higher than in control CSF, and there is asignificant correlation between intrathecal MAC levels
and post-traumatic BBB dysfunction [130].
In animal models, immunoreactivity for C3 was found
around the lesion but not in the uninjured contralateral
hemisphere, while deposition of C9, a key component of
the membrane attack complex, was also observed on
damaged neurons after an experimental cerebral contu-
sion [131]. Collectively, these findings indicate that all
four complement pathways are activated in response to
TBI, and it is the widely held view that complement de-
regulation contributes to nerve cell death.
A number of studies have attempted to address the
relative contribution of specific complement activation
pathways to secondary injury following TBI. Factor B
null (fB−/−) mice, which lack a functional alternative
pathway, show significantly attenuated complement acti-
vation and neuronal death in addition to upregulation of
Fas receptor and Bcl-2 in response to TBI compared to
brain homogenates of fB+/+ (i.e. WT) littermates [132].
In a follow-up study, administration of monoclonal anti-
factor B antibody (mab1379), which strongly inhibits
alternative pathway activation, 1 and 24 h post-injury,
significantly attenuated C5a levels in serum, in addition
to general inflammation and neuronal apoptosis, whilst
also yielding a neuroprotective pattern of intracerebral
gene expression [133]. Importantly, however, no differ-
ence was detected in neurological grade relative to con-
trols. This was attributed to a combination of the short
half-life of mab1379, compensatory inflammatory effects
(i.e. release of tumour necrosis factor (TNF) and inter-
leukins (IL) -1β, -8, -12, -18), and the need to apply
more sensitive neurological testing systems [133]. Fur-
ther experiments are therefore required to determine
the optimal dosage, injection route and time points of
mab1379 to fully determine the feasibility and thera-
peutic merit of targeting the alternative pathway. One
option may also be to use alternative pathway-targeted
therapies in combination with those targeting other
complement activation routes.
Another study evaluated the combined influence of the
classical and lectin pathways on the outcome from TBI by
administering C1-INH to mice that underwent controlled
cortical impact [134]. The investigation revealed attenu-
ation in motor deficits and cognitive dysfunction as well
as reduced contusion volumes in the group given C1-INH
at 10 min post-injury. When C1-INH treatment was
delayed to 60 min post-injury, improvements were only
seen in recovery of motor function compared to the
saline-treated group [134]. Although a more potent re-
combinant C1 inhibitor has been developed [100], as of
yet, there are no reports detailing the efficacy of this com-
pound in TBI or SCI models.
Unequivocal evidence that complement activation
contributes to secondary damage in TBI has come from
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hemeoxygenase-1 levels, and reduced microglia activa-
tion and neutrophil infiltration around the clot following
intracerebral haemorrhage; usage of the affected fore-
limb was improved as compared to WT controls [135].
In a cryoinjury model, C3−/− mice again showed fewer
infiltrating immune cells, less haemorrhage and better
preservation of cytoplasm compared to injured WT
brains [136]. Targeted overexpression in the CNS of
complement receptor type 1-related protein y (Crry), a
functional homologue of the human complement-
regulatory proteins CD55 and CD46 that inhibits
complement activation at the C3 convertase level, also
significantly improved neurological outcome for up to
4 weeks after trauma compared to WT mice [137]. Al-
though this model is perhaps less clinically relevant, its
findings led to a follow-up study that used systemic ad-
ministration of the recombinant Crry molecule (Crry-Ig)
in a standardised mouse model of closed head injury
[138]. When given 1 and 24 h after trauma, significant
neurological improvements and tissue preservation were
observed, and this phenotype was associated with upre-
gulation of neuroprotective genes (Bcl-2, C1-Inh, CD55,
CD59) in the injured hemisphere compared to the
vehicle-treated control group [138].
The role of the MAC in focal closed head injury was
investigated using CD59−/− mice, which have over-
exuberant MAC deposition because of a lack of this
negative complement regulator [139]. As anticipated,
CD59−/− mice had significantly exacerbated ‘neurological
severity scores’ and displayed increased neuronal cell
death. Interestingly, there was no difference in Fas, FasL,
Bax or Bcl-2 expression between CD59−/− mice and WT
littermates [139].
The role of the anaphylatoxins in the pathophysiology
of TBI has also been explored in recent years. A reduc-
tion in secondary damage after traumatic brain cyroin-
jury was observed in C5−/− mice or in mice treated with
a CD88 antagonist [136]. Similarly, treatment with a
C5aR antagonist [hexapeptide-derived macrocycle AcF
(OPdChaWR)] in a mouse model of intracerebral haem-
orrhage significantly improved neurological function as
assessed by spatial memory retention in the Morris
water-maze test, corner turn test and a 28-point neuro-
logical scale at 24, 48 and 72 h post-injury, and
decreased oedema and granulocyte infiltration relative to
vehicle-treated animals [140]. These effects were more
marked when combined with a C3aR antagonist, al-
though this result should again be interpreted with some
caution as the compound SB290157 can display full
agonist activity in certain cell types, as mentioned earlier
[124,125]. Thus, anaphylatoxin signalling also appears to
negatively influence TBI outcomes, at least acutely. It is,
however, necessary to determine whether the beneficialeffects of anaphylatoxin antagonism are dependent on
timing of the treatment and if they can be sustained
long-term without producing deleterious side effects to
the host, as observed in other models of neurotrauma
(vide infra [4]).
In summary, the above-mentioned studies demon-
strate that complement is potently activated following
TBI and that targeted interventions can rescue neigh-
bouring intact tissue after head injury with the potential
to improve functional outcomes.
Dual roles for complement activation in spinal cord
injury?
Following traumatic spinal cord injury (SCI), a robust
and complex inflammatory response is initiated through
the recruitment and activation of infiltrating leukocytes
and resident microglia. It is the widely held view that
this inflammatory cascade again exacerbates the primary
injury by damaging neighbouring neurons that were ori-
ginally spared [141,142]. A prominent role for comple-
ment activation in post-SCI inflammation and associated
secondary damage is becoming increasingly clear.
Early studies on complement activation in a rat
weight-drop model of SCI established that the classical
(C1q and C4), alternative (Factor B) and terminal (C5b-9)
pathways are strongly activated within 1 day post-injury,
and that activation fragments remain on neurons and
oligodendrocytes for up to 6 weeks as far as 20 mm
rostral to the site of injury [14]. Complement inhibitor
proteins such as factor H and clusterin are also report-
edly expressed at elevated levels on both neurons and
oligodendrocytes after SCI in rats, perhaps in an en-
dogenous attempt to constrain inflammation to the pri-
mary injury area [14,93]. These findings led to several
studies in which the therapeutic potential of comple-
ment pathway inhibition was tested via pharmacological
agents.
The effect of inhibiting the classical/alternative path-
way [143] and C3b/C4b activity [144] was investigated in
Sprague–Dawley rats subjected to moderate weight-drop
SCI. In these studies, treated animals had decreased
complement deposition and leukocyte infiltration, which
was paralleled by increased tissue sparing and improved
locomotor recovery compared to vehicle-treated animals
subjected to SCI.
In mouse models of contusive SCI, genetic deficiency
of factor B [16], C1q [91] C3 [93,94] resulted in
improved sensory and locomotor outcomes as well as
increased tissue sparing in comparison to WT mice.
Blocking the alternative pathway with the CR2 inhibitor,
Crry [93] or a factor B neutralising antibody [16] simi-
larly improved histological and functional parameters as
compared to untreated mice. It has also been shown that
SCI potently activates B cells, resulting in the production
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[12]. Such immune complexes serve as a substrate for
ligation by C1q and phagocytic/cytolytic cells bearing
IgG receptors (Fc receptors). Indeed, injection of puri-
fied antibodies into uninjured spinal cord produced con-
sistent paralysis and pathology, involving the activation
of C1q and cells bearing Fc receptors. Conversely, in B
cell-deficient mice, which lack antibody production and
thus cannot form immune complexes, minimal C1q de-
position was observed at and near the lesion site, which
in turn was associated with improved recovery of loco-
motor function [12].
Although the above-detailed studies point to a prom-
inent role for complement-mediated pathology after SCI,
particularly via the MAC, the precise role of other acti-
vation fragments such as the anaphylatoxins is yet to be
conclusively determined. A recent study illustrated these
complexities in a rat model of contusive SCI where an-
tagonism of the high-affinity C5a receptor CD88 at
14 days post-SCI worsened locomotor recovery, demye-
lination and altered macrophage/microglia recruitment
[4]. We have now independently confirmed these results
in CD88−/− mice, while a similarly novel anti-
inflammatory role for C3aR in SCI was also determined
in our laboratory. These intriguing findings suggest that
activation of these receptors, at least during certain
phases post-injury, serve a regulating and perhaps posi-
tive role in repair processes, which may be by aiding in
the elimination of toxic proteins and debris [4]. With
other studies having demonstrated clearly detrimental
roles for general complement activation following CNS
injury, most likely through formation of the MAC, it is
at present difficult to judge the true importance of ana-
phylatoxin signalling following neurotraumatic events,
and whether or not the above detailed findings are spe-
cific to SCI. It would therefore be of interest to further
study the role of C3a and C5a under conditions where
MAC assembly is prevented but anaphylatoxins can still
be generated, e.g. through the use of C6-deficient mice
[145].
Conclusion and future outlook
Although complement activation is a necessary part of
normal wound healing in the body, its deregulation or ex-
cessive activation following neurotraumatic events has
emerged as a major contributor to secondary tissue dam-
age. All available lines of evidence suggest that targeting
complement may represent a novel and effective strategy
for attenuating or ameliorating acute CNS trauma. How-
ever, because of the multifarious roles of complement in
the normal CNS, non-selective and chronic anti-
complement therapies may be a less favourable option
when aiming to translate complement-directed therapeu-
tics into the clinic. Detrimental outcomes have alreadybeen observed in SCI following long-term interference
with anaphylatoxin receptor signalling and similar effects
could perhaps be anticipated with other approaches, par-
ticularly when one considers that, similar to development,
complement activation may play vital roles in post-injury
plasticity; specifically the rewiring of local neural circuits
that is thought to underpin functional recovery following
SCI [146]. As such, it will be critical to elucidate the pre-
cise spatiotemporal function of specific complement acti-
vation fragments in future years. This will allow the design
of novel and optimally effective therapeutic strategies that
can harness ameliorative factors and neutralise or regulate
toxic components in an appropriate and timely fashion.
As progress is being made towards the translation of
complement-based therapeutics into the clinic, consider-
ation should also be given to the fact that there are
known functional differences in complement system ac-
tivity between species that could influence the efficacy of
the intervention and thus trial outcomes. Although stud-
ies in genetically modified mice have greatly advanced
our understanding of complement activation in neuro-
trauma, unlocking a number of promising avenues for
therapeutic intervention, certain strains of mice are also
known to have lower complement activity compared to
other mammals such as rats, rabbits, guinea pigs and
humans [147-151]. These observations highlight the im-
portance of understanding the limitations of experimen-
tal models and, where appropriate, the need to use
intermediate animal models between mice and humans
in translational complement research.Abbreviations
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This study investigated the role of the complement activation fragmentC5a in secondarypathology following contusive spinal cord injury
(SCI).C5ar/mice, which lack the signaling receptor for C5a, displayed signs of improved locomotor recovery and reduced inflamma-
tion during the first week of SCI compared with wild-type mice. Intriguingly, the early signs of improved recovery in C5ar/ mice
deteriorated fromday 14 onward,with absence of C5aRultimately leading to poorer functional outcomes, larger lesion volumes, reduced
myelin content, andmore widespread inflammation at 35 d SCI. Pharmacological blockade of C5aRwith a selective antagonist (C5aR-A)
during the first 7 d after SCI improved recovery compared with vehicle-treated mice, and this phenotype was sustained up to 35 d after
injury. Consistent with observations made in C5ar/ mice, these improvements were, however, lost if C5aR-A administration was
continued into themore chronic phase of SCI. Signaling through the C5a-C5aR axis thus appears injurious in the acute period but serves
a protective and/or reparative role in the post-acute phase of SCI. Further experiments in bonemarrow chimericmice suggested that the
dual and opposing roles of C5aR on SCI outcomes primarily relate to its expression on CNS-resident cells and not infiltrating leukocytes.
Additional in vivo and in vitro studies provided direct evidence that C5aR signaling is required during the postacute phase for astrocyte
hyperplasia, hypertrophy, and glial scar formation. Collectively, these findings highlight the complexity of the inflammatory response to
SCI and emphasize the importance of optimizing the timing of therapeutic interventions.
Keywords: anaphylatoxin; CNS trauma; demyelinating pathology;macrophage; oligodendrocyte precursor cell; secondary degeneration
Introduction
The complex inflammatory response to traumatic spinal cord
injury (SCI) contains elements that are known to be required for
successful wound healing in other tissues; in context of CNS in-
jury, these can, however, also cause additional damage to spared
neural tissue (Donnelly and Popovich, 2008). A more in-depth
understanding of these seemingly opposing roles of inflamma-
tion is therefore required, such that new and effective
immune-modulatory therapies can be developed to improve
recovery from SCI, and potentially other acquired CNS inju-
ries. The innate immune complement system, composed of
30 soluble and membrane-bound proteins, receptors, and
regulators, is a major component of trauma-induced neuro-
inflammation (Anderson et al., 2004; Brennan et al., 2012).
Previous studies have already shown that SCI outcomes can be
improved through genetic deletion or pharmacological block-
ade of complement opsonins (Ankeny et al., 2009), the lytic
membrane attack complex (Li et al., 2009), as well as more
general interference with the main (i.e., classical, lectin, and
alternative) pathways for complement system activation
(Reynolds et al., 2004; Qiao et al., 2006, 2010; Guo et al., 2010).
The role of the C5a activation fragment in the immune re-
sponse to SCI remains, however, uncertain.
C5a is a 74 amino acid peptide that is generated by the
proteolysis of complement protein C5. It is known to be a
potent chemoattractant molecule through interaction with its
G-protein-coupled receptor C5aR (CD88) (Ward and Newman,
1969), which is present on most leukocytes (Chenoweth and
Hugli, 1978; Chenoweth et al., 1982). In the CNS, C5aR expres-
sion has been reported on neurons (Stahel et al., 1997; O’Barr et
al., 2001; Be´nard et al., 2004; Woodruff et al., 2006; Humayun et
al., 2009), astrocytes (Gasque et al., 1995; Lacy et al., 1995;Wood-
ruff et al., 2008), microglia (Lacy et al., 1995; Griffin et al., 2007),
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oligodendrocytes (Nataf et al., 2001), and neural progenitor cells
(Farkas et al., 1999; Rahpeymai et al., 2006).
Previous in vivo studies have shown that parenchymal C5a/
C5aR expression is increased in models of traumatic brain injury
(Stahel et al., 1997), intracerebral hemorrhage (Xi et al., 2001),
and ischemic injury (Van Beek et al., 2000; Pavlovski et al., 2012),
as well as in the plasma of human patients with stroke (Mocco et
al., 2006) and subarachnoid hemorrhage (Mack et al., 2007).
More importantly, acute inhibition of the C5a-C5aR axis im-
proves outcomes from experimental ischemic stroke (Kim et al.,
2008; Pavlovski et al., 2012) and intracerebral hemorrhage (Gar-
rett et al., 2009). Intriguingly, although acute C5aR blockade is
thought to attenuate inflammation, delayed antagonism of this
receptor, starting 2 weeks after injury, led to significantly exacer-
bated SCI outcomes (Beck et al., 2010). These findings suggest a
novel neuroprotective/reparative role for C5aR signaling in the
postacute phase of neurotrauma, although the mechanisms be-
hind these observations are poorly understood. In the present
study, we used C5aR knock-out (C5ar/) mice, pharmacolog-
ical targeting of C5aR, bone marrow chimeras, and in vitro stud-
ies to better understand the role of the C5a-C5aR axis in SCI.
Materials andMethods
Animals. Adult female age- and weight-matched C57BL/6J (wild-type
[WT]; n  147), C5ar/ (n  62) (Hollmann et al., 2008), and
Macgreen (Csf1r-EGFP, n 24) (Sasmono et al., 2003)micewere used in
this study. C5ar/ and Macgreen mice had been backcrossed for10
generations onto the C57BL/6J genetic background. All animals were
obtained from local breeding colonies at the University of Queensland’s
Biological Resources facility. Mice were maintained in individually ven-
tilated cages under standard conditions on a 12 h light-dark cycle with ad
libitum access to food and water. All experimental procedures were ap-
proved by the University of Queensland’s Animal Ethics Committee and
conducted in accordance with the relevant National Health andMedical
Research Council of Australia policies.
SCI. Mice were anesthetized with a mixture of tiletamine/zolezepam
(50 mg/kg; Virbac) and xylazine (20 mg/kg; Troy Laboratories), after
which they underwent contusive SCI. In brief, this involved identifica-
tion of the ninth thoracic (T) vertebra based on anatomical landmarks
(Harrison et al., 2013), followed by dorsal laminectomy of T9 as de-
scribed previously (Scheff et al., 2003; Blomster et al., 2013a). Next, a
severe (70 kdyne) contusion injury was inflicted on the spinal cord
using the Infinite Horizon impactor device (Precision Systems and In-
strumentation). Following this, muscle and skin were closed separately
using 6–0 polyglactin dissolvable sutures (Ethicon) and Michel wound
clips (Kent Scientific), respectively. Investigators performing surgery
were blinded to the genotype and/or treatment condition of the animals.
Postoperatively, animals received a single injection of buprenorphine
(0.5 mg/kg s.c.) in Hartmann’s sodium lactate solution for analgesia and
were administered antibiotics (1.0mg/kg gentamicin s.c.) for the first 5 d
after injury. Bladders were manually voided twice daily for the duration
of the experiments.
C5a ELISA. To determine the time course of C5a generation following
SCI, WT mice were subjected to either SCI or sham surgery and then
killed with sodium pentobarbitone (100 mg/kg i.p., Virbac) at 30 min,
2 h, 6 h, 12 h, 1 d, 4 d, 7 d, or 35 d after injury (n 4 or 5 per time point).
An additional 4 unoperated (i.e., naive) mice were used to assess C5a
levels under normal homeostatic conditions (time point 0).
At the appropriate time point, 0.5 ml of volume of blood was collected
directly from the heart via cardiac puncture using a syringe containing 30
l of 4 mM EDTA. Blood samples were mixed immediately with 10 l of
the complement inhibitor FUT175 (5mg/ml; BDBiosciences) and stored
on ice. Samples were centrifuged at 13,000  g for 10 min at 4°C, after
which the supernatant was collected, aliquoted, and stored at 80°C.
The T11-T13 spinal cord segment was also dissected immediately after
the cardiac bleed, snap frozen in liquid nitrogen, and then stored at
80°C. Spinal cord samples were ground to a fine powder using amortar
and pestle on dry ice, then dissolved in 200 l of NP-40 lysis buffer
(Invitrogen) containing 1 mM PMSF (reconstituted in DMSO) (Sigma-
Aldrich), 92.6 M FUT175 (BD Biosciences), and 5 l of protease inhib-
itor mixture (Sigma-Aldrich). Samples were vortexed for 1 min,
incubated on ice for 1 h, and then centrifuged at 13,000 g for 30min at
4°C. Supernatants were collected, aliquoted, and stored at 80°C. An
ELISA (R&D Systems, #DY2150) was then used to determine the con-
centration of C5a in blood plasma and spinal cord samples according to
the manufacturer’s instructions; all samples were detected within the
linear aspect of the standard curve. For spinal cord samples, the mea-
sured concentration of C5a was always normalized to the protein con-
centration of the sample, which was measured by a BCA protein assay
(Thermo Scientific, #23227) according to the manufacturer’s
instructions.
Tissue processing for MRI and histology. Mice were anesthetized with
sodium pentobarbitone (100 mg/kg i.p., Virbac) at their specified end-
points (see Results).Mice were then transcardially perfusedwith 20ml of
saline (0.9% NaCl) containing 10 IU/ml heparin (Pfizer) and 2%
NaNO3, followed by 30 ml of phosphate-buffered Zamboni’s fixative
(2% picric acid, 2% formaldehyde, pH 7.2–7.4). The perfused vertebral
column was then dissected out and postfixed overnight at 4°C. Spinal
cord specimens were then imaged where applicable (see MRI), dissected
out from the vertebral column, and cryoprotected via subsequent over-
night incubations in 10% and 30% sucrose solutions. Next, the lesion
segment of the spinal cord was embedded in Optimal Cooling Temper-
ature (OCT) compound (ProSciTech), snap-frozen using dry ice-cooled
isopentane, and then stored at80°C until sectioning. Coronal sections
(20 m thick) were cut on a Leica cryostat CM3050-S, collected on
Superfrost Plus slides (1:5 series; Lomb Scientific), and stored at80°C
until staining.
Analysis of C5aR expression. Immunofluorescent staining techniques
were used to assess the expression and distribution of C5aR in the injured
spinal cord. A rat anti-C5aR antibody (clone 10/92, 1:200; AbD Serotec)
was used for these experiments. Antibody specificity was confirmed
through staining of spinal cord tissue from injuredC5ar/mice, aswell
as omission of the primary antibody incubation step onWT tissue. Stain-
ing for C5aR was combined with immunolabeling for ionized calcium
binding adaptor molecule 1 (rabbit anti-Iba1, 1:500; Wako Pure Chem-
ical Industries) to label microglia/macrophages, or with GFAP (rabbit
anti-GFAP, 1:1000;Dako) to identify astrocytes. Slideswere defrosted for
1 h at room temperature (RT) and then washed in PBS (3  10 min).
Next, slides were incubated in blocking solution (0.2% Triton X-100,
Sigma-Aldrich; 2% BSA, Sigma-Aldrich; in PBS) for 1 h at RT to perme-
abilize the sections and reduce nonspecific antibody binding. This solu-
tion was also used as the antibody diluent. After blocking, spinal cord
sections were incubated overnight at 4°C with primary antibodies in a
humidified chamber. The following day, slides were washed in PBS (3
10 min) to remove unbound antibody, followed by incubation with sec-
ondary antibodies goat anti-rat IgG-AlexaFluor-555 (1:500; Invitrogen)
and goat anti-rabbit IgG-AlexaFluor-488 (1:200; Invitrogen) for 1 h at
RT. Slides were then washed again in PBS (3  10 min), coverslipped
with Dako fluorescent mounting medium containing Hoechst 33342
nuclear dye (1:1000; Sigma-Aldrich), and imaged using an Olympus
BX61 confocal microscope.
Assessment of functional recovery.Mouse hindlimb locomotor recovery
in WT and C5ar/mice was assessed at 1, 3, 7, 10, 14, 21, 28, and 35 d
after injury using the 10 point Basso Mouse Scale (BMS), which is spe-
cifically designed for mouse models of SCI (Basso et al., 2006). Two
investigators assessed various aspects of each mouse’s locomotion in
open field for 4 min. For mice that achieved a score of frequent plantar
stepping (i.e., a BMS score  5), BMS subscores were also assigned to
quantify the finer aspects of locomotion. For the initial experiments
comparing the recovery of WT and conventional C5ar/ mice, the
actual applied force was 71.9 0.56 kdyne (n 12, mean SEM) and
72.2 0.52 kdyne (n 8,mean SEM), with an average tissue displace-
ment of 593.4 6.57m (mean SEM) and 597.4 9.71m (mean
SEM), respectively. There were no significant differences in injury pa-
rameters between experimental groups (p 0.05).
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For pharmacological studies involving C5aR antagonism during the
first week of injury (see C5aR-A treatment), ledged tapered beam walk-
ing was used as a second, independent measure to assess hindlimb loco-
motor ability. The beam itself, which was elevated 1 m above the floor,
was 90 cm long and had a starting width of 3 cm that narrowed to 0.5 cm
at the end. Mice were trained to cross the beam for 5 consecutive times
during 2 d of habituation trials before the testing day. On the test day
itself (35 d after SCI), eachmouse was again required to cross the beam 5
times and videotaped while performing the task. The total number of
steps, the number of footfalls, and the traversing time were recorded. For
each animal, the mean data from the five crossings were calculated for
each of these parameters. A group of sham-operated Macgreen mice
(n  6) was included to determine baseline performance for this
functional task. Assessors were blinded to the experimental condition
(genotype/treatment group) during all behavioral testing to avoid
experimenter bias.
MRI. For postmortem MRI analysis at 35 d after injury, spinal cord
samples were washed extensively in 0.1MPBS after overnight postfixing,
followed by immersion for 48 h in PBS containing gadolinium contrast
agent (0.2% Magnevist, Bayer HealthCare Pharmaceuticals). Vertebral
columnswith the spinal cord in situwere imaged on a 16.4T small animal
MRI (Bruker BioSpin) as detailed previously (Blomster et al., 2013b). A
stack of 256 two dimensional T2 slices was generated for each imaged
specimen.MRI datasets were analyzed using AVIZO version 6.2 software
(Visualization Sciences Group), with an orthoslice along the sagittal
plane and two user-defined (oblique) slices along the coronal and trans-
verse planes, respectively. The Apply-Transform function was used to set
these axes as the reference points for further analyses. A 3D image of the
lesion core was reconstructed by manually outlining the hypointense
core in the coronal plane of every slice using the Lasso tool; the sagittal
and transverse planes were also viewed to confirm that the complete
lesion core was highlighted. As areas of demyelination can be difficult to
distinguish from remnants of spared gray matter, only the hypointense
core was outlined for reconstruction and calculation of lesion volumes.
Image quantification was performed with the investigator blinded to the
experimental group.
General staining procedures and analysis of histopathology. Fluoro-
Myelin Red staining (1:150; Invitrogen) was performed as per the man-
ufacturer’s instructions to assess white matter myelin content at and
around the lesion site (Blomster et al., 2013a). FluoroMyelinRed staining
was combined with immunostaining for GFAP as detailed above, except
for experiments that involved Macgreen mice, where a separate set of
sections were stained for GFAP using a goat anti-rabbit IgG-AlexaFluor-
546 secondary antibody (1:250; Invitrogen). Stained spinal cord sections
were photographed using an Olympus SZX12 Research Fluorescence
Stereo Microscope (Spectra Services). The proportional area of myelin
and GFAP staining (relative to the section area) was measured using the
freehand selection tool and threshold functions in ImageJ. The average
pixel intensity for GFAP immunofluorescence was also determined as
detailed previously (Schmid et al., 2013). For each experimental animal,
the lesion epicenter was defined as the coronal section with the least
amount of FluoroMyelin Red staining relative to the section area (Blom-
ster et al., 2013a). Image acquisition and data analysis were again per-
formed with experimenter blinding.
To evaluate the cellular immune response in the injured spinal cord,
immunohistochemical staining with rat anti-Ly6b.2 (1:400; AbD Sero-
tec) was used to visualize infiltrating neutrophils (and a subset of inflam-
matory monocytes) (Rosas et al., 2010). Rat anti-CD11b (1:200; AbD
Serotec) was used to label granulocytes, macrophages, andmicroglia. Rat
anti-CD3 (1:400; AbD Serotec) was used to stain T lymphocytes. For all
of these stains, slides were first washed in PBS (3 10 min). To quench
endogenous peroxidase activity, slides were incubated at RT in PBS con-
taining 10%methanol for 10min and then incubated for 20min at RT in
PBS containing 10%methanol and 0.3%H2O2. Slides were then washed
again in PBS (3 10 min) and incubated with blocking solution for 1 h
at RT, before overnight incubation with primary antibody in a humidi-
fied chamber at 4°C. The following day, slides were washed in PBS and
incubated for 1.5 h at RT with biotinylated donkey anti-rat IgG (1:250;
AbD Serotec). Sections were then washed again in PBS (3 10min) and
incubated with Vectastain Elite ABC reagent (1:200; Vector Laborato-
ries) for 1 h at RT. After another set of 3  10 min washes in PBS, the
staining was developed by incubating each slide for 5 min at RT with 0.5
ml of 3,3-diaminobenzidine (Sigma-Aldrich). Stained sections were de-
hydrated through graded series of ethanol (70%–100%), washed twice in
xylene, and coverslipped using Depex mounting media (Electron Mi-
croscopy Sciences). Immunohistochemically stained slides were digi-
tized using a ScanScope XT scanner (Aperio) and ImageScope (Leica
Biosystems).
For quantitative analysis, Ly6b.2 and CD3 cell numbers in the
spinal cordwere counted using themanual tag function in ImageProPlus
Version 6.3 (Media Cybernetics) and expressed as number of cells per
mm2 based on the section area outlined in ImageJ. The CD11b im-
mune infiltratewas quantified and expressed as a proportional area of the
section (Kigerl et al., 2006). The analyzer was blinded to the experimental
condition during counting and image analysis.
C5aR-A treatment. A cohort of Macgreen mice was used for pharma-
cological inhibition of C5aR during the acute/subacute phase. These
mice underwent SCI as described above and then administered either
the cyclic C5aR peptide antagonist (C5aR-A; [hydrocinnamate-
(OPdChaWR)], 1 mg/kg, i.p., n  8) (Finch et al., 1999) or a vehicle
solution (5% glucose, i.p., n  10). Treatment started at 30 min after
injury and was repeated every 12 h for the first 7 d after injury. The actual
applied force for this experiment was 72.5 0.65 kdyne and 72.5 0.54
kdyne (mean SEM) for vehicle-treated and C5aR-A-treated mice, re-
spectively. The associated tissue displacement was 539.2  7.5 m and
528.7 12.4m(mean SEM), respectively. There were no differences
in injury parameters between groups (p  0.05). These mice were sub-
jected to BMS scoring, ledged tapered beam walking, and postmortem
analysis of histopathology, all as detailed earlier.
In a separate experiment, WT mice were subjected to SCI and treated
with either C5aR-A (n  4) or vehicle (n  5) as detailed above, every
12 h until the experimental endpoint of 21 d after SCI. The actual applied
force here was 72.0 1 kdyne (mean SEM) for C5aR-A-treated mice
and 72.60 0.68 kdyne (mean SEM) for vehicle-treated controls; the
associated tissue displacement was 534.7  25.9 m and 522.7  29.7
m (mean SEM), respectively. A cohort ofC5ar/mice (n 5) was
also included in this experiment; the applied force for these animals was
72.8 0.8 kdyne (mean SEM), with an associated tissue displacement
of 521.6 33.4 m (mean SEM). There were no differences in injury
severity parameters between experimental groups (p 0.05). All of the
animals in this experiment were also injected with the thymidine analog
BrdU (BDBiosciences, 50mg/kg, i.p.) every 24 h for the first 7 d after SCI
to label proliferating cells (see below). This period was chosen for BrdU
injection as it is thought to capture the onset of oligodendrocyte precur-
sor cell and astrocyte proliferation after rodent CNS trauma (Bush et al.,
1999; Zai and Wrathall, 2005; Lytle and Wrathall, 2007; Tripathi and
McTigue, 2007; Wanner et al., 2013). Functional recovery in this exper-
iment was monitored via BMS scoring with investigator blinding.
Cytokine quantification. For analysis of cytokine levels in acute SCI, the
injured spinal cord segment (vertebral levels T8-T10) from bothWT and
C5ar/ mice was collected at 12 h after SCI (n  5 per group) and
processed as detailed earlier (see C5a ELISA). This segment of spinal cord
was also collected from sham-operated (i.e., laminectomy with no sub-
sequent SCI)WT andC5ar/mice to establish baseline cytokine levels
(n 4 per group).
The concentrations of CXCL1 and IL-1 in spinal cord supernatants
were determined using cytokine Flex Sets (BD Biosciences, #558340 and
#560232, respectively). Levels of IL-12p70, TNF, IFN, MCP-1, IL-10,
and IL-6 were also determined using a Cytometric Bead Array (BD Bio-
sciences, #552364) as per the manufacturer’s instructions. The latter
sampleswere analyzed on an LSRII flow cytometer (BDBiosciences), and
concentrations computed using FCAP array version 3.0 software. For all
assays, samples were appropriately diluted, such that they were always
detected within the linear aspect of the standard curves. The calculated
cytokine concentrations were normalized to the total protein content of
each sample, which was measured by a BCA protein assay (Thermo Sci-
entific, #23227) according to the manufacturer’s instructions.
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Flow cytometry. Flow cytometrywas used to quantify the inflammatory
infiltrate in the injured spinal cord at 7 d after SCI. In brief, injured spinal
cord of WT and C5ar/ mice (T11–13 segments) was dissociated as
reported previously (Beck et al., 2010; Blomster et al., 2013a). Cells were
then resuspended in flow cytometry blocking buffer (0.5% BSA, 2 mM
EDTA, in DPBS, pH 7.2), followed by incubation with rat-anti-CD16/32
(1:200; BD Biosciences) for 10 min at 4°C to block Fc receptors. Cells
were immunolabeled with rat anti-Ly6G-Alexa-647 (1:200, BD Biosci-
ences), rat anti-Ly6C-V450 (1:200; BD Biosciences), and rat anti-
CD45-PE (1:200; BD Biosciences). For the exclusion of dead cells,
samples were also incubated with near infrared-conjugated viability dye
(Zombie NIR, 1:100; BioLegend). Stained samples were then analyzed
using an LSR II flow cytometer (BD Biosciences) and BD FACS Diva
software. After acquisition, compensation was applied to remove Zom-
bie NIR/Ly6G-Alexa-647 spectral overlap; cell doublets, triplets, etc.
were excluded based on FSC-A/FSC-H linearity. Inflammatory mono-
cytes/macrophages were defined as the CD45hiLy6CLy6G popula-
tion, and neutrophils as the CD45Ly6CLy6G population.
Propidium iodide-fluorescing counting beads (5 l; Beckman Coulter)
were added as an internal control to enable quantification of absolute cell
numbers according to the manufacturer’s instructions.
Bone marrow (BM) chimeras. To assess the impact of selective C5aR
deletion within the peripheral immune compartment on recovery from
SCI, [WT¡WT] (n 6), and [C5ar/¡WT] (n 7) BM chimeric
mice were generated as detailed previously (Chinnery et al., 2010). These
micewere allowed to recover for 8weeks after chimerization before being
subjected to SCI surgery as detailed above. For this experiment, the actual
applied forcewas 72.86 0.80 kdyne versus 72.29 0.87 kdyne (mean
SEM), with an associated tissue displacement of 518.6  14.9 m and
511.1  12.18 m (mean  SEM) for [WT¡ WT] and [C5ar/¡
WT] BM chimeras, respectively. There were no significant differences in
injury parameters between experimental groups (p  0.05). SCI out-
comes for these mice were assessed via BMS scoring and postmortem
analysis of histopathology as detailed earlier.
Assessment of glial cell proliferation and apoptosis. Spinal cord tissue
frommice that were chronically treated with C5aR-A, and also adminis-
tered BrdU during the first week following SCI, was used to determine
whether C5aR targeting influenced the proliferative response(s) of oligo-
dendrocyte precursor cells and astrocytes (study endpoint: 21 d after
SCI). Immunofluorescent staining of spinal tissuewas done using similar
procedures as described above, but with the inclusion of a denaturing
step (20 min incubation in 2 NHCl at 37°C) to expose the BrdU epitope
within the nuclear DNA. After blocking, sections were probed with rat
anti-BrdU antibody (1:100; AbD Serotec) in combination with rabbit
anti-GFAP (1:1000; Dako) for astrocytes, or mouse anti-CC1 (1:100;
Abcam) for oligodendrocytes. For the latter, the HistoMouse kit (Invit-
rogen) was used as per the manufacturer’s instructions to allow for the
use of mouse primary antibodies on mouse tissue. An incubation with
biotinylated donkey anti-rat IgG (1:200; Vector Laboratories) secondary
antibody (1 h at RT) was followed by a 1 h incubation with streptavidin-
AlexaFluor-546 (1:200; BDBiosciences), combinedwith either goat anti-
rabbit IgG-AlexaFluor-488 (1:200; Invitrogen) forGFAP staining orwith
goat anti-mouse IgG-AlexaFluor-488 (1:200; Invitrogen) for CC1 stain-
ing. Tiled optical sections were captured on a Zeiss fluorescence micro-
scopewithApoTome attachment, afterwhich the total BrdUGFAPor
BrdUCC1 cell numbers were counted in spinal cord cross-sections at
regular intervals away from the lesion epicenter, with the analyzer being
blinded to the experimental condition. Section areas were measured in
ImageJ (up to 1mmin rostral and caudal directions), allowing the cell count
tobe expressedasnumberof cells permm2.Lesionvolumes in these animals
were estimated by outlining the lesion core area (delineated by GFAP stain-
ing) in every relevant section using ImageJ; obtained values were thenmul-
tiplied by the section thickness and totaled for each animal.
To also compare and contrast oligodendrocyte cell death between the
various genotypes and/or experimental conditions at the study endpoint,
a separate set of sections were stained for CC1 and active Caspase-3
(anti-Cleaved Caspase-3 rabbit polyclonal; 1:200; BD Biosciences
PharMingen). The number of CC1CleavedCaspase-3 cells were then
counted within each section and expressed as the number of cells per
mm2 based on the section area outlined in ImageJ. The analyzer was
again blinded to the experimental condition during analysis.
In vitro astrocyte proliferation. Astrocyte cultures were established
from the brains of WT or C5ar/ pups (P1-P3; n  8 per culture)
(Gordon et al., 2011). In brief, brains were harvested, the meninges re-
moved, and the tissue placed in ice-cold DMEM/F-12 nutrient mixture
(Invitrogen, #11320) supplemented with 10% heat-inactivated FBS, 50
U/ml penicillin, 50g/ml streptomycin, 2mM L-glutamine, 100M non-
essential amino acids, and 2 mM sodium pyruvate (Invitrogen). The tis-
sue was then incubated in 0.25% trypsin (Sigma-Aldrich) at 37°C for 30
minwith gentle agitation. Trypsinizationwas stopped by adding an equal
volume of DMEM/F12 complete media, followed by three washes in the
samemedia. A single-cell suspension of the tissue was prepared by gentle
trituration and passing of the solution through a 70 m nylon mesh cell
strainer to remove tissue debris and aggregates, after which the remain-
ing cell suspension was seeded into two T-75 flasks per mouse brain.
Primary astrocytes were purified by daily media changes for 3 d and
residual microglial cells were maximally depleted by treatment with the
lysosomotropic agent leucinemethylester (5mM) for 6 h to obtain98%
pure astrocytes. The purity of astrocyte cultures was routinely verified by
immunocytochemistry for GFAP and Iba1.
For the proliferation assay, purified astrocytes were plated out at a
density of either 0.5 or 1 104 cells per well in a 48 well plate withmedia
containing DMEM/F12, 10% FBS, 1% nonessential amino acids, 1%
penicillin/streptomycin, 1% L-glutamine, and 1% sodium pyruvate. The
next day, cells were switched to media containing 2% FBS, and recombi-
nant mouse C5a (Hycult Biotech) was added at a concentration of 0, 5,
10, 50, 100, or 200 nM in triplicate. For experiments that aimed to deter-
mine whether phosphorylation of Signal Transducer and Activator of
Transcription 3 (STAT3) was involved in astrocyte proliferation in the
presence of C5a, 5 M of the STAT3 inhibitor (BP-1-102, Millipore) was
added 10 min before C5a (50 nM) exposure; BP-1-102 disrupts STAT3-
STAT3 dimerization and STAT3-phospho-tyrosine (pTyr) peptide in-
teractions (Zhang et al., 2012). Plates were then incubated for 48 h under
standard cell culture conditions (37°C, 5%CO2). The extent of astrocyte
proliferation under the various experimental conditions was measured
using a CyQUANT assay (Invitrogen) according to the manufacturer’s
instructions.
Western blotting. Separate sets of astrocyte cultures were established
and randomly allocated to one of the following groups: (1) no treatment,
(2) 50 nMC5a only, (3) 50 nMC5a 10MBP-1-102 (STAT3-inhibitor),
and (4) 10 M BP-1-102 only. Astrocytes were exposed to C5a for 1 h;
where applicable, BP-1-102 was added to the culture medium 10 min
before C5a exposure. After incubation, cells were scraped off the flasks
and collected via (low-speed) centrifugation at 300 g for 6min. Super-
natants were removed and the cell pellets stored at 80°C until lysis in
150l ofmodifiedRIPAbuffer containing the following: 10mMTris, 100
mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 nM Na4P2O7, 2 nM
Na3VO4, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, 10%
glycerol, and 10 l/ml Halt protease/phosphatase inhibitor mixture
(Thermo Scientific). Cell lysates were vortexed for 1 min at RT, incu-
bated on ice for 30min, and then centrifuged for 30min at 4°C to remove
debris. The protein concentration in the supernatant was determined
using a standard BCA protein assay (Thermo Scientific).
The Bio-Rad electroblotting system was used for Western blotting
experiments. To determine the ratio of phosphorylated STAT3 (P-
STAT3) to STAT3, 30 g of protein was diluted 1:3 in loading buffer
(250 mM Tris HCl, 8% SDS, 0.008% bromophenol blue, 20%
-mercaptoethanol, 40%glycerol, pH 6.8), heated to 96°C for 4min, and
then stored on ice for 5 min. Samples and dual-color protein standards
(Bio-Rad) were separated on 10% SDS-polyacrylamide gels using a 3 A
(114 V) current in running buffer (0.19 M Tris, 1.92 M glycine, 0.35 M
SDS in ddH2O) for 1 h. Immobilon PVDF membranes (Millipore) were
primedwith a 15 s wash inmethanol, followed by a 2minwash in ddH2O
and a 5minwash in transfer buffer (4.68Mmethanol in running buffer).
Proteins were then transferred over 1 h onto the membranes using a 3 A
(100 V) current in transfer buffer. After the transfer, membranes were
washed (3 10min) in Tris-buffered saline (TBS)-Tween (TBST; 50mM
Tris, 150 mM NaCl, 0.05% Tween 20), followed by blocking in Odyssey
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blocking buffer (LI-COR) for 1 h at RT on a rotator. Membranes were
then cut and probed with primary antibodies against -actin (1:1000;
Cell Signaling Technology, #4967) and anti-STAT3 (79D7) (1:2000; Cell
Signaling Technology, #4904) overnight at 4°C on a rotator. The follow-
ingmorning, membranes were washed on a rotator at RT (3 10min in
TBST). Next, membranes were incubated with secondary antibody (goat
anti-rabbit IgG-IRDye 800CW (1:20,000; LI-COR, #926-32211) for 1 h
at RT on a rotator. After 3 10 min washes in TBST, blots were imaged
using theOdyssey Infrared Imaging System (LI-COR). Bound antibodies
were then stripped from the membrane using Newblot PVDF stripping
buffer (LI-COR, #928-40032) as per themanufacturer’s instructions, and
the membranes incubated again for 10 min on a rotator in Odyssey
blocking buffer (LI-COR).Membranes were then washed (3 10min in
TBST) and probed for -actin (1:1000; Cell Signaling Technology,
#4967) and P-STAT3 (1:1000; Cell Signaling Technology, #9131) over-
night at 4°C. The nextmorning, blots were washed (3 10min in TBST)
and incubated with secondary antibody (goat anti-rabbit IgG-IRDye
800CW, 1:20,000; LI-COR, #926-32211) for 1 h at RT on a rotator. After
another series of washes in TBST, blots were imaged again using the
Odyssey Infrared Imaging System (LI-COR). The ratio of P-STAT3 to
STAT3 in each lane was calculated after normalization to the -actin
band using the Analyze Gel function in ImageJ.
To confirm C5aR expression by cultured astrocytes, 40 g of protein
was loaded into the Bio-Rad electroblotting system. Rat anti-C5aR anti-
body (clone 10/92; 1:1000; Hycult Biotech, #HM1077), in combination
with goat anti-rat IgG IRDye-700CW (1:10,000; LI-COR, #926-32219),
was used to detect C5aR using similar procedures as detailed above. After
stripping, blots were probed for -actin (1:1000; Cell Signaling Technol-
ogy, #4967) followed by goat anti-rabbit IgG-IRDye 800CW (1:20,000;
LI-COR, #926-32211) to control for loading and confirm appropriate
protein transfer. WT mouse brain homogenate was used as a positive
control. Protein homogenized from C5ar/ mouse brain was also in-
cluded to confirm again the specificity of the antibody that was used to
detect C5aR.
Statistical analysis.GraphPadPrism (GraphPad Software)was used for
all data visualization and statistical analyses. In vivo BMS data were ana-
lyzed using two-way repeated-measures ANOVA with Bonferroni post
hoc tests. Two-sided Student’s t tests were used to directly compare dif-
ferences in lesion size and/or histological data (myelin, GFAP, Ly6b.2,
CD11b, andCD3 staining) at the lesion epicenter. Data from the narrow-
ing beam walk, in vitro cell culture, and Western blot experiments were
analyzed using one-way ANOVAwith Newman–Keuls post hoc tests. For
the comparison of C5a levels in the spinal cord and blood plasma, in vivo
glial cell proliferation/survival, Ly6b.2 and CD3 cell numbers along
the length of the injured cord, and cytokine levels between experimental
groups/conditions, two-way ANOVA with Newman–Keuls post hoc test
was used. Pearson’s correlation test was used to examine the relationship
between astrocyte proliferation and lesion size, and for correlating lesion
volume, myelin or GFAP staining with BMS scores. All data are mean
SEM, with statistical significance determined at p	 0.05.
Results
C5a production and expression of C5aR
C5a levels in homogenized spinal cord and plasma samples were
measured by ELISA to determine the temporal profile of comple-
ment activation after SCI. Baseline C5a levels were low (2.6 
0.25 pg/g protein) in spinal cord samples fromunoperatedmice
(time point 0). C5a levels in samples from naive mice were not
different from samples from sham-operated mice at any time
point after surgery (p  0.05). Following SCI, a rapid and dra-
matic increase in tissue C5a levels was observed, which peaked at
1 d after injury (9.3 1.4 pg/g protein, a 4.5-fold increase over
sham-operated controls). Spinal cord C5a levels were still signif-
icantly higher in SCI mice compared with sham-operated con-
trols at 4 (7.0 1.1 vs 2.2 0.68 pg/g protein) and 7 d (6.1
0.85 vs 1.8 0.63 pg/g protein) after surgery (Fig. 1A). Tissue
C5a levels remained slightly elevated at 35 d after SCI, but this was
not statistically significant compared with sham-operated mice
when using ANOVA. In the plasma, a rapid increase in circulat-
ing C5a levels was observed following SCI, with these being sig-
nificantly elevated above the amount of C5a present in matching
samples from sham-operated mice at 30 min, 2 h, 6 h, 12 h, and
1 d after surgery (Fig. 1B). Although still elevated, C5a levels were
no longer different between sham and SCI mice from 4 d after
injury onwards.
Immunofluorescent staining was used to examine the pattern
and distribution of C5aR expression in the injured spinal cord. At
1 d after SCI, prominentC5aR stainingwas observed on surviving
Iba1 microglia and population of smaller, round/ovoid Iba1
cells that are most likely infiltrating neutrophils (Fig. 1C). At 7 d
after SCI, C5aR stainingwas apparent on cells with amoeboid and
ramified morphology. Staining with Iba1 indicated that many of
these cells were activated microglia and clustered macrophages
(Fig. 1D). C5aR staining also localized to a subset of GFAP
astrocytes in the rim of spared white matter surrounding the
lesion core (Fig. 1E). No C5aR staining was present on injured
spinal cord tissue from C5ar/mice (Fig. 1F), indicating anti-
body specificity. Expression of C5aR by astrocytes was also con-
firmed in vitro through Western blotting (Fig. 1G).
Genetic ablation of C5aR reveals a dual role for C5a signaling
in SCI
BMS locomotor scoring with experimenter blinding was per-
formed on C5ar/ and WT mice for 5 weeks after injury to
determine the contribution of C5aR to SCI outcomes. Before
SCI, all mice displayed normal overground locomotion, achiev-
ing BMS scores of 9. SCI produced near-complete paralysis (BMS
scores 0–1) in all mice at 1 d after SCI. By 7 d after SCI, C5ar/
mice displayed significantly more hindlimbmotor function than
WT mice (p 	 0.05) (Fig. 2A,B). These early improvements
were, however, not sustained and no longer present by 10 d after
SCI. Indeed, by 21 d after SCI,C5ar/mice now showed signs of
impaired functional recovery, and their BMS scores were signif-
icantly below those of WT mice at 28 and 35 d after injury (Fig.
2A,C). Endpoint postmortem analysis of lesion volume and his-
topathology provided additional support of an ultimately poorer
outcome as a result of C5aR ablation. Specifically, a reconstruc-
tion of the lesion site from ex vivoMRI datasets revealed signifi-
cantly larger lesion core volumes in C5ar/ mice compared
with WT mice at 35 d after SCI (Fig. 2D,E; p  0.023). Lesion
core volumes in WT and C5ar/ mice were negatively corre-
lated with the BMS scores of individual animals at the study
endpoint (r2 0.71; p 0.002).
In addition, FluoroMyelin Red staining revealed a reduction
in myelin content in C5ar/ mice (Fig. 2F,G; p  0.012).
GFAP immunoreactivity (Fig. 2F) was also found to be reduced
in C5ar/ mice at 35 d after injury with regards to both the
immunoreactive area (Fig. 2H; p  0.0073) and the intensity of
GFAP staining (Fig. 2I; p  0.017). FluoroMyelin and GFAP
staining at the lesion epicenter of WT and C5ar/ mice was
positively correlated with BMS scores at the study endpoint
(r2  0.73 and r2  0.51, respectively; p 	 0.003). Last, a more
widespread presence of Ly6b.2 cells (Fig. 2J; p  0.0007) and
CD3T cells (Fig. 2K; p 0.0057) was observed along the length
of the spinal cord at the study endpoint.
Acute but not sustained C5aR antagonism improves
SCI outcomes
Because the genetic ablation of C5aR appeared beneficial during
the (sub)acute period of SCI, it was hypothesized that transient
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pharmacological blockade of C5aR during only the first 7 d after
SCI would lead to sustained improvements in SCI recovery. Sim-
ilar to C5ar/ mice, administration of C5aR-A to Macgreen
mice with SCI during the first week of injury resulted in a clear
trend for improved recovery compared with vehicle-treated
Macgreen mice. This improvement was sustained into the more
chronic phase of injury and significantly different from vehicle-
treated controls at 21, 28, and 35 d after injury (p 	 0.05) (Fig.
3A,B). The ledged tapered beam walk test was also used at the
study endpoint as a second, independent measure of the efficacy
of (sub)acute C5aR-A treatment. Sham-operated control mice
had no difficulty mastering this task, making very few mistakes
and crossing the beam relatively fast (Fig. 3C,D). Although SCI
consistently led to impaired performance in this test, C5aR-A-
treated mice made significantly fewer stepping mistakes (p 
0.0024; Fig. 3C) and also traversed the beam faster (p  0.017)
(Fig. 3D) compared with vehicle-treated mice with SCI. Histo-
logical assessment of injured spinal cords at 35 d after SCI con-
firmed attenuated pathology as a result of (sub)acute C5aR-A
treatment, with C5aR-A-treated mice having significantly more
myelin content compared with the vehicle-treated animals (Fig.
3E,F; p 0.0088). TheGFP infiltrate in the lesion core was also
significantly reduced (p  0.0061; Fig. 3E,G). There was, how-
ever, no difference in the GFAP area (p  0.67; Fig. 3H, I) or
staining intensity (p 0.48; Fig. 3H, J) between groups. Collec-
tively, these data indicate that C5aR antagonism, when limited to
a 7 day window during the (sub)acute period of SCI, leads to
improvements in neurological recovery that are sustained into
the chronic phase of injury.
Importantly, continued antagonism of C5aR beyond the first
week of injury in WTmice produced a phenotype similar to that
of C5ar/ mice. Specifically, an early trend toward improved
recovery after C5aR-A treatment was again observed at 7 d after
SCI, but this did not persist into the more chronic phase (Fig.
3K). Thus, the benefits of therapeutically targeting C5aR are an-
nulled if blockade is maintained beyond the first week of spinal
trauma.
C5ar/mice have reduced levels of proinflammatory
cytokines and attenuated macrophage recruitment early after
SCI
To begin exploring why there were consistent signs of improved
recovery during the (sub)acute phase in the absence of C5aR
signaling, we first investigated whether the inflammatory re-
sponse to SCI was altered by C5aR ablation. We theorized that a
dampened production of proinflammatory cytokines acutely af-
ter SCI may have yielded neuroprotection, which in turn under-
pinned the early functional improvements seen inC5ar/mice.
A cytometric bead array (BD Biosciences) was therefore used to
measure the concentration of a panel of cytokines within the
injured spinal cord of WT and C5ar/ mice at 12 h after SCI.
This time point was specifically selected because various key pro-
inflammatory cytokines are elevated or at peak concentrations
here (Pineau and Lacroix, 2007); it also precedes the peak of the
first wave of peripheral immune cell infiltration (i.e., neutro-
phils) (Kigerl et al., 2006; Beck et al., 2010), thereby allowing
some differentiation between leukocyte-derived and glial/neuro-
nally derived cytokines. There was no difference in baseline (i.e.,
sham-surgery) levels of any cytokine between WT and C5ar/
mice (p  0.05). In both genotypes, SCI elicited significant in-
creases in spinal cord levels of MCP-1 (Fig. 4A), TNF (Fig. 4B),
CXCL1 (Fig. 4C), IL-6 (Fig. 4D), IL-1 (Fig. 4E), and IL-10 (Fig.
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Figure1. Productionof C5aandexpressionof C5aR in the injured spinal cord.A, C5aprotein concentration in injuredWTspinal cord is significantly increased comparedwithbothnaive (timepoint
0) and sham levels at 2 h, 6 h, 12 h, 1 d, 4 d, and 7 d after SCI (n 4 or 5 per time point, two-way ANOVAwith Newman–Keuls post hoc tests). *p	 0.05. **p	 0.01. ****p	 0.0001. B, WT C5a
levels are also increased in the plasma in response to SCI, exceeding levels observed in sham-operatedmice at 30min, 2 h, 6 h, 12 h, and 1 d after injury (n 4 or 5 per time point, two-way ANOVA
with Newman–Keuls post hoc tests). *p	 0.05. **p	 0.01. ***p	 0.001. C–E, Representative confocal images showing C5aR expression in the injured spinal cord at 1 and 7 d after injury. C, At
1 d after injury, C5aR appeared present at the lesion epicenter on nucleated Iba1 cells (arrow) aswell as numerous smaller circular/ovoid cells that did not express Iba1 (arrowheads). Scale bar, 6.0
m.D, At 7 d after injury, C5aR is present on cellswith amoeboidmorphology inWTmice,which appear to be clustered Iba1macrophages/microglia (arrow). Scale bar, 10m.E, C5aRexpression
was also observed on more elongated GFAP astrocytes (arrows), alongside C5aRGFAP cells with macrophage-like morphology (arrowhead). Scale bar, 13m. F, Only a very low level of
nonspecific background fluorescence was observed following C5aR staining of lesioned C5ar/ spinal cord tissue. Scale bar, 35 m. G, Representative Western blots demonstrating C5aR
expression by astrocytes in vitro. Left and middle lanes contain WT and C5ar/whole mouse brain homogenates, respectively. Right lane contains protein sample from cultured WT astrocytes.
6522 • J. Neurosci., April 22, 2015 • 35(16):6517–6531 Brennan et al. • C5aR Controls Neuroinflammation in SCI
4F) over baseline. IL-12p70 and IFN levels were not increased in
response to SCI at this time point in either genotype (data not
shown). Notably, many SCI-induced changes in cytokine levels
were attenuated in the absence of C5aR, with significant re-
ductions observed in CXCL1 (40%, p	 0.05), IL-6 (33%, p	
0.01), and IL-1 (75%, p 	 0.0001) levels within the injured
spinal cord.
We also quantified the number of granulocytes and inflam-
matory monocytes/macrophages at 1 and 7 d after injury (i.e.,
time points that represent the respective peak recruitment/infil-
tration times for these cells). Immunolabeling of Ly6b.2 cells
(which predominantly represent neutrophils acutely after injury)
revealed no statistically significant reduction in the recruitment
of these cells between genotypes at 1 d after SCI (Fig. 4G; p 
0.11). Flow cytometric analysis of the spinal cord at 7 d after SCI
also showed no significant difference in the Ly6G infiltrate be-
tween genotypes (p 0.07; Fig. 4H). There was, however, a clear
reduction in the number of CD45hiLy6CLy6G cells (inflam-
matory monocytes/macrophages) in C5ar/ mice at this time
point (p 0.002) (Fig. 4I). In summary, these findings indicate
that acute disabling of the C5a-C5aR axis significantly reduces
local proinflammatory cytokine production and the recruitment
of inflammatory monocytes/macrophages.
Lack of C5aR in the peripheral immune compartment does
not affect SCI outcomes
Having observed a clear dual and time-dependent role for C5aR
in the response to SCI, we next aimed to better understand the
mechanisms resulting in this phenotype. To this end, BM chime-
ric mice were generated to better appreciate the role of C5aR
expression within the peripheral immune compartment (i.e., cir-
culating leukocytes)with regards to SCI outcomes (Fig. 5A). BMS
locomotor scoring with experimenter blinding revealed that
transplantation of C5ar/ BM into conditioned WT hosts
([C5ar/¡WT] BMchimeras) did not lead to altered recovery
from SCI compared with [WT¡WT] chimerasmice for up to at
least 35 d after SCI (Fig. 5B,C). There were also no statistically
significant differences in lesion histopathology, including the
Figure 2. C5ar/ mice have a dual phenotype after SCI. A, BMS locomotor scoring revealed that C5ar/ mice have significantly improved hindlimb motor function at 7 d after injury
compared with WT mice. This trend reversed with time such that, at 28 and 35 d after SCI, WT mice had regained significantly more motor function than C5ar/mice (two-way ANOVA with
Bonferronipost hoc tests,n8–12).B, PooledBMS scores for individualmice fromvarious experiments at 7 d after injury (Student’s two-sided t test,n18–21).C, Graph showing theBMS scores
for individual mice at 35 d after injury from longitudinal scores plotted in A (Student’s two-sided t test, n 8–12). D, Postmortem T2*-weighted MRI images showing lesion sites in WT and
C5ar/mice. Scale bar (top left image): coronal images, 400m; sagittal images, 1 mm. E, Quantitative analysis revealed significantly larger lesion core volumes in C5ar/mice. Represen-
tative reconstructions of lesion cores for each genotype are shown in gray. F,G, A reduction inmyelin contentwas observed in C5ar/mice at 35 d after SCI (Student’s two-sided t test, n 8 per
group). Scale bar: F (top left image), 200m.H, I, Reductions in the proportional area (H ) and intensity (I ) of GFAP stainingwere also observed in C5ar/mice (Student’s two-sided t tests, n
8 per group). J, K, Amore widespread presence of Ly6b.2 cells (J ) and CD3 T cells (K ) was observed in C5ar/mice at 35 d after injury (two-way ANOVAwith Newman–Keuls post hoc tests,
n 5 per group), as also confirmed by area under the curve analysis (Student’s two-sided t test, n 5 per group). *p	 0.05. **p	 0.01. ***p	 0.001. ****p	 0.0001.
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amount of myelin at the lesion epicenter (Fig. 5D), Ly6b.2 cel-
lular infiltrate (Fig. 5E), CD11b immunoreactivity (Fig. 5F),
andCD3T-cell numbers (Fig. 5G). Together, these data suggest
that both the early injurious role of C5aR and its more delayed
neuroprotective/reparative actions in the postacute phase are
mostly mediated through resident CNS cells and not circulating
immune cells.
C5aR regulates astrocyte proliferation and glial scar
formation in vivo
Our next aim was to understand why genetic ablation or contin-
ued pharmacological blockade of C5aR adversely affected recov-
ery in the more chronic period of SCI. Based on one of our initial
observations that C5ar/ mice had reduced myelin content at
35 d after SCI (Fig. 2F,G), we first explored whether C5aR sig-
naling may be required for oligodendrocyte precursor cell prolif-
eration (and/or survival) in response to SCI. To test this, BrdU
was administered daily for the first 7 d after SCI to WT mice that
were treated for 21 d with either C5aR-A or vehicle, as well as to a
cohortof vehicle-treatedC5ar/mice.Theexperimental endpoint
of 21 d after SCI was chosen based on a previous study showing that
deficiency in C5 (i.e., the parental protein fromwhich C5a is gener-
ated) leads to impaired remyelination in experimental autoimmune
encephalitis at this stage (Weerth et al., 2003).
Quantification of the total (CC1) and newly generated
(CC1BrdU) oligodendrocytes in spared white matter at and
Figure 3. Acute, but not sustained, antagonism of C5aR improves SCI outcomes inMacgreenmice.A, BMS locomotor scores ofmice treatedwith a C5aR antagonist (C5aR-A) for 7 d after SCI have
significantly higher BMS scores than vehicle (Veh)-treated mice at 21, 28, and 35 d after injury. *p	 0.05 (two-way ANOVA with Bonferroni post hoc tests, n 8–10). B, A scatter plot depicting
the BMS scores of individualmice at 35 d after SCI. *p 0.029 (Student’s two-tailed t test, n 8–10). C,D, Data from the ledged tapered beamwalk task also indicated that C5aR blockade during
the acute period improved long-term recovery,with C5aR-A-treatedmicemaking significantly fewer steppingmistakes (C), and also traversing the beam faster (D) than vehicle-treated SCI controls.
*p	 0.05; **p	 0.01; ***p	 0.001; ****p	 0.0001 (one-way ANOVAwith Newman–Keuls post hoc tests, n 6–10). E, F, (Sub)acute C5aR-A treatment resulted in significantlymoremyelin
being present at the lesion epicenter at 35 d after SCI comparedwith vehicle-treatedmice. **p 0.0088 (Student’s t test, n 5 per group). Scale bar: E (top left), 200m. E,G, The GFP infiltrate
in the lesion coreofMacgreenmicewasalso significantly reduced following theC5aR-A treatment regimen. **p0.0061 (Student’s two-sided t test,n5pergroup).H–J, GFAP immunoreactivity
at 35 d after SCI was not significantly different between treatment groups based on analysis of both proportional area (I ) and staining intensity (J ). Scale bar: H (top left), 200m. K, Improved
recovery from SCI was not sustained with continued C5aR-A administration. *p	 0.05, C5ar/ vehicle versus WT vehicle (two-way ANOVA with Bonferroni post hoc tests, n 4 or 5).
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around the lesion epicenter at 21 d after SCI revealed no signifi-
cant differences between any of the experimental groups (p 
0.93). Specifically, a total of 27  7 newborn oligodendrocytes
were observed at the lesion epicenter in vehicle-treatedWTmice
comparedwith 29 4 cells inC5aR-A-treatedWTmice and 26
3 cells forC5ar/mice. Total CC1 cell numbers were also not
different between the experimental groups (p  0.94), with
356  46 cells counted in vehicle-treated controls compared
with 351 65 cells for C5aR-A-treatedWTmice and 328 57
cells for C5ar/mice. We also observed no differences in the
number of apoptotic (Cleaved Caspase-3 CC1) oligoden-
drocytes between the experimental groups at the lesion epi-
center (p  0.87). Specifically, a total of 10  3 cells was
counted here in vehicle-treated WT mice, compared with 9
2 cells in C5aR-A-treated WT mice and 11  2 cells in
C5ar/ mice. Similar results for each of the above quantita-
tive analyses were obtained between experimental groups for
distances up to at least 600 m in both
rostral and caudal directions (data not
shown).
Given that neither genetic nor phar-
macological disabling of the C5a-C5aR
axis appeared to affect oligodendrocyte
generation and survival, we next inves-
tigated whether astrocyte proliferation
was impaired under C5aR-deficient
conditions. Quantification of
BrdUGFAP cells revealed that there
was a significant reduction in the number
of newly generated astrocytes present at
the lesion margins in the absence of C5aR
signaling at 21 d after SCI (Fig. 6A; p 	
0.05). These findings are in agreement
with the observation that C5ar/ mice
had less GFAP immunoreactivity at 35 d
after SCI (Fig. 2F,H,I), and indicate that
impaired formation of the glial scar may
have led to a greater spread of secondary
injury due to a failure to effectively seal off
the lesion site (Faulkner et al., 2004; Herr-
mann et al., 2008). Consistent with that, the
total number of BrdUGFAP astrocytes
across the analyzed segment of the le-
sioned spinal cord was strongly and nega-
tively correlated with the lesion volume
(Fig. 6B; p	 0.0001).
C5a promotes astrocyte proliferation
and STAT3 phosphorylation in vitro
Given the observation that interference
with C5aR signaling reduced astrocyte
proliferation in vivo, we next directly
tested the premise that C5a promotes the
proliferation of these cells in vitro. Expo-
sure of cultured astrocytes to C5a indeed
elicited a dose-dependent proliferative re-
sponse, with significantly more astrocytes
being present in the cultures following
stimulation with C5a concentrations of
10, 50 100, and 200 nM compared with
baseline (Fig. 6C). Having already estab-
lished that cultured astrocytes express
C5aR (Fig. 1G), we next examined
whether the proliferative effect of C5a was mediated via activa-
tion of this particular receptor. Exposure of C5ar/ astrocytes
to C5a failed to induce a proliferative response (Fig. 6D), thereby
confirming that this effect requires the presence of C5aR.
Based on previous demonstrations that activation of the
STAT3 pathway plays a critical role in astrocyte proliferation and
the neuroprotective properties of the glial scar (Okada et al.,
2006; Herrmann et al., 2008; Wanner et al., 2013), we next inves-
tigated whether STAT3 phosphorylation in astrocytes occurs
downstream of C5aR following C5a stimulation. The amount of
phosphorylated STAT3 (P-STAT3) was found to bemarkedly (2.5-
fold) increased in response to C5a stimulation (50 nM), an effect
that could be blocked if the STAT3 inhibitor BP-1-102 was added
just before C5a exposure (Fig. 6E). No increase in STAT3 phos-
phorylation was observed in C5ar/ astrocytes following expo-
sure to C5a (Fig. 6F). In the final experiment, we tested whether
Figure 4. Inflammation in the (sub)acute period of SCI is reduced with C5aR elimination. A–F, Levels of MCP-1 (A), TNF (B),
CXCL1 (C), IL-6 (D), IL-1 (E), and IL-10 (F )wereall significantly increasedat12hafter SCI comparedwith sham-operated controls,
regardless of genotype. C5aRdeficiency did, however, result in significant reductions in CXCL1, IL-6, and IL-1 in the injured spinal
cord compared with WT mice. *p	 0.05; **p	 0.01; ***p	 0.001; ****p	 0.0001 (two-way ANOVA with Newman–Keuls
post hoc tests, n 4 or 5).G,H, No significant differences in the Ly6b.2 inflammatory cell infiltrate were observed betweenWT
and C5ar/mice at 1 d (G) and 7 d (H ) after SCI. Scale bar: G (bottom image), 40m. I, A significant reduction in the number
of inflammatory monocytes/macrophages was observed in injured C5ar/ spinal cord at 7 d after SCI. **p	 0.01 (Student’s
two-sided t test). n 5 per group.
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activation of the STAT3 pathway was driving astrocyte prolifer-
ation in response to C5a. Treatment with BP-1-102 indeed an-
nulled the proliferative effect of C5a on astrocytes (Fig. 6G).
Collectively, these findings indicate that C5a-induced phosphor-
ylation of STAT3 occurs downstream of C5aR, which in turn
drives astrocyte proliferation.
Discussion
Complement activation in CNS injury is predominantly consid-
ered deleterious to recovery. Specifically, complement proteins
are thought to contribute to secondary injury through opsoniza-
tion and membrane attack complex formation (for review, see
Brennan et al., 2012). Other complement activation products
appear to have more complex or even biphasic roles (Beck et al.,
2010).We report that eliminating C5aR signaling attenuates pro-
inflammatory cytokine expression at the lesion site acutely after
injury. This was followed by reduced macrophage recruitment
and improved recovery of hindlimb function at 7 d after SCI.
Importantly, and consistent with Beck et al. (2010), lack of C5aR
signaling in the postacute period was detrimental to recovery.
Experiments in BM chimeric mice suggested that these dual and
opposing roles of C5aR are predominantly mediated via CNS
cells and not infiltrating immune cells. Additional in vivo and in
vitro studies demonstrated that C5aR signaling regulates astro-
cyte proliferation, at least partly by STAT3 phosphorylation. We
therefore postulate that whereas acute/subacute blockade of
C5aR improves recovery, prolonged interference with C5aR sig-
naling leads to impaired scar formation and reduced ability to
confine pathology, as evidenced by poorer neurological recovery,
larger lesion volumes, andmore widespread presence of immune
cells along the spinal axis.
Time course of complement activation in SCI
Previous studies clearly demonstrated the occurrence of comple-
ment system activation following SCI, with abnormal expression
and/or deposition of C1q, factor B, C3, C4, C7, and membrane
attack complex on neurons, glia, and infiltrating immune cells
(Anderson et al., 2004; Qiao et al., 2006; Nguyen et al., 2008;
Ankeny et al., 2009). The present data show that complement
activation peaks locally at 12–24 h after SCI based on C5a levels.
Extrinsic pathway activity likely plays a major role in C5a gener-
ation during this early phase due tomicrohemorrhaging (Huber-
Lang et al., 2006). C5a levels remained significantly elevated up to
7 d after SCI but decreased thereafter to concentrations that were
only slightly elevated from baseline. SCI also elicited a sharp rise
in plasma C5a levels, which were significantly elevated over
sham-operated controls up to 1 d after injury. Thus, robust in-
creases inC5a levels occur in the blood and spinal cord during the
first week of injury.
Figure 5. C5aR deficiency in the peripheral immune compartment does not alter the outcome from SCI.A, Flow cytometry data showing chimerization efficacy. [C5ar/¡WT] BM chimeras
(i.e., WTmice that received a C5ar/ bonemarrow transplant) only express background levels of C5aR on circulating granulocytes, equivalent to the amount of nonspecific staining observed on
C5ar/ cells. ***p	0.001 (one-wayANOVAwithNewman–Keulspost hoc).n3–7.B, BMS locomotor scoring revealedno significantdifferences in functional recoveryas a result of select C5aR
deficiency in the peripheral immune compartment compared with [WT¡WT] controls (two-way ANOVA with Bonferroni post hoc tests; n 6 or 7). C, Scatter plot showing main BMS scores for
individualmice at 35dafter SCI.D, Nodifferencewas observedbetween the experimental groups in the amount ofmyelinwithin the ventrolateralwhitematter at 35dafter SCI (Student’s two-sided
t test, p 0.05; n 6 or 7). Scale bar:D (top), 200m. E–G, Quantification of the inflammatory infiltrate also showed no differences between the experimental groups in the number of Ly6b.2
cells (E), the proportional area of CD11b immunoreactivity (F ), and the number of CD3 lymphocytes (G) present at the lesion epicenter (Student’s two-sided t tests, p 0.05; n 6 or 7).
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C5aR inhibition in the acute/(sub)acute phase improves
SCI recovery
Characterization of the cellular infiltrate showed that recruit-
ment of CD45hiLy6CLy6G granulocytes was not affected by
C5aR deficiency at both 1 and 7 d after SCI. There was, however,
a clear and significant reduction in the CD45hiLy6CLy6G in-
filtrate at 7 d after SCI in C5ar/ mice, suggesting reduced
recruitment of inflammatory monocytes/macrophages (Blom-
ster et al., 2013a). Overall, these findings are in agreement with
previous observations that C5aR antagonism in an equivalent rat
model does not dramatically alter granulocyte presence but
markedly reduces the number of ED1 microglia/macrophages
at 7 d after injury (Beck et al., 2010). Collectively, these data
suggest that blockingC5aR signaling attenuates activation and/or
recruitment of select inflammatory cell populations, which coin-
cides with improved recovery early on.
AsC5aR is expressed in theCNS andperipheral immune com-
partment (Woodruff et al., 2010), BM chimera experiments were
performed to determine the impact of C5aR deficiency exclu-
sively on circulating leukocytes in relation to SCI outcomes. The
outcome of these experiments suggested that the dual and oppos-
ing roles of C5aR in SCI are predominantly mediated via CNS-
resident cells. Consistent with this, injury-induced expression of
IL-6, IL-1, and CXCL1 within the spinal cord was significantly
abrogated in absence of C5aR signaling at 12 h after SCI, a time
point that coincides with high complement activation but pre-
cedes the first major wave of leukocyte infiltration (Kigerl et al.,
2006; Beck et al., 2010).
IL-1 has previously been shown to promote injurious local
inflammation, which correlates with impaired functional recov-
ery (de Rivero Vaccari et al., 2012; Boato et al., 2013). Similarly,
IL-6 polarizes macrophage toward a proinflammatory M1 phe-
notype, and treatment with anti-IL-6 antibody leads to a pre-
dominance of tissue-reparative M2 macrophages and improved
recovery (Mukaino et al., 2010; Guerrero et al., 2012). Although
we did not identify the precise cell population(s) responsible for
proinflammatory cytokine production, astrocytes and microglia
are likely candidates as they express C5aR (Fig. 1C) and rapidly
respond to trauma (Pineau and Lacroix, 2007; Donnelly and
Popovich, 2008; Pineau et al., 2010). We therefore postulate that
the benefits of C5aR blockade during the acute/subacute phase of
Figure 6. Signaling through the C5a-C5aR axis promotes astrocyte proliferation in vivo and in vitro. A, Quantification of BrdUGFAP astrocytes at the lesion site of WT SCI mice that were
chronically administered C5aR-A (orange) or vehicle (Veh, blue) solution, and vehicle-treated C5ar/mice (red). Note the significantly reduced presence of newly generated astrocytes along the
rostral and caudal margins of the lesion in the absence of C5aR signaling (two-way ANOVA with Newman–Keuls post hoc tests; n 4 or 5 per group). *p	 0.05. **p	 0.01. B, A significant,
negative correlation was observed between the total number of BrdUGFAP cells and lesion volumes (Pearson’s correlation, p	 0.0001). C, C5a stimulates the proliferation ofWT astrocytes in
vitro in adose-dependentmanner at concentrations10nM (one-wayANOVAwithNewman–Keulspost hoc tests). *p	0.05. ***p	0.001.Graph is representativeof three experimental repeats.
D,C5ar/astrocytesdidnotproliferate in response tohigh-doseC5a (50nM; Student’s two-sided t test,p0.05).E, Exposureof culturedastrocytes toC5a (50nM) resulted ina significant increase
in the ratio of P-STAT3 to STAT3. Addition of the STAT3 Inhibitor BP-1-102 (10M) just before C5a stimulation blocked this increase in STAT3phosphorylation (one-wayANOVAwithNewman–Keuls
post hoc tests). **p	 0.01. F, Stimulation of C5ar/ astrocyteswith 50 nM of C5a did not lead to a significant change in STAT3 phosphorylation (Student’s two-sided t test, p 0.05).G, Addition
of BP-1-102 (5M) blocked C5a-induced astrocyte proliferation in vitro (one-way ANOVAwith Newman–Keuls post hoc tests). **p	 0.01. ***p	 0.001. Dotted line indicates the initial number
of cells plated. D–F, Data are mean SEM, with n 6 biological replicates. ns, Not significant.
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SCI are primarily mediated through reduced proinflammatory
cytokine production and associated neuroprotection (Farkas et
al., 1998; Humayun et al., 2009; Pavlovski et al., 2012), with re-
duced recruitment of inflammatory Ly6C monocytes/macro-
phages at 7 d after SCI as a direct reflection of attenuated
secondary injury. Targeting the C5a-C5aR pathway during the
first hours to days after SCI is thus a credible therapeutic avenue
to promote SCI recovery (Fig. 7).
C5aR activation regulates astrocyte proliferation and
glial scarring
Although our findings clearly demonstrate that C5aR activation
is deleterious to recovery in the acute/subacute period of SCI, lack
of C5aR signaling in the chronic phase ultimately led to exacer-
bated injury outcomes. Specifically, C5ar/ mice exhibited
lower BMS scores, larger lesion volumes, less white matter my-
elin, and reduced glial scarring at 35 d after injury. Improvements
obtained through pharmacological blockade of C5aR were also
lost if treatment was extended beyond the acute phase. Although
a recent study by Li et al. (2014) did not report such a dual role for
C5aR, our findings are consistent with earlier observations by
Beck et al. (2010) who independently showed that chronic
C5aR-A treatment similarly impairs recovery in rats. Unfortu-
nately, Li et al. (2014) did not report lesion volumes or axonal/
myelin sparing as an independent accompaniment to functional
testing,making a direct comparison between our studies difficult;
additional differences in the lesion model of choice (computer-
controlled impact vs manual compression with forceps) and
mouse strains used (C57BL/6J vs BALB/c) (Kigerl et al., 2006) are
likely contributors to this disparity. Regardless, the mecha-
nism(s) contributing to the reparative/neuroprotective role of
C5aR in contusive SCI had remained unclear. Although previous
studies suggested a possible role for C5a in reparative remyelina-
tion following cuprizone treatment (Ingersoll et al., 2010), oligo-
dendrocyte survival and/or proliferation of oligodendrocyte
precursor cells appeared unaffected by disabling C5aR signaling
in the context of SCI. As we observed a reduction in GFAP
immunoreactivity in C5ar/ mice at the study endpoint, we
investigated whether C5aR signaling had any effect on astrocyte
proliferation. Our in vivo data revealed that both genetic ablation
and pharmacological blockade of C5aR inhibit astrocyte prolif-
eration. This finding was supported by additional in vitro data
showing that activation of C5aR by C5a induces astrocyte prolif-
eration in a dose-dependent manner.
With previous research indicating a key role for STAT3 in
protective glial scar formation (Okada et al., 2006; Herrmann et
al., 2008; Wanner et al., 2013), we evaluated whether C5aR sig-
naling in astrocytes promotes STAT3 pathway activation. Expo-
sure of cultured astrocytes to C5a indeed leads to STAT3
phosphorylation via C5aR, an event that is critical for initiating
downstream transcriptional events and cell proliferation. In-
triguingly, Okada et al. (2004) demonstrated that IL-6 also pro-
motes astrocyte proliferation via STAT3, which could be
inhibited with anti-IL-6R antibody treatment (Okada et al.,
2004). As we observed reduced IL-6 levels in C5ar/mice, it is
likely that this may have further impaired astrocyte proliferation
in vivo. Activation of the C5a-C5aR axis may thus stimulate as-
trocyte proliferation directly as well as indirectly via IL-6 release
from astrocytes and/or microglia.
Figure 7. Diagram showing the proposed dual and time-dependent role of C5aR in SCI. In the (sub)acute period (0–7 d after SCI), activated astrocytes andmicroglia proliferate and/or migrate
to the site of injury. Activation of these cells occurs in part through increased C5a levels as a result of complement activation, which in turn augments their production and release of inflammatory
cytokines at the lesion site. Release of CXCL1 is a key signal for neutrophil recruitment to the site of SCI. IL-1 and IL-6 aid in the recruitment of bloodmonocytes andmacrophages, which promote
secondary injury if adopting an M1 phenotype. In the postacute to chronic period of SCI (7 d after SCI onwards), C5aR signaling is critically required for STAT3-mediated astrocyte proliferation and
glial scar formation, which seals the injury site and prevents the spread of secondary injury. Through its regulation of IL-6 levels, C5aRmay also be involved IL-6R-dependent astrocyte proliferation.
1(Andersonet al., 2004, 2005;Nguyenet al., 2008); 2(Lacyet al., 1995;Griffin et al., 2007;Ager et al., 2010); 3(Gasqueet al., 1995; Lacyet al., 1995;Woodruff et al., 2008); 4(Acarin et al., 2000; Pineau
and Lacroix, 2007; Pineau et al., 2010); 5(Klusman and Schwab, 1997; Romano et al., 1997; Dinarello, 2009); 6(Baggiolini and Clark-Lewis, 1992; Harada et al., 1994; Taub et al., 1996); 7(Gensel et
al., 2009; Kigerl et al., 2009; Blomster et al., 2013a); 8(Gensel et al., 2009; Shechter et al., 2009, 2013); 9(Okada et al., 2006); and 10(Bush et al., 1999; Faulkner et al., 2004; Okada et al., 2006;
Herrmann et al., 2008; Wanner et al., 2013).
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Importantly, pleiotropic roles for astrocytes and the glial scar
have been ascribed (i.e., inhibitory from a regeneration perspec-
tive but neuroprotective with regards to secondary injury) (Bush
et al., 1999; Faulkner et al., 2004; Silver and Miller, 2004; Rolls et
al., 2009; Pineau et al., 2010; Cregg et al., 2014; Pekny et al., 2014).
On the latter, demarcation of the lesion is achieved partly
through astrocyte hyperplasia, which increases cell density up to
fourfold in spinal whitematter (Ertu¨rk et al., 2012). By separating
the injury core from neighboring intact neural tissue, astrocytes
limit the spread of immune cells along the spinal axis, as previ-
ously reported (Okada et al., 2006), and observed here for the
Ly6b.2 and CD3 infiltrate. We therefore postulate that the
reparative/neuroprotective functions attributed to C5aR signal-
ing in the postacute phase of SCI (Beck et al., 2010) include its
role in glial scar formation. Whether exogenous stimulation of
astrocyte proliferation via C5aR agonism during the postacute
phase could indeed benefit recovery remains an outstanding
question. It is also worth mentioning that our findings do not
necessarily exclude a role for the alternate C5a receptor, C5L2, in
SCI. They do, however, show that, at least for the induction of
proinflammatory cytokine expression and astrocyte prolifera-
tion, expression of C5aR is required.
In conclusion, the present findings confirmC5aR as a promising
therapeutic target in SCI, demonstrating that timely pharmacologi-
cal inhibitionof this receptor can reduce immune-mediated second-
arydamage and improve recovery.The identified key role forC5aR
signaling in astrocyte proliferation and glial scarring during the
chronic phase of SCI also highlights the importance, however, of
fully understanding the dual and time-dependent functions that
inflammatory mediators like C5a may have, such that adverse
outcomes can be prevented by restricting treatments to critical
windows.
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Keywords:
Magnetic resonance imaging
Neurotrauma
Spinal cord injury
Tractography
Demyelination
Wallerian degenerationThis study examined the sensitivity of ultra-high ﬁeld (16.4 T) diffusion tensor imaging (DTI; 70 μm in-plane
resolution, 1 mm slice thickness) to evaluate the spatiotemporal development of severe mid-thoracic
contusive spinal cord injury (SCI) in mice. In vivo imaging was performed prior to SCI, then again at 2 h,
1 day, 3 days, 7 days, and 30 days post-SCI using a Bruker 16.4 T small animal nuclear magnetic resonance
spectrometer. Cross-sectional spinal cord areas were measured in axial slices and various DTI parameters,
i.e. fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (λ||) and radial diffusivity (λ⊥), were
calculated for the total spared white matter (WM), ventral funiculi (VF), lateral funiculi (LF) and dorsal col-
umns (DCs) and then correlated with histopathology. Cross-sectional area measurements revealed signiﬁ-
cant atrophy (32% reduction) of the injured spinal cord at the lesion epicentre in the chronic phase of
injury. Analysis of diffusion tensor parameters further showed that tissue integrity was most severely affect-
ed in the DCs, i.e. the site of immediate impact, which demonstrated a rapid and permanent decrease in FA
and λ||. In contrast, DTI parameters for the ventrolateral white matter changed more gradually with time,
suggesting that these regions are undergoing more delayed degeneration in a manner that may be amenable
to therapeutic intervention. Of all the DTI parameters, λ⊥ was most closely correlated to myelin content
whereas changes in FA and λ|| appeared more indicative of axonal integrity, Wallerian degeneration and as-
sociated presence of macrophages. We conclude that longitudinal DTI at 16.4 T provides a clinically relevant,
objective measure for assessing white matter pathology following contusive SCI in mice that may aid the
translation of putative neuroprotective strategies into the clinic.
© 2013 Elsevier Inc. All rights reserved.Introduction
The adult mammalian spinal cord has very limited inherent capac-
ity for repair. Neurotraumatic events that affect this part of the central
nervous system (CNS) thus lead to permanent motor, sensory and
autonomic impairments, with the degree of physical debilitation de-
termined by the anatomical level and severity of the spinal cord inju-
ry (SCI) (Bunge et al., 1993; Gonzalez et al., 2003; Park et al., 2004).
CNS neurons that survive the initial mechanical insult become increas-
ingly exposed during the acute and post-acute phases to an ischemictensor imaging; DCs, dorsal
I, magnetic resonance imaging;
ord injury; T, Tesla; VF, ventral
ueensland, School of Biomedical
766.
(N.D. Kurniawan),
rights reserved.and toxicmicroenvironment that includes increased levels of excitatory
amino acids and ions (excitotoxicity), reactive oxygen species (oxida-
tive stress) and potent inﬂammatory mediators. This compounds
further damage by propagating the loss of neural tissue beyond the ini-
tial impact site, a process collectively known as secondary injury
(Donnelly and Popovich, 2008; Dumont et al., 2001).
As most SCIs are anatomically incomplete contusion injuries, in-
volving crushed or fractured vertebrae that bruise and/or compress
the spinal cord (Bunge et al., 1993; Norenberg et al., 2004), the pro-
cess of secondary injury is highly amenable to therapeutic interven-
tion, and several putative therapies targeting these sequealae are
currently being developed in animal models of SCI or undergoing
clinical evaluation (Cadotte and Fehlings, 2011; Gensel et al., 2011;
Hawryluk et al., 2008; Kwon et al., 2010). The simultaneous develop-
ment of non-invasive imaging methods to quantitatively assess the
effectiveness of such therapeutic interventions will be an important
step for successful translation of candidate therapies from the labora-
tory into the clinic. In particular, the incorporation of advanced mag-
netic resonance imaging (MRI) techniques in preclinical studies offers
575F.H. Brennan et al. / NeuroImage 82 (2013) 574–585an objective and independent accompaniment that could be used
alongside functional testing. Whilst informative, functional improve-
ments seen in animal models, particularly rodents, may not be directly
transferable to the human context because of differences in anatomical
organization of the spinal cord and the amount of supraspinal control
that is required for quadrupedal versus bipedal locomotion (Courtine
et al., 2007). MRI is not hampered by these limitations.
In the present study, we used diffusion tensor imaging (DTI) to
chronologically assess SCI pathology in live mice at a microscopic
scale (Le Bihan et al., 2001). In uninjured spinal white matter, water
molecules predominantly diffuse along the longitudinal plane (the
‘axial diffusivity’ λ||). Conversely, the Brownian motion at right angles
to the direction of white matter tracts (the ‘radial diffusivity’ λ⊥) is
more restricted by both axonal membranes and myelin sheaths
(Stroman et al., 2012). The overall degree of directionality (anisotro-
py) of water diffusion in tissues can be measured as fractional anisot-
ropy (FA) (Beaulieu and Allen, 1994). Tissues with a high degree of
diffusion directionality, such as spinal white matter, are anisotropic
and have FA values of ~0.8 (Underwood et al., 2011). Conversely,
more isotropic tissues in which water diffusion is much less restrict-
ed, e.g. the grey matter or cerebrospinal ﬂuid (CSF), have an FA
value of ~0.2 or lower (Mori and Zhang, 2006; Sundgren et al.,
2004). The mean diffusivity (MD) provides an index of the overall
magnitude of water molecular diffusion independent of direction
(Maas and Mukherjee, 2005).
Combined, these quantitative parameters enable the detection of
subtle and/or progressive changes in the integrity of the spinal white
matter as a result of pathology that cannot be detected through conven-
tional MRI techniques (Chang et al., 2010; Hesseltine et al., 2006;
Huisman et al., 2001; Mulcahey et al., 2011; Rajasekaran et al., 2010;
Schwartz and Hackney, 2003; Shanmuganathan et al., 2008; Yin et al.,
2010). Indeed, DTI measures have statistically stronger correlations
with clinical examination data (Chang et al., 2010; Mulcahey et al.,
2011). A previous report by Kim et al., (2007) showed that DTI at a
ﬁeld strength of 4.7 Tesla (T) can also reveal and quantify developing
pathology in mice. In the present study, we used ultra-high ﬁeld
(16.4 T) DTI, which allowed for stronger b values, to longitudinally
assess gross pathology and region-speciﬁc changes in the various diffu-
sion parameters for up to 30 days post-SCI. This was followed by a
detailed assessment of the histopathological correlate.
Methods
Animals
All experiments were conducted in accordance with the Australian
Code of Practice for the Care and Use of Animals for Scientiﬁc Purposes,
with approval from The University of Queensland Animal Ethics Com-
mittee. Female C57BL6/J mice (n = 4)were used in this study; animals
were 12–16 weeks of age at the time of the pre-injury scan. Experimen-
tal mice were housed individually under conventional conditions, with
a 12 hour light–dark cycle and ad libitum access to food and water.
Experimental spinal cord injury
Mice were anaesthetised with xylazine (10 mg/kg i.p.) and
zolazepam (50 mg/kg i.p.) prior to undergoing surgical laminectomy
and severe (70 kdyne) contusive SCI. This involved making a dorsal
incision along themidline of the lower thoracic region. Next, the under-
lying paravertebralmuscleswere carefully split anddorsal laminectomy
performed at thoracic (T) vertebral level T9 to expose the animal's intact
dura overlying the spinal cord. The vertebral column was stabilized
by rostral and caudal clamping with Adson microforceps, after which
the mice were subjected to severe force-controlled contusion SCI
using the Inﬁnite Horizon Impactor with 1.3 mm diameter probe (Pre-
cision Systems and Instrumentation, Fairfax Station, VA, USA) asdescribed previously (Scheff et al., 2003). The average applied force
was 71.3 ± 1.03 kdyne (mean ± SEM) and the associated tissue dis-
placement was 608 ± 51.1 μm (mean ± SEM). Following impact, the
muscles and skinwere sutured closed. Post-operative care involved a sin-
gle dose of buprenorphine (0.05 mg/kg) diluted in 1 ml of Hartmann's
solution, gentamicin (1 mg/kg) daily for 5 days post-injury, and
twice-daily bladder expression for the duration of the experiment.
In vivo DTI
All data was collected at the Centre for Advanced Imaging (CAI,
The University of Queensland, Australia) using a 16.4 T nuclear mag-
netic resonance scanner with a 89 mm vertical bore magnet (Bruker
BioSpin, Karlsruhe, Germany) and a transmit/receive linear surface
coil (1.5 × 3.0 cm). Gradients were maintained at 30 °C. Animals
were anaesthetised using an isoﬂurane/oxygen mixture (0.5–1.5%).
Animal respiration rate was monitored using a Biotrig Animal Moni-
toring System (M2M Imaging, Brisbane, Australia). Mice heads were
held in position via a tooth bar and nose/head cone; they were sup-
ported inferiorly by a foam pad (see Suppl. Fig. 1A). In this position,
their dorsum was situated parallel to the coil. For each imaging
session, the hypo-intense lesion core was identiﬁed and centred in
pilot axial, sagittal and transverse T1-weighted MR images (see
Suppl. Figs. 1B–E). Slice angles were always set perpendicular to the
long axis of the spinal cord. Vertebral landmarks (Harrison et al.,
2013) were also used to further identify the relative position of the le-
sion core and to conﬁrm that laminectomy was indeed performed at
the level of T9. Images were acquired using respiratory gating, a DTI
spin-echo sequence with interleaved slice acquisition using TR/TE =
2400/21 ms. Diffusion sensitising gradients were applied in 12 non-
collinear, uniformly distributed directions with the gradient strength
b = 1500 s/mm2, 2 ms diffusion encoding and 14 ms diffusion
separation and 1 image that was acquired with the b-value set to ‘0’
(b0). The acquisition matrix was 128 × 170 over the ﬁeld of view
9 × 12 mm2 to produce a ﬁnal in-plane resolution of 70 × 70 μm2,
with 1.0 mm slice thickness. The number of excitations and the partial
Fourier encoding acceleration were both 2, and the total acquisition
time was 2 h. Sixteen axial images covering part of the thoracic and
lumbar spine were acquired as previously reported (Underwood et al.,
2011). Live imaging was performed prior to injury, then again at 2 h,
and 1, 3, 7 and 30 days after injury.
The diffusion tensor eigenvalues (λ1, λ2, λ3) were computed using
the Paravision 5.0 (Bruker BioSpin, Karlsruhe, Germany) diffusion
tensor calculation module. The axial diffusivity (λ||) is a measure of the
diffusivity along the principal axis of the diffusion tensor (λ|| = λ1).
The radial diffusivity (λ⊥) was calculated using the twominor diffusion
axes (λ⊥ = (λ2 + λ3) / 2). The fractional anisotropy (FA) was calcu-
lated using the equation: FA = √1/2(√((λ1 − λ2)2 + (λ1 − λ3)2 +
(λ2 − λ3)2) / √(λ12 + λ22 + λ32)).
Paravision 5.0 (Bruker BioSpin) was used for all image analysis.
The cross-sectional areas of the spinal cord were deﬁned by manually
outlining the circumference of the spinal cord on transverse b0 and FA
scans for each time point. Of the sixteen diffusion axial images ac-
quired, the ten axial slices centred on the lesion core were used for
subsequent analyses (see Suppl. Fig. 1). Regions of interest (ROIs),
speciﬁcally the total spared white matter (WM), ventral funiculi
(VF), lateral funiculi (LF) and dorsal columns (DCs), were manually
outlined on transverse DTI FA images as shown in Suppl. Fig. 2.
Tissue preparation for ex vivo DTI
At 30 days post-injury, animals were deeply anaesthetised with so-
dium pentobarbital (150 mg/kg i.p.) and transcardially perfused with
20 ml of 0.9% saline solution containing 0.1% heparin and 2% NaNO2,
followed by 30 ml ﬁxative (4% paraformaldehyde in phosphate-
buffered saline (PBS: 1.7 mM NaH2PO4, 9 mM Na2HPO4, 0.15 M NaCl,
576 F.H. Brennan et al. / NeuroImage 82 (2013) 574–585pH 7.4)). The vertebral columnwas dissected out and submerged inﬁx-
ative for 48 h at 4 °C. Next, samples were washed in PBS containing
gadolinium contrast agent over 2 weeks (0.2% v/v Magnevist, Bayer).
Ex vivo DTI and tractography
Fixed specimens of the lower thoracic vertebral spinewere trimmed
in such a way that they ﬁtted tightly into a glass tube and immersed in
Fomblin oil. The tube was then placed inside a 15 mm SAW linear coil
(M2M Imaging). Spinal cords were imaged using a 3DDTI spin-echo se-
quence with the parameters: TR/TE = 400/20.8 ms, 2.5 ms diffusion
encoding and 10 ms diffusion separation, 12 non-collinear directions,
2 b0 images, and the gradient strength b = 3000 s/mm2. The data
was acquired with 1 excitation and 1.2 partial Fourier phase encoding
acceleration factor. The sweep width was 50 kHz over a ﬁeld of view
of 3.07 × 0.48 × 0.54 mm with 512 × 80 × 90 matrix to produce
60 μm isotropic resolution. The total scan time was 12 h and 40 min.
Diffusion data were processed using the DTImodule of Diffusion Toolkit
software (v. 0.6.2.1).
Fibertracks were visualised using TrackVis (v. 0.5.2.1) by drawing
ROIs (as shown in Suppl. Fig. 2) on transverse slices (ex vivo b0
maps), 1 mm rostral and caudal to the lesion epicentre; FA and angle
thresholds were 0.1 and 45°, respectively. A three-dimensional recon-
struction of the lesion site was produced by manually outlining the
hypo-intense regions of the lesion core on transverse and sagittal b0
slices in the same program.
Tissue preparation for histological analysis
Following the conclusion of imaging, spinal cords were dissected
out of the vertebral column and washed extensively in PBS. Tissue
specimens were cryoprotected through subsequent overnight incuba-
tions in PBS containing 10% and 30% sucrose, respectively. Spinal
cords were then snap-frozen in dry ice-cooled isopentane and stored
at −80 °C until further processing. Samples were cut into 20 μm
thick transverse sections using a Leica cryostat CM3050-S and collect-
ed in 1:5 series on Superfrost Plus slides (Menzel-Gläser). Slides were
air-dried for 2 h and stored at −80 °C until further processing.
Assessment and quantiﬁcation of histopathology
For quantiﬁcation of myelin content, spinal cord sections were
stained with FluoroMyelin Red (1:150; Molecular Probes, Invitrogen
Detection Technologies) in combination with immunoﬂuorescent la-
belling of astrocytes (rabbit anti-GFAP, 1:1000; Dako) as described
previously (Blomster et al., 2013). Images were captured using Olym-
pus SZX12 Research Fluorescence Stereo Microscope (Spectra Ser-
vices) with NIS-Elements 3.0 software (Nikon Instruments Inc.) and
analysed using the Java-based program ImageJ v1.43. The total sec-
tion area and myelin-containing regions in the spared white matter
were outlined using the freehand selection tool. The image was
converted to an 8-bit ﬁle and the level of FluoroMyelin signal in the
white matter determined using the threshold function. Myelin con-
tent was calculated by dividing the FluoroMyelin-positive area
by the total area of the section. Similar procedures were followed
for the analysis of GFAP staining. A separate set of sections was
stained for neuroﬁlament (NF200) (rabbit anti-NF200, 1:200; Sigma-
Aldrich) in combination with FluoroMyelin Red and Hoechst nuclear
dye (1:1000; Sigma-Aldrich). A third set of sections from each animal
was stained for ionised calcium binding adaptor protein 1 (Iba1; rab-
bit anti-Iba1, 1:500; Wako), which labels all microglia/macrophages,
the activation marker CD68 (rat anti-CD68, 1:200, Serotec), and
Hoechst nuclear dye. Stained sections were captured using an Axio
Imager Azure (Zeiss). Immunopositive areas for NF200 and Iba1
were measured through thresholding in ImageJ for the relevant ROIs,
i.e. the DCs and ventrolateral white matter.Statistical analysis
Data was analysed using GraphPad Prism 4.0 software (GraphPad
Software Inc., La Jolla, CA, USA). Two-way ANOVA with Bonferroni
post-hoc was used to analyse the changes in cross-sectional area of
the spinal cord after injury, with the ‘within group factor’ being the
slice number and the ‘between group factor’ being time. One-way
ANOVA with Newman–Keuls post-hoc analysis was used to compare
lesion core data with time. Two-way ANOVA with Bonferroni post-
hoc was used to analyse DTI parameters along the injured spinal
cord for detection of Wallerian degeneration. Datasets were consid-
ered to be signiﬁcantly different at p b 0.05. All experimental data is
presented as mean ± standard error of the mean (SEM).
Results
A reduction in spinal cord area in the chronic phase of injury indicates
tissue atrophy
Longitudinal assessment of lesion development showed shrinkage
of the cross-sectional area (atrophy) at 30 days post-injury. Compared
to pre-SCI, signiﬁcant decreases in cord area were observed for up to
2 mm away from the lesion epicentre at the end point (Figs. 1A, B).
The mean cross-sectional areas of the spinal cord, at and around
the lesion epicentre, were slightly higher in the acute period (2 hours
post-SCI) compared to pre-injury data, suggesting some minor tissue
swelling but this did not reach statistical signiﬁcance. Nonetheless,
the MD of the identiﬁed white matter (WM) was measured to deter-
mine the possible effect of oedema on injured spinal cord anatomy
(Fig. 1C). For WM, a signiﬁcant reduction in MD was observed at the
2 h, 1 day, 3 day and 7 day time points compared to pre-injury mea-
surements, indicating the possible presence of some intracellular
and axonal oedema. At 30 days post-injury, MD values were similar
to pre-injury values, whichwould be consistent with the view that tis-
sue oedema should have largely resolved in the more chronic phase of
SCI (Norenberg et al., 2004). Regional analysis showed that the decline
in MD in the acute phase was most pronounced in the more dorsal
aspects of the spinal cord, that is, the immediate site of impact.
No signiﬁcant change in MD was observed for other speciﬁc ROIs,
i.e. the ventral funiculi (VF) and lateral funiculi (LF) of the spinal
cord, although values were generally lower during the ﬁrst week
post-SCI (data not shown). Wemust note, however, that the changes
in MD appeared to bemostly driven by a reducedλ|| and no clear reduc-
tions in λ⊥ were observed for the various ROIs during the acute phase
(see also below), which thus appears to argue against a signiﬁcant pres-
ence of cytotoxic oedema in the various white matter regions analysed.
FA values at the lesion epicentre progressively decrease with time
Fractional anisotropy (FA) values were calculated from diffusion
tensor datasets for the total WM, VF, LF and DCs as outlined in
Suppl. Fig. 2. A progressive decrease in FA was observed at the lesion
epicentre as time progressed for the total WM, VF and LF following
contusive SCI (Fig. 2). To best illustrate the progressive deterioration
of FA values over time, we compared all earlier data points against
30 days post-SCI. FA values for each of the aforementioned regions
were indeed signiﬁcantly higher before injury as well as at 2 h,
1 day and 3 days after injury as compared to the experimental end-
point of 30 days post-SCI (Table 1). The DCs, on the other hand,
showed the most dramatic and rapid decline in FA over time. Specif-
ically, although the FA in this region was still signiﬁcantly higher
before SCI and 2 h after injury compared to endpoint values, values
were already maximally diminished at 1 day post-injury for this
ROI. Hence, there was no signiﬁcant difference between the FA mea-
sured at 1, 3 and 7 days post-SCI compared to 30 days post-injury for
the DCs (Table 1 and Fig. 2D). These ﬁndings suggest that the VF and
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Fig. 1. The change in appearance of the lesion core with time after injury indicates general tissue atrophy and early cytotoxic oedema. (A) In vivo serial images of the same mouse
spinal cord lesion core, showing the FA, MD, λ∥ and b0. For simplicity, only the pre-injury, 2 h, 7 day and 30 day scans are shown. The grey matter and white matter of the spinal
cord can still be clearly distinguished in the pre-injury scans as well as 2 h after SCI but the normal anatomical appearance progressively deteriorates thereafter. Note that the
cross-sectional area of the spinal cord decreases with time, which is particularly evident at 30 days post-SCI. Note the increased amount of ﬂuid (CSF) around the spinal cord at
this time point in the b0 map as a result of this tissue shrinkage. (B) Quantiﬁcation of the cross-sectional area of the spinal cord in transverse views conﬁrmed the occurrence of
spinal cord atrophy between 7 and 30 days post-injury. Of note, the rostrocaudal asymmetry that was observed at all time points results from a changing cross-sectional area
between the lumbar enlargement and lower thoracic region of the spinal cord. (C) A signiﬁcant reduction in MD values was observed during the ﬁrst week post-SCI. Data points
represent mean ± SEM (n = 4 per group); *, p b 0.05; **, p b 0.01; and ns, not signiﬁcant (repeated measures two-way ANOVA with Bonferroni post-hoc).
577F.H. Brennan et al. / NeuroImage 82 (2013) 574–585LF undergo more gradual degeneration and/or tissue remodelling
after injury, which may be amenable for therapeutic intervention.
In contrast, the rapid changes in diffusivity parameters for the DCs,
i.e. within the ﬁrst day of contusive SCI, indicate severe and likely
irreversible damage.0 303 71
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To gain a better understanding of what factors might be driving
the progressive decline in FA values after SCI, changes in diffusion ei-
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Table 1
Summary of the temporal changes at the lesion epicentre in fractional anisotropy (FA), axial diffusivity (λ||) (mm2 s−1) and radial diffusivity (λ⊥) (mm2 s−1) for the various regions
of interest (ROIs), i.e. the spared white matter (WM), ventral funiculi (VF), lateral funiculi (LF) and dorsal columns (DCs).
Time point → Pre-SCI 2 hours post-SCI 1 day post-SCI
DTI Parameter → FA || (x10-3) a (x10-3) FA || (x10-3) (x10-3) FA || (x10-3) (x10-3)
ROI Mean SEM Mean SEM SEM SEM SEM Mean SEM SEM SEM SEM
WM 0.75***
0.01 1.79 0.03 0.03 0.02 0.12 0.04 0.05 0.09 0.03
VF 0.74***
0.03 1.84 0.05 0.04 0.04 0.12 0.39
**
0.02 0.05 0.07 0.02
LF 0.76***
0.02 1.78 0.05 0.02 0.04 0.14 0.38
***
0.01 0.03 0.05 0.01
DC 0.78***
0.01 1.86 0.04 0.01 0.02 0.03 0.33
**
0.02 0.04 0.03 0.06
Time point → 3 days post-SCI 7 days post-SCI 30 days post-SCI
DTI Parameter → FA || (x10-3) (x10-3) FA || (x10-3) (x10-3) FA a || (x10-3) (x10-3) a
ROI SEM SEM SEM SEM SEM Mean SEM SEM Mean SEM
WM 0.05 0.19 0.07 0.25 0.06 0.31 0.02 0.06 0.75 0.05
VF 0.05 0.16 0.04 0.12 0.07 0.30 0.04 0.14 0.76 0.11
LF 0.05 0.19 0.06 0.08 0.05 0.30 0.02 0.10 0.78 0.08
DC 0.06 0.15 0.05 0.07 0.06 0.31 0.04 0.14 0.78 0.15
→
→
Mean
1.07
*
1.08
**
1.04
**
1.05
***
Mean
0.46
*
0.45
*
0.45
**
0.33
ns
Mean
0.48
***
0.52
**
0.47
***
0.58
ns
Mean
0.41
ns
0.40
ns
0.37
ns
0.29
ns
SEM
0.03
0.02
0.01
0.03
Mean
1.06
*
0.88
***
0.90
***
0.74
***
Mean
0.48
**
0.46
**
0.49
***
0.49
*
Mean
1.16
*
1.16
***
1.22
**
1.21
***
Mean
0.38
***
0.41
**
0.37
***
0.35
**
Mean
0.60
***
0.58
***
0.60
***
0.49
*
Mean
1.20
*
1.16
**
1.16
**
0.72
***
0.41
***
Mean
0.53
**
0.51
**
0.52
***
0.35
ns
Mean
0.99
*
1.03
***
1.07
**
0.88
***
Mean
0.39
***
0.43
**
0.42
***
0.52
*
Repeated measures one-way ANOVA with Newman–Keuls post-hoc tests; n = 4 per group; ns, not signiﬁcant.
a Denotes the time point for the indicated DTI parameter against which statistical comparisons were made, i.e. 30 days post-injury for FA and radial diffusivity (λ⊥), and pre-SCI
for axial diffusivity (λ||).
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
578 F.H. Brennan et al. / NeuroImage 82 (2013) 574–585λ||, generally considered an indicator for axonal integrity (Budde et
al., 2009; Kim et al., 2006), showed a profound and signiﬁcant decline
(~40%; p b 0.05) for identiﬁed WM at 2 h post-injury, with no obvi-
ous change thereafter (Fig. 3A and Table 1). Region-speciﬁc analysis
showed that the λ|| was also signiﬁcantly decreased for each of the
respective ROIs, i.e. the VF, LF and DC, at 2 h post-SCI compared to
pre-injury baseline (Figs. 3B–D and Table 1). This decline was most
marked for the DCs (p b 0.001), followed by the VF and LF
(p b 0.01). The λ|| remained signiﬁcantly below pre-injury values at
all other time points analysed, i.e. up until 30 days post-SCI for each
ROI (p b 0.01). Together, these ﬁndings indicate that DTI is able to de-
tect acute axonal damage as a result of SCI. However, since the λ|| did
not signiﬁcantly change further as a function of post-injury time, the
chosen imaging protocol appeared not sensitive enough to detect the
more subtle loss of axons, if occurring, as part of secondary degener-
ation. All data points were therefore also compared to pre-injury
measurements for this parameter.
In contrast to λ||, the radial diffusivity λ⊥, generally considered to
be an indicator of myelination status (Song et al., 2002, 2005) and
possibly gliosis (Harsan et al., 2007), progressively increased as a
function of time at the lesion epicentre (Fig. 4 and Table 1). As a re-
sult, this parameter was signiﬁcantly higher at 30 days post-SCI for
each ROI compared to all previous time points, including pre-injury
(p b 0.05). Statistical comparisons here were again made against
the endpoint, i.e. 30 days post-SCI, to best illustrate the progressive
increase in λ⊥ over time. Subsequent post-mortem histological analy-
sis conﬁrmed decreased myelin content as well as astrogliosis at and
in close proximity to the lesion epicentre (Fig. 5). The loss of myelin
corresponded well with the drop in FA values in WM at the lesion
site (Fig. 5A) whilst an inverse relationship was observed between
myelin content and λ⊥ as anticipated (Fig. 5B). GFAP immunoreactiv-
ity, used as an indicator of astrogliosis, was prominently elevated at
the lesion epicentre, in close correspondence with axial slices that
showed the lowest FA values (Fig. 5C) and highest λ⊥(not shown).Distal changes in FA and λ|| as indicators of Wallerian degeneration
Region-speciﬁc analysis of FA along the injured spinal cord seg-
ment showed a signiﬁcant rostrocaudal asymmetry, which was
most pronounced for the DC area (Suppl. Fig. 3). Here, FA values
returned to normal levels at a distance of ~3 mm caudal to the lesion
epicentre. Rostral to the injury site, however, FA values remained sig-
niﬁcantly below baseline for a distance of at least up to 5 mm (Suppl.
Fig. 3A; p b 0.05). We theorised that this rostrocaudal asymmetry
may have resulted fromWallerian degeneration as this region mostly
contains ascending sensory ﬁbres. Therefore, severed axons that orig-
inated from dorsal root ganglia below the level of the spinal injury
would no longer be connected to the neuronal cell body and thus
undergo degeneration. Consistent with this hypothesis, a similar
degree of asymmetry was observed for λ|| in the DCs (Suppl. Fig. 3D;
p b 0.01). The oppositewas observed for the ventrolateralwhitematter
where descending tracts dominate. Here, FA values were similar to
pre-injury baseline measurements at ≥2 mm rostral but they did not
return to normal for up to 4 mm caudal to the lesion epicentre (Suppl.
Figs. 3B, C; p b 0.05). A loss of axonal integrity, resulting from degener-
ation of the distal portion of severed axons, appeared again evident
based on a signiﬁcantly decreased λ|| for at least 5 mm caudal to the
lesion epicentre (Suppl. Figs. 3E, F; p b 0.05).
A comparison with the relative density of neuroﬁlament staining
conﬁrmed that the observed rostrocaudal asymmetry for the various
ROIs was indeed reﬂective of Wallerian degeneration (Fig. 6). Specif-
ically, the pattern of axonal loss for the DCs was most pronounced at
and rostral to the lesion epicentre (Figs. 6A, D–F), closely correlating
with the observed rostrocaudal asymmetry in FA (Fig. 6A) and λ||
(Fig. 6B). For the ventrolateral white matter, rostrocaudal asymmetry
in the relative density of neuroﬁlament staining again closely
matched the pathology detected by DTI, with reduced FA values
detected for up to 4 mm caudal to the injury site (Figs. 6C, D–F). Im-
munoﬂuorescent staining for Iba1 and CD68 conﬁrmed a prominent
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Fig. 3. SCI-induced changes in axial diffusivity (λ∥) for the white matter (WM) (A), ventral funiculi (VF) (B), lateral funiculi (LF) (C), and dorsal columns (DCs) (D) as a function of
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579F.H. Brennan et al. / NeuroImage 82 (2013) 574–585presence of macrophages at and around the lesion epicentre as
expected (Fig. 7). However, a clear rostrocaudal asymmetry was
again observed in identiﬁed ROIs undergoingWallerian degeneration,
with Iba1 staining being strongest in more distant areas where the
greatest degree of axonal loss was observed based on neuroﬁlament
staining (compare with Fig. 6). Speciﬁcally, in the DC, the immunore-
active area for Iba1 was greatest close to the lesion epicentre, as
expected. However, a signiﬁcantly greater presence of macrophages0 303 71
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
***
(m
m2
se
c-
1 )
(m
m2
se
c-
1 )
***
Days post-injury
0 303 71
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
***
***
***
**
Day spost-injury
A B
C D
Spared White Matter 
Lateral Funiculi 
***
***
******
Fig. 4. SCI-induced changes in radial diffusivity (λ⊥) for the white matter (WM) (A), ventral
post-injury time. Note the progressive increase in λ⊥ after SCI, with a signiﬁcantly greater v
imental time points (except for the DCs at 3 days post-injury). Data points represent mean
sures one-way ANOVA with Newman–Keuls post-hoc).was observed in rostral direction, for up to at least 5 mm away from
the lesion epicentre as compared to caudal (Figs. 7E–H; p b 0.05). In
general, macrophage presence correlated inversely with FA (Fig. 7A)
and λ|| (Fig. 7B). For the ventrolateral white matter, the Iba1 immu-
noreactive area was greater caudal to the lesion site compared to
rostral as would be anticipated based on the pattern of Wallerian de-
generation and associated presence of macrophages (Figs. 7E–H). The
observed asymmetry here again correlated inversely with FA data0 303 71
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alues obtained for this parameter at 30 days post-injury compared to all other exper-
± SEM (n = 4 per group); *, p b 0.05; **, p b 0.01; and ***, p b 0.001 (repeated mea-
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Fig. 5. Correlation between myelin content, GFAP immunoreactivity and select DTI parameters for the spinal cord white matter (WM) at 30 days post-injury. (A) Note that the re-
duction in FluoroMyelin™ staining (red line) is closely associated with the decline in FA (grey line); both are maximally reduced at the lesion epicentre. (B) An inverse relationship
was observed between myelin content (red line) and the radial diffusivity (λ⊥; grey line) across the injury site. (C) Quantiﬁcation of GFAP immunoreactivity revealed an inverse
relationship between astrogliosis and FA. Note that the maximum decrease in FA (grey line) corresponds with the peak of GFAP immunoreactivity (green line) in proximity to
the epicentre. (D–F) Representative photomicrographs of the injured mouse spinal cord at 30 days post-SCI, showing relatively normal myelin staining (red) and low GFAP immu-
noreactivity (green) in more distant areas (D, F), but diminished myelin content and increased GFAP immunoreactivity at the lesion epicentre (E). Scale bar: 300 μm.
580 F.H. Brennan et al. / NeuroImage 82 (2013) 574–585(Fig. 7C) and λ|| values (Fig. 7D). The varying degree of damage to
ascending and descending pathways in the DCs, VF and LF, along
with the change in various DTI parameters, was further conﬁrmed
and visualised through tractography (Fig. 8). Of note, the absolute
values for λ⊥ have changed here compared to the preceding in vivo
measurements due to tissue ﬁxation.
Discussion
Conventional MRI is the standard method for evaluating human SCI
(Bozzo et al., 2011).MRI has also proved a valuable tool in various animal
models of SCI, including dogs (Boekhoff et al., 2012), cats (Takahashi
et al., 1996), rats (Kozlowski et al., 2008; Martirosyan et al., 2010;
Sandner et al., 2009; Scholtes et al., 2011) and mice (Gonzalez-Lara
et al., 2009; Tatar et al., 2009), to identify tissue compression, oedema,haemorrhage and scarring (Blomster et al., 2013; Mhuircheartaigh et
al., 2006; O'Beirne et al., 1993).We demonstrate here thatmacroscopic
assessment of longitudinal MRI data can also reveal the progression of
atrophy in mice, with a signiﬁcant tissue shrinkage detected between
7 and 30 days post-SCI. These observations are consistent with ﬁndings
in human patients where spinal cord atrophy also occurs (Freund et al.,
2011).
Although conventional MRI allows for macroscopic assessment of
pathology, it is not normally an accurate predictor of functional out-
comes as this technique does not provide quantitative information
on the overall integrity and/or partial sparing of white matter tracts
(Sundgren et al., 2004). Such information can, however, be obtained
through DTI, which indeed provides a better correlation with clinical
outcomes in SCI patients (Chang et al., 2010; Mulcahey et al., 2011).
Yet, this imaging technique is not commonly applied to animal
581F.H. Brennan et al. / NeuroImage 82 (2013) 574–585models of SCI, particularly mice. Technical challenges posed by the
small size of the spinal cord, along with physiological motion and sus-
ceptibility artefacts, can make the acquisition of high-quality images
difﬁcult (Cohen-Adad et al., 2008). Despite these obstacles, longitudi-
nal in vivo DTI has the potential to considerably improve our under-
standing of secondary SCI pathology and to also identify potentially
salvageable tissue through repeated imaging of the same animal.
We show here that longitudinal assessment of speciﬁc DTI parame-
ters reveals several key abnormalities following SCI in mice.
MD values transiently declined during the acute period but
returned to control levels at 30 days post-SCI. This change is not likely
the result of vasogenic oedema, i.e. leakage of plasma ﬂuid into the ex-
tracellular space due to blood–spinal cord barrier dysfunction, as this
would normally lead to an increased MD. Qualitative inspection of b0
(T2-weighted) images post-injury also did not reveal any obvious
signs of ﬂuid accumulation (hyperintensity) for the ROIs. Our experi-
mental data also suggest minimal presence of cytotoxic oedema for the
various white matter ROIs. After CNS injury, a variety of pathophysi-
ological changes, including ischemia, energy depletion, excitotoxicity
and/or intracellular Ca2+ accumulation, can all contribute to a de-
creased extracellular and increased intracellular ﬂuid content. The
resulting cell swelling (i.e. cytotoxic oedema) has been associated
with a decreased MD, particularly in grey matter (Ellingson et al.,
2008; Loubinoux et al., 1997). However, whilst a rapid decline in λ||A
B
C
Fig. 6. Correlation between neuroﬁlament staining and select DTI parameters. (A, B) Note th
staining (NF200; green line), closely correlates with observed rostrocaudal asymmetry in FA
rostrocaudal asymmetry in DTI parameters again correlated well with the pattern of axonal
tative photomicrographs of the injured mouse spinal cord at 30 days post-SCI, showing NF
nuclear dye). Images on the right show a higher magniﬁcation of the boxed areas in the left h
epicentre (D) as compared to caudal (F). For the ventral white matter, NF200 staining was hi
it (F). Scale bars: 300 μm (D–F) and 50 μm (insets).was observed along with the drop in MD, we did not see a concomi-
tant reduction in λ⊥, which thus appears to argue against this type
of oedema being prominently present.
A decrease in FA values at the lesion core became increasingly ap-
parent over time for all ROIs. These ﬁndings are in line with clinical
studies, which have reported reduced FA values near the injury site in
SCI patients (Kamble et al., 2011; Petersen et al., 2012; Rajasekaran et
al., 2010; Shanmuganathan et al., 2008). As the FA correlates well
with both the clinical completeness of SCI and electrophysiological
measures (Petersen et al., 2012), this parameter thus likely also pro-
vides a relevant and translatable indicator to assess damage and/or
treatment efﬁcacy in experimental animal studies.
The drop in FA was most pronounced for the DCs. Given that this
area was directly impacted and thus severely damaged, this dramatic
decline in FA is perhaps not surprising. Indeed, tractography at
30 days post-injury failed to show any indications of pathway preserva-
tion in this region. Previous studies at 4.7 T indicated that axonal dam-
age following contusive SCI in rodents is reﬂected by a decrease in λ||
(Budde et al., 2007), which most likely results from increased barriers
to diffusion due to the collapse of axonal membranes and the accumu-
lation of myelin debris within areas of necrosis (Loy et al., 2007). We
therefore used this parameter to further assess pathway integrity in
our model at 16.4 T. Reductions in λ|| conﬁrmed that contusive SCI
inﬂicted immediate and irreversible axonal damage for all ROIs, butD
E
F
at the pattern of axonal loss for the dorsal columns (DCs), as detected by neuroﬁlament
(A) and λ|| (B) (grey lines). (C) For the ventrolateral white matter (WM), the observed
loss as detected by NF200 staining and shown here for FA (grey line). (D–F) Represen-
200 (green) and FluoroMyelin™ (red) staining; cell nuclei are shown in blue (Hoechst
and image. Note the loss of NF200 staining in the DC area at (E) and rostral to the lesion
ghest rostral to the lesion epicentre (D), diminishing at the injury site (E) and caudal to
EF
G
H
A
B
C
D
Fig. 7. Relationship between macrophage presence and select DTI parameters in areas undergoing Wallerian degeneration. Note that immunoreactive area for Iba1 staining (blue
line) is greater for regions with reduced FA and λ|| (grey lines), in both the dorsal columns (DCs; A, B) and ventrolateral white matter (C, D). (E–H) Representative photomicro-
graphs of the injured mouse spinal cord at 30 days post-SCI, showing Iba1 (green) and CD68 (red) staining; cell nuclei are shown in blue (Hoechst nuclear dye). Images on the
right show a higher magniﬁcation of the boxed areas in the left hand image. Note that for the DCs, there is an increased abundance of Iba1+CD68+macrophages rostral to the lesion
epicentre (relative to caudal; compare E1, F1 with H1), which correlates inversely with the rostrocaudal asymmetry in FA and λ||. The opposite pattern was observed for the ven-
trolateral white matter. Of note, in contrast to the ventrolateral white matter, macrophage presence for the DC region peaks just rostral to the lesion epicentre as relatively fewer
numbers of these cells occupy the ﬁbrotic scar that replaces the severely damaged neural tissue over time (compare F1 to G1). Scale bars: 250 μm (E–H) and 30 μm (insets).
582 F.H. Brennan et al. / NeuroImage 82 (2013) 574–585particularly the DCswhere the declinewas greatest. The injury-induced
reduction in λ|| at 2 h post-SCI was less pronounced for regions more
distant to the site of impact, i.e. the VF and LF and a considerable level
of anisotropic tissue integrity indeed conﬁrmed through tractography
at the experimental endpoint, 30 days post-SCI. Of note, a slight in-
crease in λ|| was observed here compared to the 7-day time point al-
though values remained well below baseline in all cases. It remains to
be determined if, and to what degree, axonal sprouting, gliosis and/orscarring contribute to this phenomenon. In this context, it is important
to point out that the presumptive DC region (for the lesion epicentre
only) had to be extrapolated based on proximal and distal slices for
the subacute and late time points after injury as the normal tissue archi-
tecture was completely disrupted here; this may explain the greater
level of variability in λ|| (relative to other ROIs) that was observed at
the lesion epicentre. Thus, region-speciﬁc analysis of λ|| at 16.4 T can
provide information on pathway integrity in a mouse model of SCI
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Fig. 8. Representative tractography images from ex vivo DTI data at 30 days post-SCI. A three-dimensional reconstruction of the lesion core is shown in yellow for each panel.
Streamlines are colour-coded for FA (left) and λ⊥ (right), with blue and red representing the low- and high-end values of the scale, respectively. Note the dramatic loss of tissue
anisotropy for the dorsal column (DC) area at the lesion site (A, B), indicating near complete damage to white matter tracts through this ROI. For the lateral (C, D) and ventral (E, F)
funiculi, track reconstructions still indicated substantial tissue damage although some preservation of ﬁbres was still evident for both these ROIs. Note also that FA values are de-
creased close to the lesion epicentre whilst λ⊥ is increased. The rostrocaudal asymmetry in FA and λ⊥ can also be observed, most clearly for the DCs. Scale bar: 1 mm.
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ary degeneration, at least up to 7 days post-injury. However, larger
cohorts of mice, along with customised imaging protocols (Hui et al.,
2010), are likely required to gain enough statistical power to reliably
detect these latter changes.
Interestingly, a more comprehensive spatial analysis of SCI-induced
changes in FA andλ|| revealed anROI-dependent rostrocaudal asymme-
try at the experimental endpoint. Similar observations were previously
made at 4.7 T inmice (Kim et al., 2007) and,more recently, at 3 T in cats
(Cohen-Adad et al., 2011). Consistent with previous ﬁndings after
dorsal root axotomy (Zhang et al., 2009), we believe these changes to
be indicative of Wallerian degeneration based on the post-mortem
histological correlate. Speciﬁcally, for the DCs, we observed reductions
in FA and λ|| for up to at least 5 mm away from the lesion epicentre in
rostral but not caudal direction. As the dorsal funiculus mostly contains
ascending sensory ﬁbres, a drop in FA, λ|| and ﬁbre density as a result of
Wallerian degenerationwould bemost notable rostral to the injury site,
which was indeed the case. Increased macrophage presence was also
noted here.Weobserved the opposite for the ventral and lateral funiculi
where descending motor pathways dominate. Assessment of rostro-
caudal asymmetry in FA and λ|| thus provides a non-invasive means
to assess damage to ascending and descending tracts in SCI through
region speciﬁc analysis.
As the FA takes into account both λ|| and λ⊥, any changes at the le-
sion site are likely not just reﬂective of axonal degeneration but also
demyelination and possibly gliosis (Harsan et al., 2006, 2007; Qin et
al., 2012). The disruption of barriers to transverse diffusion, particu-
larly myelin sheaths, would permit greater movement of water in
the perpendicular plane over time. Consistent with this, a progressive
increase in λ⊥ was indeed observed at the lesion epicentre for all
ROIs. These observations are in line with previous reports showing a
close association between increased λ⊥ and demyelination in the
diseased CNS (Harsan et al., 2006; Hoﬂing et al., 2009; Song et al.,2002, 2005). We conﬁrmed the existence of a similarly inverse rela-
tionship between λ⊥ values and myelin content for our spinal cord
samples through post-mortem histological analysis although DTI
appeared to be more sensitive for detecting subtle pathology at the
lesion margins. The relatively quick spatial normalisation of λ⊥ (with-
in ~2 mm of the lesion epicentre) also suggests that the established
presence of tissue macrophages in more distant areas undergoing
Wallerian degeneration exerts a minimal inﬂuence over this para-
meter. Assessment of λ⊥ thus provides important information on
myelination status and, considering the close correlation between
white matter preservation and functional deﬁcits (Bresnahan et al.,
1987; Noble and Wrathall, 1989), also likely yield translatable in-
sights on the efﬁcacy of targeted therapeutic interventions.
In summary, this is the ﬁrst longitudinal study to report on the use
of ultra-high ﬁeld (16.4 T) in vivo DTI to quantitatively monitor the
progression of white matter damage following contusive SCI in mice
for up to 30 days post-injury. We then conducted a detailed post-
mortem microscopic analysis of key pathological changes, i.e. axonal
loss, demyelination, astrogliosis and inﬂammation, to explain what
factors might drive the observed changes in diffusion parameters
after SCI. Collectively, our ﬁndings suggest that the acute changes in
FA are mostly driven by reductions in λ|| due to the disruption of tis-
sue integrity as a result of impact. As time goes by, a loss of myelin
and the onset of glial scarring appear to contribute to a progressive
increase in λ⊥, which in turn leads to further reductions in FA. Addi-
tional studies are, however, required in which the change in diffusion
parameters is directly correlated to histopathology early after SCI to
more deﬁnitively characterise this point. Only one other group has
utilised in vivo DTI to chronologically examine SCI pathology in
mice although at a lower magnetic ﬁeld strength (4.7 T) and only
for up to 14 days post-injury (Kim et al., 2007). Consistent with our
data, these authors reported a decreased FA and λ|| for the spared
ventrolateral white matter in the injured spinal cord segment whilst
584 F.H. Brennan et al. / NeuroImage 82 (2013) 574–585λ⊥was increased (Kim et al., 2007; Tu et al., 2010); these SCI-induced
changes reportedly plateaued between 7 and 14 days post-injury. In
the present study, a continued increase in λ⊥was, however, observed
up until the late survival point of 30 days post-SCI, indicating ongoing
and progressive demyelination. Differences in ﬁeld strength and/or a
more optimal b-value to detect changes in λ⊥ (Hui et al., 2010) likely
account for this seeming discrepancy. Our ﬁndings are also in general
agreement with other in vivo and ex vivo DTI studies of SCI in different
species such as rats (DeBoy et al., 2007; Ellingson et al., 2008, 2010a;
Kim et al., 2012; Krzyzak et al., 2005; Zhang et al., 2012) and cats
(Cohen-Adad et al., 2008; Ellingson et al., 2010b; Qin et al., 2012).
Most importantly, the changes inDTI parameters inmicewith SCI close-
ly match those observed in human patients (Bosma and Stroman, 2012;
Chang et al., 2010; Cheran et al., 2011;Mulcahey et al., 2011; Petersen et
al., 2012), highlighting its signiﬁcance as a non-invasive, clinically rele-
vant assessment tool to assess white matter integrity and/or treatment
effects in translational research.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.neuroimage.2013.06.019.Acknowledgments
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PERSPECTIVE
Targeting acute inflammation to 
complement spinal cord repair
Immune effector mechanisms play key roles in the progres-
sive (secondary) neurodegenerative changes that follow 
spinal cord injury (SCI). In our recent paper (Brennan et 
al., 2015), we showed that the inflammatory response to SCI 
includes rapid and robust activation of the innate immune 
complement system, with tissue levels of complement com-
ponent 5a (C5a – an activation product generated by the 
proteolysis of complement factor 5 (C5)) peaking 12 to 24 
hours post-injury.
Complement system activation normally forms the front-
line of host defense to microbial challenges. It is now widely 
recognized, however, that the activation of complement can 
also modify disease course and/or outcomes in sterile inflam-
matory conditions, including those that affect the nervous 
system like SCI. Complement activation in such conditions 
has been mostly thought as detrimental, but several reports 
have emerged in recent years ascribing positive roles in tissue 
regeneration and repair to at least some components of the 
complement cascade (e.g., Haynes et al., 2013). In studying 
the role of C5a in SCI, we generated novel insights regarding 
how this particular complement activation product also ap-
pears involved in endogenous repair processes. Specifically, 
we showed that engagement of the primary receptor for C5a, 
C5aR1 (also known as C5aR or CD88), regulates astrocyte 
proliferation during the post-acute phase of SCI (Brennan et 
al., 2015). Here, we overview these newly identified mecha-
nisms and highlight outstanding questions that remain to be 
addressed when considering therapeutic targeting of the C5a-
C5aR1 axis to treat central nervous system (CNS) injury.
Breakdown of the blood-spinal cord barrier (BSB) follow-
ing a neurotraumatic event permits the entry of circulating 
blood serum proteins, including complement factors, into 
the injured parenchyma. Permeability to larger macromole-
cules such as the parent protein of C5a, i.e., C5 (~180 kDa), 
is likely restricted to the first hours to days after SCI (e.g., 
Lee et al., 2014), but may be longer for smaller molecules 
like C5a (12–14.5 kDa). Although the liver is a major source 
of complement proteins in the body, many of these can also 
be synthesized by cells that are intrinsic to the CNS. The 
pathophysiological role of the complement system in SCI is 
therefore not necessarily restricted to the (sub-) acute phase 
when the BSB is most compromised.  
Proteolytic cleavage (i.e., activation) of C5 following neu-
rotrauma is a key event that is thought to contribute signifi-
cantly to secondary neuroinflammatory pathology via 1) 
activation of the terminal pathway (which causes cell death 
via formation of the lytic membrane attack complex (MAC) 
on target cells), and 2) injurious pro-inflammatory C5a 
signaling via C5aR1. Neutralizing either C5 or its bioactive 
cleavage products, C5a and C5b, is therefore a promising 
therapeutic strategy to attenuate secondary immune-me-
diated pathology in SCI and other forms of acquired CNS 
injury. Intriguingly, interference with C5a-C5aR1 signaling 
in the more chronic phase of SCI (14 days post-injury on-
wards) does not yield a therapeutic benefit. In fact, injury 
outcomes under these conditions are worsened in both 
rat and mouse models of contusive SCI (Beck et al., 2010; 
Brennan et al., 2015). These findings suggest more complex 
roles for C5a signaling in neurotrauma, with some aspects 
appearing neuroprotective and/or aiding repair. A key focus 
of our laboratory over the past few years has been to better 
understand these roles of C5a in the context of SCI.
It is now firmly established by our own work (Brennan 
et al., 2015) and that of others (Li et al., 2014) that a lack of 
C5aR1 signaling in the very acute phase of injury (12 hours 
post-SCI) leads to significant reductions in pro-inflammato-
ry cytokine levels (e.g., interleukin-1 beta (IL-1β), IL-6 and 
chemokine (C-X-C motif) ligand 1 (CXCL1)) at the lesion 
site, which correlate with improved outcomes, at least when 
generic targeting of C5aR1 is restricted to the (sub-) acute 
phase. CNS cells, in particular astrocytes but also microglia, 
most likely mediate these beneficial effects of disarming the 
C5a-C5aR1 axis as they are known to be the primary source 
of pro-inflammatory cytokines early after SCI (Pineau and 
Lacroix, 2007) and express C5aR1. The fact that expression 
of key pro-inflammatory cytokines is at least in part regulat-
ed via C5aR1 is of significance because elevated levels of e.g., 
IL-1β have been directly associated with neuronal death and 
axon retraction in vivo and in vitro. Improved outcomes in 
absence of C5aR1 signaling therefore likely involve neuro-
protection due to an abrogation of the acute inflammatory 
response to SCI. 
Pro-inflammatory cytokines like IL-1β and IL-6 also fa-
vor polarization of activated microglia and macrophages 
towards a classical pro-inflammatory M1 phenotype, which 
is generally considered injurious and not supportive of re-
generation. Specifically, M1-polarized macrophages are an 
additional source of pro-inflammatory cytokines, and they 
exacerbate secondary SCI pathology by direct neurotoxicity 
and axonal retraction (Gensel et al., 2009). Whether the po-
larization of activated microglia and macrophages following 
SCI is, at least transiently, more biased towards are genera-
tion-favoring M2 phenotype in absence of C5aR1 signaling 
due to associated reductions in pro-inflammatory cytokine 
levels is still to be determined. It also remains to be seen 
whether or not C5aR1 is directly involved in recruitment of 
pro-inflammatory Ly6Chi monocytes/macrophages, which 
normally peaks between 4 and 7 days post-SCI. Although 
C5aR1 appears largely dispensable for neutrophil recruit-
ment in SCI, significantly fewer Ly6Chi monocytes/macro-
phages are present at the lesion site following inhibition of 
the C5a-C5aR1 axis (Beck et al., 2010; Brennan et al., 2015). 
Such a chemotactic role for C5aR1 may, however, be difficult 
to entangle from e.g., diminished recruitment of inflam-
matory monocytes as a result of reduced pro-inflammatory 
cytokine levels in absence of C5a-C5aR1 signaling or, alter-
natively, attenuated secondary injury; these two possibilities 
are also not mutually exclusive. Specific targeting of C5aR1 
in blood monocytes may shed some light on this issue and 
potentially unlock new C5aR1-based therapeutic strategies 
to reduce recruitment of these cells to the inflamed CNS.
As SCI is hallmarked by chronic, non-resolving and 
M1-biased inflammation (e.g., Kroner et al., 2014), the 
finding that continued or prolonged interference with the 
pro-inflammatory C5a-C5aR1 axis leads to a worsening 
rather than improvement in SCI outcomes seems, at least at 
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first sight, somewhat surprising. When investigating the pos-
sible neuroprotective and/or reparative mechanisms that are 
driven by C5aR1 signaling in the post-acute phase of SCI, we 
discovered that astrocytes depend on the C5a-C5aR1 axis for 
proliferation; this dependency is the likely the key to the dual 
and opposing roles for C5aR1 signaling in SCI. 
Various molecular signals, including pro-inflammatory 
cytokines, have previously been implicated in promoting as-
trocyte hypertrophy, proliferation and/or migration toward 
sites of inflammation. This proliferation and accumulation 
of reactive astrocytes along the margins of the necrotic le-
sion core is part of a critical, barrier-forming process that 
limits the spread of secondary pathology into neighboring 
neural tissue that is vulnerable to degeneration but not di-
rectly affected by the initiating neurotraumatic event (Okada 
et al., 2006). Our latest findings add C5a to the repertoire of 
molecules that regulate this beneficial aspect of the glial ‘scar’ 
by showing that C5a can directly induce astrocyte prolifer-
ation, most likely through activating the STAT-3 pathway 
downstream of C5aR1. In addition to the direct mitogenic 
effect of C5a, C5aR1 signaling may also influence astrocyte 
proliferation via its regulation of IL-6 production (Okada et 
al., 2004), either in a direct autocrine fashion or indirectly 
via activated microglia and macrophages; these possibilities 
are again not mutually exclusive and may act simultaneously.
Consistent with the view that prolonged interference with 
C5a-C5aR1 signaling negatively impacts on endogenous 
wound healing responses, a chronic lack of C5aR1 signaling 
not only resulted in reduced astrogliosis at and around the 
lesion epicenter, it also significantly increased lesion size and 
the spread of infiltrating immune cells across the injured 
spinal cord segment. These histopathological changes direct-
ly correlated with worsened SCI outcomes. If impairments 
in the endogenous proliferative response of astrocytes fol-
lowing SCI were indeed responsible for the late worsening in 
outcomes under C5aR1-deficient conditions, then the num-
ber of newly generated astrocytes at and around the lesion 
site should negatively correlate with lesion volume, which 
was indeed the case as revealed by pulse-chase studies with 
5-bromo-2′-deoxyuridine (BrdU). Furthermore, as short-
term (up to 7 days post-injury) antagonism of C5aR1 led 
to sustained improvements in SCI outcomes (i.e., no dual 
phenotype with early improvements but a late worsening), 
it also stands to reason that the astroglial response at and 
around the lesion epicenter in this scenario then, at a mini-
mum, should be similar to that of vehicle-treated controls, as 
was observed. Thus, abnormal astrocytic responses with sus-
tained absence of C5aR1 signaling are likely a key contribut-
ing factor to a worsening of outcomes in the more chronic 
phase of SCI due to a failure to effectively segregate the 
necrotic lesion core from neighboring intact tissue. Specific 
ablation of C5aR1 in astrocytes (and microglia) via condi-
tional gene targeting approaches in future experiments could 
provide more direct and definitive evidence for this prem-
ise. Whether or not exogenous stimulation of C5aR1 in the 
post-acute phase of injury could in fact aid recovery by aug-
menting astrocyte proliferation, and in doing so, accelerate 
sealing of the injury site, also remains to be addressed. The 
adverse pro-inflammatory consequences of C5aR1 agonism 
are, however, likely to outweigh any such benefits. Further-
more, augmenting the astrogliotic response to SCI would 
likely also increase the non-permissive/repulsive nature of 
the scar and thus have a negative bearing on (complementa-
ry) strategies aimed at promoting axonal regeneration; these 
Figure 1 Overview of established and 
proposed roles for C5a-C5aR1 signaling 
in traumatic spinal cord injury (SCI). 
Complement activation and C5a gener-
ation after SCI contributes to secondary 
inflammatory pathology through C5aR1 
via the induction of pro-inflammatory 
cytokine expression, neuronal apoptosis 
and/or endothelial cell dysfunction, which 
increases leakiness of the blood-spinal 
cord barrier. Reparative aspects of C5a-
C5aR1 signaling in the post-acute phase 
of SCI likely include its role in astrocyte 
proliferation, which is required for the 
effective formation of a glial barrier (scar) 
between the necrotic lesion core and 
spared spinal cord tissue. BSB: Blood-spi-
nal cord barrier; C5a: component 5a; 
C5aR1: complement component 5a 
receptor 1; CXCL1: chemokine (C-X-C 
motif) ligand 1; IL-6: interleukin-6; IL-
1β: interleukin-1 beta.Astrocytes
·  Pro-inflammatory cytokine
      production (→ IL-6, IL-1β, CXCL1)
· Proliferation/glial scar formation
Microglia
·  Polarisation towards M1 macrophages
· Pro-inflammatory cytokine production 
    (→ IL-6, IL-1β, CXCL1)
Oligodendrocytes
·  Modulation demyelination and/or    
      remyelination?
Endothelial cells
·  Increased BSB dysfunction?
·  Apoptosis?
Neurons 
·  Apoptosis?
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issues should be carefully contemplated and balanced when 
designing C5aR1-based interventions.
In summary, our recent work has identified a critical time 
window to which therapeutic inhibition of the C5a-C5aR1 
axis in SCI should be restricted in order to avoid adverse 
outcomes. The more delayed beneficial aspects of C5a-
C5aR1 signaling (> 7 days post-injury) likely involve facil-
itating astrocyte proliferation as part of the natural wound 
healing response to SCI. Although acute targeting of the 
C5a-C5aR1 pathway remains a credible and promising ther-
apeutic avenue to promote SCI recovery, a number of signif-
icant questions remain. Specifically, the exact mechanism(s) 
via which pharmacological blockade of C5aR1 signaling 
during the acute phase improves SCI outcomes remain 
largely unknown and require further investigation (Figure 1). 
Although we did not find a role for C5aR1 signaling in 
the generation and survival of oligodendrocytes after SCI, a 
possible requirement for functional maturation of these cells 
cannot be excluded at present; specific deletion of the C5ar1 
gene in the oligodendrocyte lineage could resolve this out-
standing issue via detailed histological studies. Apart from 
CNS glia, various neuronal populations are also thought to 
express C5aR1 and reportedly upregulate this receptor in 
neurodegenerative disease. Activation of C5aR1 has been 
directly implicated in neuronal apoptosis in vitro. Specific 
targeting of C5aR1 expression in neurons could again reveal 
a direct role in neuronal death in vivo; conditional ablation 
in other cell populations may reveal indirect neuroprotec-
tive effects. A vascular mechanism in relation to C5a-C5aR1 
signaling in SCI pathophysiology should also be explored. 
Endothelial cells are known to express C5aR1 (Jacob et al., 
2011), and its activation by C5a causes nuclear translocation 
of nuclear factor kappaB and endothelial cell apoptosis. In 
vivo, C5aR1 antagonism preserved the integrity of endo-
thelial cells in a mouse model of lupus cerebritis, which 
coincided with reduced neuronal apoptosis. Conditional 
knockout approaches would again be required to specifically 
demonstrate whether the targeting of C5aR1 directly ame-
liorates endothelial cell dysfunction and BSB breakdown 
in SCI, or whether this is an epiphenomenon of attenuated 
inflammation. In order to fully appreciate the complex roles 
of C5a in SCI, the role of its alternate receptor, complement 
5a receptor-like protein 2 (C5L2 – now renamed as C5aR2) 
must also be investigated, for example through the use of 
C5l2–/– mice (Chen et al., 2007). Lastly, and perhaps the most 
pertinent question from the viewpoint of clinical translation, 
is how long C5aR1 antagonism can be delayed before losing 
therapeutic efficacy. As tissue levels of C5a do not peak until 
at least 12 hours post-SCI, it seems reasonable to assume 
that initiation of C5aR1 antagonism could likely be delayed 
for at least several hours but this remains to be tested. Until 
then, the future seems bright for C5aR1-based therapeutics 
as a putative immunomodulatory intervention to treat acute 
SCI.
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